0001333493-12-000075.txt : 20121106 0001333493-12-000075.hdr.sgml : 20121106 20121105214217 ACCESSION NUMBER: 0001333493-12-000075 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121106 DATE AS OF CHANGE: 20121105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eHealth, Inc. CENTRAL INDEX KEY: 0001333493 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 770470789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33071 FILM NUMBER: 121181619 BUSINESS ADDRESS: STREET 1: 440 EAST MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-584-2700 MAIL ADDRESS: STREET 1: 440 EAST MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 10-Q 1 ehth-20120930x10q.htm 10-Q d8262b5c7aa4471

 

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549 

 

 

 

FORM 10-Q

 

þ     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 

For the quarterly period ended September 30, 2012 

 

OR 

 

¨  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 

For the transition period from                 to 

 

001-33071 

(Commission File Number)  

_____________________________________________ 

EHEALTH, INC. 

(Exact name of registrant as specified in its charter) 

_____________________________________________

 

 

 

 

 

 

 

Delaware 

(State or other jurisdiction of 

incorporation or organization)

 

56-2357876 

(I.R.S Employer  

Identification No)

440 EAST MIDDLEFIELD ROAD 

MOUNTAIN VIEW,  CALIFORNIA 94043 

 (Address of principal executive offices) 

 

(650) 584-2700 

(Registrant’s telephone number, including area code) 

 

Not Applicable 

(Former name, former address and former fiscal year, if changed since last report) 

____________________________________________________________ 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO ¨ 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES x NO ¨ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 

 

 

 

Large accelerated filer         ¨

 

Accelerated filer                  x

Non-accelerated filer          ¨

 

Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES ¨ NO x 

 

The number of shares of the registrant’s common stock, par value $0.001 per share, outstanding as of October  31, 2012 was 20,251,748 shares 

 

  

 

 

 

 


 

EHEALTH, INC. FORM 10-Q 

TABLE OF CONTENTS

 

 

 

 

 

 

PART I FINANCIAL INFORMATION

PAGE

 

 

 

Item 1.

Financial Statements (unaudited)

1

 

Condensed Consolidated Balance Sheets at December 31, 2011 and September 30, 2012

1

 

Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2011 and 2012

2

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2011 and 2012

3

 

Notes to Condensed Consolidated Financial Statements

4

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

14

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

34

 

 

 

 

PART II OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

36

Item 6.

Exhibits

61

 

Signatures

62

 

  

 

 

 

 


 

PART I 

FINANCIAL INFORMATION 

 

 

 

ITEM 1.

FINANCIAL STATEMENTS

 

 

EHEALTH, INC. 

CONDENSED CONSOLIDATED BALANCE SHEETS 

(In thousands)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

Assets

 

 

(unaudited)

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

123,607 

 

$

130,800 

 

 

Accounts receivable

 

8,055 

 

 

3,256 

 

 

Deferred income taxes

 

4,622 

 

 

4,306 

 

 

Prepaid expenses and other current assets

 

3,377 

 

 

5,078 

 

 

Total current assets

 

139,661 

 

 

143,440 

 

 

Property and equipment, net

 

4,631 

 

 

6,131 

 

 

Deferred income taxes

 

3,390 

 

 

3,735 

 

 

Other assets

 

5,641 

 

 

8,848 

 

 

Intangible assets, net

 

10,526 

 

 

9,265 

 

 

Goodwill

 

14,096 

 

 

14,096 

 

 

Total assets

$

177,945 

 

$

185,515 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

2,391 

 

$

4,571 

 

 

Accrued compensation and benefits

 

7,904 

 

 

8,819 

 

 

Accrued marketing expenses

 

6,195 

 

 

3,864 

 

 

Deferred revenue

 

314 

 

 

704 

 

 

Other current liabilities

 

1,547 

 

 

1,864 

 

 

Total current liabilities

 

18,351 

 

 

19,822 

 

 

Non-current liabilities

 

3,920 

 

 

4,117 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

Common stock

 

26 

 

 

27 

 

 

Additional paid-in capital

 

215,364 

 

 

225,070 

 

 

Treasury stock, at cost

 

(81,557)

 

 

(89,998)

 

 

Retained earnings

 

21,661 

 

 

26,296 

 

 

Accumulated other comprehensive income

 

180 

 

 

181 

 

 

Total stockholders’ equity

 

155,674 

 

 

161,576 

 

 

Total liabilities and stockholders’ equity

$

177,945 

 

$

185,515 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

  

1 

 


 

 

 

EHEALTH, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) 

(In thousands, except per share amounts, unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

Commission

$

28,206 

 

$

31,291 

 

$

89,045 

 

$

93,358 

Other

 

6,581 

 

 

6,295 

 

 

19,483 

 

 

16,810 

Total revenue

 

34,787 

 

 

37,586 

 

 

108,528 

 

 

110,168 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

1,781 

 

 

1,099 

 

 

6,987 

 

 

3,538 

Marketing and advertising

 

13,826 

 

 

13,988 

 

 

38,403 

 

 

39,142 

Customer care and enrollment

 

6,245 

 

 

8,823 

 

 

16,265 

 

 

21,152 

Technology and content

 

5,548 

 

 

5,503 

 

 

16,433 

 

 

16,018 

General and administrative

 

6,917 

 

 

6,744 

 

 

20,299 

 

 

19,938 

Amortization of intangible assets

 

427 

 

 

354 

 

 

1,281 

 

 

1,261 

Total operating costs and expenses

 

34,744 

 

 

36,511 

 

 

99,668 

 

 

101,049 

Income from operations

 

43 

 

 

1,075 

 

 

8,860 

 

 

9,119 

Other income (expense), net

 

(21)

 

 

 

 

(61)

 

 

41 

Income before provision for income taxes

 

22 

 

 

1,079 

 

 

8,799 

 

 

9,160 

Provision for income taxes

 

271 

 

 

874 

 

 

4,335 

 

 

4,525 

Net income (loss)

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.01)

 

$

0.01 

 

$

0.21 

 

$

0.24 

Diluted

$

(0.01)

 

$

0.01 

 

$

0.20 

 

$

0.23 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of shares used in per share amounts:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

Diluted

 

21,054 

 

 

20,750 

 

 

21,974 

 

 

20,563 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

Foreign currency translation adjustment

 

(9)

 

 

 

 

(24)

 

 

Comprehensive income (loss)

$

(258)

 

$

208 

 

$

4,440 

 

$

4,636 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

  

 

2 

 


 

 

 

EHEALTH, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(In thousands, unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

2011

 

2012

 

 

 

 

Operating activities

 

 

 

 

 

Net income

$

4,464 

 

$

4,635 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Deferred income taxes

 

3,696 

 

 

2,373 

Depreciation and amortization

 

1,799 

 

 

1,740 

Amortization of book-of-business consideration

 

366 

 

 

1,990 

Amortization of intangible assets

 

1,281 

 

 

1,261 

Stock-based compensation expense

 

5,622 

 

 

4,326 

Excess tax benefits from stock-based compensation

 

(2,734)

 

 

(2,358)

Deferred rent

 

 

 

50 

Loss on disposal of fixed assets

 

38 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

Accounts receivable

 

7,698 

 

 

4,799 

Prepaid expenses and other current assets

 

1,876 

 

 

1,708 

Other assets

 

(494)

 

 

(2,364)

Accounts payable

 

(1,654)

 

 

2,180 

Accrued compensation and benefits

 

455 

 

 

913 

Accrued marketing expenses

 

691 

 

 

(2,332)

Deferred revenue

 

(1,632)

 

 

390 

Other current liabilities

 

(1,475)

 

 

341 

Net cash provided by operating activities

 

20,004 

 

 

19,653 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

Purchases of property and equipment

 

(1,932)

 

 

(3,128)

Consideration paid in connection with book-of-business transfers

 

(3,906)

 

 

(6,243)

Net cash used in investing activities

 

(5,838)

 

 

(9,371)

 

 

 

 

 

 

Financing activities

 

 

 

 

 

Net proceeds from exercise of common stock options

 

184 

 

 

4,014 

Cash used to net-share settle equity awards

 

(548)

 

 

(991)

Excess tax benefits from stock-based compensation

 

2,734 

 

 

2,358 

Repurchase of common stock

 

(18,033)

 

 

(8,441)

Principal payments in connection with capital leases

 

(46)

 

 

(31)

Net cash used in financing activities

 

(15,709)

 

 

(3,091)

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

(30)

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

(1,573)

 

 

7,193 

Cash and cash equivalents at beginning of period

 

128,074 

 

 

123,607 

Cash and cash equivalents at end of period

$

126,501 

 

$

130,800 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

  

 

 

3 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

 

 

Note 1 - Summary of Business and Significant Accounting Policies

 

 

Description of BusinesseHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is the leading online source of health insurance for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com,  www.eHealthInsurance.com,  www.eHealthMedicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans.  Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process. We are licensed to market and sell health insurance in all 50 states and the District of Columbia. 

  

Basis of Presentation—The accompanying condensed consolidated balance sheet as of September 30, 2012, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2011 and 2012 and the condensed consolidated statements of cash flows for the nine months ended September  30, 2011 and 2012, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2011 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011, which was filed with the Securities and Exchange Commission on March 15, 2012. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  

 

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2011, and include all adjustments necessary for the fair presentation of eHealth’s statement of financial position as of September 30, 2012, its results of operations for the three and nine months ended September 30, 2011 and 2012 and its cash flows for the nine months ended September 30, 2011 and 2012. All adjustments are of a normal recurring nature. The results for the three months ended September 30, 2012 are not necessarily indicative of the results to be expected for any subsequent quarter or for the fiscal year ending December 31, 2012.   

 

Seasonality—The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear.  

 

The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year. 

 

In the third quarters of 2011 and 2012, we significantly increased our temporary customer care center staff in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater

4 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur in future years.  

 

Based on these seasonal trends, we expect our revenue to be highest in the first and fourth quarters of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year.  

 

Book-of-Business TransfersWe  have entered into several agreements with a broker partner, whereby the partner has transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these transfers occurred in November 2010 and the most recent in June 2012. Total consideration for these transfers amounted to $13.9 million,  of which $6.2  million is related to transfers during the nine months ended September 30, 2012. Consideration for these transfers is included in “Prepaid expenses and other current assets and also in “Other assets in the accompanying condensed consolidated balance sheets. The consideration, which was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member, is being amortized to “Cost of revenue in the condensed consolidated statements of comprehensive income (loss) and is presented as “Amortization of book-of-business consideration” in the condensed consolidated statements of cash flows as we recognize commission revenue related to the transferred Medicare plan members, over a period of up to five years. The amount of consideration we amortize to cost of revenue each quarter is proportional to the amount of commission revenue we recognize on the underlying policies each quarter. Amortization expense recorded to cost of revenue for these books-of-business for the three months ended September 30, 2011 and 2012 totaled $0.1 million and  $0.6 million, respectively. Amortization expense recorded to cost of revenue for these books-of-business for the nine months ended September 30, 2011 and 2012 totaled $0.4 million and $2.0 million, respectively. Cash consideration paid in connection with the book-of-business transfers are presented under investing activities in the condensed consolidated statements of cash flows. 

Recent Contractual Obligations—In August 2012, we extended our existing lease for office space in Gold River, California, for an additional two years expiring on December 31, 2014. Rent payments will total $0.9 million in both 2013 and 2014. 

In May 2012, we entered into an agreement to lease office space in South Jordan, Utah. The term of the operating lease is 65 months and commences in August 2012. The lease significantly increases our office space for our customer care and enrollment activities and replaces an expiring operating lease for office space at another location in South Jordan, Utah. Rent payments begin in January 2013 and total approximately $0.5 million per year through December 2017.    

In March 2012, we entered into an agreement to lease a building to be constructed in Mountain View, California, adjacent to our headquarters office. The term of the operating lease is ten years from the date the building is delivered to us and the base rent is approximately $0.6 million for the first year of the lease. The base rent increases annually by 3%. Future minimum payments related to this operating lease are estimated to total $6.8 million over the ten-year term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease, but may differ depending on actual rentable square footage. Lease payments are expected to begin in the second or third quarter of 2013, although the actual commencement of lease payments will depend upon the date of completion and delivery of the newly constructed building. 

 

Upon signing the Mountain View, California lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.  

 

In March 2012, we entered into a service agreement with a vendor to support our customer care center telephonic system and equipment. Service obligations related to this agreement total $0.7 million over the three-year term of the agreement.   

 

Recent Accounting PronouncementsIn June 2011, the FASB issued authoritative guidance related to the presentation of comprehensive income. The guidance requires that all non-owner changes in stockholders’ equity be

5 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

presented in a single continuous statement of comprehensive income or in two separate but consecutive statements. The guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. This guidance is effective for interim and annual periods beginning after December 15, 2011. The new guidance is to be applied retrospectively. We adopted the guidance beginning in the first quarter of 2012 and the adoption of this guidance did not have a material impact on our consolidated financial results. 

 

In July 2012, the FASB updated the accounting guidance related to testing indefinite-lived intangible assets for impairment. This update permits an entity to first make a qualitative assessment of whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. An entity is not required to calculate the fair value of an indefinite-lived intangible asset and perform the quantitative impairment test unless the entity determines that it is more likely than not that the asset is impaired. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This update is effective for annual and interim impairment tests performed in fiscal years beginning after September 15, 2012 (our fiscal year 2013); however, early adoption is permitted, provided that the entity has not yet performed its annual impairment test or issued its financial statements. We do not expect the adoption of this accounting guidance to have an impact on our consolidated financial results. 

 

  

 

Note 2  – Cash, Cash Equivalents and Accounts Receivable 

 

Cash and Cash EquivalentsAs of December 31, 2011 and September 30,  2012, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At December 31, 2011 and September 30,  2012, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the three and nine months ended September 30, 2011 and 2012.   

 

As of December 31, 2011 and September 30, 2012, our cash and cash equivalent balances were invested as follows (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Cash

$

17,256 

 

$

17,441 

Money market funds

 

106,351 

 

 

113,359 

Total cash and cash equivalents

$

123,607 

 

$

130,800 

 

We used observable prices in active markets in determining the classification of our money market funds as Level 1. 

 

Accounts ReceivableAs of December 31, 2011 and September 30, 2012, our accounts receivable consisted of the following (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Accounts receivable - from other revenues

$

7,702 

 

$

1,862 

Commissions receivable

 

353 

 

 

1,394 

Total accounts receivable

$

8,055 

 

$

3,256 

6 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

  

 

 

 

 

Note 3 – Stockholders’ Equity

 

Stock PlansThe following table summarizes option activity under our 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands, except per share amounts and weighted average remaining contractual life data): 

 

 

 

 

 

Shares Available for Grant (1)

Shares available for grant December 31, 2011

3,870 

Additional shares authorized (2)

795 

Options granted

(731)

Restricted stock units granted

(203)

Options cancelled

280 

Restricted stock units cancelled

75 

Shares available for grant September 30, 2012

4,086 

 

(1)

Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30,  2012, respectively, that could be granted if we determined to do so. 

 

(2)

On January 1, 2012, the number of shares authorized for issuance under the 2006 Equity Incentive Plan was automatically increased pursuant to the terms of the 2006 Equity Incentive Plan by 0.8 million shares.  

 

The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Stock Options

 

Weighted Average Exercise Price

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding at December 31, 2011

3,412 

 

$

11.36 

 

3.80 

 

$

17,078 

Granted

731 

 

$

16.86 

 

 

 

 

 

Exercised

(709)

 

$

5.67 

 

 

 

 

 

Cancelled

(280)

 

$

18.58 

 

 

 

 

 

Balance outstanding at September 30, 2012

3,154 

 

$

13.27 

 

3.98 

 

$

18,787 

Vested and expected to vest at September 30, 2012

3,055 

 

$

13.17 

 

3.90 

 

$

18,536 

Exercisable at September 30, 2012

2,056 

 

$

11.79 

 

2.89 

 

$

15,767 

 

(1)

The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 and the exercise price of in-the-money options as of those dates. 

The total grant date fair value of stock options vested during the three months ended September 30, 2011 and 2012 was $0.9 million and $0.5 million, respectively. The total grant date fair value of stock options vested during the nine months ended September 30, 2011 and 2012 was $3.8  million and $1.9 million, respectively.

7 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

 

 

The following table summarizes restricted stock unit activity under the Stock Plans (in thousands, except weighted average remaining contractual life data): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number Outstanding

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding as of December 31, 2011

474 

 

1.92 

 

$

6,958 

Granted

203 

 

 

 

 

 

Vested

(235)

 

 

 

 

 

Cancelled

(75)

 

 

 

 

 

Balance outstanding as of September 30, 2012

367 

 

2.36 

 

$

6,890 
(1)

The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 multiplied by the number of restricted stock units outstanding as of December 31, 2011 and September 30, 2012, respectively.  

 

The fair value of the restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense is recognized on a straight-line basis over the vesting period. The total grant date fair value of restricted stock units vested during the nine months ended September 30, 2011 and 2012 was $1.7 million and $3.7 million, respectively. 

Stock Repurchase Programs—On September 10, 2012, we announced that our board of directors approved a stock repurchase program authorizing us to purchase up to an additional $30.0 million of our common stock. Purchases under this program may be made in the open market or unsolicited negotiated transactions and are expected to comply with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing of the purchases and the exact number of shares to be purchased will depend upon market conditions. The program does not require us to acquire a specific number of shares, and the program may be suspended from time to time or discontinued at any time. The cost of the repurchased shares will be funded from available working capital. 

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. 

Stock repurchase activity under our stock repurchase programs during the nine months ended September 30, 2012 is summarized as follows (dollars in thousands, except share and per share amounts): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Number of Shares Purchased

 

Average Price Paid per Share (2)

 

Amount of Repurchase

Cumulative balance at December 31, 2011 (1)

5,797,806 

 

$

14.07 

 

$

81,557 

Repurchases of common stock

554,284 

 

$

15.23 

 

 

8,441 

Cumulative balance at September 30, 2012 (1)

6,352,090 

 

$

14.17 

 

$

89,998 
(1)

Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.  

(2)  Average price paid per share includes commissions. 

8 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

In addition to the 6.4 million shares repurchased under our repurchase programs as of September 30, 2012, we have in treasury 0.2 million shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2011 and September 30, 2012, we had a total of 5.9 million shares and 6.5 million shares, respectively, held in treasury. 

Stock-Based Compensation—The fair value of stock options granted to employees for the three and nine months ended September 30, 2011 and 2012 was estimated using the following weighted average assumptions: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

(1)

 

 

 

 

 

 

 

 

 

Expected term

 

N/A

 

 

4.6 years

 

 

4.6 years

 

 

4.7 years

Expected volatility

 

N/A

 

 

43.3% 

 

 

49.0% 

 

 

44.3% 

Expected dividend yield

 

N/A

 

 

0% 

 

 

0% 

 

 

0% 

Risk-free interest rate

 

N/A

 

 

0.61% 

 

 

2.02% 

 

 

0.90% 

Weighted-average fair value

$

N/A

 

$

6.46 

 

$

5.34 

 

$

6.41 

 

(1)

There were no stock options granted to employees during the three months ended September 30, 2011.   

The following table summarizes stock-based compensation expense recorded during the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Common stock options

$

845 

 

$

717 

 

$

2,893 

 

$

2,076 

Restricted stock units

 

979 

 

 

622 

 

 

2,729 

 

 

2,250 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

The following table summarizes stock-based compensation expense by operating function for the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and advertising

$

252 

 

$

330 

 

$

774 

 

$

932 

Customer care and enrollment

 

83 

 

 

90 

 

 

264 

 

 

243 

Technology and content

 

411 

 

 

233 

 

 

1,336 

 

 

783 

General and administrative

 

1,078 

 

 

686 

 

 

3,248 

 

 

2,368 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

 

  

 

 

9 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

 

 

 

 

 

 

Note 4 – Income Taxes

 

The following table summarizes our provision for income taxes and our effective tax rates for the three and nine months ended September 30, 2011 and 2012 (provision for income taxes is in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes

$

22 

 

$

1,079 

 

$

8,799 

 

$

9,160 

Provision for income taxes

$

271 

 

$

874 

 

$

4,335 

 

$

4,525 

Effective tax rate

 

1,231.8% 

 

 

81.0% 

 

 

49.3% 

 

 

49.4% 

 

Our effective tax rates in the three and nine months ended September 30, 2011 and 2012 were higher than statutory federal and state tax rates due primarily to non-deductable lobbying expenses and tax shortfalls related to share-based payments.  

 

During the nine months ended September 30, 2011 and 2012, we utilized excess federal and state tax benefits related to share-based payments, which resulted in increases of $2.7 million and $2.4  million, respectively, in “Additional paid-in capital in the condensed consolidated balance sheets. These amounts are also classified in the condensed consolidated statements of cash flows as both a reduction to operating cash flows and as a financing cash inflow. 

   

  

10 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

 

 

  

 

Note 5 – Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding for the period (excluding shares subject to repurchase). Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all potential dilutive common stock, including options, restricted stock and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted earnings per share by application of the treasury stock method.  

 

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except per share amounts):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

Basic:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common stock shares

 

25,683 

 

 

19,970 

 

 

25,642 

 

 

20,276 

Weighted average number of common stock shares held in treasury

 

(4,629)

 

 

 -

 

 

(4,378)

 

 

(565)

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—basic:

$

(0.01)

 

$

0.01 

 

$

0.21 

 

$

0.24 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

Weighted average number of options

 

 -

 

 

703 

 

 

680 

 

 

750 

Weighted average number of restricted stock units

 

 -

 

 

77 

 

 

30 

 

 

102 

Total common stock shares used in per share calculation

 

21,054 

 

 

20,750 

 

 

21,974 

 

 

20,563 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—diluted:

$

(0.01)

 

$

0.01 

 

$

0.20 

 

$

0.23 

11 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

 

For each of the three and nine months ended September 30, 2011 and 2012, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Common stock options

3,565 

 

1,484 

 

1,909 

 

1,327 

Restricted stock units

538 

 

 -

 

156 

 

 -

Total

4,103 

 

1,484 

 

2,065 

 

1,327 

 

  

 

 

 

Note 6  Geographic Information and Significant Customers

 

Geographic InformationAs of December 31, 2011 and September 30,  2012, our long-lived assets consisted primarily of property and equipment, goodwill and other indefinite-lived intangible assets and finite-lived intangible assets. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area were as follows (in thousands):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of

 

As of

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

United States

$

34,469 

 

$

38,054 

China

 

425 

 

 

286 

Total

$

34,894 

 

$

38,340 

 

Significant Customers—Substantially all revenue for the three and nine months ended September 30, 2011 and 2012 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three and nine months ended September 30, 2011 and 2012 are presented in the table below: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Humana

9% 

 

19% 

 

6% 

 

16% 

WellPoint (1)

11% 

 

13% 

 

12% 

 

13% 

UnitedHealthcare (2)

13% 

 

12% 

 

14% 

 

13% 

 

 

 

 

 

 

 

 

 

(1)

Wellpoint includes other carriers owned by Wellpoint. 

(2)

UnitedHealthcare includes other carriers owned by UnitedHealthcare. 

Commission revenue attributable to major medical individual and family health insurance plans was approximately 86% and 79% of our commission revenue in the three months ended September 30, 2011 and 2012, respectively. Commission revenue attributable to major medical individual and family health insurance plans was approximately 88% and

12 

 


 

Table of Contents 

EHEALTH, INC. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONTINUED 

 

 

78% of our commission revenue in the nine months ended September 30, 2011 and 2012, respectively. We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related health insurance plan offerings or other ancillary products such as small business, short-term, stand-alone dental, life and student insurance plan offerings. 

 

As of December 31, 2011, one customer represented 73% of our $8.1 million outstanding accounts receivable balance. As of September 30, 2012, two customers represented 37% and 14%, respectively, for a combined total of 51%  of our $3.3 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2011 and September 30, 2012. We believe the potential for collection issues with any of our customers is minimal as of September 30, 2012.  

  

 

 

 

 

 

13 

 


 

 

 

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

 

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, among other things, statements regarding our expectations relating to revenue, sources of revenue, profitability, cost of revenue, seasonality, marketing and advertising expenses, customer care and enrollment employees and expenses, technology and content expenses, general and administrative expenses, tax rates and cash outlay for taxes; our future commission rate structure; our intention to perform services for substantially all Medicare leads as a health insurance agent; the seasonality of our business; our potential for collection issues; the timing and amount of our future lease obligations; the impact of health care reform laws on the health insurance industry and on our business; our plans and expectations relating to our Medicare business and factors impacting its success; impact of medical loss ratio regulations and commission rate changes; our expectations and projections relating to membership and commission rates; the timing and source of our Medicare-related revenue; estimates relating to critical accounting policies and related impact on our financial statements; the sufficiency of our cash and cash equivalents; future capital requirements; our projections relating to future revenue growth and earnings per share; our future competitors; expansion into new business areas and additional geographic regions; our need for additional regulatory licenses and approvals; as well as other statements regarding our future operations, financial condition, prospects and business strategies. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report, and in particular, the risks discussed under the heading “Risk Factors” in Part II, Item 1A of this report and those discussed in our other Securities and Exchange Commission filings. The following discussion should be read in conjunction with our Annual Report on Form 10-K as filed with the Securities and Exchange Commission in March 2012, and the audited consolidated financial statements and related notes contained therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. 

 

Overview 

We are the leading online source of health insurance for individuals, families and small businesses. Through our website addresses (www.eHealth.com,  www.eHealthInsurance.com,  www.eHealthMedicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers.  As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process.  

We have invested heavily in technology and content related to our ecommerce platform. We have also invested significant time and resources in obtaining licenses to sell health insurance in all 50 states and the District of Columbia, developing diverse member acquisition programs, obtaining necessary regulatory approvals of our websites and establishing relationships and appointments with over 180 leading insurance carriers, enabling us to offer thousands of health insurance plans online. Our ecommerce platforms can be accessed directly through our website as well as through our network of marketing partners. 

We generate revenue primarily from commissions we receive from health insurance carriers whose health insurance policies are purchased through our ecommerce platform. Commission revenue represented 83% and 85% of total revenue in the three and nine months ended September 30,  2012, respectively, and represented 81%  and 82% of total revenue in the three and nine months ended September 30, 2011. The commission payments we receive for individual and family, small business and ancillary health insurance policies are typically a percentage of the premium on the health insurance policy that we sold and are typically made to us on a monthly basis for as long as the policy remains active with us.  

We actively market the availability of Medicare-related health insurance plans through our and our subsidiary’s online Medicare plan platforms (www.eHealthMedicare.com and www.PlanPrescriber.com). Our Medicare plan platforms enable consumers to research and compare Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Commission payments we receive for Medicare Advantage and Medicare Part D prescription drug plans sold by us are typically fixed and are earned over a period of up to six years, or longer depending on the carrier arrangement, and are paid to us either monthly or annually. Medicare commissions we receive are included in commission revenue. 

14 

 


 

As a result of our commission structure, much of our revenue for a given financial reporting period relates to health insurance plans that we sold prior to the beginning of the period and is recurring in nature. Additionally, health insurance pricing, which is set by the health insurance carrier and approved by regulators, is not subject to negotiation or discounting by health insurance carriers or our competitors. 

In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have and will continue to change the health insurance industry in substantial ways.  Among several other provisions, they include a mandate requiring individuals to be insured or face tax penalties; a mandate that certain employers offer their employees group health insurance coverage or face tax penalties; a requirement that persons 26 years of age and younger be able to stay on a parent’s health insurance plan; prohibitions against insurance companies using pre-existing health conditions as a reason to deny an application for health insurance; establishment of state and/or federal health insurance exchanges to facilitate access to, and the purchase of, health insurance; subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels; minimum requirements for benefits offered under health insurance plans; and medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality and, if they do not, to provide rebates to policyholders. While many aspects of health care reform do not become effective until 2014, health insurance carriers have been required to maintain medical loss ratios of eighty percent in their individual and family health insurance business since the beginning of 2011. The implementation of the medical loss ratio requirements by insurance carriers has resulted in a reduction in the commission rates that we are paid as a result of our selling individual and family health insurance plans. These commission rate changes began to impact our individual and family health insurance plan commission-based revenue in 2011. Beginning in 2014, health insurance carriers offering coverage in the individual or small group health insurance market must ensure that such coverage includes certain minimum health benefits. Individuals are required to hold plans providing minimum essential coverage to meet the mandate for health insurance and avoid a tax penalty. While these minimum benefits have yet to be fully defined by regulation, the Patient Protection and Affordable Care Act lists certain benefits and services as a minimum threshold for coverage, and the Department of Health and Human Services is to define the essential health benefit package so that the scope of benefits is equivalent to that of a typical employer provided health insurance plan. Many of the individual and small group health insurance plans we have sold may not cover all of the minimum essential benefits. Although the impact of the various other provisions of the health care reform laws remains unclear, we continue to prepare for these changes that are expected to become effective in 2014.  

We derive revenue from our online sponsorship and advertising program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee and a performance-based fee based on metrics such as submitted health insurance applications. We also offer Medicare advertising services, which allow Medicare plan carriers to purchase advertising on a separate website developed, hosted and maintained by us. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue over the service period. 

We derive revenue from licensing the use of our health insurance ecommerce technology. Our technology platform enables health insurance carriers and agents to market and distribute health insurance plans online. We have licensed our ecommerce technology for use by government agencies.  

We also derive revenue from referral fees paid to us based on leads generated by our online platforms that are delivered and sold to third parties. In early  2012 we began directly servicing most of the Medicare leads we generated as a health insurance agent, while significantly reducing the number of Medicare leads we sold to third parties.  To the extent that we assist in the sale of Medicare-related insurance plans as a health insurance agent, we generate revenue from commissions we receive from health insurance carriers, rather than one-time referral fees we receive for the sale of Medicare leads. 

 

Sources of Revenue  

 

Commission Revenue  

 

We generate revenue primarily from commissions we receive from health insurance carriers whose health insurance policies are purchased through us. Commissions for individual and family, small business and ancillary health insurance policies sold by us generally represent a percentage of the insurance premium and, to a much lesser extent, commission override payments that insurance carriers pay us for achieving sales volume thresholds or other objectives. Commission rates vary by carrier and by the type of plan purchased by a member. Commission rates can vary based upon the amount of time that the policy has been active, with commission rates for individual and family plans typically being higher in the first

15 

 


 

twelve months of the policy. After the first twelve months, commission rates generally decline significantly. As a result, if we do not add a sufficient number of members on new policies, our revenue growth will be negatively impacted. Individuals, families and small businesses purchasing health insurance through us typically pay their premiums on a monthly basis. Insurance carriers typically pay commissions to us on these policies monthly, after they receive the premium payment from the member. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance policy is cancelled or we otherwise do not remain the agent on the policy. As a result, the majority of our commission revenue is recurring in nature. 

 

Our individual and family health insurance plan commission revenue was adversely impacted in 2011 due to the reduction in the commission rates that we are paid on new policies sold subsequent to the implementation of the medical loss ratio requirements beginning in 2011 as a result of health care reform legislation. Commission rate changes due to the implementation of the medical loss ratio requirements applied prospectively to applicable commissions earned on or after January 1, 2011 and the majority of the changes applied only to commissions earned on new individual and family plan members approved in 2011 and thereafter. We define a member as an individual covered by an insurance plan, including individual and family, Medicare-related, small business and ancillary plans, for which we are entitled to receive compensation. For the majority of individual and family plan members that were approved prior to the effective date of the commission rate changes, we are being paid commissions at the rates in effect prior to the changes. As a result, the adverse impact to our overall individual and family health insurance commission rate structure is phasing in as the number of members approved after the commission rate changes becomes a greater proportion of our individual and family plan membership. Although we expect our overall individual and family health insurance commission rate structure to stabilize by early 2013, our actual future individual and family commission rate structure will depend on the total number of our individual and family plan members, the mix between individual and family plan members approved prior to the commission rate changes and those approved after the changes, any future changes to commission rates and the mix of new approved members by state, health insurance carrier and type of health plan, among other factors. Additionally, other programs that health insurance carriers have supported, such as commission overrides and our sponsorship and advertising programs, have also been reduced as carriers look to reduce costs to comply with the new medical loss ratio requirements.  

 

We generally recognize individual and family, small business and ancillary health insurance plan revenue when commissions are reported to us by a health insurance carrier, net of an estimate for future forfeiture amounts payable to carriers due to policy cancellations. Commissions are reported to us by a cash payment and commission statement.  We generally receive these communications simultaneously. In instances when we receive the cash payment and commission statement separately and in different accounting periods, we recognize revenue in the period that we receive the earliest communication, provided we receive the second corroborating communication shortly after the end of the accounting period. If the second corroborating communication is not received shortly after the end of the accounting period, we recognize revenue in the period the second communication is received. We use the data in the commission statements to help identify the members for which we are receiving a commission payment and the amount received for each member, and to estimate forfeitures payable to carriers. As a result, we recognize the net amount of compensation earned as the agent in the transaction. Commission override revenue, which we recognize on the same basis as premium commissions, is generally reported to us in a more irregular pattern than premium commissions. As a result, our revenue for a particular quarter could be higher or lower than expectations due to the timing of the reporting of commission override revenue to us.  

Commission revenue attributable to major medical individual and family health insurance plans was 79% and 78% of commission revenue in the three and nine months ended September 30, 2012, respectively, compared to 86% and 88% in the three and nine months ended September 30, 2011, respectively. The decline in the three and nine months ended September 30, 2012 was due primarily to an increase in commission revenue attributable to Medicare-related insurance plans and to a decrease in individual and family health insurance plans commission revenue as a result of a decrease in commission rates we are paid on those plans. Major medical individual and family health insurance plans do not include small business or Medicare-related health insurance plan offerings and do not include other ancillary products such as stand-alone dental, life, vision and short-term insurance plan offerings. 

We actively market the availability of Medicare-related insurance plans through our online Medicare plan platforms (www.eHealthMedicare.com and www.PlanPrescriber.com). These platforms enable consumers to research and compare Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. We offer online application and telephonic enrollment capabilities for certain Medicare plans. To the extent that we assist in the sale of Medicare-related insurance plans as a health insurance agent, through either online applications or telephonically, we generate revenue from commissions we receive from health insurance carriers. The commission payments we receive for Medicare Supplement plans are typically a percentage of the premium on the policy that we sold and are paid to us on a monthly basis for as long as a policy remains active with us. For both Medicare Advantage and

16 

 


 

Medicare Part D prescription drug plans, we receive a fixed, annual commission from insurance carriers after the policy is approved by the carrier and either a fixed, monthly commission beginning with and subsequent to the second policy year for a Medicare Advantage policy or a fixed, annual commission beginning with and subsequent to the second policy year for a Medicare Part D prescription drug policy. We may earn commission revenue for both Medicare Advantage and Medicare Part D prescription drug plans typically for a period of up to six years, or longer depending on the carrier arrangement, provided that the policy remains active with us. 

We recognize commission revenue for both Medicare Advantage and Medicare Part D prescription drug plans for the entire policy year once the annual or first monthly commission amount for the policy year is reported to us by the carrier, net of an estimate for future forfeiture amounts due to policy cancellations. For commissions paid to us on a monthly basis, we record a receivable for the commission amounts to be received over the remainder of the policy year, net of an estimate for commission amounts not expected to be collected due to policy cancellations, which is included in “Accounts receivable in the accompanying condensed consolidated balance sheets.  We continue to receive the commission payments from the relevant insurance carrier until the earlier of our being notified that the health insurance policy has been cancelled, our no longer remaining the agent on the policy, or our commission term with the carrier expires, typically up to six years from the effective date of the policy. We determine that there is persuasive evidence of an arrangement when we have a commission agreement with a health insurance carrier. Our services are complete when a carrier has approved an application in the initial year and when a member has renewed in a renewal year. The seller’s price is fixed or determinable and collectibility is reasonably assured when a carrier has approved an application and the carrier reports to us the annual or first monthly renewal commission amount for each policy year. 

We expect to recognize a majority of our first year Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the fourth quarter of each year as a result of the Medicare annual enrollment period, which occurs in the fourth quarter of each year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year.     

 

We expect commission revenue to increase in absolute dollars in 2012 compared to 2011, primarily as a result of an increase in Medicare-related commission revenue. 

 

Other Revenue  

 

In addition to the commission revenue we derive from the sale of health insurance plans, we derive other revenue from our online sponsorship and advertising program, from licensing the use of our ecommerce technology and from generating and delivering leads, primarily for Medicare plans. 

Online Sponsorship and Advertising.     We derive revenue from our online sponsorship and advertising program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee and a performance-based fee based on metrics such as submitted health insurance applications. We also offer advertising services for our Medicare plan carriers to purchase advertising on a separate website developed, hosted and maintained by us. In these instances, we are typically paid a fixed, up-front fee, which we recognize as revenue over the service period. 

Technology Licensing.     We derive revenue from licensing the use of our health insurance ecommerce technology. Our technology platform enables health insurance carriers and agents to market and distribute health insurance plans online.  In our technology licensing business, we are paid implementation fees and performance-based fees that are based on metrics such as submitted health insurance applications. Typically, we are paid a one-time implementation fee commencing once the technology is available for use by the third party. In addition, we generate revenue based on performance criteria that are either measured based on data tracked by us, or based on data tracked by the third party. In instances where the performance criteria data are tracked by us, we recognize revenue in the period of performance. In instances where the performance criteria data are tracked by the third party, we recognize revenue when the amounts earned are fixed or determinable and collection is reasonably assured. Typically, this occurs through our receipt of a cash payment from the third party along with a detailed statement containing the data that is tracked by the third party. 

 Medicare Lead Referral.   Our online Medicare plan platforms (www.eHealthMedicare.com and www.PlanPrescriber.com) enable consumers to research and compare Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. The Medicare-related revenue we have generated includes referral fees paid to us based on Medicare leads generated by our online platforms that are delivered and sold to third parties. The majority of our lead referral revenue has been generated during the Medicare annual enrollment

17 

 


 

period, which occurs during the fourth quarter of the calendar year. In the second quarter of 2012, we  began to perform services for substantially all Medicare leads ourselves as a health insurance agent, for which we are entitled to receive commissions. As a result, our Medicare lead referral revenue has declined substantially. In the future, we intend to continue to perform services for substantially all Medicare leads ourselves as a health insurance agent. 

We expect other revenue to decline in absolute dollars in 2012 compared to 2011 due primarily to a  decrease in Medicare lead referral revenue as a result of our strategic decision to directly service most of the Medicare leads we generate as a health insurance agent, while significantly reducing the number of Medicare leads we sell to third parties. As a result of this decision, we expect Medicare-related commission revenue to increase in 2012. We expect the decline in Medicare lead referral revenue to be partially offset by an increase in online sponsorship and advertising revenue.  

 

Member Acquisition  

 

An important factor in our revenue growth is the growth of our member base. Our marketing initiatives are an important component of our strategy to grow our member base and are focused on three primary member acquisition channels: direct, marketing partners and online advertising. Our marketing initiatives are primarily designed to encourage consumers to complete an application for health insurance. In addition, we may refer Medicare-eligible individuals to third parties who may assist them in enrolling in a Medicare plan. Our marketing channels are as follows: 

 

Direct.    Our direct member acquisition channel consists of consumers who access our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com and www.PlanPrescriber.com) either directly or through algorithmic natural search listings on Internet search engines and directories. For the three months ended September  30, 2011 and 2012, applications submitted through us for individual and family health insurance from our direct channel constituted 44% and 48%, respectively, of all individual and family health insurance applications submitted on our website. For the nine months ended September  30, 2011 and 2012, applications submitted through us for individual and family health insurance from our direct channel constituted 44% and 46%, respectively, of all individual and family health insurance applications submitted on our website. 

 

Marketing Partners.    Our marketing partner member acquisition channel consists of consumers who access our websites through a network of affiliate partners and financial services and other companies. Growth in our marketing partner channel depends upon our expanding marketing programs with existing partners and adding new partners to our network.  For the three months ended September 30,  2011 and 2012, applications submitted through us for individual and family health insurance plans from our marketing partner member acquisition channel constituted approximately 33% and 31%, respectively, of all individual and family health insurance applications submitted on our website. For the nine months ended September 30, 2011 and 2012, applications submitted through us for individual and family health insurance plans from our marketing partner member acquisition channel constituted approximately 32% and 32%, respectively, of all individual and family health insurance applications submitted on our website. 

 

Online Advertising.    Our online advertising member acquisition channel consists of consumers who access our websites through paid keyword search advertising from search engines such as Google, Bing and Yahoo!, as well as various Internet marketing programs such as banner advertising and email marketing. For the three months ended September 30, 2011 and 2012, applications submitted through us for individual and family health insurance plans from our online advertising channel constituted approximately 23% and 20%, respectively, of all individual and family health insurance applications submitted on our website. For the nine months ended September 30, 2011 and 2012, applications submitted through us for individual and family health insurance plans from our online advertising channel constituted approximately 24% and 22%, respectively, of all individual and family health insurance applications submitted on our website. 

 

In addition to our marketing channels, we have acquired individual and family as well as Medicare members through transactions with broker partners, whereby these brokers have transferred certain of their existing individual and family plan and Medicare plan members to us as the broker of record on the underlying policies. 

 

Operating Costs and Expenses  

 

Cost of Revenue  

 

Included in cost of revenue are payments related to health insurance policies sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements. In order to enter into a revenue-sharing

18 

 


 

arrangement, marketing partners must be licensed to sell health insurance in the state where the policy is sold. Costs related to revenue-sharing arrangements are expensed as the related revenue is recognized.  

 

In the three and nine months ended September 30, 2011, cost of revenue also included direct labor and other direct costs incurred in connection with a contract with the federal government, the term of which expired in January 2012. 

 

Additionally, cost of revenue includes the amortization of consideration we paid to certain broker partners in connection with the transfer of their health insurance members to us as the new broker of record on the underlying policies. These transfers include primarily Medicare plan members. Total consideration paid in connection with these transfers amounted to $6.2 million during the nine months ended September 30, 2012. Consideration for all book-of-business transfers is being amortized to cost of revenue as we recognize commission revenue related to the transferred members over a period of up to five years for each arrangement. 

 

We expect cost of revenue to decrease in absolute dollars in 2012 compared to 2011 due to a decrease in direct labor and other direct costs incurred in connection with the expiration of a contract with the federal government in January 2012, partially offset by an increase in amortization of the consideration we paid in connection with the transfer of certain Medicare members to us from a partner. 

 

Marketing and Advertising  

 

Marketing and advertising expenses consist primarily of member acquisition expenses associated with our direct, marketing partner and online advertising member acquisition channels, in addition to compensation and other expenses related to marketing, business development, partner management, public relations and carrier relations personnel who support our offerings. Our direct channel expenses primarily consist of costs for e-mail marketing and may also include costs for television advertising, radio advertising, print advertising, direct mail and email marketing. 

 

Our marketing partner channel expenses consist primarily of fees paid to marketing partners with which we have a relationship. We compensate a significant number of our marketing partners by paying a fee each time a consumer referral from a partner results in a submitted health insurance application, regardless of whether the consumer’s application is approved by the health insurance carrier. Many of our marketing partners have tiered arrangements in which the amount of the fee increases as the volume of submitted applications we receive from the marketing partner increases over a particular period. We recognize these expenditures in the period when a marketing partner’s referral results in the submission of a health insurance application. The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening in individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter.  Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our website, those expenses are influenced by these patterns. In addition, because the total volume of submitted applications that we receive from our marketing partners is largely outside of our control, particularly during any short-term period, and because of our tiered marketing partner arrangements, we could incur expenses in excess of, or below, the amounts we had planned in periods of rapid change in the volume of submitted applications from marketing partner referrals. An unanticipated increase in submitted applications resulting from marketing partner referrals could cause our net income to be lower than our expectation, since the revenue to be derived from submitted applications that are approved by health insurance carriers will not be recognized until future periods. 

  

Paid keyword search advertising on search engines represents the majority of expenses in our online advertising channel. We incur expenses associated with search engine advertising in the period in which the consumer clicks on the advertisement.  Similar to our marketing partner channel, expenses in our online advertising channel will increase or decrease in relation to any increase or decrease in consumers referred to our website as a result of search engine advertising.  For example, due to the substantial increase in the number of consumers referred to our website from paid keyword search advertising during the Medicare annual enrollment period in the fourth quarter of 2011, we experienced a significant increase in online advertising expenses during the fourth quarter of 2011 compared to other quarters in 2011. We also increased our discretionary spending for Medicare plan-related online advertising in the third and fourth quarters of 2011, compared to first and second quarters, in conjunction with the Medicare annual enrollment period in the fourth quarter of 2011. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our discretionary online advertising expenses had a negative impact on our profitability during the third quarter of 2011. We expect these seasonal patterns to occur again in 2012.  

19 

 


 

We expect our marketing and advertising expenses to increase in absolute dollars in 2012 compared to 2011 due to an increase in our Medicare-related online marketing and advertising expenditures during 2012, including paid keyword search advertising. 

  

Customer Care and Enrollment  

Customer care and enrollment expenses primarily consist of compensation and benefits costs for personnel engaged in pre-sales assistance to applicants who call our customer care center and for enrollment personnel who assist applicants during the underwriting process. In the third quarters of 2011 and 2012, we hired, trained and obtained health insurance licenses and health insurance carrier appointments for additional employees in our customer care centers to service the increase in the volume of Medicare leads we received in the fourth quarter as a result of the Medicare annual enrollment period. Many of these additional customer care center employees were temporary and their employment will end at or near the conclusion of the Medicare annual enrollment period in December. As a result of our temporary customer care center staffing requirements, we expect our customer care and enrollment costs to be higher in the third and fourth quarters of each year compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs incurred in the third quarters of both 2011 and 2012 had a significant negative impact on our profitability during those quarters.  We have experienced these seasonal trends during first three quarters of 2012 and we expect they will continue in the fourth quarter of 2012 and in future years.   

We expect customer care and enrollment expenses to increase in absolute dollars and as a percentage of total revenue in 2012 compared to 2011 as a result of additional personnel we expect to hire to service the expected increase in the volume of Medicare demand in 2012 and due to an increase in expenditures to develop and expand our Medicare plan sales capabilities. 

 

Technology and Content  

 

Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. A majority of our technology and content group is located at our wholly-owned subsidiary in China, where technology development costs are generally lower than in the United States.  

 

We expect technology and content expenses to remain relatively flat in absolute dollars in 2012 compared to 2011. 

 

General and Administrative  

 

General and administrative expenses include compensation and benefits costs for staff working in our executive, finance, corporate development, investor relations, government affairs, legal, human resources, internal audit, facilities and internal information technology departments. These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs and information technology fees.  

 

We expect our general and administrative expenses to remain relatively flat in absolute dollars and to decline as a percentage of total revenue in 2012 compared to 2011 due primarily to an increase in total revenue while general and administrative expenses remain relatively flat. 

20 

 


 

 

Summary of Selected Metrics 

 

The following table shows certain selected quarterly metrics as of September 30, 2011 and 2012 and for the three months ended September 30, 2011 and 2012: 

 

 

 

 

 

 

 

 

 

 

 

 

 

Key Metrics:

Three Months Ended September 30, 2011

 

Three Months Ended September 30, 2012

 

 

 

 

 

Operating cash flows (1)

$

5,413,000 

 

$

6,928,000 

 

 

 

 

 

 

IFP submitted applications (2)

 

114,800 

 

 

120,100 

 

 

 

 

 

 

IFP approved members (3)

 

95,400 

 

 

99,500 

Total approved members (4)

 

140,300 

 

 

174,500 

 

 

 

 

 

 

Commission revenue (5)

$

28,206,000 

 

$

31,291,000 

Commission revenue per estimated member for the period (6)

$

34.94 

 

$

34.70 

 

 

 

 

 

 

Total revenue (7)

$

34,787,000 

 

$

37,586,000 

Total revenue per estimated member for the period (8)

$

43.09 

 

$

41.68 

 

 

 

 

 

 

 

As of

 

As of

 

September 30, 2011

 

September 30, 2012

 

 

 

 

 

 

IFP estimated membership (9)

 

683,400 

 

 

698,600 

Total estimated membership (10)

 

810,400 

 

 

926,600 

 

 

 

 

 

 

 

Three Months Ended September 30, 2011

 

Three Months Ended September 30, 2012

 

 

 

 

 

 

Marketing and advertising expenses (11)

$

13,826,000 

 

$

13,988,000 

Marketing and advertising expenses as a percentage of total revenue (12)

 

40% 

 

 

37% 

 

 

 

 

 

 

Other Metrics:

 

 

 

 

 

 

 

 

 

 

 

Source of IFP submitted applications (as a percentage of total IFP applications for the period):

 

 

 

 

 

Direct (13)

 

44% 

 

 

48% 

Marketing partners (14)

 

33% 

 

 

32% 

Online advertising (15)

 

23% 

 

 

20% 

Total

 

100% 

 

 

100% 

21 

 


 

 

Notes: 

 

 

 

(1)

Net cash provided by operating activities for the period from the condensed consolidated statements of cash flows.

(2)

IFP applications submitted on eHealth’s website during the period. Applications are counted as submitted when the applicant completes the application, provides a method for payment and clicks the submit button on our website and submits the application to us. The applicant generally has additional actions to take before the application will be reviewed by the insurance carrier, such as providing additional information and providing an electronic signature. In addition, an applicant may submit more than one application. We include applications for IFP plans for which we receive commissions as well as other forms of payment. We define our “IFP” offerings as major medical individual and family health insurance plans, which does not include small business, short-term, stand-alone dental, life, student or Medicare-related health insurance plans.

(3)

New IFP members reported to eHealth as approved during the period. Some members that are approved by a carrier do not accept the approval and therefore do not become paying members.

(4)

New members for all plans, including Medicare plans, reported to eHealth as approved during the period. Some members that are approved by a carrier do not accept the approval and therefore do not become paying members.

(5)

Commission revenue (from all sources) recognized during the period from the condensed consolidated statements of comprehensive income (loss).

(6)

Calculated as commission revenue recognized during the period (see note (5) above) divided by average estimated membership for the period (calculated as beginning and ending estimated membership for all plans for the period, divided by two).

(7)

Total revenue (from all sources) recognized during the period from the condensed consolidated statements of comprehensive income (loss).

(8)

Calculated as total revenue recognized during the period (see note (7) above) divided by average estimated membership for the period (calculated as beginning and ending estimated membership for all plans for the period, divided by two).

(9)

Estimated number of members active on IFP insurance policies as of the date indicated.

(10)

Estimated number of members active on all insurance policies, including Medicare policies, as of the date indicated.

(11)

Marketing and advertising expenses for the period from the condensed consolidated statements of comprehensive income (loss).

(12)

Calculated as marketing and advertising expenses for the period (see note (11) above) divided by total revenue for the period (see note (7) above).

(13)

Percentage of IFP submitted applications from applicants who came directly to the eHealth website through algorithmic search engine results or otherwise. See note (2) above for further information as to what constitutes a submitted application.

(14)

Percentage of IFP submitted applications from applicants sourced through eHealth’s network of marketing partners. See note (2) above for further information as to what constitutes a submitted application.

(15)

Percentage of IFP submitted applications from applicants sourced through paid search and other online advertising activities. See note (2) above for further information as to what constitutes a submitted application.

 

Our insurance carrier partners bill and collect insurance premiums paid by our members. Carrier partners do not report to us the number of members that we have as of a given date. The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date. We estimate the number of continuing members on all policies other than small business insurance policies as of a specific date by taking the sum of (i) the number of members for whom we have received or applied a commission payment for the month that is six months (or three months in the case of Medicare, short-term, student and dental insurance) prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over, as applicable, the three-month or six-month period); and (ii) the number of approved members over the six-month period (or three months in the case of Medicare, short-term, student and dental insurance) prior to the date of estimation (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). We estimate the number of small business group members using the number of initial members at the time the group is approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier in the period it is reported. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us. Additionally, our carrier partners often do not communicate this information to us. We often are made aware of policy cancellations at the time of annual renewal and update our membership statistics accordingly in the period they are reported. 

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an

22 

 


 

active member of ours. For instance, we reconcile information carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated our membership. Conversely, carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. We reflect updated information regarding our membership in the membership estimate for the current period that we are estimating, if applicable. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernable over periods longer than from one quarter to the next. In addition, and as a result of the delay we experience in receiving information about our membership, it is difficult for us to determine with any certainty the impact of current economic and other conditions on our membership retention.  

Critical Accounting Policies and Estimates  

 

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, requires us to make judgments, assumptions, and estimates that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. These estimates and assumptions are based on current facts, historical experience, and various other factors that we believe are reasonable under the circumstances to determine reported amounts of assets, liabilities, revenue and expenses that are not readily apparent from other sources. To the extent there are material differences between our estimates and the actual results, our future consolidated results of operations may be affected. 

 

An accounting policy is considered to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the effect of the estimates and assumptions on financial condition or operating performance. The accounting policies we believe to reflect our more significant estimates, judgments and assumptions and are most critical to understanding and evaluating our reported financial results are as follows:   

 

"

Revenue Recognition; 

"

Stock-Based Compensation;   

"

Goodwill and Intangible Assets; and 

"

Accounting for Income Taxes. 

During the nine months ended September 30, 2012, there were no significant changes to our critical accounting policies and estimates. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2011, for a complete discussion of our critical accounting policies and estimates. 

23 

 


 

 

Results of Operations  

 

The following table sets forth our operating results and the related percentage of total revenues for the three and nine months ended September 30, 2011 and 2012 (dollars in thousands):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2011

 

2012

 

2011

 

2012

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commission

$

28,206 

 

81 

%

$

31,291 

 

83 

%

$

89,045 

 

82 

%

$

93,358 

 

85 

%

Other

 

6,581 

 

19 

 

 

6,295 

 

17 

 

 

19,483 

 

18 

 

 

16,810 

 

15 

 

Total revenue

 

34,787 

 

100 

 

 

37,586 

 

100 

 

 

108,528 

 

100 

 

 

110,168 

 

100 

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

1,781 

 

 

 

1,099 

 

 

 

6,987 

 

 

 

3,538 

 

 

Marketing and advertising

 

13,826 

 

40 

 

 

13,988 

 

37 

 

 

38,403 

 

35 

 

 

39,142 

 

36 

 

Customer care and enrollment

 

6,245 

 

18 

 

 

8,823 

 

23 

 

 

16,265 

 

15 

 

 

21,152 

 

19 

 

Technology and content

 

5,548 

 

16 

 

 

5,503 

 

15 

 

 

16,433 

 

15 

 

 

16,018 

 

15 

 

General and administrative

 

6,917 

 

20 

 

 

6,744 

 

18 

 

 

20,299 

 

19 

 

 

19,938 

 

18 

 

Amortization of intangible assets

 

427 

 

 

 

354 

 

 

 

1,281 

 

 

 

1,261 

 

 

Total operating costs and expenses

 

34,744 

 

100 

 

 

36,511 

 

97 

 

 

99,668 

 

92 

 

 

101,049 

 

92 

 

Income from operations

 

43 

 

 

 

1,075 

 

 

 

8,860 

 

 

 

9,119 

 

 

Interest and other income (expense), net

 

(21)

 

(0)

 

 

 

 

 

(61)

 

(0)

 

 

41 

 

 

Income before provision for income taxes

 

22 

 

 

 

1,079 

 

 

 

8,799 

 

 

 

9,160 

 

 

Provision for income taxes

 

271 

 

 

 

874 

 

 

 

4,335 

 

 

 

4,525 

 

 

Net income (loss)

$

(249)

 

(1)

%

$

205 

 

%

$

4,464 

 

%

$

4,635 

 

%

Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and advertising

$

252 

 

$

330 

 

$

774 

 

$

932 

Customer care and enrollment

 

83 

 

 

90 

 

 

264 

 

 

243 

Technology and content

 

411 

 

 

233 

 

 

1,336 

 

 

784 

General and administrative

 

1,078 

 

 

686 

 

 

3,248 

 

 

2,367 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

 

24 

 


 

 

Three and Nine Months Ended September  30, 2011 and 2012 

 

Revenue  

The following table presents our commission, other revenue and total revenue and the absolute dollar and percentage changes from the comparable prior year periods (dollars in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commission

$

28,206 

 

$

31,291 

 

$

3,085 

 

11% 

 

$

89,045 

 

$

93,358 

 

$

4,313 

 

5% 

Percentage of total revenue

 

81% 

 

 

83% 

 

 

 

 

 

 

 

82% 

 

 

85% 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

$

6,581 

 

$

6,295 

 

$

(286)

 

(4%)

 

$

19,483 

 

$

16,810 

 

$

(2,673)

 

(14%)

Percentage of total revenue

 

19% 

 

 

17% 

 

 

 

 

 

 

 

18% 

 

 

15% 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue

$

34,787 

 

$

37,586 

 

$

2,799 

 

8% 

 

$

108,528 

 

$

110,168 

 

$

1,640 

 

2% 

 

Three Months Ended September 30, 2012 and 2011Commission revenue increased $3.1 million, or 11%, in the three months ended September 30,  2012 compared to the three months ended September 30,  2011,  due primarily to a  $2.2 million increase in Medicare-related commission revenue, which was driven by an increase in Medicare plans sold through us.  Additionally, commission revenue related to ancillary health insurance products, primarily dental, accident and vision health insurance increased substantially. 

  

Other revenue decreased $0.3 million, or 4%, in the three months ended September 30,  2012 compared to the three months ended September 30, 2011, due primarily to a $1.4 million decrease in revenue related to our government systems business and a $2.0 million decrease in Medicare-related health insurance product lead referral revenue. Our government systems business revenue was adversely impacted by the expiration of our technology licensing contract with the federal government in January 2012. The decrease in lead referral revenue was the result of our strategic decision to reduce the number of Medicare leads sold to third parties and to instead act as a health insurance agent to those leads. These decreases in other revenue were partially offset by  a  $3.1 million increase in online sponsorship and advertising revenue, primarily related to Medicare plan carriers. 

 

Nine Months Ended September 30, 2012 and 2011—Commission revenue increased $4.3 million, or 5%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011,  due primarily to a  $8.4 million increase in Medicare-related commission revenue. Partially offsetting this increase was a $4.1 million decrease in non-Medicare commission revenue, primarily individual and family health insurance commission revenue, due to a reduction in the commission rates we are paid on individual and family health insurance policies as a result of the implementation of the medical loss ratio requirements by insurance carriers.  

 

Other revenue decreased $2.7 million, or 14%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011, due primarily to a $5.5 million decrease in revenue related to our government systems business and a $4.2 million decrease in Medicare-related health insurance product lead referral revenue. Partially offsetting these decreases was a  $6.8 million increase in online sponsorship and advertising revenue, primarily related to Medicare plan carriers. 

 

25 

 


 

 

Operating Costs and  Expenses 

 

Cost of Revenue 

The following table presents our cost of revenue and the dollar and percentage change from the comparable prior year periods (dollars in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

$

1,781 

 

$

1,099 

 

$

(682)

 

(38%)

 

$

6,987 

 

$

3,538 

 

$

(3,449)

 

(49%)

Percentage of total revenue

 

5% 

 

 

3% 

 

 

 

 

 

 

 

6% 

 

 

3% 

 

 

 

 

 

 

Three Months Ended September 30, 2012 and 2011Cost of revenue decreased $0.7 million, or 38%, in the three months ended September 30,  2012 compared to the three months ended September 30,  2011,  due primarily to a decrease of $1.2 million in costs related to our technology licensing contract with the federal government,  which expired in January 2012, partially offset by an increase of $0.5 million  in amortization expense associated with the consideration paid in connection with several transactions in which we acquired broker of record status on a number of Medicare health insurance plans.   

 

Nine Months Ended September 30, 2012 and 2011Cost of revenue decreased $3.4 million, or 49%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011,  due primarily to a decrease of $4.7 million in costs related to our technology licensing contract with the federal government and a $0.4 million decrease in revenue-sharing expenses with partners, partially offset by an increase of $2.4 million in amortization expense associated with the consideration paid in connection with several transactions in which we acquired broker of record status on a number of Medicare health insurance plans.  

 

Marketing and Advertising  

The following table presents our marketing and advertising expenses and the dollar and percentage change from the comparable prior year periods (dollars in thousands):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and advertising

$

13,826 

 

$

13,988 

 

$

162 

 

1% 

 

$

38,403 

 

$

39,142 

 

$

739 

 

2% 

Percentage of total revenue

 

40% 

 

 

37% 

 

 

 

 

 

 

 

35% 

 

 

36% 

 

 

 

 

 

Three Months Ended September 30, 2012 and 2011Marketing and advertising expenses increased $0.2 million, or 1%, in the three months ended September 30, 2012 compared to the three months ended September 30, 2011,  due primarily to an increase of $0.6 million in compensation, benefits, stock-based compensation and other personnel costs. Additionally, fees we pay to marketing partners for referrals that result in the submission of a health insurance application on our website increased. Partially offsetting these increases was a decrease in online advertising costs of $0.6 million. In the three months ended September 30, 2012, we directed a larger portion of our online advertising spending to Medicare-related plans and away from individual and family plans. 

 Nine Months Ended September 30, 2012 and 2011Marketing and advertising expenses increased $0.7 million, or 2%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011, due primarily to an increase of $0.8 million in compensation, benefits, stock-based compensation and other personnel costs. Additionally, fees we pay to marketing partners for referrals that result in the submission of a health insurance application on our website increased $0.5 million. Partially offsetting these increases was a decrease in online advertising costs of $0.5 million as we 

26 

 


 

directed a larger portion of our online advertising spending to Medicare-related plans and away from individual and family plans while decreasing our overall level of online spending. 

 

27 

 


 

 

Customer Care and Enrollment  

The following table presents our customer care and enrollment expenses and the dollar and percentage change from the comparable prior year periods (dollars in thousands):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer care and enrollment

$

6,245 

 

$

8,823 

 

$

2,578 

 

41% 

 

$

16,265 

 

$

21,152 

 

$

4,887 

 

30% 

Percentage of total revenue

 

18% 

 

 

23% 

 

 

 

 

 

 

 

15% 

 

 

19% 

 

 

 

 

 

 

Three Months Ended September 30, 2012 and 2011Customer care and enrollment expenses increased $2.6 million, or 41%, in the three months ended September 30, 2012 compared to the three months ended September 30,  2011, due primarily to additional customer care center personnel hired to service the increase in volume of Medicare leads serviced directly by us as a health insurance agent. As a result, compensation, benefits, stock-based compensation and other personnel costs increased $1.9 million and insurance licensing costs increased $0.3 million. Additionally, costs related to customer call center telephonic equipment, as well as telephone expense, increased $0.4 million. 

 

Nine Months Ended September 30, 2012 and 2011Customer care and enrollment expenses increased $4.9 million, or 30%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011, due primarily to additional customer care center personnel hired to service the increase in volume of Medicare leads serviced directly by us as a health insurance agent. As a result, compensation, benefits, stock-based compensation and other personnel costs increased $3.7 million and insurance licensing costs increased $0.6 million. Additionally, costs related to customer call center telephonic equipment, as well as telephone expense, increased $0.6 million. 

 

Technology and Content  

The following table presents our technology and content expenses and the dollar and percentage change from the comparable prior year periods (dollars in thousands):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Technology and content

$

5,548 

 

$

5,503 

 

$

(45)

 

(1%)

 

$

16,433 

 

$

16,018 

 

$

(415)

 

(3%)

Percentage of total revenue

 

16% 

 

 

15% 

 

 

 

 

 

 

 

15% 

 

 

15% 

 

 

 

 

 

 

Three Months Ended September 30, 2012 and 2011Technology and content expenses decreased in the three months ended September 30, 2012 compared to the three months ended September 30,  2011, due to a decrease in compensation, benefits, stock-based compensation and other personnel costs.  

 

Nine Months Ended September 30, 2012 and 2011Technology and content expenses decreased $0.4 million, or 3%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011, due primarily to a decrease of $0.7 million in compensation, benefits, stock-based compensation and other personnel costs. Partially offsetting this decrease was a $0.3 million increase in internet and data center infrastructure costs.  

28 

 


 

 

General and Administrative  

The following table presents our general and administrative expenses and the dollar and percentage change from the comparable prior year periods (dollars in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

$

6,917 

 

$

6,744 

 

$

(173)

 

(3%)

 

$

20,299 

 

$

19,938 

 

$

(361)

 

(2%)

Percentage of total revenue

 

20% 

 

 

18% 

 

 

 

 

 

 

 

19% 

 

 

18% 

 

 

 

 

 

 

Three Months Ended September 30, 2012 and 2011General and administrative expenses decreased $0.2 million, or 3%, in the three months ended September 30, 2012 compared to the three months ended September 30, 2011, due primarily to a decrease of $0.4 million in lobbying fees, partially offset by an increase in rent expense.   

 

Nine Months Ended September 30, 2012 and 2011General and administrative expenses decreased $0.4 million, or 2%, in the nine months ended September 30, 2012 compared to the nine months ended September 30, 2011, due primarily to a decrease of $0.5 million in lobbying fees and a  $0.2 million decrease in compensation, benefits, stock-based compensation and other personnel costs. Partially offsetting these decreases was an increase in rent expense. 

 

Amortization of Intangible Assets 

 

Three and Nine Months Ended September 30, 2012 and 2011Amortization expense related to intangible assets purchased through our acquisition of PlanPrescriber remained relatively flat in the three and nine months ended September 30, 2012 compared to the three and nine months ended September 30, 2011, respectively.   

 

Other Income  (Expense), Net  

The following table presents our other income  (expense), net, and the dollar and percentage change from the comparable prior year periods (dollars in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Change

 

Nine Months Ended September 30,

 

Change

 

2011

 

2012

 

$

 

%

 

2011

 

2012

 

$

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

$

(21)

 

$

 

$

25 

 

119% 

 

$

(61)

 

$

41 

 

$

102 

 

167% 

Percentage of total revenue

 

(0%)

 

 

0% 

 

 

 

 

 

 

 

(0%)

 

 

0% 

 

 

 

 

 

 

Three and Nine Months Ended September 30, 2012 and 2011Other income (expense), net increased in the three and nine months ended September 30, 2012 compared to the three and nine months ended September 30,  2011, respectively, due primarily to a decrease in investment management fees. Administrative bank fees, management fees and interest expense on our capital lease obligations more than offset interest earned on our invested cash in the three and nine months ended September 30, 2011.   

 

Provision for Income Taxes  

The following table presents our provision for income taxes and the dollar change from the comparable prior year periods (dollars in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

 

 

 

Nine Months Ended September 30,

 

 

 

 

2011

 

2012

 

Change $

 

2011

 

2012

 

Change $

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

$

271 

 

$

874 

 

$

603 

 

$

4,335 

 

$

4,525 

 

$

190 

Percentage of total revenue

 

1% 

 

 

2% 

 

 

 

 

 

4% 

 

 

4% 

 

 

 

Effective tax rate

 

1,231.8% 

 

 

81.0% 

 

 

 

 

 

49.3% 

 

 

49.4% 

 

 

 

29 

 


 

 

 

Three Months Ended September 30, 2012 and 2011In the three months ended September 30, 2011 and 2012, we recorded a provision for income taxes of $0.3 million and $0.9 million,  respectively, representing effective tax rates of 1,231.8% and 81.0%, respectively. Our effective tax rates for the three months ended September 30, 2011 and 2012 were higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses and tax shortfalls related to share-based payments.  

 

Nine Months Ended September 30, 2012 and 2011In the nine months ended September 30, 2011 and 2012, we recorded provisions for income taxes of $4.3 million and $4.5 million, respectively, representing effective tax rates of 49.3% and 49.4%, respectively. Our effective tax rates for the nine months ended September 30,  2011 and 2012  were higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses and tax shortfalls related to share-based payments. 

 

Liquidity and Capital Resources  

 

At September 30, 2012, our cash and cash equivalents totaled $130.8 million. Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, primarily consist of money market funds. At December 31, 2011, our cash and cash equivalents totaled $123.6 million.  

On September 10, 2012, we announced that our board of directors approved a stock repurchase program authorizing us to purchase up to an additional $30.0 million of our common stock. Purchases under this program may be made in the open market or unsolicited negotiated transactions and are expected to comply with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing of the purchases and the exact number of shares to be purchased will depend upon market conditions. The program does not require us to acquire a specific number of shares, and the program may be suspended from time to time or discontinued at any time. The cost of the repurchased shares will be funded from available working capital. 

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method.  

Stock repurchase activity under our stock repurchase programs during the nine months ended September 30, 2012 is summarized as follows (dollars in thousands, except share and per share amounts): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Number of Shares Purchased

 

Average Price Paid per Share (2)

 

Amount of Repurchase

Cumulative balance at December 31, 2011 (1)

5,797,806 

 

$

14.07 

 

$

81,557 

Repurchases of common stock

554,284 

 

$

15.23 

 

 

8,441 

Cumulative balance at September 30, 2012 (1)

6,352,090 

 

$

14.17 

 

$

89,998 
(1)

Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.  

(2)  Average price paid per share includes commissions. 

In addition to the 6.4 million shares repurchased under our repurchase programs as of September 30, 2012, we have in treasury 0.2 million shares that were surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2011 and September 30,  2012, we had a total of 5.9 million shares and 6.5 million shares, respectively, held in treasury. 

  

30 

 


 

The following table presents a summary of our cash flows for the nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

2011

 

2012

 

 

 

 

 

 

Net cash provided by operating activities

$

20,004 

 

$

19,653 

Net cash used in investing activities

$

(5,838)

 

$

(9,371)

Net cash used in financing activities

$

(15,709)

 

$

(3,091)

 

Operating Activities 

 

Cash provided by operating activities primarily consists of net income, adjusted for certain non-cash items including deferred income taxes, depreciation and amortization, including amortization of intangible assets, stock-based compensation expense, excess tax benefits from stock-based compensation, and the effect of changes in working capital and other activities.  

 

The timing of the recognition of our commission revenue depends upon the timing of our receipt of commission reports and associated commission payments from health insurance carriers. If we were to experience a delay in receiving a commission payment from a health insurance carrier at the end of a quarter, our operating cash flows for that quarter could be adversely impacted. Additionally, commission override payments are reported to us in a more irregular pattern than premium commissions. For example, a carrier may make a commission override payment to us on an annual basis, which would positively impact our cash flows in the quarter the payment is received. The majority of our annual commission override payments is typically received during the first quarter of the year.  

 

Historically, we have experienced a reduction in operating cash flows during the first quarter of the year compared to the other quarters due to the payment of annual performance bonuses to employees in the first quarter of the year. In the first quarter of 2012, we collected a substantial amount of lead referral payments related to Medicare leads sold during the annual enrollment period in the fourth quarter of 2011. The seasonal impact of Medicare lead referral collections is expected to be minimal in 2013 as we transition away from lead referral transactions. A significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform. Since our marketing and advertising costs are expensed as incurred and the revenue from approved applications is recognized as commissions are subsequently reported to us, our operating cash flows could be adversely impacted by a substantial increase in the volume of applications submitted during a quarter or positively impacted by a substantial decline in the volume of applications submitted during a quarter. 

 

Nine Months Ended September 30, 2012—Our operating activities generated cash of $19.7 million during the nine months ended September 30, 2012 and consisted of net income of $4.6 million, increased by non-cash items of $9.4 million and cash provided by working capital and other activities of $5.6 million. Adjustments for non-cash items primarily consisted of $2.4 million of deferred income taxes, $4.3 million of stock-based compensation expense and $5.0 million of depreciation and amortization, including amortization of book-of-business consideration and amortization of intangible assets, partially offset by $2.4 million of excess tax benefits from stock-based compensation. Cash provided by working capital and other activities primarily consisted of a decrease of $4.8 million in accounts receivable, an increase of $2.2 million in accounts payable, a decrease of $1.7 million in prepaid expenses and other current assets, an increase of $0.9 million in accrued compensation and other benefits and an increase of $0.4 million in deferred revenue, partially offset by an increase of $2.4 million in other assets and a decrease of $2.3 million in accrued marketing expenses. Other assets increased primarily from consideration paid in connection with book-of-business transfers. Accounts payable increased due primarily to the timing of payments to our vendors,  accrued compensation and benefits decreased primarily due to the payment of performance bonuses to employees that were earned during 2011 and accounts receivable decreased due collections.   

 

Nine Months Ended September 30, 2011Our operating activities generated cash of $20.0 million during the nine months ended September 30, 2011 and consisted of net income of $4.5 million, increased by non-cash items of $10.1 million and cash provided by working capital and other activities of $5.5 million. Adjustments for non-cash items primarily consisted of $5.6 million of stock-based compensation expense, $3.7 million of deferred income taxes and $3.1 million of

31 

 


 

depreciation and amortization, including amortization of book-of-business consideration and amortization of acquired intangible assets, partially offset by approximately $2.7 million of excess tax benefits from stock-based compensation. Cash provided by working capital and other activities primarily consisted of a decrease of $7.7 million in accounts receivable, a decrease of $1.9 million in prepaid expenses and other current assets,  an increase of $0.7 million in accrued marketing expense and an increase of $0.5 million in accrued compensation and benefits, partially offset by a decrease of $1.7 million in accounts payable, a decrease of $1.6 million in deferred revenue and a decrease of $1.5 million in other current liabilities. Accounts receivable decreased primarily due to collections of receivables from our government systems business as well as collection of Medicare lead referral receivables recorded during the Medicare annual enrollment period in the fourth quarter of 2010. Accounts payable decreased due primarily to the timing of payments to our vendors, accrued compensation and benefits decreased primarily due to the payment of performance bonuses to employees that were earned during 2010 and accounts receivable decreased due to collections. 

 

Investing Activities  

 

Our investing activities primarily consist of purchases of computer hardware and software to enhance our website and to support our growth and include consideration paid to a partner in connection with the transfer to us of certain Medicare plan members for whom we expect to earn future commissions.  

 

Nine Months Ended September 30, 2012—Net cash used in investing activities of $9.4 million during the nine months ended September 30, 2012 was attributable to consideration of $6.2 million paid to a partner related to the transfer of two books-of-business in the nine months ended September 30, 2012, whereby we became the broker of record on the underlying policies for certain Medicare insurance members that were transferred to us, and capital expenditures of $3.1 million.  

 

Nine Months Ended September 30, 2011—Net cash used in investing activities of $5.8 million during the nine months ended September 30, 2011 was attributable to consideration of $3.1 million paid to a partner related to the transfer of a  book-of-business during the nine months ended September 30, 2011, and a $0.8 million final payment related to the transfer of a book-of-business in the fourth quarter of 2010. For both transfers, we became the broker of record on the underlying policies for certain Medicare insurance members that were transferred to us. Additionally, net cash used by investing activities included capital expenditures of $1.9 million.  

 

Financing Activities  

 

Nine Months Ended September 30,  2012Net cash used in financing activities of $3.1 million during the nine months ended September  30, 2012 was due to $8.4 million used to repurchase 0.6 million shares of our common stock and $1.0 million used to net-share settle the tax obligation related to vesting equity awards, partially offset by $4.0 million of net proceeds from the exercise of common stock options and $2.4 million of excess tax benefits from stock-based compensation.  

 

Nine Months Ended September 30, 2011—Net cash used in financing activities of $15.7 million during the nine months ended September 30, 2011 was due to $18.0 million used to repurchase 1.4 million shares of our common stock and $0.5 million used to net-share settle the tax obligation related to equity awards, partially offset by $2.7 million of excess tax benefits from stock-based compensation. 

 

Future Needs 

 

We believe that cash generated from operations and our current cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months. Our future capital requirements will depend on many factors, including our level of investment in technology and advertising initiatives. We currently do not have any bank debt, line of credit facilities or other borrowing arrangements. To the extent that available funds are insufficient to fund our future activities, we may need to raise additional capital through public or private equity or debt financing to the extent such funding sources are available. 

 

Contractual Obligations and Commitments 

 

Operating Lease Obligations 

 

32 

 


 

We lease certain of our office, operating facilities, equipment and furniture and fixtures under various operating leases, the latest of which expires in August 2018. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. 

In March 2012, we entered into an agreement to lease a building to be constructed in Mountain View, California, adjacent to our headquarters office. The term of the operating lease is ten years from the date the building is delivered to us and the base rent is approximately $0.6 million for the first year of the lease. The base rent increases annually by 3%. Future minimum payments related to this operating lease are estimated to total $6.8 million over the ten-year term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease, but may differ depending on actual rentable square footage. Lease payments are expected to begin in the second or third quarter of 2013, although the actual commencement of lease payments will depend upon the date of completion and delivery of the newly constructed building. 

 

Upon signing the Mountain View, California lease agreement, we  entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.   

 

In May 2012, we entered into an agreement to lease office space in South Jordan, Utah. The term of the operating lease is 65 months and commences in August 2012. The lease significantly increases our office space for our customer care and enrollment activities and replaces an expiring operating lease for office space at another location in South Jordan, Utah. Rent payments begin in January 2013 and total approximately $0.5 million per year through December 2017.   

In August 2012, we extended our existing lease for office space in Gold River, California, for an additional two years expiring on December 31, 2014. Rent payments will total $0.9 million in both 2013 and 2014. 

   

Service and Licensing Obligations  

 

We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. We record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.  

 

In March 2012, we entered into a service agreement with a vendor to support our customer care center telephonic system and equipment. Service obligations related to this agreement total $0.7 million over the three-year term of the agreement. 

 

The following table presents a summary of our future minimum payments under non-cancellable operating lease agreements and certain contractual service and licensing obligations as of September 30, 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ending December 31,

Operating Lease Obligations

 

Service and Licensing Obligations

 

Total Obligations

 

 

 

 

 

 

 

 

2012 (three months)

$

690 

 

$

178 

 

$

868 

2013

 

2,753 

 

 

1,118 

 

 

3,871 

2014

 

2,347 

 

 

986 

 

 

3,333 

2015

 

1,215 

 

 

138 

 

 

1,353 

2016

 

1,226 

 

 

 -

 

 

1,226 

Thereafter

 

1,741 

 

 

 -

 

 

1,741 

Sub-Total

$

9,972 

 

$

2,420 

 

$

12,392 

New building - Mountain View, California (estimated commitment) (1)

 

6,833 

 

 

 -

 

 

6,833 

Total (estimate)

$

16,805 

 

$

2,420 

 

$

19,225 

33 

 


 

 

(1)

Future minimum payments related to the new Mountain View, California operating lease are estimated to total $6.8 million over the ten-year term of the lease, but may differ depending on actual rentable square footage. Lease payments are expected to begin in the second or third quarter of 2013, although the actual commencement of lease payments will depend upon the date of completion and delivery of the newly constructed building. This lease is generally non-cancellable, except in the case of non-delivery of the newly constructed building.  

Off-Balance Sheet Arrangements  

 

We do not have any off-balance sheet arrangements, investments in special purpose entities or undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.

34 

 


 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

 

 

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash and cash equivalents and accounts receivable. As of December 31, 2011 and September 30, 2012, our cash and cash equivalents were invested as follows (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Cash (1)

$

17,256 

 

$

17,441 

Money market funds (2)

 

106,351 

 

 

113,359 

Total cash and cash equivalents

$

123,607 

 

$

130,800 

 

(1)

We deposit our cash and cash equivalents in accounts with major banks and financial institutions and such deposits are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Renminbi and are not insured by the U.S. federal government.   

 

(2)

At December 31, 2011 and September 30,  2012 money market funds consisted of U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. 

 

We do not require collateral or other security for our accounts receivable. As of December 31, 2011, one customer represented 73% of our $8.1 million outstanding accounts receivable balance. As of September 30, 2012, two customers represented 37% and 14%, respectively, for a combined total of 51% of our $3.3 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2011 and September 30, 2012. We believe the potential for collection issues with any of our customers is minimal as of September 30, 2012. Accordingly, our estimate for uncollectible amounts at September 30, 2012 was not material. 

 

Significant Customers 

 

Substantially all revenue for the three and nine months ended September 30, 2011 and 2012 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three months ended September 30, 2011 and 2012 are presented in the table below: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Humana

9% 

 

19% 

 

6% 

 

16% 

WellPoint (1)

11% 

 

13% 

 

12% 

 

13% 

UnitedHealthcare (2)

13% 

 

12% 

 

14% 

 

13% 

 

 

 

 

 

 

 

 

(1)

Wellpoint includes other carriers owned by Wellpoint. 

(2)

UnitedHealthcare includes other carriers owned by UnitedHealthcare. 

Foreign Currency Exchange Risk  

 

To date, substantially all of our revenue has been derived from transactions denominated in United States Dollars. We have exposure to adverse changes in exchange rates associated with operating expenses of our foreign operations, which are denominated in Chinese Yuan Renminbi. Foreign currency fluctuations have not had a material impact historically on our results of operations; however, there can be no assurance that future fluctuations will not have material adverse effects on our results of operations. We have not engaged in any foreign currency hedging or other derivative transactions to date.  

35 

 


 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

 

 

 

Evaluation of Our Disclosure Controls and Procedures 

 

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q.   

 

Based on management’s evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.  

 

Changes in Internal Control Over Financial Reporting 

 

There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.  

 

Inherent Limitations on Effectiveness of Controls 

 

Our management, including our chief executive officer and chief financial officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 

 

36 

 


 

PART II 

OTHER INFORMATION 

 

ITEM 1.

LEGAL PROCEEDINGS 

 

 

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We also have become, and may in the future become, involved in litigation in the ordinary course of our business.  

 

 

37 

 


 

ITEM 1A.

RISK FACTORS

 

 

In addition to other information in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods. 

 

Risks Related to Our Business 

  

Changes and developments in the structure of the health insurance system in the United States could harm our business. 

 

Our business depends upon the private sector of the United States health insurance system, its relative role in financing health care delivery and health insurance carriers’ use of, and payment of commissions to, agents and brokers to market individual and family health insurance plans. In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have and will continue to change the industry in which we operate in substantial ways. Among several other provisions, they include a mandate requiring individuals to be insured or face tax penalties; a mandate that certain employers offer their employees group health insurance coverage or face tax penalties; requirements relating to employer contribution to employee health coverage; prohibitions against insurance companies using pre-existing health conditions as a reason to deny an application for health insurance; prohibitions on rescission of health insurance; prohibitions on lifetime coverage limits; requirements for guaranteed renewability of health insurance plans; health insurance premium setting guidelines; limitations on deductibles and cost-sharing; medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality and, if they do not, to provide rebates to policyholders; minimum benefit levels for health insurance plans; establishment of state and/or federal health insurance exchanges to facilitate access to, and the purchase of, health insurance; open enrollment periods for individual health insurance; assistance for member run health insurance issuers; creation of multi-state health insurance plans to be offered on the exchanges and with oversight from the Office of Personnel Management; requirements for uniform disclosure relating to the costs and benefits of health insurance; government subsidized high risk pools; an expansion of Medicaid so that more individuals will be insured under state Medicaid programs; and subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels. Many aspects of health care reform do not go into effect until 2014, although certain provisions currently are effective, such as medical loss ratio requirements for individual and family and small business health insurance, a prohibition against insurance companies using pre-existing health conditions as a reason to deny the application of children for health insurance and a requirement that persons 26 years of age and younger be able to stay on a parent’s health insurance plan.  Health care reform legislation requires various departments of the executive branch to adopt regulations implementing its provisions. In addition, state governments have adopted, and will continue to adopt, changes to their existing laws and regulations in light of federal health care reform legislation and regulations.   

 

The implementation of health care reform could increase our competition; reduce or eliminate the need for health insurance agents or demand for the health insurance for individuals, families or small businesses that we sell; decrease the number of health insurance plans that we sell as well as the number of health insurance carriers offering them; cause health insurance carriers to apply more rigorous underwriting standards (until provisions in health care reform legislation limiting underwriting go into effect in 2014) or change the benefits and/or premiums for the plans they sell; cause a substantial reduction in our membership; or cause health insurance carriers to reduce the amount they pay for our services or change our relationship with them in other ways, any of which could materially harm our business, operating results and financial condition.  For instance, beginning in 2014 health insurance carriers offering coverage in the individual or small group health insurance market must ensure that such coverage includes certain minimum health benefits.  Individuals are required to hold plans providing minimum essential coverage to meet the mandate for health insurance and avoid a tax penalty.  While these minimum benefits have yet to be fully defined by regulation, the Patient Protection and Affordable Care Act lists certain benefits and services as a minimum threshold for coverage, and the Department of Health and Human Services is to define the essential health benefit package so that the scope of benefits is equivalent to that of a typical employer provided health insurance plan.  Many of the individual and small group health insurance plans we have sold may not cover all of the minimum essential benefits.  In the event this aspect of health care reform results in the termination of these plans,

38 

 


 

or a reduction in our membership, our business, operating results and financial condition would be materially harmed. Various aspects of health care reform also could cause health insurance carriers to determine to limit the type of health insurance plans we sell and the geographies in which we sell them, to exit the business of selling insurance plans in a particular jurisdiction, to eliminate certain categories of products or attempt to move members into new plans for which we receive lower or no commissions, any of which would materially harm our business, operating results and financial condition.   

 

As a part of healthcare reform, each state is required to implement a health insurance exchange by October 2013 where individuals and small businesses can purchase health insurance. If a state does not implement a health insurance exchange, the federal government will implement and operate the exchange for that state. Among other things, the exchanges will have websites where individuals and small businesses can shop for and purchase health insurance, and they also will have offline customer support. The exchanges will be a new source of competition for us. In the event our existing members purchase health insurance directly through health insurance exchanges, we will no longer receive commission revenue as a result of our sale of health insurance to them, and exchanges will compete with us for new members. Competitive pressure from health insurance exchanges may result in our experiencing increased marketing costs, decreased traffic to our website and loss of market share, or may otherwise harm our business, operating results and financial condition. 

 

In addition to the expansion of Medicaid eligibility as a part of health care reform, individuals and families whose incomes are between 133% and 400% of the federal poverty level will generally be entitled beginning in 2014 to subsidies in connection with their purchase of health insurance. In order to be eligible for a subsidy, qualified individuals must purchase subsidy qualifying health plans through a health insurance exchange. These qualified health plans are required to be purchased during an initial open enrollment period beginning in October 2013 and running through March 2014, and qualified individuals can thereafter change their qualified health plan only during an annual enrollment period to occur from October 15 through December 7 of each year thereafter, subject to states extending the period and exceptions for special enrollment periods for certain qualifying events. A federal regulation promulgated under the Patient Protection and Affordable Care Act has been issued that clarifies that states may, but are not required to, allow agents and brokers such as us to market the plans that subsidy-eligible individuals must purchase in order to receive the subsidies. While there are details that need to be clarified by the federal government, states and health insurance carriers, it is clear that, in order to offer subsidy-eligible health insurance plans, agents and brokers must meet certain conditions, such as entering into an agreement with the state health insurance exchange, ensuring that the enrollment and subsidy application is completed through the state’s health insurance exchange and complying with privacy, security and conflict of interest standards.  In the event Internet-based agents and brokers such as us use the Internet for plan selection purposes, their websites are required to meet certain additional conditions, such as compliance with standards for display of health plan and related information; providing consumers the ability to view all subsidy-eligible plans offered on the state’s exchange; displaying all subsidy-eligible health plan data on the state’s exchange; and providing a mechanism for consumers to withdraw from the application process to the state exchange. A substantial number of our existing members may become eligible for subsidies in connection with their purchase of health insurance.  We may experience difficulty in satisfying the conditions required to offer plans to individuals and families who are entitled to subsidies under health care reform, and even if we are able to satisfy them, we depend upon states to permit us to offer these plans and upon health insurance companies to allow us to sell them and to pay us commissions in connection with their sale. In the event we are not successful in gaining the ability to sell individual and family health insurance products to health care reform subsidy-eligible individuals, or if health insurance carriers pay us no commissions or reduced commissions in connection with the sale of these plans, we could lose a substantial number of existing and potential members and the related commission revenue we receive as a result of the sale of individual and family and small business health insurance products to them, which would materially harm our business, operating results and financial condition.  In addition, even if we are able to sell qualified health plans to subsidy eligible individuals, we will be subject to the same execution risks that we face in selling Medicare plans, given that a substantial number of qualified health plans may only be sold during a limited period of time. 

 

The medical loss ratio requirements that are a part of health care reform have harmed and will continue to harm our business. 

 

The federal Patient Protection and Affordable Care Act enacted in March 2010 and related amendments in the Health Care and Education Reconciliation Act of 2010 contain provisions requiring health insurance carriers to maintain specified medical loss ratios. The medical loss ratio requirements for both individual and family and small business health insurance are effective for calendar year 2011 and later years and, among other things, require health insurance companies to spend 80% of their premium revenue in each of their individual and small group businesses on reimbursement for clinical services and activities that improve health care quality. The medical loss ratio requirement for Medicare Advantage plans is 85% and

39 

 


 

goes into effect in 2014. If a health insurance carrier fails to meet medical loss ratio requirements, the health insurance carrier is required to rebate a portion of its premium revenue to its members to make up for the difference. 

 

Carrier reaction to the individual and family medical loss ratio requirements has been to significantly reduce the commissions we receive in connection with the sale of these plans. These commission rate reductions have and will continue to significantly impact our business and operating results. Health insurance carriers may determine to reduce or further reduce our commissions as a result of the medical loss ratio requirements or other aspects of health care reform, which would harm our business, operating results and financial condition. In addition, if health insurance companies fail to meet medical loss ratio requirements, we may be required to pay back commissions that are related to any premium amounts the carriers are required to rebate policy holders as a result, which would harm our business, operating results and financial condition. The medical loss ratio requirements also may cause certain health insurance carriers to limit the geographies in which they sell health insurance or exit certain markets altogether, place less reliance on agents to distribute their plans, apply stricter underwriting standards (until provisions in health care reform registration limiting underwriting go into effect in 2014) or limit their health insurance offerings in any number of other ways, each of which would harm our business, operating results and financial condition.  The implementation of medical loss ratio requirements has caused and could further cause health insurance carriers to reduce the amount they are willing to spend in connection with our sponsorship and advertising and technology licensing businesses, which also could harm our business, operating results and financial condition. 

 

Our business may be harmed if we lose our relationship with health insurance carriers or our relationship with health insurance carriers is modified. 

 

We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason.  In many cases, health insurance carriers also may amend the terms of our agreements unilaterally on short notice.  Carriers may be unwilling to allow us to sell their existing or new health insurance plans, or desire to amend our agreements with them, for a variety of reasons, including for competitive or regulatory reasons, as a result of health care reform, as a result of a reluctance to distribute their plans over the Internet or because they do not want to be associated with our brand.   In the future, and as a result of health care reform or for other reasons, an increasing number of health insurance carriers may decide to rely on their own internal distribution channels, including traditional in-house agents and carrier websites, to sell their own plans and, in turn, could limit or prohibit us from selling their plans on our ecommerce platform.  For instance, carriers may choose to exclude us from their most profitable or popular plans or may determine not to distribute insurance plans in the individual and family and small business markets in certain geographies or altogether. The termination or amendment of our relationship with a carrier could reduce the variety of health insurance plans we offer, which could harm our business, operating results and financial condition. It also could adversely impact, or cause the termination of, commissions for future sales and for past sales, which would materially harm our business, operating results and financial condition. Our business could also be harmed if in the future we fail to develop new carrier relationships and are unable to offer consumers a wide variety of health insurance plans.  

 

The health insurance industry in the United States has experienced a substantial amount of consolidation over the past several years, resulting in a decrease in the number of health insurance carriers. In the future, we may be forced to offer insurance policies from a reduced number of insurance carriers or to derive a greater portion of our revenue from a more concentrated number of carriers as our business and the health insurance industry evolve. We derived 19% and 16% of our total revenue in the three and nine months ended September 30, 2012, respectively, from Humana. We derived 13% of our total revenue in both the three and nine months ended September 30,  2012 from carriers owned by Wellpoint. We derived 12% and 13% of our total revenue in the three and nine months ended September 30, 2012, respectively, from carriers owned by UnitedHealthcare. We have several agreements that govern our sale of individual health insurance plans with these health insurance carriers. Many of them may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact or cause the termination of the commission payments that we receive from these health insurance carriers, which would harm our business, operating results and financial condition. Notwithstanding our separate agreements with various carriers directly or indirectly owned by the same entity, certain carriers have attempted and may continue to attempt to consolidate our relationship with them, which could increase the impact of carrier concentration on us, decrease the commission rates we receive and adversely affect our financial results, particularly in states where we offer health insurance from a relatively smaller number of carriers or where a small number of carriers dominates the market.  The termination, amendment or consolidation of our relationship with these and other health insurance carriers could harm our business, operating results and financial condition. 

 

Our revenues and earnings may continue to decline.  

40 

 


 

 

We have recently experienced a significant reduction in the commission rates that health insurance carriers pay us on the individual and family health insurance plans that we sell. We also have in the past and may in the future continue to make significant expenditures related to the development of our business, including expenditures relating to marketing, website technology development and the development of our business selling Medicare-related health insurance plans. Our ability to resume revenue and earnings per share growth on a consistent basis will be dependent upon a number of factors, including the success of our Medicare plan marketing and sales business, our ability to attract individuals, families and small businesses to purchase health insurance through our ecommerce platform, our maintaining our relationships with health insurance carriers and the commission rates we receive for our sale of health insurance plans, our ability to maintain our relationship with existing members within historical levels and our success in entering into relationships to perform services and license our technology for use in the implementation of health care reform-related endeavors. If we are not successful in these areas, our business, operating results and financial condition will be harmed. 

 

Our revenue will be adversely impacted if our membership does not grow. The individual and family and Medicare-related commission rates that we receive are typically higher in the first twelve months of a policy. After the first twelve months, they generally decline significantly. Accordingly, to the extent that our net addition of new members slows or we experience a reduction in the number of our members, our revenue would be adversely impacted due to a decline in commissions we receive for members whose policies have been active for more than twelve months in addition to the reduction in revenue growth that would occur solely as a result of a decline in our membership growth rate. The commission rates we receive are impacted by a variety of other factors, including the particular health insurance policies chosen by our members, the carriers offering those policies, our members’ states of residence, the laws and regulations in those jurisdictions and health care reform. Our commission rate per member has, and could in the future, decrease as a result of either reductions in contractual commission rates or unfavorable changes in health insurance carrier override commission programs, each of which may be beyond our control and may occur on short notice. To the extent these and other factors cause our commission rate per member to decline, our rate of revenue growth may decline and our business, operating results and financial condition would be harmed. 

 

We may not be successful in our efforts to market and sell Medicare-related health insurance plans as a health insurance agent.  

 

In 2010 we began to actively market the availability of Medicare-related health insurance plans using our ecommerce platforms, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. We refer to these plans as Medicare plans. We market Medicare plans to Medicare-eligible individuals, who are predominately senior citizens over the age of 65. The sale of Medicare Advantage and Medicare Part D prescription drug plans are subject to an annual enrollment period during the fourth quarter of each year, when a substantial percentage of the annual sales of these plans occur. We sell Medicare plans as a health insurance agent using our websites and customer care centers.   

  

We have a limited number of relationships with health insurance carriers to sell Medicare plans, and our Medicare plan related revenue is concentrated in a small number of health insurance carriers.  The success of our entry into the market for Medicare plans as a health insurance agent will depend upon our ability to enter into and maintain relationships with health insurance carriers on favorable economic terms. We may temporarily or permanently lose the ability to market and sell Medicare plans for our Medicare plan carrier partners.  For instance, a carrier may terminate our relationship. In addition, the Centers for Medicare and Medicaid Services, or CMS, has and will continue to penalize health insurance carriers for certain regulatory violations by not allowing them to market and sell Medicare plans for significant periods of time.  Given the small number of our Medicare carrier relationships, if we lose a relationship with a health insurance carrier to market their Medicare plans temporarily or permanently for this or any other reason, our sales as a health insurance agent and Medicare plan related revenue could suffer significantly, and our business, operating results and financial condition would be harmed. In addition, the agreements that we have with health insurance carriers to sell Medicare plans may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact, or cause the termination of, the commission payments that we receive for selling their Medicare plans, which would harm our business operating results and financial condition. 

 

CMS must approve our websites and call center scripts for us to be able to generate Medicare plan demand and sell Medicare plans to Medicare-eligible individuals as a health insurance agent.  Moreover, we use Medicare plan cost and benefit data collected and made publicly available by CMS.  In the event that CMS disapproves, or delays approval, of our websites or call center scripts, or does not timely release Medicare plan cost and benefit data for the following year’s Medicare plans prior to the annual enrollment period, we could lose a significant source of Medicare plan demand and our

41 

 


 

ability to sell Medicare plans would be adversely impacted, each of which would harm our business, operating results and financial condition. 

 

Our success in expanding into the Medicare plan market as a health insurance agent will also depend upon a number of additional factors, including:   

 

·

our ability to continue to adapt our ecommerce platform to market Medicare plans, including our development or acquisition of marketing tools and features important in the sale of Medicare plans online and the modification of our existing user experience for new plans targeted at a different demographic; 

 

·

our success in marketing our ecommerce platform to Medicare-eligible individuals and in entering into business development relationships to drive Medicare-eligible individuals to our ecommerce platform; 

 

·

our effectiveness in entering into and maintaining relationships with marketing partners, including existing pharmacy chain partners that refer Medicare-eligible individuals to us; 

 

·

our ability to hire and retain additional employees with experience in Medicare, including our ability to timely implement Medicare sales expertise into our customer care centers; 

 

·

our ability to implement and maintain an effective information technology infrastructure for the sale of Medicare plans, including the infrastructure and systems that support our websites, call centers and call recording; 

 

·

our ability to comply with the numerous, complex and changing laws and regulations and CMS guidelines relating to the marketing and sale of Medicare plans, including continuing to conform our online and offline sales processes to those laws and regulations; and 

 

·

the effectiveness with which our competitors market the availability of Medicare plans from sources other than our ecommerce platform. 

 

As a result of these factors, we may prove unsuccessful in marketing Medicare plans and acting as a health insurance agent in connection with their sale, which would harm our business, operating results and financial condition. In addition, if our efforts to market Medicare plans during any annual enrollment period were impeded due to lack of health insurance carrier or CMS approval, or for other reasons, the impact on our business, operating results and financial condition would be significantly greater given the seasonality of our Medicare-related revenues and expenses and the fact that much of the sales of Medicare plans occur during this period. 

 

Our ability to sell Medicare-related health insurance plans as a health insurance agent is dependent upon our ability to timely hire, train and retain licensed health insurance agents for our customer care center operations and our ability to maintain information technology systems to facilitate their sale of Medicare plans.   

 

In addition to our websites, we rely upon our customer care centers to sell Medicare plans. The success of our customer care center operations is largely dependent on licensed health insurance agents.  In order to sell Medicare-related health insurance plans, our health insurance agent employees must first be licensed by the states in which they are selling plans and certified and appointed with the health insurance carrier that offers the plans in each state that the Medicare-related health insurance product is being sold by the agent. Because the vast majority of Medicare plans are sold in the fourth quarter each year during the Medicare annual enrollment period, we are required to hire and train a significant number of additional employees on a temporary or seasonal basis in a limited period of time.  We must also ensure that these employees are timely licensed in a significant number of states and certified and appointed with the health insurance carriers whose products we sell. We depend upon state departments of insurance and health insurance carriers for their licensing, certification and appointment. We may not be successful in timely hiring a sufficient number of additional licensed agents for the Medicare annual enrollment period, and even if we are successful, these employees may experience delays in obtaining health insurance licenses and certifications and health insurance carrier appointments with our health insurance carrier partners.  If we and our health insurance agent employees are not successful in these regards, our ability to sell Medicare-related health insurance plans will be impaired during the annual enrollment period, which would harm our business, operating results and financial condition. 

42 

 


 

 

The success of our Medicare plan customer care center operations also is dependent on information technology systems.  The vast majority of our Medicare plan members utilize our customer care center in connection with their purchase of a Medicare plan.  CMS rules require that our health insurance agent employees utilize approved scripts in connection with the sale of Medicare plans and that we record and maintain the recording of telephonic interactions relating to the sale of Medicare plans.  We rely on telephone, call recording and customer relationship management systems in our Medicare customer care center operations related to these and other functions, and we are dependent on third parties for some of them, including our telephone and call recording systems.  The effectiveness and stability of our Medicare customer care center systems are critical to our ability to sell Medicare plans, particularly during the Medicare annual enrollment period, and the failure or interruption of any of these systems and any inability to handle increased volume during the annual enrollment period would harm our business, operating results and financial condition. 

 

Factors beyond our control may negatively impact our ability to market and sell Medicare plans. 

 

We determined to enter into the Medicare plan market because we believe the number of individuals becoming eligible for Medicare is increasing and these individuals are increasingly using the Internet to shop for health insurance plans. We also believe that, on average, member retention rates and the commissions that health insurance carriers pay in connection with the sale of Medicare plans compare favorably to the member retention rates and commissions we receive in connection with our sale of individual and family health insurance. Should we prove to be wrong, or should these circumstances reverse, our success in marketing Medicare plans would be materially and adversely impacted, which could harm our business, operating results and financial condition. For instance, portions of health care reform impose significant changes to original Medicare and the Medicare Advantage program by, among other things, increasing the benefits original Medicare provides, reducing payments to Medicare Advantage plans and imposing medical loss ratio requirements for Medicare Advantage plans.  In the event health care reform or other circumstances decrease the demand for Medicare Advantage plans or other alternatives to original Medicare, or cause a reduction in the amount paid to agents in connection with the sale of these plans, our business operating results and financial condition could be harmed. 

 

      The marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws and regulations, and any noncompliance with them could harm our business, operating results and financial condition.  

 

The marketing and sale of Medicare plans are subject to numerous laws, regulations and guidelines at the federal and state level. The marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans are principally regulated by CMS. The marketing and sale of Medicare Supplement plans are principally regulated on a state-by-state basis by state departments of insurance. The laws and regulations applicable to the marketing and sale of Medicare plans are numerous, ambiguous and complex, and, particularly with respect to regulations and guidance issued by CMS for Medicare Advantage and Medicare Part D prescription drug plans, change frequently.  As a result of these laws, regulations and guidelines, we have altered, and likely will have to continue to alter, our websites and sales process to comply with several requirements that are not applicable to our sale of non-Medicare-related health insurance plans. For instance, many aspects of our online platforms and our marketing material and processes, as well as changes to these platforms, materials and processes, including call center scripts, must be approved on a regular basis by CMS and by health insurance carriers in light of CMS requirements.  In addition, certain aspects of our Medicare plan marketing partner relationships with pharmacy chains have been in the past, and will be in the future, subjected to CMS and health insurance carrier review.  Changes to the laws, regulations and guidelines relating to Medicare plans, their interpretation or the manner in which they are enforced could be incompatible with these relationships, our platforms or our sale of Medicare plans.  Due to changes in CMS guidance or enforcement or interpretation of existing guidance, or as a result of new regulations and guidelines, CMS, state departments of insurance or health insurance carriers may determine to object to or not to approve aspects of our online platforms or marketing material and processes and may determine that certain existing aspects of our Medicare-related business are not in compliance.  As a result, the progress of our Medicare operations could be slowed or we could be prevented from operating aspects of our Medicare revenue generating activities altogether, which would harm our business, operating results and financial condition, particularly if it occurred during the Medicare annual enrollment period. It could also result in the write-down of the value of goodwill and intangible assets acquired in our PlanPrescriber acquisition. 

 

The impact that health care reform legislation will have on the market for Medicare plans is unclear, but it could change demand for Medicare plans, the way these plans are delivered, the commissions that carriers pay to health insurance agents in connection with their sale or could adversely impact us in other ways. In the event that laws and regulations adversely impact our ability to market the availability of any type of Medicare plan on our ecommerce platform, or the amounts that

43 

 


 

health insurance agents are paid for selling these plans, our business, operating results and financial condition would be harmed. 

 

We have reduced our cost of acquisition and other expenses in connection with the sale of our individual and family health insurance plans, which may harm our operating results. 

 

As a result of the reduction in the commission rates we receive for selling individual and family health insurance plans, we reduced our marketing and advertising and other expenses in this area of our business. The maintenance of a lower cost of acquisition depends significantly on the rate at which visitors to our website submit health insurance applications, particularly with respect to paid search advertising, as our paid search costs are incurred on the referral of a potential member rather than on the submission of a health insurance application.  As a result, we may not be successful in maintaining an acceptable individual and family health insurance cost of acquisition in the event we experience a decline in the rate at which visitors to our platform submit individual and family health insurance applications, which would harm our business, operating results and financial condition. 

 

Our future operating results are likely to fluctuate and could fall short of expectations.  

 

Our operating results are likely to fluctuate as a result of a variety of factors, including the factors described elsewhere in this “Risk Factors” section, many of which are outside of our control. As a result, comparing our operating results on a period-to-period basis may not be meaningful and you should not rely on our past results as an indication of our future performance, particularly as a result of the commission rate reductions that we have experienced in our individual and family health insurance business, which began impacting our financial results in 2011. If our revenue or operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially.  

 

Our business model is characterized primarily by revenue based on commissions we receive from insurance carriers whose policies are purchased by our members. We receive commissions and record related revenue for an individual and family, small business, ancillary or Medicare Supplement health insurance policy, typically on a monthly basis, until the health insurance policy is cancelled or we otherwise do not remain the agent on the policy. For both Medicare Advantage and Medicare Part D prescription drug plans, we record commission revenue on an annual basis but may receive commission payments from insurance carriers on either a monthly or annual basis typically for a period of up to six years, or longer depending on the carrier arrangement, provided that the policy remains active with us and we remain the agent on the policy. 

 

A significant component of our marketing and advertising expenses consists of expenses incurred in search engine advertising at the time a consumer clicks on an advertisement and payments owed to our marketing partners in connection with applications submitted on our ecommerce platform by potential members referred to us by our marketing partners. As a result of this timing difference between expense and associated revenue recognition, our operating results and cash flows may be adversely affected in periods where we experience a significant increase in new applicants. In addition, if we incur other unanticipated or one-time expenses in a particular quarter or if we lose a significant amount of our member base for any reason, we would likely be unable to offset these expenses by increasing sales within that quarter or to replace lost revenue in the quarter with revenue from new members. As a result, our quarterly results may suffer due to unanticipated expenses, one-time charges or significant member turnover.  

 

Current economic conditions and other factors beyond our control may negatively impact our business, operating results and financial condition.  

 

Our revenue depends upon demand for health insurance in the individual and family and small business markets, which can be influenced by a variety of factors beyond our control. For instance, an increased number of individuals have become self-employed or unemployed. In addition, as a result of substantial health insurance premium inflation in recent years, we believe that many employers have sought to reduce the costs associated with providing health insurance to their employees, including offering fewer benefits to employees, reducing or eliminating dependent coverage, increasing employee health insurance premium contributions and eliminating health insurance benefits altogether. We have no control over the economic and other factors that influence these trends, and they may reverse, including as a result of health care reform legislation. If economic or other factors beyond our control negatively impact our business, our business, operating results and financial condition could be harmed.  

 

44 

 


 

We believe that demand for the health insurance and services we offer have been adversely impacted by recent economic conditions. We cannot be certain of the future impact that the recent recession and other economic conditions will have on our business. A further softening of demand for health insurance and services offered by us, whether caused by changes in customer preferences or a weak U.S. economy, including as a result of disruptions in the global financial markets or a decrease in general consumer confidence, could adversely impact our operating results. Consumers may attempt to reduce expenses by cancelling existing health insurance purchased through us, determine not to purchase new health insurance through us, or purchase health insurance plans with lower premiums for which we receive lower commissions. To the extent the economy or other factors adversely impact our membership retention or the number or type of health insurance applications submitted through us and that are approved by health insurance carriers, our rate of growth will decline and our business and operating results will be harmed. A continuing negative economic environment could also adversely impact the health insurance carriers whose plans are offered on our ecommerce platform, and they may determine to reduce their commission rates, change their underwriting practices so that fewer health insurance applications are approved or take other actions that would negatively impact our sale of health insurance as well as our sponsorship and technology licensing businesses. 

 

Economic conditions have caused interest rates to decline. We have experienced a significant reduction in the rate of return on our investments both as a result of the decline in interest rates and as a result of our implementation of more conservative investment policies. Economic conditions could materially and adversely impact our investments in the future, including loss of our principal investment, despite our implementation of more conservative investment policies. 

 

Our business may not grow if consumers are not informed about the availability and accessibility of affordable health insurance.  

 

Numerous health insurance plans are available to consumers in any given market. Most of these plans vary by price, benefits and other policy features. Health insurance terminology and provisions are often confusing and difficult to understand. As a result, researching, selecting and purchasing health insurance can be a complex process. We believe that this complexity has contributed to a perception held by many consumers that individual health insurance is prohibitively expensive and difficult to obtain. We attempt to make the health insurance research and application process on our website understandable and user-friendly. We also attempt to use our website and other means to educate consumers about the accessibility and affordability of health insurance. If consumers are not informed about the availability and accessibility of affordable health insurance or our ecommerce platform is difficult to navigate, our business may not grow and our operating results and financial condition would be harmed.  

 

If we are not successful in cost-effectively converting visitors to our website into members, our business and operating results would be harmed.  

 

Our growth depends in large part upon growth in our membership. The rate at which consumers visiting our ecommerce platform and seeking to purchase health insurance are converted into members is a significant factor in the growth of our membership. A number of factors have influenced, and could in the future influence, the conversion rate for any given period, some of which are outside of our control. These factors include:  

 

·

changes in consumer shopping behavior due to circumstances outside of our control, such as economic conditions, consumers’ ability or willingness to pay for health insurance, availability of unemployment benefits or proposed or enacted legislative or regulatory changes impacting our business; 

 

·

the quality of and changes to the consumer experience on our ecommerce platform or with our customer care center; 

 

·

regulatory requirements, including those that make the experience on our online platforms cumbersome or difficult to navigate; 

 

·

the variety and affordability of the health insurance plans that we offer; 

 

·

system failures or interruptions in the operation of our ecommerce platform or call center operations; 

 

·

changes in the mix of consumers who are referred to us through our direct, marketing partner and online advertising member acquisition channels; 

45 

 


 

 

·

the health insurance carriers offering the health insurance plans for which consumers have expressed interest, and the degree to which our technology is integrated with those carriers; 

 

·

health insurance carrier underwriting practices and guidelines applicable to applications submitted by consumers and the amount of time a carrier takes to make a decision on that application; and 

 

·

competitive offerings. 

 

Our conversion rates can be impacted by changes in the mix of consumers referred to us through our member acquisition channels. For example, our conversion rates have historically been lower with respect to consumers referred to us by Internet lead aggregators and relatively higher with respect to consumers coming to us through our direct member acquisition channel. In addition, we may make changes to our ecommerce platform or undertake other initiatives in an attempt to improve consumer experience or for other reasons. These changes in the past, and may in the future, have the unintended consequence of adversely impacting our conversion rates. A decline in the percentage of consumers who submit health insurance applications on our ecommerce platform and are converted into members could cause an increase in our cost of acquiring members on a per member basis. To the extent the rate at which we convert consumers visiting our ecommerce platform into members suffers, our membership growth rate may decline, which would harm our business, operating results and financial condition.  

 

If we are unable to retain our members, our business and operating results would be harmed.  

 

We receive revenue from commissions health insurance carriers pay to us for health insurance policies sold through our ecommerce platform. When one of these policies is cancelled, or if we otherwise do not remain the agent on the policy, we no longer receive the related commission revenue. Individuals, families and small businesses may choose to discontinue their health insurance policies for a variety of reasons. For example, individuals and families may replace a health insurance policy purchased through us with a health insurance policy provided by a new or existing employer or may determine that they cannot afford health insurance. In addition, our members may choose to purchase new policies using a different agent if, for example, they are not satisfied with our customer service or the health insurance plans that we offer. Consumers may also purchase health insurance policies from state health insurance exchanges after their implementation as a result of health care reform. Health insurance carriers may also terminate health insurance plans purchased and held by our members. If we are not successful in transferring members covered under a terminated plan to another policy that we offer, we will lose these members and associated commission revenue. Our cost in acquiring a new member is substantially greater than the cost involved in maintaining our relationship with an existing member. If we are not able to successfully retain existing members and limit member turnover, our revenue and operating margins will be adversely impacted and our business, operating results and financial condition would be harmed.  

 

Changes in the quality and affordability of the health insurance plans that carriers offer on our ecommerce platform could harm our business and operating results.  

 

The demand for health insurance marketed through our ecommerce platform is impacted by, among other things, the variety, quality and price of the health insurance plans we offer. If health insurance carriers do not continue to allow us to sell a variety of high-quality, affordable health insurance plans in the individual and family, small business, ancillary and Medicare markets, or if their offerings are limited or terminated as a result of consolidation in the health insurance industry, health care reform legislation or otherwise, our sales may decrease and our business, operating results and financial condition could be harmed.  

 

Health insurance carriers could determine to reduce the commissions paid to us or change their underwriting practices in ways that reduce the number of insurance policies sold through our ecommerce platform, which could harm our business and operating results.  

 

Our commission rates, and the commission override payments we receive from health insurance carriers for achieving sales volume thresholds or other objectives, are either set by each carrier or negotiated between us and each carrier. Carriers have altered, and may in the future alter, the contractual relationships we have with them on short notice, either by renegotiation or unilateral action. If these contractual changes result in reduced commissions, our business may suffer and our operating results and financial condition would be harmed. In addition, carriers periodically change the criteria they use for determining whether they are willing to insure individuals as well as other underwriting practices. At various times,

46 

 


 

carriers have applied more stringent underwriting criteria and practices to applications for health insurance. These practices result in a decrease in the rate at which insurance applications submitted through our ecommerce platform are approved. Changes in carrier underwriting criteria or practices could negatively impact sales of insurance policies on our ecommerce platform and could harm our business, operating results and financial condition. 

 

If we are not able to maintain and enhance our brand, our business and operating results will be harmed.  

 

We believe that maintaining and enhancing our brand identity is critical to our relationships with existing members, marketing partners and health insurance carriers and to our ability to attract new members, marketing partners and health insurance carriers. The promotion of our brand in these and other ways may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these branding initiatives may become increasingly difficult and expensive. Our brand promotion activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our operating results could be harmed.  If we do not successfully maintain and enhance our brand, our business may not grow and we could lose our relationships with health insurance carriers, marketing partners and/or members, which would harm our business, operating results and financial condition.  

 

In addition, we have historically received media attention in connection with our public relations efforts. While we cannot be certain of the impact of media coverage on our business, if it were to be reduced, the number of consumers visiting our platform could decrease, and our cost of acquiring members could increase as a result of a reduction in the number of members coming from our direct member acquisition channel, both of which could harm our business, operating results and financial condition. 

 

System failures or capacity constraints could harm our business and operating results.  

 

The performance, reliability and availability of our ecommerce platforms and underlying network infrastructures are critical to our financial results, our brand and our relationship with members, marketing partners and health insurance carriers. Although we regularly attempt to enhance our ecommerce platform and system infrastructure, system failures and interruptions may occur if we are unsuccessful in these efforts, if we are unable to accurately project the rate or timing of increases in our website traffic or for other reasons, some of which are completely outside our control. Although we have experienced only minor system failures and interruptions to date, we could experience significant failures and interruptions in the future, which would harm our business, operating results and financial condition.  

 

We rely in part upon third-party vendors, including data center and bandwidth providers, to operate our ecommerce platforms. We cannot predict whether additional network capacity will be available from these vendors as we need it, and our network or our suppliers’ networks might be unable to achieve or maintain a sufficiently high capacity of data transmission to allow us to process health insurance applications in a timely manner or effectively download data, especially if our website traffic increases. Any system failure that causes an interruption in or decreases the responsiveness of our services would impair our revenue-generating capabilities and harm our business and operating results and damage our reputation. In addition, any loss of data could result in loss of customers and subject us to potential liability. Our database and systems are vulnerable to damage or interruption from human error, earthquakes, fire, floods, power loss, telecommunications failures, physical or electronic break-ins, computer viruses, acts of terrorism, other attempts to harm our systems and similar events. In addition, our operations are vulnerable to earthquakes in the San Francisco Bay Area and elsewhere in Northern California.  

 

Consumers may access our customer care centers for assistance in connection with submitting health insurance applications. We depend upon third parties, including telephone service providers and third party software providers, to operate our customer care centers. Any failure of the systems that we rely upon in the operation of our customer care center could negatively impact sales as well as our relationship with consumers and members, which could harm our business, operating results and financial condition. 

 

If consumers or carriers opt for more traditional or alternative channels for the purchase and sale of health insurance, our business will be harmed.  

 

Our success depends in part upon widespread consumer and health insurance carrier acceptance of the Internet as a marketplace for the purchase and sale of health insurance. Consumers and health insurance carriers may choose to depend

47 

 


 

more on traditional sources, such as individual agents, or alternative sources may develop, including as a result of health care reform legislation. Our future growth, if any, will depend in part upon: 

  

·

the growth of the Internet as a commerce medium generally, and as a market for consumer financial plans and services specifically; 

 

·

consumers’ willingness to conduct their own health insurance research; 

 

·

our ability to make the process of purchasing health insurance online an attractive alternative to traditional and new means of purchasing health insurance; 

 

·

our ability to successfully and cost-effectively market our services as superior to traditional or alternative sources for health insurance to a sufficiently large number of consumers; and 

 

·

health insurance carriers’ willingness to use us and the Internet as a distribution channel for health insurance plans. 

 

If consumers and health insurance carriers determine that other sources for health insurance and health insurance applications are superior, our business will not grow and our operating results and financial condition would be harmed.  

 

We depend upon Internet search engines to attract a significant portion of the consumers who visit our website, and if we are unable to effectively advertise on search engines on a cost-effective basis, our business and operating results would be harmed.  

 

We derive a significant portion of our website traffic from consumers who search for health insurance through Internet search engines, such as Google, Bing and Yahoo!. A critical factor in attracting consumers to our website is whether we are prominently displayed in response to an Internet search relating to health insurance. Search engines typically provide two types of search results, algorithmic listings and paid advertisements. We rely on both algorithmic listings and paid advertisements to attract consumers to our websites.  

 

Algorithmic search result listings are determined and displayed in accordance with a set of formulas or algorithms developed by the particular Internet search engine. The algorithms determine the order of the listing of results in response to the consumer’s Internet search. From time to time, search engines revise these algorithms. In some instances, these modifications have caused our website to be listed less prominently in algorithmic search results, which has resulted in decreased traffic to our website. We may also be listed less prominently as a result of new websites or changes to existing websites that result in these websites receiving higher algorithmic rankings with the search engine. Our website may become listed less prominently in algorithmic search results for other reasons, such as search engine technical difficulties, search engine technical changes and changes we make to our website. In addition, search engines have deemed the practices of some companies to be inconsistent with search engine guidelines and decided not to list their website in search result listings at all. If we are listed less prominently in, or removed altogether from, search result listings for any reason, the traffic to our websites would decline and we may not be able to replace this traffic, which in turn would harm our operating results. If we decide to attempt to replace this traffic, we may be required to increase our marketing expenditures, which would also increase our cost of member acquisition and harm our operating results.  

 

We purchase paid advertisements on search engines in order to attract consumers to our website. We typically pay a search engine for prominent placement of our name and website when particular health insurance-related terms are searched for on the search engine, regardless of the algorithmic search result listings. In some circumstances, the prominence of the placement of our advertisement is determined by a combination of factors, including the amount we are willing to pay and algorithms designed to determine the relevance of our paid advertisement to a particular search term. As with algorithmic search result listings, search engines may revise the algorithms relevant to paid advertisements and websites other than our ecommerce platform may become more optimized for the algorithms. These changes may result in our having to pay increased amounts to maintain our paid advertisement placement in response to a particular search term. We could also have to pay increased amounts should the market share of major search engines continue to become more concentrated with a single search engine. Additionally, we bid against our competitors and others for the display of these paid search engine advertisements. Many of our competitors, including many health insurance carriers, have greater resources with which to bid and better brand recognition than we do. We have experienced increased competition from health insurance carriers and some of our marketing partners for both algorithmic search result listings and for paid advertisements, which has increased

48 

 


 

our marketing and advertising expenses. If this competition increases further, or if the fees associated with paid search advertisements increase as a result of algorithm changes or other factors, our advertising expenses could rise significantly or we could reduce or discontinue our paid search advertisements, either of which could harm our business, operating results and financial condition.  

 

We rely significantly on marketing partners and our business and operating results would be harmed if we are unable to maintain effective relationships with our existing marketing partners or if we do not establish successful relationships with new marketing partners.  

 

In addition to marketing through Internet search engines, we frequently enter into contractual marketing relationships with other online and offline businesses that promote us to their customers. These marketing partners include financial and online service companies, affiliate programs and online advertisers and content providers. We also have relationships with marketing partners, including pharmacy chains, that promote our Medicare platforms to their customers.  We compensate many of our marketing partners for their referrals on a submitted health insurance application basis and, if they are licensed to sell health insurance, may share a percentage of the commission we earn from the health insurance carrier for each member referred by the marketing partner.  

 

Many factors influence the success of our relationship with our marketing partners, including: 

 

·

the continued positive market presence, reputation and growth of the marketing partner; 

 

·

the effectiveness of the marketing partner in marketing our website and services, including whether the marketing partner is successful in maintaining the prominence of its website in algorithmic search result listings and paid Internet advertisements; 

 

·

the compliance of our marketing partners, and of the manner marketing partners refer consumers to our platforms, with applicable laws, regulations and guidelines; 

 

·

the interest of the marketing partner’s customers in the health insurance plans that we offer on our ecommerce platform; 

 

·

the contractual terms we negotiate with the marketing partner, including the marketing fees we agree to pay a marketing partner; 

 

·

the percentage of the marketing partner’s customers that submit applications or purchase health insurance policies through our ecommerce platform; 

 

·

the ability of a marketing partner to maintain efficient and uninterrupted operation of its website; and 

 

·

our ability to work with the marketing partner to implement website changes, launch marketing campaigns and pursue other initiatives necessary to maintain positive consumer experiences and acceptable traffic volumes. 

 

For instance, we partner with Internet lead aggregators who refer a significant number of consumers to our online platforms. Major search engines have in the past and may in the future determine not to list lead aggregator websites prominently in search result listings for various reasons, which would cause a significant reduction in the number of consumers referred to us through our marketing partner channel. If we are unable to maintain successful relationships with our existing marketing partners or fail to establish successful relationships with new marketing partners, our business, operating results and financial condition will be harmed.  

 

The impact that health care reform will have on our relationships with marketing partners is unclear. To the extent that health care reform makes it less profitable or desirable for marketing partners to promote us to their customers, we may lose relationships with existing marketing partners and may have difficulty entering into relationships with new marketing partners. We may also need to reduce the compensation that we pay to marketing partners to the extent that health care reform has the effect of reducing commissions for individual and family health insurance. There is no guarantee that we will be able to amend our agreements to reduce the compensation that we pay to acceptable levels in light of the commission rates that we receive. If we are not able to do so, our business, operating results and financial condition could be harmed.  In addition, the promulgation of laws, regulations or guidelines, or the interpretation of existing laws, regulations and

49 

 


 

guidelines, by state departments of insurance or by CMS, could cause our relationships with our marketing partners to be in noncompliance with those laws, regulations and guidelines.  For instance, as a result of our acquisition of PlanPrescriber, we have marketing partner relationships with pharmacy chains that utilize aspects of our platform and tools.  Our relationships with these pharmacy chains result in the referral of a significant number of individuals to us who are interested in purchasing Medicare plans.  If CMS or state departments of insurance were to change existing laws, regulations or guidelines, or interpret existing laws, regulations or guidelines, to prohibit these arrangements, we would experience a significant decline in the number of Medicare-eligible individuals who are referred to our platforms and customer care centers, which would harm our business, operating results and financial condition and could result in a write-down of the value of goodwill and intangible assets acquired in our PlanPrescriber acquisition.   

  

We rely on health insurance carriers to accurately and regularly prepare commission reports, and if these reports are inaccurate or not sent to us in a timely manner, our business and operating results could be harmed. We also may not recognize trends in our membership as a result of a lack of information from health insurance carriers. 

 

For individual and family, small business, ancillary and Medicare Supplement health insurance plans, health insurance carriers typically pay us a specified percentage of the premium amount on a health insurance policy that we have sold during the period that a member maintains coverage under the policy. For both Medicare Advantage and Medicare Part D prescription drug policies, health insurance carriers typically pay us a fixed commission amount during the period the policy remains active, typically for up to six years, or longer depending on carrier the arrangement, provided that the policy remains active with us. We rely on health insurance carriers to timely and accurately report the amount of commissions earned by us, and we calculate our commission revenue, prepare our financial reports, projections and budgets and direct our marketing and other operating efforts based on the reports we receive from health insurance carriers. There have been instances where we have determined that policy cancellation data reported to us by a health insurance carrier has not been completely accurate. Although we recognize commissions reported to us net of estimated cancellations, the extent to which health insurance carriers are inaccurate in their reporting of policy cancellations could cause us to change our cancellation estimates, which could adversely impact our revenues. It is often difficult for us to independently determine whether or not carriers are accurately reporting commissions due to us. To the extent that health insurance carriers understate or fail to accurately report the amount of commissions due to us in a timely manner or at all, we will not recognize revenue to which we are entitled, which would harm our business, operating results and financial condition.  

 

We also are dependent on health insurance carriers and others for data related to our membership. For instance, with respect to health insurance plans other than small business group health insurance, health insurance carriers do not directly report member cancellations to us, resulting in the need for us to determine cancellations using payment data that carriers provide. We infer cancellations from this payment data by analyzing whether payments from members have ceased for a period of time, and we may not learn of a cancellation for several months, given that some of our members pay on a schedule less frequently than monthly (e.g., quarterly). With respect to our small business group membership, many groups notify the carrier directly with respect to increases or decreases in group size and policy cancellations. Our insurance carrier partners often do not communicate this information to us, and it often takes a significant amount of time for us to learn about small business group cancellations and changes in our membership within the group itself. We often are not made aware of policy cancellations until the time of the group’s annual renewal.  

 

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. We also reconcile information health insurance carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated our membership. Additionally, health insurance carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. For these and other reasons, including if current trends in membership cancellation are inconsistent with past cancellation trends that we use to estimate our membership or if carriers subsequently report changes to the commission payments that they previously reported to us, our actual membership could be different from our estimates, perhaps materially. Total revenue per estimated member for the period would also change if our estimated membership changed. Our estimate regarding the average amount of time our members maintain their health insurance plans also could be inaccurate as it is dependent upon the accuracy of our membership estimates.  

  

Our operating results fluctuate depending upon health insurance carrier payment practices and the timing of our receipt of commission reports from health insurance carriers.  

50 

 


 

 

The timing of our revenue depends upon the timing of our receipt of commission reports and associated payments from health insurance carriers. There have been instances where their report of commissions and payment have been delayed, such as during holiday periods. Any delay could materially impact our financial results for a given quarter as we would not be able to recognize the related commission revenue in that quarter. In addition, much of our commission override revenue is not reported and paid to us in accordance with a scheduled pattern, and some is only reported and paid to us once per year. This could result in a large amount of commission revenue from a carrier being recorded in a given quarter that is not indicative of the amount of revenue we may receive from that carrier in subsequent quarters, causing fluctuations in our operating results. We could report revenue below the expectations of our investors or securities analysts in any particular period if a material report or payment from a health insurance carrier were delayed or not received within the time frame required for revenue recognition.  

 

We may be unsuccessful in competing effectively against current and future competitors.  

The market for selling health insurance plans is highly competitive. We compete with entities and individuals that offer and sell health insurance plans utilizing traditional distribution channels as well as the Internet. Our competitors include local insurance agents across the United States who sell health insurance plans in their communities. There are a number of agents that operate websites and provide an online shopping experience for consumers interested in purchasing health insurance. Some local agents use “lead aggregator” services that use the Internet to find consumers interested in purchasing health insurance and are compensated for referring those consumers to the traditional agent.   In addition to health insurance brokers and agents, many health insurance carriers directly market and sell their plans to consumers through call centers and their own websites. Although we offer health insurance plans for many of these carriers, they also compete with us by offering their plans directly to consumers. We will also compete with state and federal health insurance exchanges implemented as a result of health care reform. Health care reform also will result in health insurance plan cost and benefit data being more readily accessible, which could facilitate additional competition. In connection with our marketing of Medicare plans, we also compete with the original Medicare program.  In addition, CMS offers plan information, comparison tools, call centers and online enrollment for Medicare Advantage and Medicare Part D prescription drug plans. 

 

In licensing our health insurance purchasing platform, we compete with companies providing technology that automates premium quoting, research and analysis of health insurance plans, member enrollment and other tools that support online sales efforts by health insurance carriers and their agents and brokers. 

 

We may not be able to compete successfully against our current or future competitors. Some of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition and significantly greater financial, technical, marketing and other resources than we do. As compared to us, our current and future competitors may be able to:  

  

·

undertake more extensive marketing campaigns for their brands and services; 

 

·

devote more resources to website and systems development; 

 

·

negotiate more favorable commission rates and commission override payments; and 

 

·

make more attractive offers to potential employees, marketing partners and third-party service providers. 

 

In addition, CMS has the ability to regulate our marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans.  

 

Competitive pressures may result in our experiencing increased marketing costs, decreased traffic to our website and loss of market share, or may otherwise harm our business, operating results and financial condition.  

 

There are many risks associated with our operations in China.  

 

A portion of our operations is conducted in China. Among other things, we use employees in China to maintain and update our ecommerce platform. This and other information is delivered to us through secured communications over the Internet. Our business would be harmed if this connection temporarily failed and we were prevented from promptly updating our software or implementing other changes to our database and systems. Our operations in China also expose us

51 

 


 

to different and unfamiliar laws, rules and regulations, including different intellectual property laws, which are not as protective of our intellectual property as the laws in the United States, and different labor and tax laws. United States and Chinese trade laws may impose restrictions on the importation of programming or technology to or from the United States. Additionally, we have recently experienced greater competition for qualified personnel in China, which has raised market salaries and increased our compensation costs related to employees in that location. If competition for personnel increases further, our compensation expenses could rise considerably or, if we determine to not increase compensation levels, our ability to attract and retain qualified personnel in China may be impaired, which could harm our business, operating results and financial condition. These risks could cause us to incur increased expenses and could harm our ability to effectively and successfully manage our operations in China, which in turn could cause our business, operating results and financial condition to suffer.  

 

Our subsidiary in China has a subsidiary business insurance agency license in the Fujian province in China pursuant to which we may sell health, accident and life insurance in the Fujian province. Our license is up for renewal at the end of 2014. We have relationships with insurance companies to host on our technology platform certain of those companies’ products that are offered throughout China. Additionally, we have entered, and may in the future continue to enter, into relationships with marketing partners to refer additional consumers to our website. We have limited experience marketing or selling insurance in China or in adapting our business and ecommerce platform to Chinese markets and cultures, legal and regulatory regimes or business customs. For instance, the laws and regulations applicable to our marketing and selling insurance online and assisting others in those efforts in China are unclear, and our operations may be in violation of them. In addition, insurance laws and regulations in China are in a state of development, and the laws and regulations may change to prohibit or restrict our marketing insurance online. The consequences of violating insurance and other applicable laws and regulations in China are unclear, but they could result in the termination of our license and our ability to host insurance products on our technology platform, payment of fines and damages and could harm our business as a whole. For various reasons, we may not expand in China, and even if we do, there can be no assurance that our ecommerce platform in China would ever generate a significant amount of revenue or otherwise be successful. Our success in establishing an insurance-related business in China is also dependent upon many of the factors that influence the success of our business in the United States, including, but not limited to, our receiving regulatory approvals (including the renewal of our license), acceptance of the Internet and our ecommerce platform as a marketplace for the purchase of insurance, our success in marketing our ecommerce platform and in retaining members who purchase insurance through that platform, our ability to enter into and maintain relationships with insurance carriers, commission rates, the affordability of the insurance products offered, insurance carrier business practices, the effectiveness with which we establish a brand identity, performance, reliability and availability of our ecommerce platform, competition, the regulatory environment and the manner in which health care delivery is financed and changes to such environment or manner, our ability to attract and retain qualified personnel and network security. 

 

Our participation and success in the insurance market in China may be impacted by additional factors given that outside of Xiamen city, the insurance products offered on our website are offered directly by insurance carriers.  As a result, our success in selling insurance outside of Xiamen city is dependent upon many factors, including our dependence on insurance carriers for the products on our website, the insurance carriers’ relationship with consumers, our relationship with the insurance carriers, the insurance carriers’ ability to maintain licenses and regulatory approvals, and the number, quality and attractiveness of the insurance products offered by the insurance carriers through our platform. While there is no certainty that we would be able to expand our presence in the insurance industry in China, we may attempt to do so. If we decide to do so, we will need to receive additional government licenses and approvals or enter into additional relationships and we may face disadvantages in doing so as a result of our subsidiary in China being wholly foreign owned.  

  

Our sponsorship and advertising business may not be successful.  

 

We sell advertising space to health insurance carriers on our website through our sponsorship and advertising program. Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website.  Health insurance carriers have and may continue to determine to eliminate or reduce spending on our sponsorship and advertising program as a result of various aspects of health care reform, including the medical loss ratio requirements that became effective in 2011.  As a result, our business, operating results and financial condition could be harmed.  To the extent that economic conditions, health care reform or other factors impact the amount health insurance carriers are willing to pay for advertising on our ecommerce platform, our sponsorship and advertising program will be adversely impacted. The success of our sponsorship and advertising program is dependent upon a number of other factors, including the effectiveness of the sponsorship and advertising program as a cost-effective method for carriers to obtain additional members, consumer and health insurance carrier adoption of the Internet and our ecommerce platform as a

52 

 


 

medium for the purchase and sale of health insurance, our ability to attract consumers visiting our ecommerce platform and convert those consumers into members, the existence of a relationship between us and a diverse group of carriers that offer a number of health insurance plans in the markets in which we attempt to sell advertising, the cost, benefit and brand recognition of the health insurance plan that is the subject of the advertising, the impact the advertising has on the sale of the health insurance plan that is the subject of the advertising and the effectiveness of the carrier’s other means of advertising. In addition, while our practice of selling advertising is described on our ecommerce platform, it could cause consumers to perceive us as not objective, which could harm our brand and result in a decline in our health insurance sales. It also could adversely impact our relationship with health insurance carriers that do not purchase our advertising. As a result, our business, operating results and financial condition could be harmed.  

 

We also develop, host and maintain carrier dedicated Medicare plan websites through our advertising program.  Our success in doing so is dependent upon the same factors that could impact our sponsorship program. In addition, since we maintain relationships with a limited number of health insurance carriers to sell their Medicare plans, our Medicare plan-related advertising revenue is concentrated in a small number of health insurance carriers and our ability to generate Medicare plan-related advertising revenue would be harmed by the termination or non-renewal of any of these relationships.  Moreover, in light of the regulations applicable to the marketing and sale of Medicare plans, and given that these regulations are often unclear, change frequently and are subject to changing interpretations, we may in the future not be permitted to sell Medicare plan related advertising.  If we are not successful in generating Medicare plan related advertising revenue, our business operating results and financial condition could be harmed.  

 

We may not be successful in licensing the use of our ecommerce technology to health insurance carriers and other third parties.  

 

We license the use of our ecommerce technology to health insurance carriers and agents. Carriers use our platform to offer their own health insurance policies on their websites, and agents use it to power their quoting and online content. If we do not grow our revenue from the license of our technology, or if the rate of growth declines, our business, operating results and financial condition may be harmed. The impact that health care reform may have on our technology licensing business is unclear. Health care reform could reduce health insurance carrier and agent demand for our technology licensing platform as a result of the medical loss ratio requirements that became effective in 2011 or for other reasons, and health insurance carriers who currently use the platform could determine to cease using it, reduce the number and type of plans offered on the platform or renegotiate the fees that they pay, any of which would reduce the revenue we receive from our technology licensing business.  

 

The business of licensing the use of our technology to others could facilitate carrier, health insurance agent and other third party competition with us in the sale of health insurance over the Internet and is subject to a number of additional risks and uncertainties, including consumer and health insurance carrier adoption of our ecommerce platform as a medium for the purchase and sale of health insurance, our ability to establish relationships with new health insurance carriers, the reliability and performance of our ecommerce platform and the relative cost of developing competing technology. If we are not able to offer health insurance carriers and other third parties a reliable platform to cost-efficiently offer their plans over the Internet, our technology licensing business will be unsuccessful.  

We may not be successful in licensing the use of our technology or performing services pursuant to federal or state government contracts. 

We may license the use of our technology and provide services to government entities in connection with health care reform and its requirement that states establish health insurance exchanges.  While we have been a party to a small number of government contracts as a prime contractor or as a subcontractor, we are new to government contracting.  Generally, government contracts are offered through a competitive bidding process.  A number of entities may compete for the award of any particular government contract or related subcontract, and we may not be able to outbid our competitors.  Even if we are awarded a contract, unsuccessful bidders may protest or challenge the contract award, which could result in our losing the contract.  Complicated rules apply to doing business with the federal and state governments, including without limitation procurement laws and regulations.  In addition, socio-economic obligations, including various restrictions relating to those of our employees that may perform under the government contract, may accompany government contracts.  These requirements may require us to restructure aspects of our operations to perform under a contract, which may be difficult or impossible.  As a government contractor, we are subject to audits, cost reviews and investigations by oversight agencies.  We may not be successful in our effort to enter into government contracts, and even if we are, we may face difficulty and unanticipated expense in adapting our platform and software, and complying with applicable laws, regulations and

53 

 


 

contractual requirements.  If we are not successful in our government contracting efforts, our business, operating results and financial condition could be harmed.  In addition, if we fail to comply with the terms of one or more of our government contracts or applicable laws and regulations, we could be suspended or barred from future government projects for a significant period of time, as well as face damages and civil or criminal fines and penalties, which would harm our business, operating results and financial condition. 

Government contracts that we have entered into for the use of our services or licensing the use of our technology have short terms.  Our government contracts may not be renewed for any reason, including as a result of performance of the contract, competing solutions or a change in the governmental entity’s preferences.  Furthermore, the contracts may be terminated as a result of our performance or as a result of the performance or actions of third parties involved in the contracts, such as a subcontractor or the prime contractor where we are a subcontractor.  The termination or non-renewal of any of our government contracts could harm our business, operating results and financial condition and make it more difficult to successfully bid on future government contracting opportunities. 

We may not be able to adequately protect our intellectual property, which could harm our business and operating results.  

 

We believe that our intellectual property is an essential asset of our business and that our technology infrastructure currently gives us a competitive advantage in the distribution of individual and family and small business health insurance. We rely on a combination of copyright, trademark and trade secret laws as well as confidentiality procedures and contractual provisions to establish and protect our intellectual property rights in the United States. Although we have applied for patents in the United States, they may not result in issued patents. We have not filed for protection of our intellectual property in any foreign jurisdiction other than China. We have Chinese-registered computer software copyrights for an internally-developed software system and a project management tool and have certain trademarks in China. We have not filed any patent applications in China. The efforts we have taken to protect our intellectual property may not be sufficient or effective, and our trademarks, copyrights and patents if issued, may be held invalid or unenforceable. Moreover, the law relating to intellectual property is not as developed in China, and our intellectual property rights may not be as respected in China as they are in the United States. Any United States or other patents issued to us may not be sufficiently broad to protect our proprietary technologies, and given the costs of obtaining patent protection, we may choose not to seek patent protection for certain of our proprietary technologies. We may not be effective in policing unauthorized use of our intellectual property, trade secrets and other confidential information, and even if we do detect violations, litigation may be necessary to enforce our intellectual property rights. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive, could divert our management’s attention and may result in a court determining that our intellectual property or other rights are unenforceable. If we are not successful in cost-effectively protecting our intellectual property rights, trade secrets and confidential information, our business, operating results and financial condition could be harmed.  

  

We may in the future be subject to intellectual property rights claims, which are extremely costly to defend, could require us to pay significant damages and could limit our ability to use certain technologies in the future.  

 

There are a large number of patents, copyrights, trademarks and trade secrets applicable to the internet and technology industries and entities frequently enter into litigation based on allegations of infringement or other violations of intellectual property rights. We have received, and may in the future receive, notices that claim we have misappropriated, infringed or misused other parties’ intellectual property rights, and, to the extent we gain greater visibility, we face a higher risk of being the subject of intellectual property infringement claims. There may be third-party intellectual property rights, including issued or pending patents that cover significant aspects of our technologies or business methods or that cover third-party technology that we use as a part of our websites. Any intellectual property claim against us, with or without merit, could be time consuming, expensive to settle or litigate and could divert our management’s attention and other resources. These claims also could subject us to significant liability for damages and could result in our having to stop using technology found to be in violation of a third party’s rights. We might be required to seek a license for third-party intellectual property, which may not be available on reasonable terms or at all. Even if a license is available, we could be required to pay significant royalties, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant effort and expense. If we cannot license or develop technology for any infringing aspect of our business, we would be forced to limit our services and may be unable to compete effectively. Any of these results would harm our business, operating results and financial condition. 

 

54 

 


 

Any legal liability, regulatory penalties, or negative publicity for the information on our website or that we otherwise distribute or provide will likely harm our business and operating results.  

 

We provide information on our website, through our customer care centers and in other ways regarding health insurance in general and the health insurance plans we market and sell, including information relating to insurance premiums, coverage, benefits, provider networks, exclusions, limitations, availability, plan comparisons and insurance company ratings. A significant amount of both automated and manual effort is required to maintain the considerable amount of insurance plan information on our website. Separately, from time to time, we use the information provided on our website and otherwise collected by us to publish reports designed to educate consumers, facilitate public debate, and facilitate reform at the state and federal level relating to the accessibility and affordability of health insurance. We also regularly provide health insurance plan information in our customer care centers. If the information we provide on our website, through our customer care centers or otherwise is not accurate or is construed as misleading, or if we do not properly assist individuals and businesses in purchasing health insurance, members, health insurance carriers and others could attempt to hold us liable for damages, our relationships with health insurance carriers could be terminated and regulators could attempt to subject us to penalties, revoke our licenses to transact health insurance business in a particular jurisdiction, and/or compromise the status of our licenses to transact health insurance business in other jurisdictions, which could result in our loss of our commission revenue. In the ordinary course of operating our business, we have received complaints that the information we provided was not accurate or was misleading. Although in the past we have resolved these complaints without significant financial cost, we cannot guarantee that we will be able to do so in the future. In addition, these types of claims could be time-consuming and expensive to defend, could divert our management’s attention and other resources, and could cause a loss of confidence in our services. As a result, whether or not we are able to successfully resolve these claims, they could harm our business, operating results and financial condition.  

 

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We have become, and may in the future become, involved in litigation in the ordinary course of our business. If we are found to have violated laws or regulations, we could lose our relationship with health insurance carriers and be subject to various fines and penalties, including revocation of our licenses to sell insurance, and our business, operating results and financial condition would be materially harmed. We would also be harmed to the extent that related publicity damages our reputation as a trusted source of information relating to health insurance and its affordability. It could also be costly to defend ourselves regardless of the outcome. 

 

Changes in our management and key employees could affect our financial results.   

 

Our success is dependent upon the performance of our senior management and key personnel. Our management and employees can terminate their employment at any time.  Many of our senior management and key employees have sold shares of our common stock in the open market, and some have sold a significant portion of their vested holdings.  These employees may be more likely to leave us given that they have liquidated some or a substantial percentage of their holdings. The loss of the services of any of our executive officers or key employees could harm our business. For example, we appoint a single writing agent with each insurance carrier. If we lose the service of our appointed writing agent, the duties of writing agent will need to be transitioned to other company personnel. Due to our national reach and the large number of carrier partners whose policies are purchased by our members, this transition may be difficult and requires a significant period of time to complete. If the transition is not successful or takes too long to complete, our agency relationship with particular insurance carriers may be terminated, our commission payments could be discontinued or delayed and, as a result, our business, operating results and financial condition would be harmed.  Our success is also dependent upon our ability to attract additional personnel for all areas of our organization. We may not be successful in attracting and retaining personnel on a timely basis, on competitive terms or at all. If we are unable to attract and retain the necessary personnel, our business would be harmed. 

 

We recently hired a new president and chief operating officer, and the employment of our executive vice president of business and corporate development and the employment of our chief technology officer recently terminated.  We are likely to experience change in our operations as a result.  If we are not effective in managing this transition in our leadership and changes in our operations, our business could be adversely impacted and our operating results and financial condition could be harmed.   

 

If we fail to manage the expansion of our business, our business and operating results would be harmed.  

 

55 

 


 

We have expanded our operations significantly and have recently entered into the business of selling Medicare plans and providing the use of our technology and services to governmental entities.  Our entering into these new areas of business places increasing and significant demands on our management, our operational and financial systems and infrastructure and our other resources. If we do not effectively manage this expansion, the quality of our services could suffer, which could harm our business, operating results and financial condition. In order to successfully expand our business, we need to hire, integrate and retain highly skilled and motivated employees. We also need to continue to improve our existing systems for operational and financial management, including our reporting systems, procedures and controls. These improvements could require significant capital expenditures and place increasing demands on our management. We may not be successful in managing or expanding our operations or in maintaining adequate financial and operating systems and controls. If we do not successfully implement improvements in these areas, our business, operating results and financial condition will be harmed.  

 

Seasonality may cause fluctuations in our financial results.  

 

The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear.  

 

The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year. 

 

In both 2011 and 2012, we significantly increased our temporary customer care center staff during the third quarter in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 have had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur again in future years. 

 

Based on these seasonal trends, we expect our revenue to be highest in the fourth quarter of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year.  

 

Acquisitions could disrupt our business and harm our financial condition and operating results. 

 

We may decide to acquire businesses, products and technologies. Our ability as an organization to successfully make and integrate acquisitions is unproven.  Acquisitions could require significant capital infusions and could involve many risks, including the following:  

 

·

an acquisition may negatively impact our results of operations because it will require us to incur transaction expenses, and after the transaction, may require us to incur charges and substantial debt or liabilities, may require the amortization, write down or impairment of amounts related to deferred compensation, goodwill and other intangible assets, or may cause adverse tax consequences, substantial depreciation or deferred compensation charges; 

 

·

an acquisition undertaken for strategic business purposes may negatively impact our results of operations; 

 

56 

 


 

·

we may encounter difficulties in assimilating and integrating the business, technologies, products, personnel or operations of companies that we acquire, particularly if key personnel of the acquired company decide not to work for us; 

 

·

an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management; 

 

·

we may be required to implement or improve internal controls, procedures and policies appropriate for a public company at a business that prior to the acquisition lacked these controls, procedures and policies; 

 

·

the acquired businesses, products or technologies may not generate sufficient revenue to offset acquisition costs or to maintain our financial results; 

 

·

we may have to issue equity securities to complete an acquisition, which would dilute our stockholders’ ownership and could adversely affect the market price of our common stock; and 

 

·

acquisitions may involve the entry into geographic or business markets in which we have little or no prior experience. 

 

We cannot assure you that we will be able to identify or consummate any future acquisition on favorable terms, or at all. If we do pursue an acquisition, it is possible that we may not realize the anticipated benefits from the acquisition or that the financial markets or investors will negatively view the acquisition. Even if we successfully complete an acquisition, it could harm our business, operating results and financial condition.  

 

If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements could be impaired, which could adversely affect our operating results, our ability to operate our business and our stock price. 

 

We have a complex business organization, and we recently expanded our business operations into the areas of the sale of Medicare plans and government contracting. Ensuring that we have adequate internal financial and accounting controls and procedures in place to help ensure that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently and is complicated by the expansion of our business operations.  Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all errors or all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.  

 

  

As a result, we cannot assure that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations and annual auditor attestation reports regarding disclosure controls and the effectiveness of our internal control over financial reporting required under Section 404 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder. The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to timely meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock price and potential lawsuits against us. 

 

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results. 

 

Our provision for income taxes is subject to volatility and could be adversely affected by earnings differing materially from our projections, changes in the valuation of our deferred tax assets and liabilities, expiration of or lapses in the research

57 

 


 

and development tax credit laws, tax effects of share-based compensation or by changes in tax laws, regulations, accounting principles, including accounting for uncertain tax positions, or interpretations thereof. For instance, in October 2010, the state of California approved budget legislation which substantially limited the utilization of net operating losses. The new law did not affect the amount of net operating losses and tax credits that we expect to ultimately use to offset future California taxes, but limited the amount we could utilize in 2010 and 2011, resulting in our paying higher cash taxes. To the extent that our provision for income taxes is subject to volatility or adverse outcomes as a result of tax examinations, our operating results could be harmed.  

 

Significant judgment is required to determine the recognition and measurement attribute prescribed in U.S. generally accepted accounting principles (“U.S. GAAP”) relating to accounting for income taxes. In addition, U.S. GAAP applies to all income tax positions, including the potential recovery of previously paid taxes, which if settled unfavorably could adversely impact our provision for income taxes or additional paid-in capital. In addition, we are subject to examinations of our income tax returns by the Internal Revenue Service and other tax authorities. We assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There may be exposure that the outcomes from these examinations will have an adverse effect on our operating results and financial condition.  

 

Any expansion of our business into foreign countries involves significant risks.  

 

We currently do not sell health insurance or license our technology platform outside the United States other than in China. We may attempt to expand aspects of our business to additional geographic regions. We face significant challenges in connection with expanding our business into any foreign country, since we have no prior experience marketing or selling insurance in any foreign jurisdiction. Additionally, demand for private health insurance is not significant in many foreign countries as a result of government-sponsored health care systems. In addition to facing many of the same challenges we face domestically, we also would have to overcome other obstacles such as: 

  

·

legal, political or systemic restrictions on the ability of United States companies to market insurance or otherwise do business in foreign countries; 

 

·

varied, unfamiliar and unclear legal and regulatory restrictions; 

 

·

less extensive adoption of the Internet as a commerce medium or information source and increased restriction on the content of websites; and 

 

·

the adaptation of our website and distribution model to fit the particular foreign country. 

 

As a result of these obstacles, we may find it impossible or prohibitively expensive to expand our services internationally or we may be unsuccessful should we attempt to do so, either of which could harm our business, operating results and financial condition.  

 

Risks Related to Insurance Regulation 

 

Regulation of the sale of health insurance is subject to change, and future regulations could harm our business and operating results.  

 

The laws and regulations governing the offer, sale and purchase of health insurance are subject to change, and future changes may be adverse to our business. For example, a long standing provision in each state’s law that we believe is  advantageous to our business is that once health insurance premiums are set by the carrier and approved by state regulators, they are fixed and not generally subject to negotiation or discounting by insurance companies or agents. Additionally, state regulations generally prohibit carriers, agents and brokers from providing financial incentives, such as rebates, to their members in connection with the sale of health insurance. As a result, we do not currently compete with carriers or other agents and brokers on the price of the health insurance plans offered on our website. If these regulations change, we could be forced to reduce prices or provide rebates or other incentives for the health insurance plans sold through our ecommerce platform, which would harm our business, operating results and financial condition.  

 

States have, and will continue, to adopt new laws and regulations in response to health care reform legislation.  It is too early to predict how these new laws and regulations will impact our business, but in some cases such laws and regulations

58 

 


 

could amplify the adverse impacts of health care reform, or may adopt new requirements that adversely impact our business, operating results and financial condition. 

  

We are also subject to additional insurance regulatory risks, because we use the Internet as our distribution platform. In many cases, it is not clear how existing insurance laws and regulations apply to Internet-related health insurance advertisements and transactions. To the extent that new laws or regulations are adopted that conflict with the way we conduct our business, or to the extent that existing laws and regulations are interpreted adversely to us, our business, operating results and financial condition would be harmed.  

 

If we fail to comply with the numerous laws and regulations that are applicable to the sale of health insurance, our business and operating results would be harmed.  

 

The sale of health insurance is heavily regulated by each state in the United States. For instance, state regulators require us to maintain a valid license in each state in which we transact health insurance business and further require that we adhere to sales, documentation and administration practices specific to that state. In addition, each employee who transacts health insurance business on our behalf must maintain a valid license in one or more states. Because we do business in all 50 states and the District of Columbia, compliance with health insurance-related laws, rules and regulations is difficult and imposes significant costs on our business. Each jurisdiction’s insurance department typically has the power, among other things, to:  

  

·

grant and revoke licenses to transact insurance business; 

 

·

conduct inquiries into the insurance-related activities and conduct of agents and agencies; 

 

·

require and regulate disclosure in connection with the sale and solicitation of health insurance; 

 

·

authorize how, by which personnel and under what circumstances insurance premiums can be quoted and published and an insurance policy sold; 

 

·

approve which entities can be paid commissions from carriers and the circumstances under which they may be paid; 

 

·

regulate the content of insurance-related advertisements, including web pages, and other marketing practices; 

 

·

approve policy forms, require specific benefits and benefit levels and regulate premium rates; 

 

·

impose fines and other penalties; and 

 

·

impose continuing education requirements. 

 

Due to the complexity, periodic modification and differing interpretations of insurance laws and regulations, we may not have always been, and we may not always be, in compliance with them. New insurance laws, regulations and guidelines also may not be compatible with the sale of health insurance over the Internet or with various aspects of our platform or manner of marketing or selling health insurance plans. Failure to comply with insurance laws, regulations and guidelines or other laws and regulations applicable to our business could result in significant liability, additional department of insurance licensing requirements, the revocation of licenses in a particular jurisdiction and/or our inability to sell health insurance plans, which could significantly increase our operating expenses, result in the loss of our commission revenue and otherwise harm our business, operating results and financial condition.  Moreover, an adverse regulatory action in one jurisdiction could result in penalties and adversely affect our license status or reputation in other jurisdictions due to the requirement that adverse regulatory actions in one jurisdiction be reported to other jurisdictions. Even if the allegations in any regulatory or other action against us are proven false, any surrounding negative publicity could harm consumer, marketing partner or health insurance carrier confidence in us, which could significantly damage our brand. Because some consumers, marketing partners and health insurance carriers may not be comfortable with the concept of purchasing health insurance using the Internet, any negative publicity may affect us more than it would others in the health insurance industry and would harm our business, operating results and financial condition. Changes in insurance laws, regulations and guidelines may also be incompatible with various aspects of our business and require that we make significant modifications to our existing technology or practices, which may be costly and time-consuming to implement and could also harm our business, operating results and financial condition. 

59 

 


 

 

In addition, we have received, and may in the future receive, inquiries from regulators regarding our marketing and business practices. We typically respond by explaining how we believe we are in compliance with relevant regulations or may modify our practices in connection with the inquiry. Any modification of our marketing or business practices in response to future regulatory inquiries could harm our business, operating results or financial condition.  

  

Risks Related to the Internet and Electronic Commerce  

 

Our business is subject to security risks and, if we are unable to safeguard the security and privacy of confidential data, including personal health information, our business will be harmed.  

 

Our services involve the collection and storage of confidential information of consumers and the transmission of this information to their chosen health insurance carriers. For example, we collect names, addresses, Social Security and credit card numbers, and information regarding the medical history of consumers in connection with their applications for health insurance. As a result, we are subject to various federal, state and international laws and regulations regarding the collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information.  We cannot guarantee that our facilities and systems, and those of our third party service providers, will be free of security breaches, acts of vandalism, computer viruses, misplaced or lost data, programming and/or human errors or other similar events. Compliance with privacy and security laws, requirements and regulations may result in cost increases due to new constraints on our business, the development of new processes, the effects of potential non-compliance by third party service providers, and enforcement actions.  We may be required to expend significant capital and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures, techniques used to obtain unauthorized access or to sabotage systems change frequently. As a result, we may be unable to anticipate these techniques or to implement adequate preventative measures. Additionally, although our third party service providers are required to implement appropriate security measures, we have limited control over their actions and practices. 

 

Any compromise or perceived compromise of our security could damage our reputation and our relationship with our members, marketing partners and health insurance carriers, could reduce demand for our services and could subject us to significant liability and expense as well as regulatory action or private privacy-related lawsuits, which would harm our business, operating results and financial condition. In addition, in the event that data security laws are implemented, or our health insurance carrier or other partners determine to impose new requirements on us relating to data security, we may not be able to timely comply with such requirements or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could result in our inability to sell health insurance plans in a particular jurisdiction or for a particular health insurance carrier or subject us to liability for non-compliance, any of which would damage our business, operating results and financial condition. 

 

Government regulation of the Internet could adversely affect our business.  

 

The laws governing general commerce on the Internet remain unsettled and it may take years to fully determine whether and how existing laws such as those governing intellectual property, privacy and taxation apply to the Internet. In addition, the growth and development of the market for electronic commerce may prompt calls for more stringent consumer protection laws that may impose additional burdens on companies conducting business over the Internet. Any new laws or regulations or new interpretations of existing laws or regulations relating to the Internet could harm our business and we could be forced to incur substantial costs in order to comply with them, which would harm our business, operating results and financial condition.  

 

Our business could be harmed if we are unable to correspond with our consumers or market the availability of our ecommerce platform by email.  

 

We use email to market our services to potential members and as the primary means of communicating with our existing members. The laws and regulations governing the use of email for marketing purposes continue to evolve and the growth and development of the market for commerce over the Internet may lead to the adoption of additional legislation. If new laws or regulations are adopted, or existing laws and regulations are interpreted, to impose additional restrictions on our ability to send email to our members or potential members, we may not be able to communicate with them in a cost-effective manner. In addition to legal restrictions on the use of email, Internet service providers, e-mail service providers and others attempt to block the transmission of unsolicited email, commonly known as “spam.” Many Internet and e-mail

60 

 


 

service providers have relationships with organizations whose purpose it is to detect and notify the Internet and e-mail service providers of entities that the organization believes is sending unsolicited e-mail.  If an Internet or e-mail service provider identifies email from us as “spam” as a result of reports from these organizations or otherwise, we can be placed on a restricted list that will block our email to members or potential members. If we are unable to communicate by email with our members and potential members as a result of legislation, blockage or otherwise, our business, operating results and financial condition would be harmed.  

 

Consumers depend upon third-party service providers to access our website, and our business and operating results could be harmed as a result of technical difficulties experienced by these service providers.  

 

Consumers using our website depend upon Internet, online and other service providers for access to our website. Many of these service providers have experienced significant outages, delays and other difficulties in the past and could experience them in the future. Any significant interruption in access to our website or increase in our website’s response time as a result of these difficulties could damage our relationship with insurance carriers, marketing partners and existing and potential members and could harm our business, operating results and financial condition.  

 

Risks Related to the Ownership of Our Common Stock  

 

The trading price of our common stock may be subject to significant fluctuations and volatility, and our stockholders may be unable to resell their shares at a profit.  

 

The stock markets, in general, and the markets for high technology stocks in particular, have historically experienced high levels of volatility. The market for technology stocks has been extremely volatile and frequently reaches levels that bear no relationship to the past or present operating performance of those companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, the trading price of our common stock has been subject to significant fluctuations and may continue to fluctuate or decline, particularly as a result of developments relating to health care reform legislation. Factors that could cause fluctuations in the trading price of our common stock include, but are not limited to, the following: 

 

·

price and volume fluctuations in the overall stock market from time to time; 

 

·

significant volatility in the market price and trading volume of technology companies in general, and companies in our industry; 

 

·

actual or anticipated changes in our results of operations or fluctuations in our operating results; 

 

·

actual or anticipated changes in the expectations of investors or securities analysts, including changes in financial estimates or investment recommendations by securities analysts who follow our business and changes in perceptions relating to the economy; 

 

·

speculation in the press or investment community; 

 

·

technological advances or introduction of new products by us or our competitors; 

 

·

actual or anticipated developments in our competitors’ businesses or the competitive landscape generally; 

 

·

litigation involving us, our industry or both; 

 

·

actual or anticipated regulatory developments in the United States or foreign countries, including health care reform legislation in the United States; 

 

·

major catastrophic events; 

 

·

announcements or developments relating to the economy; 

 

·

our sale of common stock or other securities in the future; 

 

61 

 


 

·

the trading volume of our common stock, as well as sales of large blocks of our stock; or 

 

·

departures of key personnel. 

 

These factors, as well as general economic and political conditions and the announcement of proposed and completed acquisitions or other significant transactions, or any difficulties associated with such transactions, by us or our strategic partners, customers or our current competitors, may materially adversely affect the market price of our common stock in the future. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against that company. Such litigation could result in substantial cost and a diversion of management’s attention and resources. In addition, volatility, lack of positive performance in our stock price or changes to our overall compensation program, including our equity incentive program, may adversely affect our ability to retain key employees.  

A limited number of stockholders have the ability to influence the outcome of director elections and other matters requiring stockholder approval.  

 

A small number of greater than 5% stockholders and their affiliated entities beneficially owned more than 75% percent of our outstanding common stock as of September 30, 2012. These stockholders, if they act together, could exert substantial influence over matters requiring approval by our stockholders, including the election of directors, the amendment of our certificate of incorporation and bylaws and the approval of mergers or other business combination transactions. This concentration of ownership may discourage, delay or prevent a change in control of our company, which could deprive our stockholders of an opportunity to receive a premium for their stock as part of a sale of our company and might reduce our stock price. These actions may be taken even if they are opposed by other stockholders. 

 

Certain provisions in our charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.  

 

Our certificate of incorporation and bylaws contain provisions that could have the effect of delaying or preventing changes in control or changes in our management without the consent of our board of directors. These provisions include:  

  

·

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; 

 

·

cumulative voting in the election of directors is prohibited, which limits the ability of minority stockholders to elect director candidates; 

 

·

the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; 

 

·

the ability of our board of directors to determine to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; 

 

·

a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; 

 

·

the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and 

 

·

advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us. 

 

62 

 


 

We are also subject to certain anti-takeover provisions under Delaware law. Under Delaware law, a corporation may, in general, not engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction.  

63 

 


 

 

 

 

 

ITEM 6.

EXHIBITS

 

 

(a)  Exhibits 

Except as so indicated in Exhibits 32.1 and 32.2, the following exhibits are filed as part of, or incorporated by reference into, this quarterly report. 

 

 

 

 

 

 

Exhibit 

Number

 

 

Description of Exhibit

 

31.1

Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2

Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

Filed herewith.

Furnished herewith.

*

Indicates a management contract or compensatory plan or arrangement.

 

 

 

64 

 


 

SIGNATURES 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 5th day of November 2012. 

 

/ s /  Gary L. Lauer 

Gary L. Lauer 

Chief Executive Officer 

(Duly Authorized Officer on Behalf of the Registrant) 

 

 

/ s /  Stuart M.  Huizinga 

Stuart M. Huizinga 

Chief Financial Officer 

(Principal Financial Officer) 

 

 


 

EXHIBIT INDEX

 

 

Exhibit 

Number

 

 

Description of Exhibit

 

31.1

Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2

Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

Filed herewith.

Furnished herewith.

*

Indicates a management contract or compensatory plan or arrangement.

 

 

  

 

 

 


 

 

 

 

 


EX-101.INS 2 ehth-20120930.xml EX-101.INS 0001333493 ehth:TwoThousandSixEquityIncentivePlanMember 2011-12-30 2012-01-02 0001333493 2011-01-01 2011-12-31 0001333493 ehth:MountainViewCaliforniaLeaseAgreementMember 2012-09-30 0001333493 us-gaap:StandbyLettersOfCreditMember 2012-09-30 0001333493 ehth:WellpointMember 2012-07-01 2012-09-30 0001333493 ehth:UnitedhealthcareMember 2012-07-01 2012-09-30 0001333493 ehth:HumanaMember 2012-07-01 2012-09-30 0001333493 ehth:WellpointMember 2012-01-01 2012-09-30 0001333493 ehth:UnitedhealthcareMember 2012-01-01 2012-09-30 0001333493 ehth:HumanaMember 2012-01-01 2012-09-30 0001333493 ehth:WellpointMember 2011-07-01 2011-09-30 0001333493 ehth:UnitedhealthcareMember 2011-07-01 2011-09-30 0001333493 ehth:HumanaMember 2011-07-01 2011-09-30 0001333493 ehth:WellpointMember 2011-01-01 2011-09-30 0001333493 ehth:UnitedhealthcareMember 2011-01-01 2011-09-30 0001333493 ehth:HumanaMember 2011-01-01 2011-09-30 0001333493 2011-09-30 0001333493 2010-12-31 0001333493 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0001333493 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0001333493 us-gaap:StockOptionsMember 2011-07-01 2011-09-30 0001333493 us-gaap:RestrictedStockMember 2011-07-01 2011-09-30 0001333493 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0001333493 us-gaap:RestrictedStockMember 2011-01-01 2011-09-30 0001333493 us-gaap:MarketingAndAdvertisingExpenseMember 2012-07-01 2012-09-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0001333493 ehth:TechnologyAndContentExpenseMember 2012-07-01 2012-09-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2012-07-01 2012-09-30 0001333493 us-gaap:MarketingAndAdvertisingExpenseMember 2012-01-01 2012-09-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0001333493 ehth:TechnologyAndContentExpenseMember 2012-01-01 2012-09-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2012-01-01 2012-09-30 0001333493 us-gaap:MarketingAndAdvertisingExpenseMember 2011-07-01 2011-09-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2011-07-01 2011-09-30 0001333493 ehth:TechnologyAndContentExpenseMember 2011-07-01 2011-09-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2011-07-01 2011-09-30 0001333493 us-gaap:MarketingAndAdvertisingExpenseMember 2011-01-01 2011-09-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-09-30 0001333493 ehth:TechnologyAndContentExpenseMember 2011-01-01 2011-09-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2011-01-01 2011-09-30 0001333493 ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2012-07-01 2012-09-30 0001333493 ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2012-01-01 2012-09-30 0001333493 ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2011-07-01 2011-09-30 0001333493 ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2011-01-01 2011-09-30 0001333493 ehth:SouthJordanUtahLeaseAgreementMember 2012-01-01 2012-09-30 0001333493 ehth:GoldRiverCaliforniaLeaseAgreementMember 2012-01-01 2012-09-30 0001333493 ehth:MountainViewCaliforniaLeaseAgreementMember 2012-01-01 2012-09-30 0001333493 2012-07-01 2012-09-30 0001333493 2011-07-01 2011-09-30 0001333493 ehth:ConcentrationRiskCustomerTwoMember 2012-09-30 0001333493 ehth:ConcentrationRiskCustomerOneMember 2012-09-30 0001333493 2011-01-01 2011-09-30 0001333493 2012-09-30 0001333493 2011-12-31 0001333493 2012-10-31 0001333493 2012-01-01 2012-09-30 ehth:state iso4217:USD xbrli:shares ehth:customer xbrli:pure iso4217:USD xbrli:shares false --12-31 Q3 2012 2012-09-30 10-Q 0001333493 20251748 Accelerated Filer eHealth, Inc. ehth 6195000 3864000 366000 1990000 P5Y <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Book-of-Business Transfers</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">We have entered into several agreements with a broker partner, whereby the partner has transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these transfers occurred in November 2010 and the most recent in June 2012. Total consideration for these transfers amounted to $</font><font style="display: inline;">13.9</font><font style="display: inline;"> million, of w</font><font style="display: inline;">hich $</font><font style="display: inline;">6.2</font><font style="display: inline;"> &nbsp;m</font><font style="display: inline;">illion is related to transfers during the nine months ended September 30, 2012. Consideration for these transfers is included in &#x201C;Prepaid expenses and other current assets&#x201D; and also in &#x201C;Other assets&#x201D; in the accompanying condensed consolidated balance sheets. The consideration, which was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member, is being amortized to &#x201C;Cost of revenue&#x201D; in the condensed consolidated statements of comprehensive income (loss) and is presented as &#x201C;Amortization of book-of-business consideration&#x201D; in the condensed consolidated statements of cash flows as we recognize commission revenue related to the transferred Medicare plan members, over a period of up to </font><font style="display: inline;">five</font><font style="display: inline;"> years.</font><font style="display: inline;"> The amount of consideration we amortize to cost of revenue each quarter is proportional to the amount of commission revenue we recognize on the underlying policies each quarter. Amortization expense recorded to cost of revenue for these books-o</font><font style="display: inline;">f-business for the three months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2011 and 2012 totaled $</font><font style="display: inline;">0.1</font><font style="display: inline;"> million and</font><font style="display: inline;"> &nbsp;$</font><font style="display: inline;">0.6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">million, respectively. Amor</font><font style="display: inline;">tization expense recorded to cost of revenue for these books-of-business for the nine months ended September 30, 2011 and 2012 totaled $</font><font style="display: inline;">0.4</font><font style="display: inline;"> million and </font><font style="display: inline;">$</font><font style="display: inline;">2.0</font><font style="display: inline;"> million, respectively. Cash consideration paid in connection with the book-of-business transfers are presented under investing activities in the condensed consolidated statements of cash flows.&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt;font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:446.40pt;margin-left:0pt;"> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 2 &#x2013; Cash, Cash Equivalents and Accounts Receivable </font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">As of December 31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At December 31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the </font><font style="display: inline;">three and nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">As of December 31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, our cash</font><font style="display: inline;"> and</font><font style="display: inline;"> cash equivalent balances were invested </font><font style="display: inline;">as</font><font style="display: inline;"> follows (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.12%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cash</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,256&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,441&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Money market funds</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,351&nbsp; </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113,359&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,607&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130,800&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">We used observable prices in active markets in determining the classification of our money market funds as Level 1.</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Accounts Receivable</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">As of December 31, 2011 and September 30, 2012, our accounts receivable consisted of the following (in thousands):&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.12%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-weight:bold;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-weight:bold;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Accounts receivable - from other revenues</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,702&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Commissions receivable</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>353&nbsp; </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,394&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total accounts receivable</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,055&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 353000 1394000 0.73 0.51 0.37 0.14 16265000 6245000 21152000 8823000 691000 -2332000 7000 50000 680000 750000 703000 30000 102000 77000 1 2 0.03 900000 600000 500000 P10Y P65M 19483000 6581000 16810000 6295000 0.10 0.88 0.86 0.78 0.79 0.25 <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.12%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-weight:bold;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-weight:bold;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Accounts receivable - from other revenues</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,702&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,862&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Commissions receivable</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>353&nbsp; </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,394&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total accounts receivable</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,055&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:26.52%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">As of</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:26.50%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">As of</font></p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:21.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">United States</font></p> </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.70%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469&nbsp; </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,054&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">China</font></p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>425&nbsp; </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>286&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,894&nbsp; </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,340&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Shares Available for Grant</font><font style="display: inline;font-size:8pt;"> (1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Shares available for grant December 31, 2011</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,870&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Additional shares authorized </font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="bottom" style="width:42.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>795&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Options granted</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(731) </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units granted</font></p> </td> <td valign="bottom" style="width:42.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(203) </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Options cancelled</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>280&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units cancelled</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Shares available for grant September 30, 2012</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,086&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:5pt"> (1)</font></td><td align="left" valign="top"><p style="font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">S</font><font style="display: inline;">hares available for grant exclude treasury stock of </font><font style="display: inline;">5.9</font><font style="display: inline;"> million</font><font style="display: inline;"> shares </font><font style="display: inline;">and </font><font style="display: inline;">6.5</font><font style="display: inline;"> million shares </font><font style="display: inline;">at December&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, respectively, that could be granted if </font><font style="display: inline;">we</font><font style="display: inline;"> determined to do so</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 58.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:5pt"> (2)</font></td><td align="left" valign="top"><p style="font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">O</font><font style="display: inline;">n January&nbsp;1, </font><font style="display: inline;">2012</font><font style="display: inline;">, the number of shares authorized for issuance under the 2006 </font><font style="display: inline;">Equity Incentive </font><font style="display: inline;">Plan was automatically increased pursuant to the terms of the 2006 </font><font style="display: inline;">Equity Incentive </font><font style="display: inline;">Plan by </font><font style="display: inline;">0.8</font><font style="display: inline;"> million </font><font style="display: inline;">shares</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp;&nbsp;</font></p></td></tr></table></div> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Seasonality&#x2014;</font><font style="display: inline;">The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear. &nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year.&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">In the third quarters of 2011 and 2012, we significantly increased our temporary customer care center staff in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur in future years.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Based on these seasonal trends, we expect our revenue to be highest in the first and fourth quarters of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year.</font> </p> <p><font size="1"> </font></p> </div> </div> P3Y 3800000 900000 1900000 500000 6958000 6890000 1700000 3700000 200000 <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:39.52%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:04.50%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:04.50%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:30.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended </font><font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30,</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="6" valign="bottom" style="width:27.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine</font><font style="display: inline;font-weight:bold;font-size:9pt;"> Months Ended </font><font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:13.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:03.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:09.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:11.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:10.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Income before provision for income taxes</font></p> </td> <td valign="bottom" style="width:03.62%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.30%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,079&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,799&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,160&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Provision for income taxes</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.30%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>874&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:10.04%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,335&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,525&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Effective tax rate</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,231.8%&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.0%&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.3%&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.4%&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 16433000 5548000 16018000 5503000 14.07 14.17 7702000 1862000 2391000 4571000 8055000 3256000 180000 181000 13900000 215364000 225070000 2700000 2400000 5622000 264000 1336000 3248000 774000 1824000 83000 411000 1078000 252000 4326000 243000 783000 2368000 932000 1339000 90000 233000 686000 330000 1281000 427000 1261000 354000 2065000 156000 1909000 4103000 538000 3565000 1327000 1327000 1484000 1484000 177945000 185515000 139661000 143440000 <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Basis of Presentation&#x2014;</font><font style="display: inline;">The accompanying condensed consolidated balance sheet as of </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">12,</font><font style="display: inline;"> the condensed consolidated statements of </font><font style="display: inline;">comprehensive income (loss) for the three and nine months ended September 30, 2011 and 2012 </font><font style="display: inline;">and the condensed consolidated statements of cash flows for the </font><font style="display: inline;">nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 20</font><font style="display: inline;">12</font><font style="display: inline;">, respectively, are unaudited. The condensed consolidated balance sheet data as of </font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> was derived from the audited consolidated financial statements included in </font><font style="display: inline;">our Annual Report on</font><font style="display: inline;"> Form 10-K for the year end</font><font style="display: inline;">ed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;">, which was filed with the Securities and Exchange Commission on March&nbsp;</font><font style="display: inline;">15</font><font style="display: inline;">, 20</font><font style="display: inline;">12</font><font style="display: inline;">. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in </font><font style="display: inline;">our Annual Report on Form</font><font style="display: inline;"> 10-K. </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or </font><font style="display: inline;">U.S. </font><font style="display: inline;">GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by </font><font style="display: inline;">U.S. </font><font style="display: inline;">GAAP for complete financial statements. </font><font style="display: inline;">T</font><font style="display: inline;">he unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in </font><font style="display: inline;">our</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Annual Report on </font><font style="display: inline;">Form 10-K</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for the year end</font><font style="display: inline;">ed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;">, and include all adjustments necessary for the fair presentation of </font><font style="display: inline;">eHealth&#x2019;s</font><font style="display: inline;"> statement of financial position as of </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">12</font><font style="display: inline;">, its results </font><font style="display: inline;">of operations for the three</font><font style="display: inline;"> and nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">1</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;"> and its cash flows for the </font><font style="display: inline;">nine</font><font style="display: inline;"> months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">1</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">. All adjustments are of a normal recurring nature. The results for the three months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">2</font><font style="display: inline;"> are not necessarily indicative of the results to be expected for any subsequent quarter or for the fiscal year ending December&nbsp;31, 201</font><font style="display: inline;">2</font><font style="display: inline;">.</font> </p> <p><font size="1"> </font></p> </div> </div> 17256000 17441000 128074000 126501000 123607000 130800000 -1573000 7193000 106351000 113359000 26000 27000 4440000 -258000 4636000 208000 6987000 1781000 3538000 1099000 99668000 34744000 101049000 36511000 3696000 2373000 314000 704000 4622000 4306000 3390000 3735000 1799000 1740000 0.21 -0.01 0.24 0.01 0.20 -0.01 0.23 0.01 <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:446.40pt;margin-left:0pt;"> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note </font><font style="display: inline;font-weight:bold;">5</font><font style="display: inline;font-weight:bold;"> &#x2013; Net Income </font><font style="display: inline;font-weight:bold;">(Loss) </font><font style="display: inline;font-weight:bold;">Per Share</font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:4.5pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Basic net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share is computed by dividing net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">by the weighted-average number of common shares outstanding for the period (excluding shares subject to repurchase). Diluted net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share is computed by dividing the net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share is computed giving effect to all potential dilutive common stock, including options, restricted stock and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted earnings per share by application of the treasury stock method. </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table sets forth the computation of basic and diluted net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share (in thousands, except per share amounts): </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:24.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="top" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Basic:</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income allocated to common stock</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(249) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,464&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,635&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 13.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of common stock shares</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,683&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,642&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,276&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of common stock shares held in treasury</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,629) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0.15pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,378) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(565) </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 27pt;text-indent: -9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net weighted average number of common stock shares outstanding</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,264&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,711&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share&#x2014;basic:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.01) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.01&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.24&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Diluted:</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">allocated to common stock</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(249) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,464&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,635&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;text-indent: -4.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net weighted average number of common stock shares outstanding</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,264&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,711&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of options</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>703&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>680&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>750&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of restricted stock units</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 30pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total common stock shares used in per share calculation</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,750&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,974&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,563&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share&#x2014;diluted:</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.01) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.01&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.20&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.23&nbsp; </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> </p> <p><font size="1"> </font></p><p style="page-break-after:always">&nbsp;</p> <p style="margin:0pt;font-family:Times New Roman;; font-size: 10pt"><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">For each of the </font><font style="display: inline;">three and nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income</font><font style="display: inline;"> (loss) </font><font style="display: inline;">per share as their effect would have been anti-dilutive.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income</font><font style="display: inline;"> (loss) </font><font style="display: inline;">per share consisted of the following (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.44%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:28.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:27.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Common stock options</font></p> </td> <td valign="bottom" style="width:12.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,565&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,484&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,909&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,327&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>538&nbsp; </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156&nbsp; </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,103&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,484&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,065&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,327&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.493 12.318 0.494 0.810 -30000 2000 7904000 8819000 -548000 -991000 34469000 38054000 425000 286000 0.06 0.14 0.12 0.09 0.13 0.11 0.16 0.13 0.13 0.19 0.12 0.13 2734000 2358000 2734000 2358000 6200000 -38000 -1000 20299000 6917000 19938000 6744000 14096000 14096000 700000 8799000 22000 9160000 1079000 <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:446.40pt;margin-left:0pt;"> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 4 </font><font style="display: inline;font-weight:bold;">&#x2013; Income Taxes</font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes our provision for income taxes and our effective tax rates for the three and nine months ended September 30, 2011 and 2012 (provision for income taxes is in thousands):</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:39.52%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:04.50%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:04.50%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:30.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended </font><font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30,</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="6" valign="bottom" style="width:27.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine</font><font style="display: inline;font-weight:bold;font-size:9pt;"> Months Ended </font><font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:13.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:39.52%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:03.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:09.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:11.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:10.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Income before provision for income taxes</font></p> </td> <td valign="bottom" style="width:03.62%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.30%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,079&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,799&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,160&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Provision for income taxes</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.30%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>874&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:10.04%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,335&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,525&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:39.52%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Effective tax rate</font></p> </td> <td valign="bottom" style="width:03.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,231.8%&nbsp; </td> <td valign="bottom" style="width:03.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.68%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.30%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.0%&nbsp; </td> <td valign="bottom" style="width:01.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.3%&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.4%&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Our effective tax rates</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">in the </font><font style="display: inline;">three and nine</font><font style="display: inline;"> months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 201</font><font style="display: inline;">1</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;"> were higher than statutory federal and state tax rates due primarily to</font><font style="display: inline;"> non-deductable lobbying expenses and</font><font style="display: inline;"> tax shortfalls related to share-based payments.</font><font style="display: inline;"> &nbsp;&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">During the nine months ended September 30,</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">2011 and 2012</font><font style="display: inline;">, we utilized excess federal and state tax benefits related to share-based payments, which resulted in </font><font style="display: inline;">increases of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">$</font><font style="display: inline;">2.7</font><font style="display: inline;"> million</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and </font><font style="display: inline;">$</font><font style="display: inline;">2.4</font><font style="display: inline;"> &nbsp;m</font><font style="display: inline;">illion, respectively, </font><font style="display: inline;">in </font><font style="display: inline;">&#x201C;A</font><font style="display: inline;">dditional paid-in capital</font><font style="display: inline;">&#x201D;</font><font style="display: inline;"> in the condensed consolidated balance sheet</font><font style="display: inline;">s. These amounts are</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">also </font><font style="display: inline;">classified in the condensed consolidated statements of cash flows as both </font><font style="display: inline;">a reduction to operating cash flows and as a </font><font style="display: inline;">financing cash inflow.</font><font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 4335000 271000 4525000 874000 -1654000 2180000 -7698000 -4799000 -1632000 390000 455000 913000 -1475000 341000 494000 2364000 -1876000 -1708000 89045000 28206000 93358000 31291000 10526000 9265000 600000 177945000 185515000 18351000 19822000 3920000 4117000 38403000 13826000 39142000 13988000 -15709000 -3091000 -5838000 -9371000 20004000 19653000 4464000 -249000 4635000 205000 34894000 38340000 50 8860000 43000 9119000 1075000 6800000 5641000 8848000 -24000 -9000 1000 3000 400000 100000 2000000 600000 1547000 1864000 -61000 -21000 41000 4000 18033000 8441000 3906000 6243000 1932000 3128000 3377000 5078000 184000 4014000 4631000 6131000 46000 31000 2729000 979000 2250000 622000 21661000 26296000 108528000 34787000 110168000 37586000 <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.44%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:28.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:27.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Common stock options</font></p> </td> <td valign="bottom" style="width:12.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,565&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,484&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,909&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,327&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>538&nbsp; </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156&nbsp; </td> <td valign="bottom" style="width:03.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:12.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,103&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,484&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,065&nbsp; </td> <td valign="bottom" style="width:03.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,327&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:24.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="top" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="top" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Basic:</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income allocated to common stock</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(249) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,464&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,635&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 13.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of common stock shares</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,683&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,642&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,276&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of common stock shares held in treasury</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,629) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0.15pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,378) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(565) </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 27pt;text-indent: -9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net weighted average number of common stock shares outstanding</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,264&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,711&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share&#x2014;basic:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.01) </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.01&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.24&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Diluted:</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Numerator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">allocated to common stock</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(249) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,464&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,635&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Denominator:</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;text-indent: -4.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net weighted average number of common stock shares outstanding</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,970&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,264&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,711&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of options</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>703&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>680&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>750&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted average number of restricted stock units</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;"> &nbsp;-</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 30pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total common stock shares used in per share calculation</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,054&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,750&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,974&nbsp; </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,563&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:51.30%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.66%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.62%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:07.68%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Net income </font><font style="display: inline;">(loss) </font><font style="display: inline;">per share&#x2014;diluted:</font></p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.66%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.01) </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.01&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.62%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.20&nbsp; </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.26%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:07.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.23&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:53.12%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September</font><font style="display: inline;font-weight:bold;font-size:9pt;"> 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cash</font></p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,256&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,441&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Money market funds</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,351&nbsp; </td> <td valign="bottom" style="width:03.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113,359&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:53.12%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,607&nbsp; </td> <td valign="bottom" style="width:03.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130,800&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes stock-based compensation expense recorded during the three </font><font style="display: inline;">and nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 2011 and 2012 (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.44%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Common stock options</font></p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>845&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.50%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>717&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,893&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.28%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,076&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>979&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>622&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,729&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,824&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,339&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,622&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,326&nbsp; </td> </tr> </table></div> <p style="margin:4.5pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes stock-based compensation expense by operating function for the </font><font style="display: inline;">three and nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;"> (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:05.76%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:05.76%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="7" valign="bottom" style="width:28.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:12.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:02.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:09.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.36%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:11.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Marketing and advertising</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>252&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:11.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.14%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>774&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>932&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Customer care and enrollment</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90&nbsp; </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>264&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Technology and content</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>411&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>233&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,336&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>783&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">General and administrative</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,078&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>686&nbsp; </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,248&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,368&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,824&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,339&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,622&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,326&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Humana</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">WellPoint </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:13.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">UnitedHealthcare</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="border-bottom:1pt none #D9D9D9 ;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">Wellpoint </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">includes other carriers owned by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Wellpoint.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (2)</font></td><td align="left" valign="top"><p style="border-top:1pt none #D9D9D9 ;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">UnitedHealthcare </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">includes other carriers owned by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">UnitedHealthcare.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:47.28%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Number Outstanding</font></p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted-Average Remaining Contractual Life (years)</font></p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Aggregate Intrinsic Value </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding as of December 31, 2011</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>474&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.92&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,958&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:15.40%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203&nbsp; </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Vested</font></p> </td> <td valign="bottom" style="width:15.40%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(235) </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75) </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding as of </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>367&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.36&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,890&nbsp; </td> </tr> </table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">T</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he aggregate intrinsic value is calculated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">eHealth&#x2019;s closing stock price </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of December&nbsp;31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2 multiplied by the number of restricted stock units outstanding </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of December&nbsp;31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2, respectively.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt 0pt 0pt 36pt;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Number of Stock Options</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted Average Exercise Price</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted-Average Remaining Contractual Life (years)</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Aggregate Intrinsic Value</font><font style="display: inline;font-size:8pt;"> (1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding at December 31, 2011</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,412&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.36&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.80&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,078&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:09.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>731&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16.86&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(709) </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.67&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(280) </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18.58&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,154&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.27&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.98&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,787&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Vested and expected to vest at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,055&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.17&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.90&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,536&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Exercisable at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,056&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.79&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.89&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,767&nbsp; </td> </tr> </table></div> <p style="margin:9pt 0pt 0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 94.00pt; display: inline;"><font style="font-size: 10pt;margin-left:76pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">T</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he aggregate intrinsic value is calculated as the difference between eHealth&#x2019;s closing stock price as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2011 and September 30, 2012</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and the exercise price of in-the-money options as of those dates</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:29.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:29.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:9pt;">(1)</font></p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected term</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.6</font><font style="display: inline;"> years</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.6</font><font style="display: inline;"> years</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.7</font><font style="display: inline;"> years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected volatility</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.3%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.0%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44.3%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected dividend yield</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.61%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.02%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.90%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted-average fair value</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.46&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.34&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.41&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 58.00pt; display: inline;"><font style="font-size: 10pt;margin-left:40pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">There were no stock options granted to employees during the three months ended September 30, 2011.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;&nbsp;</font></p></td></tr></table></div> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.74%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.52%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Total Number of Shares Purchased</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Average Price Paid per Share </font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Amount of Repurchase</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cumulative balance at December&nbsp;31, 2011 </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,797,806&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.07&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,557&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Repurchases of common stock</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>554,284&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.23&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,441&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cumulative balance at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012 </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,352,090&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.17&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,998&nbsp; </td> </tr> </table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">C</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">umulative balances at December 31, 2011 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and September 30, 2012 consist of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 200</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">(2)</font><font style="display: inline;;font-size:12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;width:6pt">&nbsp;&nbsp;</font><font style="display: inline;"></font><font style="display: inline;">A</font><font style="display: inline;">verage price paid per share includes commission</font><font style="display: inline;">s.</font><font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:446.40pt;margin-left:0pt;"> <tr> <td valign="top" style="width:446.40pt;background-color: #auto;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;background-color: #auto;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note </font><font style="display: inline;font-weight:bold;">6</font><font style="display: inline;font-weight:bold;"> &nbsp;&#x2013;</font><font style="display: inline;font-weight:bold;">&nbsp;</font><font style="display: inline;font-weight:bold;">Geographic Information and Significant Customers</font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Geographic Information</font><font style="display: inline;">&#x2014;As of December 31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, our long-lived assets consisted primarily of property and equipment, goodwill and other indefinite-lived intangible assets and finite-lived intangible assets. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area were as follows (in thousands):</font><font style="display: inline;"> &nbsp;&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:26.52%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">As of</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:26.50%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">As of</font></p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:26.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">December 31, 2011</font></p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">September 30, 2012</font></p> </td> </tr> <tr> <td valign="top" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:21.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">United States</font></p> </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.70%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,469&nbsp; </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.68%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,054&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">China</font></p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>425&nbsp; </td> <td valign="bottom" style="width:04.82%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>286&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,894&nbsp; </td> <td valign="bottom" style="width:04.82%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,340&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Significant Customers</font><font style="display: inline;">&#x2014;Su</font><font style="display: inline;">bstantially all revenue for the three and nine months ended September 30, 2011 and 2012 </font><font style="display: inline;">was generated from customers located in the United States. </font><font style="display: inline;">Carriers representing 10% or more of our total revenue in </font><font style="display: inline;">the </font><font style="display: inline;">three and nine months ended September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2 are presented in the table below</font><font style="display: inline;">:</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:31.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Humana</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">WellPoint </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:13.92%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12%&nbsp; </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">UnitedHealthcare</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="bottom" style="width:13.92%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14%&nbsp; </td> <td valign="bottom" style="width:03.54%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:33.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.92%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.98%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.88%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="border-bottom:1pt none #D9D9D9 ;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">Wellpoint </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">includes other carriers owned by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Wellpoint.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (2)</font></td><td align="left" valign="top"><p style="border-top:1pt none #D9D9D9 ;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">UnitedHealthcare </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">includes other carriers owned by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">UnitedHealthcare.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Commission r</font><font style="display: inline;">evenue attributable to major medical individual and family health insurance plans was approximately </font><font style="display: inline;">86</font><font style="display: inline;">% and </font><font style="display: inline;">79</font><font style="display: inline;">% of our commission revenue in the </font><font style="display: inline;">three months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">, respectively. </font><font style="display: inline;">Commission r</font><font style="display: inline;">evenue attributable to major medical individual and family health insurance plans was approximately</font><font style="display: inline;"> 88</font><font style="display: inline;">% and </font><font style="display: inline;">78</font><font style="display: inline;">% of our commission revenue in the </font><font style="display: inline;">nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">, respectively. We define </font><font style="display: inline;">our </font><font style="display: inline;">individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related health insurance plan offerings </font><font style="display: inline;">or other ancillary products such as </font><font style="display: inline;">small business, short-term, stand-alone dental, life</font><font style="display: inline;"> and</font><font style="display: inline;"> student insurance plan offerings.</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">As of December 31, 2011, </font><font style="display: inline;">one</font><font style="display: inline;"> customer represented </font><font style="display: inline;">73</font><font style="display: inline;">%</font><font style="display: inline;"> of our $8.1 million </font><font style="display: inline;">outstanding </font><font style="display: inline;">accounts receivable</font><font style="display: inline;"> balance</font><font style="display: inline;">. As of </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012, </font><font style="display: inline;">two</font><font style="display: inline;"> customer</font><font style="display: inline;">s</font><font style="display: inline;"> represen</font><font style="display: inline;">ted</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">37</font><font style="display: inline;">% and </font><font style="display: inline;">14</font><font style="display: inline;">%, </font><font style="display: inline;">r</font><font style="display: inline;">espectively, for a combined total of </font><font style="display: inline;">51</font><font style="display: inline;">% &nbsp;</font><font style="display: inline;">of our $</font><font style="display: inline;">3</font><font style="display: inline;">.</font><font style="display: inline;">3</font><font style="display: inline;"> million outstanding accounts receivable</font><font style="display: inline;"> balance</font><font style="display: inline;">. No other customers represented </font><font style="display: inline;">10</font><font style="display: inline;">% or more of our total accounts receivable at December 31, 2011 and </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012. We believe the potential for collection issues with any of our customers is minimal as of </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012.</font> </p> <p><font size="1"> </font></p> </div> </div> 5622000 4326000 75000 203000 474000 367000 P1Y11M1D P2Y4M10D 235000 0.00 0.00 0.00 P4Y7M6D P0Y P4Y8M12D P4Y7M6D 0.490 0.443 0.433 0.0202 0.0090 0.0061 800000 795000 3870000 4086000 15767000 2056000 11.79 P2Y10M21D 280000 18.58 731000 5.34 6.41 6.46 17078000 18787000 3412000 3154000 11.36 13.27 P3Y9M18D P3Y11M23D 18536000 3055000 13.17 P3Y10M24D 5.67 16.86 <div> <div style="margin-left:72pt"> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:100.00%;background-color: #auto;padding:0pt 6.5pt"> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:100.00%;background-color: #auto;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 3 &#x2013; Stockholders&#x2019; Equity</font></p> </td> </tr> <tr> <td valign="top" style="width:100.00%;padding:0pt 6.5pt"> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Stock Plans</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">The following table summarizes option activity under </font><font style="display: inline;">our 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the &#x201C;Stock Plans&#x201D;) </font><font style="display: inline;">(in thousands, except per share amounts and weighted average remaining contractual life data):</font><font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Shares Available for Grant</font><font style="display: inline;font-size:8pt;"> (1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Shares available for grant December 31, 2011</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,870&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Additional shares authorized </font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="bottom" style="width:42.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>795&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Options granted</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(731) </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units granted</font></p> </td> <td valign="bottom" style="width:42.54%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(203) </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Options cancelled</font></p> </td> <td valign="bottom" style="width:42.54%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>280&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units cancelled</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>75&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:57.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Shares available for grant September 30, 2012</font></p> </td> <td valign="bottom" style="width:42.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,086&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:5pt"> (1)</font></td><td align="left" valign="top"><p style="font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">S</font><font style="display: inline;">hares available for grant exclude treasury stock of </font><font style="display: inline;">5.9</font><font style="display: inline;"> million</font><font style="display: inline;"> shares </font><font style="display: inline;">and </font><font style="display: inline;">6.5</font><font style="display: inline;"> million shares </font><font style="display: inline;">at December&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and </font><font style="display: inline;">September 30, </font><font style="display: inline;">201</font><font style="display: inline;">2</font><font style="display: inline;">, respectively, that could be granted if </font><font style="display: inline;">we</font><font style="display: inline;"> determined to do so</font><font style="display: inline;">.</font><font style="display: inline;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 58.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:5pt"> (2)</font></td><td align="left" valign="top"><p style="font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">O</font><font style="display: inline;">n January&nbsp;1, </font><font style="display: inline;">2012</font><font style="display: inline;">, the number of shares authorized for issuance under the 2006 </font><font style="display: inline;">Equity Incentive </font><font style="display: inline;">Plan was automatically increased pursuant to the terms of the 2006 </font><font style="display: inline;">Equity Incentive </font><font style="display: inline;">Plan by </font><font style="display: inline;">0.8</font><font style="display: inline;"> million </font><font style="display: inline;">shares</font><font style="display: inline;">.</font><font style="display: inline;"> &nbsp;&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes </font><font style="display: inline;">stock </font><font style="display: inline;">option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Number of Stock Options</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted Average Exercise Price</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted-Average Remaining Contractual Life (years)</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Aggregate Intrinsic Value</font><font style="display: inline;font-size:8pt;"> (1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding at December 31, 2011</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,412&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.36&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.80&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,078&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:09.34%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>731&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16.86&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(709) </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.67&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(280) </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18.58&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,154&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.27&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.98&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,787&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Vested and expected to vest at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,055&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.17&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.90&nbsp; </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,536&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:43.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Exercisable at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:09.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,056&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.79&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.10%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.89&nbsp; </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,767&nbsp; </td> </tr> </table></div> <p style="margin:9pt 0pt 0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 94.00pt; display: inline;"><font style="font-size: 10pt;margin-left:76pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">T</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he aggregate intrinsic value is calculated as the difference between eHealth&#x2019;s closing stock price as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2011 and September 30, 2012</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and the exercise price of in-the-money options as of those dates</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The total grant date fair value of stock options vested during the three months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2011 and 2012 was $</font><font style="display: inline;">0.9</font><font style="display: inline;"> million and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">$</font><font style="display: inline;">0.5</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">million, respectively. The total grant date fair value of stock options vested during the </font><font style="display: inline;">nine</font><font style="display: inline;"> months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2011 and 2012 was </font><font style="display: inline;">$</font><font style="display: inline;">3.8</font><font style="display: inline;"> &nbsp;m</font><font style="display: inline;">illion and</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">$</font><font style="display: inline;">1.9</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">million, respectively.</font> </p> <p><font size="1"> </font></p><p style="page-break-after:always">&nbsp;</p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman;; font-size: 10pt"><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes restricted stock unit activity under the Stock Plans (in thousands, except weighted average remaining contractual life data):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:47.28%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Number Outstanding</font></p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Weighted-Average Remaining Contractual Life (years)</font></p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Aggregate Intrinsic Value </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding as of December 31, 2011</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>474&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.92&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,958&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:15.40%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203&nbsp; </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Vested</font></p> </td> <td valign="bottom" style="width:15.40%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(235) </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(75) </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:47.28%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Balance outstanding as of </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012</font></p> </td> <td valign="bottom" style="width:15.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>367&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.34%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.36&nbsp; </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.30%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,890&nbsp; </td> </tr> </table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">T</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he aggregate intrinsic value is calculated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">eHealth&#x2019;s closing stock price </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of December&nbsp;31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2 multiplied by the number of restricted stock units outstanding </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of December&nbsp;31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2, respectively.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The fair value of the restricted stock units is based on eHealth&#x2019;s stock price on the date of grant, and compensation expense is recognized on a straight-line basis over the vesting period. </font><font style="display: inline;">The total grant date fair value of restricted stock units vested during the </font><font style="display: inline;">nine</font><font style="display: inline;"> months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2011 and 2012 wa</font><font style="display: inline;">s $</font><font style="display: inline;">1.7</font><font style="display: inline;"> million an</font><font style="display: inline;">d $</font><font style="display: inline;">3.7</font><font style="display: inline;"> million, respectively.</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:9pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Stock Repurchase Programs&#x2014;</font><font style="display: inline;">On </font><font style="display: inline;">September 10, 2012, </font><font style="display: inline;">we </font><font style="display: inline;">announced that our board of directors approved a stock repurchase program authorizing us to purchase up to an additional $</font><font style="display: inline;">30.0</font><font style="display: inline;"> million of our common stock.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Purchases under this program </font><font style="display: inline;">may be</font><font style="display: inline;"> made in the open market </font><font style="display: inline;">or unsolicited negotiated transactions </font><font style="display: inline;">and </font><font style="display: inline;">are expected to </font><font style="display: inline;">compl</font><font style="display: inline;">y</font><font style="display: inline;"> with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. </font><font style="display: inline;">The timing of the purchases and the exact number of shares to be purchased will depend upon market conditions. The program does not require us to acquire a specific number of shares, and the program may be suspended from time to time or discontinued at any time. </font><font style="display: inline;">The cost of the repurchased shares w</font><font style="display: inline;">ill be</font><font style="display: inline;"> funded from available working capital.</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:9pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">For accounting purposes, common stock repurchased under </font><font style="display: inline;">our stock repurchase</font><font style="display: inline;"> program</font><font style="display: inline;">s</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">i</font><font style="display: inline;">s recorded based upon the settlement date of the applicable trade. </font><font style="display: inline;">Such repurchased shares are held in treasury and are presented using the cost method.</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:9pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">S</font><font style="display: inline;">tock repurchase activity under our stock repurchase programs during the </font><font style="display: inline;">nine</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">months </font><font style="display: inline;">ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">12</font><font style="display: inline;"> is summarized as follows (</font><font style="display: inline;">dollars </font><font style="display: inline;">in thousands, except share and per share amounts):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.74%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.52%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.38%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.74%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.52%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.38%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Total Number of Shares Purchased</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Average Price Paid per Share </font><font style="display: inline;font-size:8pt;">(2)</font></p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Amount of Repurchase</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cumulative balance at December&nbsp;31, 2011 </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,797,806&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.07&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,557&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Repurchases of common stock</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>554,284&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.23&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,441&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:42.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Cumulative balance at </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012 </font><font style="display: inline;font-size:8pt;">(1)</font></p> </td> <td valign="bottom" style="width:16.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,352,090&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.52%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14.17&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:15.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,998&nbsp; </td> </tr> </table></div> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 36.00pt; display: inline;"><font style="font-size: 10pt;margin-left:18pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">C</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">umulative balances at December 31, 2011 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and September 30, 2012 consist of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 200</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">(2)</font><font style="display: inline;;font-size:12pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;width:6pt">&nbsp;&nbsp;</font><font style="display: inline;"></font><font style="display: inline;">A</font><font style="display: inline;">verage price paid per share includes commission</font><font style="display: inline;">s.</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:9pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">In addition to the 6.4 million shares repurchased under our repurchase programs as of </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012, we have in treasury </font><font style="display: inline;">0.2</font><font style="display: inline;"> million shares that were </font><font style="display: inline;">previously </font><font style="display: inline;">surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2011 and </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2012, we had a total of </font><font style="display: inline;">5.9</font><font style="display: inline;"> million shares and </font><font style="display: inline;">6.5</font><font style="display: inline;"> million shares, respectively, held in treasury.</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:9pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Stock</font><font style="display: inline;font-weight:bold;font-style:italic;">-Based Compensation&#x2014;</font><font style="display: inline;">The fair value of stock options granted to employees for the </font><font style="display: inline;">three and nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">and 2012 </font><font style="display: inline;">was estimated using the following weighted average assumptions:</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:37.62%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:29.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:29.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;text-align:center;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:13.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:9pt;">(1)</font></p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected term</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.6</font><font style="display: inline;"> years</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.6</font><font style="display: inline;"> years</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">4.7</font><font style="display: inline;"> years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected volatility</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.3%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49.0%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44.3%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Expected dividend yield</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.22%;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.32%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.61%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.38%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.02%&nbsp; </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.16%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.90%&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:37.62%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Weighted-average fair value</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.22%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 3.25pt 0pt 0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">N/A</font></p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.32%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.46&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.38%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.34&nbsp; </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.04%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:10.16%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.41&nbsp; </td> </tr> </table></div> <p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" style="width: 58.00pt; display: inline;"><font style="font-size: 10pt;margin-left:40pt"> (1)</font></td><td align="left" valign="top"><p style="line-height:auto;font-family:Calibri;font-size:11pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">There were no stock options granted to employees during the three months ended September 30, 2011.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;&nbsp;</font></p></td></tr></table></div> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes stock-based compensation expense recorded during the three </font><font style="display: inline;">and nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 2011 and 2012 (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.44%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="5" valign="bottom" style="width:28.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Common stock options</font></p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>845&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.50%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>717&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,893&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.28%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,076&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Restricted stock units</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>979&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>622&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,729&nbsp; </td> <td valign="bottom" style="width:02.80%;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.44%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:04.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,824&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,339&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.56%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,622&nbsp; </td> <td valign="bottom" style="width:02.80%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,326&nbsp; </td> </tr> </table></div> <p style="margin:4.5pt 0pt 0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The following table summarizes stock-based compensation expense by operating function for the </font><font style="display: inline;">three and nine months</font><font style="display: inline;"> ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;"> (in thousands):</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:22.5pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.46%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:05.76%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.20%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:05.76%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.20%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="7" valign="bottom" style="width:28.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Three Months Ended September 30,</font></p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:27.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">Nine Months Ended September 30,</font></p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td colspan="3" valign="bottom" style="width:12.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:13.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2011</font></p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:9pt;">2012</font></p> </td> </tr> <tr> <td valign="top" style="width:41.46%;padding:0pt;"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="top" style="width:02.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:09.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.36%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:11.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="top" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Marketing and advertising</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>252&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:11.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.14%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>774&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>932&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Customer care and enrollment</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90&nbsp; </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>264&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Technology and content</font></p> </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>411&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>233&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,336&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>783&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">General and administrative</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,078&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>686&nbsp; </td> <td valign="bottom" style="width:02.70%;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,248&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,368&nbsp; </td> </tr> <tr> <td valign="bottom" style="width:41.46%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 9pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:02.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:09.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,824&nbsp; </td> <td valign="bottom" style="width:02.36%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,339&nbsp; </td> <td valign="bottom" style="width:02.70%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:09.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,622&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCFFFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,326&nbsp; </td> </tr> </table></div> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:40pt"><div style="width:100%"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <a href="#TOC"><font style="display: inline;">Table of Contents</font></a><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp; </p> </div> <p style="margin:0pt;text-align:center;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> &nbsp; </p></div><div style="margin-left:72pt"> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;font-size:1pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:446.40pt;margin-left:0pt;"> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;font-family:Times New Roman; font-size: 10pt"> <a name="Notes_To_FinancialStatements"></a><font style="display: inline;font-weight:bold;">Note 1 - Summary of Business and Significant Accounting Policies</font></p> </td> </tr> <tr> <td valign="top" style="width:446.40pt;padding:0pt 6.5pt"> <p style="margin:0pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:18pt;line-height:0pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Description of Business</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">eHealth, Inc. (the &#x201C;Company,&#x201D; &#x201C;eHealth,&#x201D; &#x201C;we&#x201D; or &#x201C;us&#x201D;) is the leading </font><font style="display: inline;">online source of health insurance for individuals, families and small businesses in the United States. Through our website addresses (</font><font style="display: inline;font-style:italic;">www.eHealth.com</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;font-style:italic;">www.eHealthInsurance.com</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;font-style:italic;">www.eHealthMedicare.com</font><font style="display: inline;"> and </font><font style="display: inline;font-style:italic;">www.PlanPrescriber.com)</font><font style="display: inline;">, consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and</font><font style="display: inline;"> offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including </font><font style="display: inline;">Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">Our ecommerce technology also enables us to deliver consumers&#x2019; health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process. </font><font style="display: inline;">We are licensed to market and sell health insurance in all </font><font style="display: inline;">50</font><font style="display: inline;"> states and the District of Columbia.&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font><font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Basis of Presentation&#x2014;</font><font style="display: inline;">The accompanying condensed consolidated balance sheet as of </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">12,</font><font style="display: inline;"> the condensed consolidated statements of </font><font style="display: inline;">comprehensive income (loss) for the three and nine months ended September 30, 2011 and 2012 </font><font style="display: inline;">and the condensed consolidated statements of cash flows for the </font><font style="display: inline;">nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">11</font><font style="display: inline;"> and 20</font><font style="display: inline;">12</font><font style="display: inline;">, respectively, are unaudited. The condensed consolidated balance sheet data as of </font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;"> was derived from the audited consolidated financial statements included in </font><font style="display: inline;">our Annual Report on</font><font style="display: inline;"> Form 10-K for the year end</font><font style="display: inline;">ed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;">, which was filed with the Securities and Exchange Commission on March&nbsp;</font><font style="display: inline;">15</font><font style="display: inline;">, 20</font><font style="display: inline;">12</font><font style="display: inline;">. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in </font><font style="display: inline;">our Annual Report on Form</font><font style="display: inline;"> 10-K. </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or </font><font style="display: inline;">U.S. </font><font style="display: inline;">GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by </font><font style="display: inline;">U.S. </font><font style="display: inline;">GAAP for complete financial statements. </font><font style="display: inline;">T</font><font style="display: inline;">he unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in </font><font style="display: inline;">our</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">Annual Report on </font><font style="display: inline;">Form 10-K</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">for the year end</font><font style="display: inline;">ed</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">December</font><font style="display: inline;">&nbsp;31, 20</font><font style="display: inline;">11</font><font style="display: inline;">, and include all adjustments necessary for the fair presentation of </font><font style="display: inline;">eHealth&#x2019;s</font><font style="display: inline;"> statement of financial position as of </font><font style="display: inline;">September 30</font><font style="display: inline;">, 20</font><font style="display: inline;">12</font><font style="display: inline;">, its results </font><font style="display: inline;">of operations for the three</font><font style="display: inline;"> and nine </font><font style="display: inline;">months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">1</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;"> and its cash flows for the </font><font style="display: inline;">nine</font><font style="display: inline;"> months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">1</font><font style="display: inline;"> and 201</font><font style="display: inline;">2</font><font style="display: inline;">. All adjustments are of a normal recurring nature. The results for the three months ended </font><font style="display: inline;">September 30</font><font style="display: inline;">, 201</font><font style="display: inline;">2</font><font style="display: inline;"> are not necessarily indicative of the results to be expected for any subsequent quarter or for the fiscal year ending December&nbsp;31, 201</font><font style="display: inline;">2</font><font style="display: inline;">. &nbsp;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Seasonality&#x2014;</font><font style="display: inline;">The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear. &nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year.&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">In the third quarters of 2011 and 2012, we significantly increased our temporary customer care center staff in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur in future years.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Based on these seasonal trends, we expect our revenue to be highest in the first and fourth quarters of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year. </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Book-of-Business Transfers</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;">We have entered into several agreements with a broker partner, whereby the partner has transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these transfers occurred in November 2010 and the most recent in June 2012. Total consideration for these transfers amounted to $</font><font style="display: inline;">13.9</font><font style="display: inline;"> million, of w</font><font style="display: inline;">hich $</font><font style="display: inline;">6.2</font><font style="display: inline;"> &nbsp;m</font><font style="display: inline;">illion is related to transfers during the nine months ended September 30, 2012. Consideration for these transfers is included in &#x201C;Prepaid expenses and other current assets&#x201D; and also in &#x201C;Other assets&#x201D; in the accompanying condensed consolidated balance sheets. The consideration, which was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member, is being amortized to &#x201C;Cost of revenue&#x201D; in the condensed consolidated statements of comprehensive income (loss) and is presented as &#x201C;Amortization of book-of-business consideration&#x201D; in the condensed consolidated statements of cash flows as we recognize commission revenue related to the transferred Medicare plan members, over a period of up to </font><font style="display: inline;">five</font><font style="display: inline;"> years.</font><font style="display: inline;"> The amount of consideration we amortize to cost of revenue each quarter is proportional to the amount of commission revenue we recognize on the underlying policies each quarter. Amortization expense recorded to cost of revenue for these books-o</font><font style="display: inline;">f-business for the three months ended </font><font style="display: inline;">September</font><font style="display: inline;"> 30, 2011 and 2012 totaled $</font><font style="display: inline;">0.1</font><font style="display: inline;"> million and</font><font style="display: inline;"> &nbsp;$</font><font style="display: inline;">0.6</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">million, respectively. Amor</font><font style="display: inline;">tization expense recorded to cost of revenue for these books-of-business for the nine months ended September 30, 2011 and 2012 totaled $</font><font style="display: inline;">0.4</font><font style="display: inline;"> million and </font><font style="display: inline;">$</font><font style="display: inline;">2.0</font><font style="display: inline;"> million, respectively. Cash consideration paid in connection with the book-of-business transfers are presented under investing activities in the condensed consolidated statements of cash flows.&nbsp;</font> </p> <p style="margin:4.5pt 0pt 0pt;background-color: #FFFFFF;text-indent:18pt;font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Recent Contractual Obligations&#x2014;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">In</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Augu</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">st 2012, we extended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">our existing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> lease for office space in Gold River, California, for an additional two years expiring on December 31, 2014. Rent payments will total $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0.9</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million in both 2013 and 2014.</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font> </p> <p style="margin:4.5pt 0pt 0pt;background-color: #FFFFFF;text-indent:18pt;font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">In May 2012, we entered into an agreement to lease office space in South Jordan, Utah. The term of the</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> operating lease is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">65</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months and commences in August 2012. The lease significantly increases our office space for our customer care and enrollment activities and replaces an expiring operating lease for office space at another location in South Jordan, Utah. Rent payments begin in January 2013 and total approximately $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0.5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million per year through December 2017.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font> </p> <p style="margin:4.5pt 0pt 0pt;background-color: #FFFFFF;text-indent:18pt;font-family:Arial Unicode MS;font-size:12pt;"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2012, we entered into an agreement to lease a building to be constructed in Mountain View, California, adjacent to our headquarters office. The term of the operating lease is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ten</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">from the date the building is delivered to us </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;background-color: #FFFFFF;">base rent is approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0.6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million for the first year of the lease. The base rent increases annually by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%. Future minimum payments related to this operating lease are estimated to total $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6.8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million over the ten-year term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease, but may diff</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;background-color: #FFFFFF;">er depending on actual rentable square footage. Lease payments are expected to begin in the second or third quarter of 2013, although the actual commencement of lease payments will depend upon the date of completion and delivery of the newly constructed building.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">Upon signing the</font><font style="display: inline;"> Mountain View, California</font><font style="display: inline;"> lease agreement, </font><font style="display: inline;">we entered into a financial guarantee consisting of a standby letter of credit for $</font><font style="display: inline;">0.6</font><font style="display: inline;"> million,</font><font style="display: inline;"> which may be reduced in increments of </font><font style="display: inline;">25</font><font style="display: inline;">% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease. </font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">In March 2012, we entered into a service agreement with a vendor to support our customer care center telephonic system and equipment. Service obligations related to this agreement total $</font><font style="display: inline;">0.7</font><font style="display: inline;"> million over the </font><font style="display: inline;">three</font><font style="display: inline;">-year term of the agreement.</font><font style="display: inline;">&nbsp;&nbsp;&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;background-color: #FFFFFF;">Recent Accounting </font><font style="display: inline;font-weight:bold;font-style:italic;background-color: #FFFFFF;">Pronouncements</font><font style="display: inline;font-weight:bold;font-style:italic;">&#x2014;</font><font style="display: inline;background-color: #FFFFFF;">In June 2011, the FASB issued authoritative guidance related to the presentation of comprehensive income. The guidance requires that all non-owner changes in stockholders&#x2019; equity be presented in a single continuous statement of comprehensive income or in two separate but consecutive statements. The guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. This guidance is effective for interim and annual periods beginning after December&nbsp;15, 2011. The new guidance is to be applied retrospectively. We adopted the guidance beginning in the first quarter of 2012 and the adoption of this guidance did not have a material impact on our consolidated financial results.&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;background-color: #FFFFFF;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;background-color: #FFFFFF;">In July 2012, the FASB updated the accounting guidance related to testing indefinite-lived intangible assets for impairment. This update permits an entity to first make a qualitative assessment of whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. An entity is not required to calculate the fair value of an indefinite-lived intangible asset and perform the quantitative impairment test unless the entity determines that it is more likely than not that the asset is impaired. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This update is effective for annual and interim impairment tests performed in fiscal years beginning after September&nbsp;15, 2012 (our fiscal year 2013); however, early adoption is permitted, provided that the entity has not yet performed its annual impairment test or issued its financial statements. We do not expect the adoption of this accounting guidance to have an impact on our consolidated financial results.&nbsp;</font> </p> <p><font size="1"> </font></p><div style="width:100%"> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> <font style="display: inline;">1</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman; font-size: 10pt"> &nbsp; </p> </div> </div> </div> 155674000 161576000 709000 2893000 845000 2076000 717000 30000000 15.23 5900000 6500000 5797806 6352090 554284 81557000 89998000 8441000 21974000 21054000 20563000 20750000 25642000 25683000 20276000 19970000 21264000 21054000 19711000 19970000 4378000 4629000 565000 The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 multiplied by the number of restricted stock units outstanding as of December 31, 2011 and September 30, 2012, respectively. Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008. Average price paid per share includes commissions. UnitedHealthcare includes other carriers owned by UnitedHealthcare. Wellpoint includes other carriers owned by Wellpoint. Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so. There were no stock options granted to employees during the three months ended September 30, 2011. On January 1, 2012, the number of shares authorized for issuance under the 2006 Equity Incentive Plan was automatically increased pursuant to the terms of the 2006 Equity Incentive Plan by 0.8 million shares. The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 and the exercise price of in-the-money options as of those dates. EX-101.SCH 3 ehth-20120930.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Schedule of Cash and Cash Equivalents) (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Schedule of Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Net Income (Loss) Per Share (Schedule Of Computation Of Basic And Diluted Net Income Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Summary Of Business And Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Cash, Cash Equivalents And Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Geographic Information And Significant Customers link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Summary Of Business And Significant Accounting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Geographic Information And Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Summary Of Business And Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Stockholders' Equity (Schedule of Stock Options Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Stockholders' Equity (Schedule Of Stock Repurchase Activity Under Stock Repurchase Programs) (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - Stockholders' Equity (Schedule Of Fair Value Of Stock Options, Valuation Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 40308 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Net Income (Loss) Per Share (Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Geographic Information And Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Geographic Information And Significant Customers (Schedule of Revenue by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink EX-31.1 4 ehth-20120930ex311f5f27a.htm EX-31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER TO EXCHANGE ACT RULE 13A-14(A)

Exhibit 31.1

CERTIFICATION

 

I, Gary L. Lauer, certify that:

1.      I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 5, 2012  

 

/s/    GARY L. LAUER 

Gary L. Lauer

Chief Executive Officer

 


EX-31.2 5 ehth-20120930ex31278bded.htm EX-31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER TO EXCHANGE ACT RULE 13A-14(A)

Exhibit 31.2

CERTIFICATION

 

I, Stuart M. Huizinga, certify that:

 

1.      I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;

2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.      The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.      The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2012

 

/s/    STUART M. HUIZINGA 

Stuart M. Huizinga

Chief Financial Officer


 

 


EX-32.1 6 ehth-20120930ex32139591b.htm EX-32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

Exhibit 32.1

 

Certification of Chief Executive Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002 

 

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarterly period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gary L. Lauer, Chief Executive Officer of eHealth,  Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:  

(1)

The Form 10-Q, to which this certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

 

 

/s/    GARY L. LAUER

Gary L. Lauer

Chief Executive Officer

November 5, 2012

 

A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-32.2 7 ehth-20120930ex322f9b653.htm EX-32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

 Exhibit 32.2 

 

Certification of Chief Financial Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002 

 

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarterly period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:  

(1)  The Form 10-Q, to which this certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

 

 

/s/     STUART M. HUIZINGA

Stuart M. Huizinga

Chief Financial Officer

November 5, 2012

 

A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 


EX-101.CAL 8 ehth-20120930_cal.xml EX-101.CAL EX-101.DEF 9 ehth-20120930_def.xml EX-101.DEF EX-101.LAB 10 ehth-20120930_lab.xml EX-101.LAB EX-101.PRE 11 ehth-20120930_pre.xml EX-101.PRE XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographic Information And Significant Customers (Schedule of Revenue by Major Customers) (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Humana [Member]
       
Revenue, Major Customer [Line Items]        
Major customer revenue, percentage 19.00% 9.00% 16.00% 6.00%
WellPoint [Member]
       
Revenue, Major Customer [Line Items]        
Major customer revenue, percentage 13.00% [1] 11.00% [1] 13.00% [1] 12.00% [1]
UnitedHealthcare [Member]
       
Revenue, Major Customer [Line Items]        
Major customer revenue, percentage 12.00% [2] 13.00% [2] 13.00% [2] 14.00% [2]
[1] Wellpoint includes other carriers owned by Wellpoint.
[2] UnitedHealthcare includes other carriers owned by UnitedHealthcare.
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Fair Value Of Stock Options, Valuation Assumptions) (Details) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Stockholders' Equity [Abstract]        
Expected term 4 years 7 months 6 days 0 years [1] 4 years 8 months 12 days 4 years 7 months 6 days
Expected volatility 43.30%    [1] 44.30% 49.00%
Expected dividend yield 0.00%    [1] 0.00% 0.00%
Risk-free interest rate 0.61%    [1] 0.90% 2.02%
Weighted-average fair value $ 6.46    [1] $ 6.41 $ 5.34
[1] There were no stock options granted to employees during the three months ended September 30, 2011.
XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share
9 Months Ended
Sep. 30, 2012
Net Income (Loss) Per Share [Abstract]  
Net Income (Loss) Per Share

 

Note 5 – Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding for the period (excluding shares subject to repurchase). Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income (loss) per share is computed giving effect to all potential dilutive common stock, including options, restricted stock and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted earnings per share by application of the treasury stock method.  

 

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except per share amounts):  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

Basic:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common stock shares

 

25,683 

 

 

19,970 

 

 

25,642 

 

 

20,276 

Weighted average number of common stock shares held in treasury

 

(4,629)

 

 

 -

 

 

(4,378)

 

 

(565)

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—basic:

$

(0.01)

 

$

0.01 

 

$

0.21 

 

$

0.24 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

Weighted average number of options

 

 -

 

 

703 

 

 

680 

 

 

750 

Weighted average number of restricted stock units

 

 -

 

 

77 

 

 

30 

 

 

102 

Total common stock shares used in per share calculation

 

21,054 

 

 

20,750 

 

 

21,974 

 

 

20,563 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—diluted:

$

(0.01)

 

$

0.01 

 

$

0.20 

 

$

0.23 

 

 

For each of the three and nine months ended September 30, 2011 and 2012, we had securities outstanding that could potentially dilute earnings per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive. The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Common stock options

3,565 

 

1,484 

 

1,909 

 

1,327 

Restricted stock units

538 

 

 -

 

156 

 

 -

Total

4,103 

 

1,484 

 

2,065 

 

1,327 

 

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y M9#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O5]/ M9E]"=7-I;F5S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I7;W)K#I7;W)K#I%>&-E;%=O5]/9E]" M=7-I;F5S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A#I7;W)K#I%>&-E;%=O5]$971A:6QS M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]38VAE9'5L95]O/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O5]38VAE9'5L M95]//"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]38VAE9'5L95]/,3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I%>&-E;%=O5]38VAE9'5L95]/-#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYE=%]);F-O;65?3&]S#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYE=%]);F-O;65?3&]S#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=E;V=R87!H:6-?26YF;W)M871I;VY?06YD7U-I9S0\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968] M,T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y M9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!);F9O2!);F9O'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UB;VP\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!296=I2!#96YT3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^,#`P,3,S,S0Y,SQS<&%N/CPO'0^ M+2TQ,BTS,3QS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S M.%\S-F$Y9#'0O:'1M;#L@8VAA M&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,P-CQS<&%N/CPO6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!S=&]C:RP@870@ M8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-3)F8C@X M8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA&-E<'0@4&5R M(%-H87)E(&1A=&$L('5N;&5S'!E;G-E'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#F%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ+#(V,3QS<&%N/CPO"!B96YE9FET'!E;G-E'!E;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!/9B!"=7-I;F5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R M9VEN+6QE9G0Z-#!P=#X\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X-"@T*"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@T*"0D)/&$@:')E9CTS1"-43T,^ M/&9O;G0@3H@:6YL:6YE.R<^5&%B;&4@;V8@0V]N M=&5N=',\+V9O;G0^/"]A/CQF;VYT('-T>6QE/3-$)V1I3I4:6UE6QE/3-$)VUA6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)VUA6QE/3-$)V1IF4Z M,7!T.R<^)FYB6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D))FYB6QE M/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`@3I4:6UE'0M:6YD96YT.C$X<'0[;&EN92UH M96EG:'0Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)W=I9'1H.C0T-BXT,'!T.W!A9&1I;F3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[)SY.;W1E(#$@+2!3=6UM87)Y(&]F($)U6QE/3-$)W=I9'1H.C0T-BXT,'!T.W!A9&1I;F3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.W1E>'0M:6YD96YT.C$X<'0[;&EN92UH96EG:'0Z,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.R<^94AE86QT M:"P@26YC+B`H=&AE("8C>#(P,4,[0V]M<&%N>2PF(W@R,#%$.R`F(W@R,#%# M.V5(96%L=&@L)B-X,C`Q1#L@)B-X,C`Q0SMW928C>#(P,40[(&]R("8C>#(P M,4,[=7,F(W@R,#%$.RD@:7,@=&AE(&QE861I;F<@/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I6QE/3-$ M)V1I6QE.FET86QI8SLG/G=W=RYE2&5A M;'1H+F-O;3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SXL("9N8G-P.SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="US='EL93II=&%L:6,[)SYW=W3H@:6YL:6YE.R<^+"`F M;F)S<#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O M;G0M3H@:6YL:6YE.R<^(&%N9"`\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M3H@:6YL:6YE.R<^+"!C;VYS=6UE2US:61E+"!A;F0@87!P;'D@9F]R M(&%N9"!P=7)C:&%S92!I;F1I=FED=6%L(&%N9"!F86UI;'DL($UE9&EC87)E M+7)E;&%T960L('-M86QL(&)U6QE/3-$)V1I3H@:6YL:6YE.R<^365D:6-A3H@:6YL:6YE M.R<^+B`F;F)S<#L\+V9O;G0^/&9O;G0@3H@:6YL M:6YE.R<^3W5R(&5C;VUM97)C92!T96-H;F]L;V=Y(&%L#(P,3D[(&AE86QT:"!I;G-U2!A;F0@ M"!A;F0@=')A9&ET:6]N86QL>2!P87!E M3H@ M:6YL:6YE.R<^5V4@87)E(&QI8V5N3H@:6YL:6YE.R<^-3`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^('-T871E'0M:6YD96YT.C$X<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE M/3-$)V1I6QE M/3-$)VUA3I4 M:6UE6QE.FET86QI8SLG/D)A#(P,30[ M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^+"`R,#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[)SXQ,BP\+V9O;G0^/&9O;G0@3H@ M:6YL:6YE.R<^('1H92!C;VYD96YS960@8V]N6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^;FEN92`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^;6]N=&AS(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[)SY397!T96UB97(@,S`\+V9O;G0^/&9O;G0@ M3H@:6YL:6YE.R<^+"`R,#PO9F]N=#X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXQ,3PO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SX@86YD(#(P/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^1&5C96UB97(\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^,34\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^+"`R,#PO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[)SXQ,CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SXN(%1H92!A8V-O;7!A;GEI;F<@6QE/3-$)V1I M3H@:6YL:6YE.R<^(#$P+4LN(#PO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\ M+V9O;G0^#0H)"3PO<#X-"@D)/'`@6QE/3-$)V1I'0M:6YD96YT.C$X<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE(&%C8V]M<&%N>6EN9R!C;VYD96YS M960@8V]N3H@:6YL:6YE.R<^52Y3+B`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`\+V9O;G0^/&9O M;G0@3H@:6YL:6YE.R<^+"`R,#$\+V9O;G0^/&9O M;G0@3H@:6YL:6YE.R<^,3PO9F]N=#X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SX@86YD(#(P,3PO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXR/"]F;VYT/CQF;VYT('-T M>6QE/3-$)V1I3H@:6YL:6YE M.R<^;FEN93PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SX@;6]N=&AS(&5N9&5D(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[)SY397!T96UB97(@,S`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^+"`R,#$\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^,3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SX@86YD(#(P,3PO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[)SXR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@ M:6YL:6YE.R<^4V5P=&5M8F5R(#,P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)V1I M3H@:6YL:6YE.R<^(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O M9B!T:&4@'!E8W1E9"!F;W(@86YY('-U8G-E<75E M;G0@<75A3H@:6YL:6YE.R<^,CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[)SXN("9N8G-P.SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`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`N.3PO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M6QE/3-$)V1I3I4:6UE3H@:6YL M:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P M=#LG/B!O<&5R871I;F<@;&5A6QE/3-$ M)V1I3I4:6UE3H@:6YL:6YE.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C`N-3PO9F]N=#X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7=E:6=H=#IB;VQD.V9O;G0M6QE/3-$)VUA3I! M6QE/3-$ M)V1I3I4:6UE6QE/3-$ M)V1I3I4:6UE6QE/3-$)V1I3I4:6UE2`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/&9O;G0@3H@ M:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#LG/C`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`Q,BP@=V4@96YT97)E M9"!I;G1O(&$@3H@:6YL:6YE.R<^(&UI;&QI;VX@;W9E6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US='EL93II=&%L:6,[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1I M3H@ M:6YL:6YE.V)A8VMG#(P,3D[(&5Q=6ET>2!B92!P M'0M:6YD96YT.C$X<'0[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V)A8VMG6QE/3-$)V1I2`R,#$R+"!T:&4@1D%30B!U<&1A=&5D('1H92!A8V-O M=6YT:6YG(&=U:61A;F-E(')E;&%T960@=&\@=&5S=&EN9R!I;F1E9FEN:71E M+6QI=F5D(&EN=&%N9VEB;&4@87-S971S(&9O2!T;R!F:7)S="!M86ME(&$@<75A M;&ET871I=F4@87-S97-S;65N="!O9B!W:&5T:&5R(&ET(&ES(&UO2!I2!D971E2UT:&%N+6YO="!T:')E6QE/3-$=VED=&@Z,3`P)3X-"@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^,3PO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H-"@D)/"]P M/@T*#0H)"3QP('-T>6QE/3-$)VUA'10 M87)T7S8U,F9B.#AC7V(P8S!?-#@Y-%]B8S,X7S,V83ED-S8Y964V90T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V-3)F8C@X8U]B,&,P7S0X.31? M8F,S.%\S-F$Y9#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`@3I!6QE/3-$)W=I9'1H.C0T-BXT,'!T.W!A9&1I;F3I4 M:6UE6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)V1I6QE M.FET86QI8SLG/B8C>#(P,30[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^,CPO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXL(&]U2!M87)K970@86-C;W5N=',@=&AA M="!I;G9E6QE/3-$)V1I3H@:6YL:6YE.R<^+"!O=7(@8V%S:"!E<75I=F%L96YT MF4@86YY('-I9VYI9FEC86YT(&=A:6YS(&]R(&QO M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I M6QE/3-$ M)V1I3H@:6YL:6YE.R<^+B`F;F)S<#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.R<^,CPO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[)SXL(&]U6QE M/3-$)V1I3H@:6YL:6YE.R<^(&-A3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA6QE/3-$ M)V1I3I#86QI8G)I.V9O;G0M3I4:6UE6QE/3-$)W=I9'1H.C$X M+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)/"]T6QE/3-$=VED=&@Z-3,N,3(E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A M;&EB6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I3I4:6UE M3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)W=I9'1H.C4S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^0V%S:#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`S+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`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`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG6QE M/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,S`L.#`P M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US='EL93II=&%L:6,[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@ M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M9F%M:6QY.D-A;&EBF4Z,7!T.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)W=I9'1H.C`S+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I# M86QI8G)I.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$Q<'0[)SXF;F)S M<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C,R)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M3I4:6UE MF4Z.7!T.R<^1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C,R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$X M+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)W=I9'1H.C4S+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^06-C;W5N=',@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$X+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXW+#6QE/3-$)V1I'0M86QI9VXZ6QE/3-$=VED=&@Z-3,N,3(E.W!A9&1I;F3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C$X+C0V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#,N,S(E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+#,Y-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`S+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T* M"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X- M"@D)/'`@6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$P,"XP M,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1I#(P,3,[(%-T;V-K:&]L9&5R#(P,3D[($5Q=6ET>3PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D) M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HQ,#`N,#`E.W!A9&1I M;F6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[)SXF(W@R,#$T M.SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SY4:&4@ M9F]L;&]W:6YG('1A8FQE('-U;6UA&-E<'0@<&5R M('-H87)E(&%M;W5N=',@86YD('=E:6=H=&5D(&%V97)A9V4@6QE/3-$ M)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)W=I9'1H.C0R+C4T)3MB86-K9W)O=6YD+6-O M;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D) M/"]T6QE M/3-$=VED=&@Z-3F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C4W+C0V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^4VAA6QE M/3-$=VED=&@Z-3F5D(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="US:7IE.CAP=#LG/B@R*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C0R+C4T)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)V1I6QE/3-$)W=I9'1H.C0R+C4T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH M-S,Q*0T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V1I6QE/3-$)W=I9'1H M.C0R+C4T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C4W+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^3W!T:6]N'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^4F5S=')I8W1E9"!S=&]C:R!U;FETF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$)W=I9'1H.C0R+C4T)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.B`S-BXP,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[;6%R9VEN+6QE9G0Z-7!T M)SX@*#$I/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T M;W`^/'`@F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^4SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[)SYH87)E6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^)FYB6QE/3-$)W=I9'1H.B`S-BXP,'!T.R!D:7-P;&%Y.B!I M;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[;6%R9VEN M+6QE9G0Z-7!T)SX@*#(I/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`^/'`@F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^3SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SYN($IA;G5A3H@:6YL:6YE.R<^,C`Q,CPO9F]N=#X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXL('1H92!N=6UB97(@;V8@6QE M/3-$)V1I2!);F-E;G1I=F4@/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^6QE/3-$)V1I3H@:6YL:6YE.R<^("9N8G-P.R9N M8G-P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H)"3QP M('-T>6QE/3-$)VUA6QE/3-$)V1I'0M:6YD96YT.C$X M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE M(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(#PO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SYS=&]C:R`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^;W!T:6]N(&%C=&EV:71Y('5N9&5R M('1H92!3=&]C:R!0;&%N&-E<'0@<&5R('-H M87)E(&%M;W5N=',@86YD('=E:6=H=&5D(&%V97)A9V4@6QE/3-$)V1I M6QE/3-$)V1IF4Z,7!T M.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I9'1H.C0S M+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C$T+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C M875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$ M)W=I9'1H.C`Y+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`Q,'!T)SX-"@D)"0D) M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V M86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/E=E:6=H=&5D($%V97)A9V4@17AE M6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CEP=#LG/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C0S+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^0F%L86YC92!O=71S=&%N M9&EN9R!A="!$96-E;6)E6QE/3-$)W=I9'1H.C`Y M+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#0Q,B9N M8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,BXX-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1IF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)A;G1E9#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`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`R+C@T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4 M:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z-#,N,C(E.W!A9&1I;FF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N.#0E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F'0M86QI9VXZ3I4:6UE M3H@:6YL:6YE M.R<^(#,P+"`R,#$R/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@3I4 M:6UE6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$T M+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXS+CDX)FYB6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I3H@ M:6YL:6YE.R<^4V5P=&5M8F5R/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W=I9'1H.C`Y+C,T M)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(MF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F3I4 M:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F6QE/3-$)V1IF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED M=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+CDP)FYB6QE/3-$=VED M=&@Z,#(N.#0E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y M+C4V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)V1I3H@:6YL:6YE.R<^(#,P+"`R,#$R/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$T+C$P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR M+C@Y)FYB6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`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`\+V9O;G0^/"]P/CQP('-T M>6QE/3-$<&%G92UB7,^)FYB'0M:6YD96YT.C$X<'0[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.SL@9F]N="US:7IE.B`Q,'!T)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H) M"3PO<#X-"@D)/'`@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUA6QE/3-$)V1I M6QE/3-$ M)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I9'1H.C0W+C(X)3MB86-K9W)O=6YD M+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE MF4Z,7!T.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C$V+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C$Q+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`E.W!A9&1I;F3I4:6UE M6QE M/3-$)W=I9'1H.C$V+C,T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)V1I'0M86QI9VXZ6QE/3-$=VED=&@Z-#3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR,#,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,S`E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,3$N,#8E.W!A9&1I;F6QE/3-$)W=I9'1H.C0W+C(X)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5F5S=&5D/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z-#F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,S`E.W!A9&1I;F3I4 M:6UE6QE/3-$=VED=&@Z,3$N,#8E.W!A9&1I;F6QE/3-$)W=I9'1H.C0W+C(X)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0F%L86YC92!O=71S=&%N9&EN9R!A3H@:6YL:6YE.R<^4V5P=&5M M8F5R/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C0P)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I M9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$)W=I9'1H.B`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`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`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`R,#PO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXQ,CPO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[)SX@:7,@3H@:6YL:6YE.R<^9&]L M;&%R3H@:6YL:6YE.R<^ M:6X@=&AO=7-A;F1S+"!E>&-E<'0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A M;&EG;CTS1&-E;G1E3H@:6YL:6YE.V9O;G0M9F%M M:6QY.D-A;&EB6QE/3-$ M)W=I9'1H.C$V+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$S+C4R M)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D) M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$)W=I9'1H.C$U+C,X)3MB86-K9W)O=6YD M+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T* M"0D)/"]T6QE/3-$=VED=&@Z-#(N,C`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB M6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/E1O=&%L($YU;6)E'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/D%V97)A M9V4@4')I8V4@4&%I9"!P97(@4VAA6QE/3-$ M)V1IF4Z.'!T.R<^*#(I/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/D%M M;W5N="!O9B!297!U6QE M/3-$)W=I9'1H.C0R+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^0W5M=6QA M=&EV92!B86QA;F-E(&%T($1E8V5M8F5R)FYB6QE/3-$)V1IF4Z.'!T M.R<^*#$I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I'0M86QI M9VXZ3I4:6UE6QE/3-$)W=I9'1H.C`S M+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)V1I6QE/3-$)W=I9'1H.C$V+C'0M86QI9VXZ M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-2XR,R9N8G-P.PT* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`S+C`T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#0T M,29N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)V1I6QE/3-$)V1IF4Z.'!T.R<^*#$I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C4R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ-"XQ-R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,RXP-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U M+C,X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@6QE/3-$)V9O;G0M3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/D,\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z,3!P=#LG/G5M=6QA=&EV92!B86QA;F-E3H@ M:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#LG/F%N9"!397!T96UB97(@,S`L(#(P,3(@8V]N3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O M;G0M6QE/3-$ M)V1I6QE/3-$ M)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3I4 M:6UE3H@:6YL:6YE.R<^(#,P+"`R,#$R+"!W92!H879E(&EN('1R M96%S=7)Y(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SXP+C(\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^ M(&UI;&QI;VX@3H@:6YL:6YE.R<^<')E=FEO=7-L>2`\+V9O;G0^/&9O;G0@ M3H@:6YL:6YE.R<^3H@:6YL:6YE.R<^(#,P M+"`R,#$R+"!W92!H860@82!T;W1A;"!O9B`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^-2XY/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V1I6QE/3-$)V1I2P@:&5L9"!I;B!T2X\+V9O;G0^/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[)SXM0F%S960@0V]M<&5N M3H@ M:6YL:6YE.R<^5&AE(&9A:7(@=F%L=64@;V8@65E3H@:6YL:6YE.R<^(&5N9&5D(#PO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SY397!T96UB M97(@,S`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^ M+"`R,#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXQ M,3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S M<#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^86YD M(#(P,3(@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE M/3-$)W=I9'1H.C,W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S M+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C M875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`Q M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA6QE/3-$)VUA3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C`T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CEP=#LG/C(P,3$\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXP-"4[8F]R9&5R+71O M<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H.C$S+C(P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE MF4Z.7!T.R<^,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I M9'1H.C,W+C8R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M6QE M/3-$)V1I6QE/3-$)W=I9'1H.C`S M+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE M/3-$)W=I9'1H.C$P+C,R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H M.C`S+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE'!E8W1E9"!T97)M/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4 M:6UE6QE/3-$)W=I9'1H.C$P+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4 M:6UE3I4:6UE6QE/3-$)W=I9'1H.C$P+C,R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.R<^('EE87)S/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^-"XV/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`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`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^3B]!/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S M+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$ M=VED=&@Z,S3I4:6UE6QE/3-$=VED M=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,3`N,C(E.W!A9&1I M;F6QE M/3-$)V1I6QE/3-$=VED=&@Z,#,N M,#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4 M:6UE6QE/3-$)W=I9'1H.C$P+C,R)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXR+C`R)29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`T)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S M+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE M/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P M+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXV+C0V)FYB6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C$P+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF M;VYT+69A;6EL>3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C$V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+C0Q)FYB6QE M/3-$)VUA6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@6QE/3-$)V9O;G0M3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/E1H97)E('=E65E6QE/3-$)V1I3I4:6UE M6QE/3-$)V1I3H@:6YL:6YE.R<^;6]N=&AS(&5N9&5D(#PO9F]N=#X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SY397!T96UB97(@,S`\ M+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^+"`R,#$Q M(&%N9"`R,#$R("AI;B!T:&]U6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O M6QE/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB86-K9W)O=6YD+6-O M;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M6QE/3-$ M=VED=&@Z-#$N-#0E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CEP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@8V]L6QE/3-$)W=I9'1H M.C(X+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z M,#(N.#`E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C(W+C(T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$=VED=&@Z-#$N-#0E.W!A9&1I M;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/B9N8G-P.SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$S+C0P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M3I4:6UE6QE/3-$)W=I9'1H M.C`R+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C`Y+C(P)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$=VED=&@Z,#(N.#`E.W!A9&1I M;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`Y+C(X)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^0V]M M;6]N('-T;V-K(&]P=&EO;G,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XR,"4[8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`Y+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF M;VYT+69A;6EL>3I4:6UE6QE/3-$ M)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`Y+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXR+#@Y,R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+C(X)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#`W M-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY-SDF;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXV,C(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`Y+C4V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR+#(U,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.C`T+C(P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMG6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ+#@R-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N9"UC M;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I M9'1H.C`R+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@ M.V)A8VMG6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXU+#8R,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.R<^("AI;B!T:&]U6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE M/3-$)W=I9'1H.C0Q+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R M+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M3I4:6UE6QE/3-$=VED=&@Z,#(N-S`E.W!A9&1I;F3I4:6UE6QE M/3-$)W=I9'1H.C$R+C3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$=VED M=&@Z-#$N-#8E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$=VED=&@Z,#(N M,S8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)W=I9'1H.C`Y+C$T)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE M/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@8V]L6QE/3-$ M)W=I9'1H.C`Y+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR-3(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V1I M'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`Y+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW-S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)V1I'0M86QI9VXZ6QE M/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`R+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9& M1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$Q M+C(P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-C0F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR-#,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&5C:&YO;&]G>2!A;F0@8V]N=&5N=#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`Y+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXT,3$F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X+CDV)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW.#,F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0V)3MB86-K9W)O M=6YD+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1V5N97)A;"!A;F0@861M:6YI'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C,V)3MB86-K9W)O M=6YD+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C$Q+C(P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#(N-S`E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C8P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`Y+C$T)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,V."9N M8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`R+C6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ+#@R-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXS-B4[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C`S+C8P)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMG6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#8R,B9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,BXV-B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T* M"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO&5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE M/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`@6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C0T-BXT,'!T.W!A9&1I;F3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M)SXF(W@R,#$S.R!);F-O;64@5&%X97,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@3I4:6UE'0M:6YD96YT.C$X M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE M(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(&]U6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)W=I9'1H.C`S+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C`T+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$=VED=&@Z,#,N-C(E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,#DN.3(E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,C(E.W!A9&1I M;F3I4:6UE6QE/3-$=VED=&@Z,#(N-C@E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,3$N,S`E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I M;F3I4:6UE6QE/3-$=VED=&@Z,#0N-3`E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#DN,30E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z M,#(N-C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N-C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#@N.38E.W!A9&1I;F3I4:6UE6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H.C,P+C'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CEP=#LG/B`S,"P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C@P)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z.7!T.R<^($UO;G1H3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CEP=#LG/E-E<'1E;6)E6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H M.C$S+C4T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)W=I9'1H.C`S+C(R)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@ M3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C`Y+CDR)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S M+C8P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X M+CDV)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)W=I9'1H.C,Y+C4R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^26YC;VUE(&)E9F]R92!P6QE/3-$)W=I9'1H.C`S+C8R)3MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C(R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8X)3MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q M+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S M+C8P)3MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W3I4:6UE6QE/3-$)W=I9'1H.C`S+C8R)3MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.W1E>'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+CDR M)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SL[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.W1E>'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I3I4:6UE6QE/3-$)W=I M9'1H.C`S+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$P+C`T)3MB86-K M9W)O=6YD+6-O;&]R.B`C875T;SL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)W=I9'1H.C`R+C8V M)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D) M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`X+CDV)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SL[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE M/3-$)W=I9'1H.C,Y+C4R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^169F96-T M:79E('1A>"!R871E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S M+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8X)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C$Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX,2XP)29N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XX,"4[ M8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X M+CDV)3MB86-K9W)O=6YD+6-O;&]R.B`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`R,#$\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^,3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SX@86YD(#(P,3PO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[)SXR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I2!F961E M2!T;SPO9F]N M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SX@;F]N+61E9'5C M=&%B;&4@;&]B8GEI;F<@97AP96YS97,@86YD/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I6UE;G1S+CPO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[)SX@)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE M.R<^,C`Q,2!A;F0@,C`Q,CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[)SXL('=E('5T:6QI>F5D(&5X8V5S6QE/3-$ M)V1I3H@:6YL:6YE.R<^(&UI;&QI;VX\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V1I3H@:6YL:6YE.R<^)#PO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[)SXR+C0\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^("9N8G-P.VT\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^:6QL:6]N+"!R97-P96-T:79E;'DL(#PO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SYI;B`\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q0SM! M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^)B-X,C`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`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^*&QO2!T M:&4@=V5I9VAT960@879E2!A<'!L:6-A=&EO;B!O9B!T:&4@ M=')E87-U3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.R<^*&QO6QE/3-$)V1I'0M:6YD M96YT.C$X<'0[;&EN92UH96EG:'0Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$ M)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I9'1H.C4Q+C,P)3MB86-K9W)O=6YD M+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE MF4Z,7!T.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)VUA6QE/3-$)V1I M3I#86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CEP=#LG/E1H6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CEP=#LG/DYI;F4@36]N=&AS($5N9&5D(%-E<'1E;6)E3I4:6UE6QE/3-$)W=I9'1H.C$P+CDR)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE MF4Z.7!T.R<^,C`Q,3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT M('-T>6QE/3-$)V1I'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA6QE/3-$)VUA3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@3I4:6UE'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3I4:6UE6QE/3-$)W=I9'1H.C`R M+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`W+C8R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K M9W)O=6YD+6-O;&]R.B`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`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I M9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R M+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+CDR)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,#4F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA M3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`W+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF M;VYT+69A;6EL>3I4:6UE3I4:6UE M6QE/3-$)VUA M3I4:6UE6QE/3-$ M=VED=&@Z,#@N-C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$ M=VED=&@Z,#@N.3(E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#@N-C8E.W!A9&1I;F3I4 M:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N M,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#@N.3(E.W!A9&1I;F3I4 M:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N M,C8E.W!A9&1I;F6QE/3-$)W=I M9'1H.C4Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3H@:6YL:6YE M.R<^5V5I9VAT960@879E6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`X+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR-2PV.#,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H M.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C(V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)V1I3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`W+C8R)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`W+C8X)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C4Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,2PP M-30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG3I4:6UE6QE/3-$)W=I9'1H.C`X+CDR)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,2PR-C0F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMG3I4:6UE6QE/3-$)W=I9'1H.C`W+C8X)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W3I4 M:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C`X+C8V)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$ M)VUA3I4:6UE M6QE M/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V M)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C`W+C8X)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^3F5T(&EN8V]M92`\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^*&QO6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I M;F6QE/3-$)V1IF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C`Q)FYB6QE/3-$=VED=&@Z,#(N,C8E M.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F6QE/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`W+C8X)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE M6QE/3-$)VUA M3I4:6UE6QE/3-$ M=VED=&@Z,#@N-C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N M,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#6QE/3-$)W=I9'1H.C4Q+C,P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1&EL=71E9#H\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,BXR-B4[8F%C:V=R;W5N9"UC;VQO'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C`W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#@N-C8E.W!A9&1I;F'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#@N.3(E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C8V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,C0Y*0T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,BXR-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXT+#0V-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXR-B4[8F%C:V=R;W5N M9"UC;VQO6QE/3-$)V1I'0M86QI9VXZ6QE/3-$=VED=&@Z-3$N,S`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`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^3F5T('=E:6=H=&5D(&%V M97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S=&]C:R!S:&%R97,@;W5T'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE M6QE M/3-$=VED=&@Z,#@N-C8E.W!A9&1I;F6QE/3-$)V1I'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)W=I9'1H.C`W+C8R M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N,C8E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXW-3`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C4Q+C,P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)V1I'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^("9N8G-P.RT\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,BXR-B4[8F%C:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA6QE/3-$)W=I9'1H.C`W+C8X M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,#(F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86P@ M8V]M;6]N('-T;V-K('-H87)E6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X+C8V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,2PP-30F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I M;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE M/3-$)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C`W+C8X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE M("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PU-C,F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A M9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C)P="!D M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[ M8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O M;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3F5T(&EN8V]M92`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^*&QO6QE/3-$ M)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`X+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXP+C`Q)FYB6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXP+C(P)FYB6QE/3-$)W=I9'1H.C`R+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`W+C8X)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C(S)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)#0H)"3PO<#X-"@D)/'`^/&9O;G0@ M6QE/3-$)VUA6QE/3-$)V1I3H@:6YL:6YE.R<^=&AR964@86YD(&YI;F4@;6]N=&AS/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^4V5P=&5M8F5R M(#,P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^,3$\ M+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^(&%N9"`R M,#$\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^,CPO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXL('=E(&AA M9"!S96-U&-L=61E9"!I;B!T:&4@8V]M<'5T871I M;VX@;V8@9&EL=71E9"!N970@:6YC;VUE/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V1I6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I'0M:6YD96YT.C$X<'0[;&EN92UH M96EG:'0Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI M;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H M.C$R+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S+C`V)3MB86-K M9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.B`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`Q,'!T)SX-"@D)"0D) M"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,#8E.W!A9&1I;F3I4:6UE M6QE/3-$)W=I9'1H.C(W+C(V)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z-#$N-#0E.W!A M9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`V M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HP,RXP M-B4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H.C$R+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE MF4Z.7!T.R<^,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I M9'1H.C0Q+C0T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M6QE M/3-$)V1I6QE/3-$)W=I9'1H M.C$R+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N M="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1T;W`@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N,#8E.W!A9&1I M;F3I4:6UE6QE/3-$)W=I9'1H.C$R+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P M.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]M;6]N('-T;V-K(&]P=&EO;G,\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,BXY."4[8F%C:V=R;W5N9"UC;VQO3I4:6UE6QE/3-$)W=I9'1H M.C$R+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ+#0X-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXP-B4[8F%C:V=R;W5N9"UC M;VQOF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`S+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$=VED=&@Z-#$N-#0E.W!A9&1I;F3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU,S@F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,#,N,#8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$R+C$V)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H M.C$R+C`T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)OF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^("9N8G-P.RT\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C$R M+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#0X-"9N8G-P.PT*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXP M-B4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ3I4:6UE6QE/3-$)W=I9'1H.C$R+C`T)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C0T-BXT,'!T.V)A M8VMG3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.C%P=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS M1'1O<"!S='EL93TS1"=W:61T:#HT-#8N-#!P=#MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P="`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`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE M/3-$)V)O6QE/3-$)W=I9'1H.C0R+C$V)3MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)W=I9'1H.C`T+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I# M86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z-#(N,38E.W!A9&1I M;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I M6QE/3-$=VED=&@Z,#0N.#(E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,C8N-3`E M.W!A9&1I;F3I4:6UE3I4:6UE3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z-#(N,38E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$=VED=&@Z,#0N.#(E.W!A9&1I M;F3I4:6UE6QE/3-$)W=I9'1H.C`T+C@R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`T+C@R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C8X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS."PP-30F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-#(N,38E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H M.C`T+C@R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR.#8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I M9'1H.C0R+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^ M5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XX,B4[8F]R9&5R+71O<#HQ<'0@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C`T+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE M6QE.FET86QI8SLG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C$X<'0[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US='EL93II=&%L:6,[)SY3:6=N:69I8V%N="!#=7-T;VUE3H@:6YL:6YE.R<^)B-X,C`Q-#M3=3PO M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SYB2!A;&P@6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.R<^=&AE(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SYT:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^,3$\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.R<^(&%N9"`R,#$\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^,B!A6QE/3-$)V1I M'0M:6YD96YT.C$X<'0[;&EN92UH96EG M:'0Z,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE M/3-$)W=I9'1H.C,S+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$S M+CDX)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`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`Q,'!T)SX-"@D)"0D) M"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N-30E.W!A9&1I;F3I4:6UE M6QE/3-$)W=I9'1H.C,Q+C0R)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,S,N-C(E M.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P M,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C4T)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG M/C(P,3$\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXU-"4[8F]R9&5R+71O<#HQ<'0@ M3I4:6UE6QE/3-$)W=I9'1H.C$S+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE MF4Z.7!T.R<^,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO M='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I M9'1H.C,S+C8R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M6QE M/3-$)V1I6QE/3-$)W=I9'1H M.C$S+CDR)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N-30E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$S+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)W=I9'1H.C,S+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA3H@:6YL:6YE.R<^2'5M86YA M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C4T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3I4:6UE6QE/3-$)W=I9'1H.C$S+C@X)3MB86-K M9W)O=6YD+6-O;&]R.B`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`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^56YI=&5D2&5A;'1H8V%R93PO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`S M+C4T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)V1I6QE/3-$=VED=&@Z,3,N.3(E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,#,N-30E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,3,N.#@E.W!A M9&1I;F6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@ M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1T;W`@6QE/3-$)V9O;G0M6QE/3-$)V1I3I4:6UE6QE/3-$)V1I3I4:6UE2`\+V9O;G0^/&9O;G0@3H@ M:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#LG/E=E;&QP;VEN="X\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^ M/"]D:78^#0H)"3QD:78@F4Z,3%P=#LG/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z,3!P=#LG/E5N:71E9$AE86QT:&-A6QE/3-$)V1I3I4:6UE2`\+V9O;G0^/&9O;G0@3H@ M:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M,3!P=#LG/E5N:71E9$AE86QT:&-A6QE/3-$ M)V1I3I4:6UE'0M M:6YD96YT.C$X<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^0V]M;6ES6QE/3-$)V1I2`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`\+V9O;G0^/&9O;G0@ M3H@:6YL:6YE.R<^+"`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`R M,#$R+"`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^ M='=O/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^ M)FYB6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^2P@9F]R(&$@8V]M8FEN960@=&]T86P@;V8@/"]F;VYT/CQF;VYT('-T>6QE M/3-$)V1I6QE/3-$ M)V1I6QE M/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^+CPO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[)SXS/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE M.R<^(&)A;&%N8V4\+V9O;G0^/&9O;G0@3H@:6YL M:6YE.R<^+B!.;R!O=&AE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^(#,P+"`R,#$R+CPO9F]N=#X-"@D)/"]P/@T* M"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V M-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA2D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@ M8V]L6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`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`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`\+V9O;G0^/&9O;G0@3H@:6YL:6YE M.R<^+"`R,#$\+V9O;G0^/&9O;G0@3H@:6YL:6YE M.R<^,3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SX@ M86YD(#(P,3PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SXR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^;FEN93PO9F]N=#X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[)SX@;6]N=&AS(&5N9&5D(#PO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SY397!T96UB97(@,S`\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^+"`R,#$\+V9O M;G0^/&9O;G0@3H@:6YL:6YE.R<^,3PO9F]N=#X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SX@86YD(#(P,3PO9F]N M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXR/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^4V5P=&5M8F5R(#,P/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^(&%R92!N;W0@;F5C97-S M87)I;'D@:6YD:6-A=&EV92!O9B!T:&4@'!E8W1E M9"!F;W(@86YY('-U8G-E<75E;G0@<75A3H@:6YL:6YE.R<^,CPO9F]N=#X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXN/"]F;VYT/@T*"0D\+W`^#0H) M"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`@ M6QE/3-$)V1I2!H96%L=&@@:6YS=7)A;F-E(&%P M<&QI8V%T:6]N2!E>'!E6QE/3-$)V1I'0M:6YD96YT.C$X<'0[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z(#$P<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE('9A M65A7!I M8V%L;'D@2`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`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1IF5D('1O("8C>#(P,4,[0V]S="!O9B!R979E;G5E)B-X,C`Q M1#L@:6X@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@6QE/3-$)V1I3H@:6YL:6YE.R<^ M('EE87)S+CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M)SX@5&AE(&%M;W5N="!O9B!C;VYS:61E6EN9R!P;VQI8VEE'!E;G-E(')E8V]R9&5D('1O(&-O3H@ M:6YL:6YE.R<^(#,P+"`R,#$Q(&%N9"`R,#$R('1O=&%L960@)#PO9F]N=#X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXP+C$\+V9O;G0^/&9O M;G0@3H@:6YL:6YE.R<^(&UI;&QI;VX@86YD/"]F M;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^;6EL;&EO M;BP@6QE/3-$)V1I MF%T:6]N(&5X<&5N3H@:6YL:6YE.R<^,"XT/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R<^)#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SXR+C`\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^(&UI;&QI;VXL(')E2X@0V%S:"!C;VYS M:61E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$=VED M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!A;&EG;CTS1&-E;G1E3H@:6YL:6YE.V9O;G0M M9F%M:6QY.D-A;&EB6QE M/3-$)W=I9'1H.C`S+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S M+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N,S(E.W!A9&1I;F3I4:6UE M6QE M/3-$=VED=&@Z,3@N-#8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,S(E M.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,S(E.W!A9&1I;F3I4:6UE M6QE M/3-$=VED=&@Z,3@N-#8E.W!A9&1I;F3I4:6UE6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H.C(Q+C'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#,N,S(E.W!A9&1I;F3I4:6UE6QE/3-$)W=I M9'1H.C(Q+C'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/B`S,"P@,C`Q,CPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D) M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C4S+C$R)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C,R)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA6QE/3-$=VED=&@Z,#,N,S(E M.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$X+C0V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-RPT-#$F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3,N,3(E.W!A9&1I;F3I4 M:6UE2!M87)K970@9G5N M9',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,RXS,B4[8F]R9&5R+71O<#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,#8L,S4Q)FYB6QE/3-$=VED=&@Z M,#,N,S(E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ,3,L,S4Y)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE'0M86QI9VXZ3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.C$Q<'0[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C,R M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$ M)V1I3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE M/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I M9'1H.C4S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^06-C;W5N=',@'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$X+C0V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW+#6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$=VED=&@Z-3,N,3(E.W!A9&1I M;F3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$ M=VED=&@Z,#,N,S(E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C,R)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#,Y-"9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$X+C0V)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C,R)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA2`H5&%B;&5S M*3QB6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)W=I9'1H.C0R+C4T)3MB86-K M9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\ M+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3F4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY M.D-A;&EB6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M3I4:6UE6QE/3-$)W=I9'1H.C4W+C0V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4VAA6QE/3-$=VED=&@Z-3F5D(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="US:7IE.CAP=#LG/B@R*3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C0R+C4T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)V1I6QE/3-$)W=I9'1H M.C0R+C4T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH-S,Q*0T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1I6QE M/3-$)W=I9'1H.C0R+C4T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C4W+C0V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3W!T:6]N6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4F5S=')I8W1E9"!S=&]C:R!U;FETF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$)W=I9'1H.C0R+C4T)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4:6UE M6QE/3-$)W=I9'1H.B`S-BXP,'!T.R!D:7-P;&%Y.B!I M;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[;6%R9VEN M+6QE9G0Z-7!T)SX@*#$I/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`^/'`@F4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^4SPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[)SYH87)E6QE/3-$)V1I M6QE/3-$ M)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^ M)FYB6QE/3-$)W=I9'1H.B`S-BXP,'!T.R!D M:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[;6%R9VEN+6QE9G0Z-7!T)SX@*#(I/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1T;W`^/'`@F4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^3SPO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SYN($IA;G5A3H@:6YL:6YE.R<^,C`Q,CPO9F]N M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXL('1H92!N=6UB M97(@;V8@6QE/3-$)V1I2!);F-E;G1I M=F4@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.R<^6QE/3-$)V1I3H@:6YL:6YE.R<^ M("9N8G-P.R9N8G-P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D M:78^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV M/B`\+V1I=CX\2!5;F1E'0^/&1I M=CX@/&1I=B!S='EL93TS1&UA6QE M/3-$)VUA3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M3I4:6UE6QE/3-$)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C@T)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$=VED=&@Z,#DN,S0E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I M;F3I4:6UE6QE/3-$=VED=&@Z,#DN-38E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,30N,3`E.W!A9&1I M;F3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED M=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#DN-38E.W!A9&1I M;F3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I4 M:6UE6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$T+C$P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z.7!T.R<^06=G3I4:6UE MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+C4V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,2XS-B9N8G-P.PT*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX M-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+C4V)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-RPP-S@F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-#,N,C(E.W!A9&1I;F3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW,S$F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+C4V)3L[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI M9VXZ'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I M;F'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H.C`Y+C,T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH M-S`Y*0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,BXX-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1I'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C`Y+C,T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`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`R,#$R/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`Y+C4V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PU,S8F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)/"]T6QE/3-$)W=I9'1H.C0S+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`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`^ M/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H)"3QP/CQF;VYT('-I>F4],T0Q M/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0^/&1I=CX@/&1I=B!S M='EL93TS1&UA6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!A;&EG;CTS1&-E;G1E3H@:6YL:6YE.V9O;G0M M9F%M:6QY.D-A;&EB6QE M/3-$)W=I9'1H.C$U+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)VUA M6QE M/3-$)V1I3I#86QI8G)I.V9O;G0M M6QE M/3-$=VED=&@Z-#F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CEP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C0P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CEP=#LG/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64@/"]F;VYT/CQF M;VYT('-T>6QE/3-$)V1IF4Z.'!T.R<^ M*#$I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0W+C(X M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0F%L86YC92!O=71S=&%N9&EN9R!A M6QE/3-$)W=I9'1H.C$U+C0P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT-S0F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C$V+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ+CDR)FYB6QE/3-$)W=I9'1H.C`S+C,P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)A;G1E9#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C$U+C0P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,S`E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,38N,S0E.W!A9&1I;F'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-& M1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,C,U*0T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXS,"4[8F%C M:V=R;W5N9"UC;VQO3I4:6UE6QE/3-$)W=I9'1H.C$Q+C`V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^0V%N8V5L;&5D/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH M-S4I#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#,N,S`E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,38N,S0E M.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-C3I4:6UE6QE/3-$)W=I9'1H.C$V+C,T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+C,V)FYB6QE/3-$)W=I9'1H M.C`S+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S+C,P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W3H@:6YL:6YE.R<^/&9O;G0@3I!6QE/3-$ M)V1I3I4:6UE6QE/3-$)V1I3I4:6UE3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG/C$\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z,3!P=#LG/B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I M3I4:6UE6QE/3-$ M)V1I3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$=VED=&@Z,3`P)3X\=&%B M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E M;G1E6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z-#(N,C`E.W!A9&1I;F3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C$V+C'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED M=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$V+C4V)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT M('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE M6QE/3-$)W=I9'1H.C$X+C0R)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)W=I9'1H.C$V M+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+#3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C,X)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX,2PU-36QE/3-$=VED=&@Z-#(N,C`E.W!A9&1I;F3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C4R)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C$U+C,X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)W=I9'1H.C0R+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^0W5M=6QA=&EV M92!B86QA;F-E(&%T(#PO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[)SY397!T96UB97(\+V9O;G0^/&9O;G0@3H@:6YL:6YE.R<^(#,P+"`R,#$R(#PO9F]N=#X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.CAP=#LG/B@Q*3PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C$V+CF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)V1I'0M86QI9VXZ3I4:6UE6QE/3-$ M)W=I9'1H.C`S+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.V)A8VMG6QE/3-$)V1I3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXX.2PY.3@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T M6QE/3-$)W=I9'1H M.B`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`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$ M)VUA'0M:6YD96YT.B`M,3AP=#MF M;VYT+69A;6EL>3I4:6UE3H@:6YL:6YE.SMF;VYT+7-I>F4Z M,3)P=#MF;VYT+69A;6EL>3I4:6UE3H@:6YL:6YE.R<^03PO9F]N=#X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SYV97)A9V4@<')I8V4@<&%I M9"!P97(@6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I M;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C M875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$ M)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D) M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T M)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D) M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$ M=VED=&@Z,3`N,C(E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$ M=VED=&@Z,3`N,S(E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$ M=VED=&@Z,3`N,S@E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$ M=VED=&@Z,3`N,38E.W!A9&1I;F3I4:6UE6QE M/3-$)VUA6QE/3-$)V1I6QE/3-$)W=I9'1H.C(Y+C8V)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT M('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C(Y+C8V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$=VED=&@Z,SF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CEP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@8V]L6QE/3-$)W=I9'1H M.C$S+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@ M3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$P+C(R)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D) M"3QF;VYT('-T>6QE/3-$)V1IF4Z.7!T M.R<^*#$I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1T;W`@6QE/3-$)VUA3I4 M:6UE6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)W=I9'1H.C$P+C$V)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C,W+C8R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^17AP96-T960@=&5R;3PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3B]!/"]F M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M3I4:6UE6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^-"XV M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)V1I65A3I4:6UE6QE/3-$)W=I M9'1H.C$P+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3H@:6YL:6YE M.R<^('EE87)S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z M,S3I4:6UE'!E8W1E9"!V;VQA=&EL:71Y/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3B]!/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT,RXS)29N8G-P.PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C`T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$=VED=&@Z,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z M,#,N,#0E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$P+C$V)3L[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI M9VXZ6QE/3-$)W=I M9'1H.C,W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^17AP96-T960@9&EV M:61E;F0@>6EE;&0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXP-"4[8F%C:V=R;W5N M9"UC;VQO6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C`T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C`T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z M,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C`T M)3MB86-K9W)O=6YD+6-O;&]R.B`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`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$P+C(R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I'0M:6YD96YT.C(R+C5P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)W=I9'1H.B`U."XP M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[;6%R9VEN+6QE9G0Z-#!P="<^("@Q*3PO9F]N=#X\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQP('-T>6QE/3-$;&EN92UH M96EG:'0Z875T;SMF;VYT+69A;6EL>3I#86QI8G)I.V9O;G0M6QE/3-$)V1I3I4:6UEF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV M('-T>6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/'`@6QE/3-$ M)V1I3H@:6YL:6YE.R<^;6]N=&AS(&5N9&5D(#PO9F]N=#X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SY397!T96UB97(@,S`\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.R<^+"`R,#$Q(&%N9"`R M,#$R("AI;B!T:&]U6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE M/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R M+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C M875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z M-#$N-#0E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP M=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L M6QE/3-$)W=I9'1H.C(X+C4P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N.#`E M.W!A9&1I;F3I4:6UE6QE M/3-$)W=I9'1H.C(W+C(T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$ M)V1I6QE/3-$=VED=&@Z-#$N-#0E.W!A9&1I;F3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/B9N8G-P.SPO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$S+C0P)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)W=I9'1H.C`R+C@P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"3QF;VYT('-T>6QE/3-$)V1I'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4 M:6UE3I4:6UE6QE/3-$)W=I9'1H.C`Y+C(P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#(N.#`E.W!A9&1I;F3I4 M:6UE6QE/3-$)W=I9'1H.C`R+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)W=I9'1H.C`Y+C(X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]M;6]N('-T M;V-K(&]P=&EO;G,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XR,"4[8F%C:V=R;W5N M9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`Y+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXX-#4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)V1I6QE M/3-$)W=I9'1H.C`R+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y M+C4V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR+#@Y,R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Y+C(X)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#`W-B9N8G-P M.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)V1I3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY-SDF;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXV,C(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C`Y+C4V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#(U M,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`T+C(P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG6QE/3-$)V1I3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ+#@R-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ3I4:6UE6QE/3-$)W=I9'1H.C`R M+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@ M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG M6QE/3-$)V1I3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXU+#8R,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXX,"4[8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE M/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^("AI M;B!T:&]U6QE/3-$)V1IF4Z,7!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I M9'1H.C0Q+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT M.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)VUA6QE/3-$)V1I M3I#86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z-#$N M-#8E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG M/E1H6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/DYI M;F4@36]N=&AS($5N9&5D(%-E<'1E;6)E3I4:6UE6QE/3-$)VUA3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,BXS-B4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H.C$S+C@V)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M3I4:6UE6QE/3-$ M=VED=&@Z,#(N-S`E.W!A9&1I;F3I4:6UE6QE/3-$)W=I M9'1H.C$R+C3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$ M)V1I6QE/3-$=VED=&@Z-#$N M-#8E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#(N,S8E.W!A M9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`Y+C$T)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)V1I M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@8V]L6QE/3-$)W=I9'1H M.C`Y+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXR-3(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Y+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXW-S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$)V1I M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C`R+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A M9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`R+C8V M)3MB86-K9W)O=6YD+6-O;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$Q+C(P)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-C0F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-#,F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&5C:&YO;&]G>2!A;F0@8V]N=&5N=#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C`R+C6QE/3-$)VUA6QE/3-$ M)W=I9'1H.C`Y+CDP)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXT,3$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R M+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X+CDV)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW.#,F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0V)3MB86-K9W)O=6YD+6-O M;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^1V5N97)A;"!A;F0@861M:6YI'0M86QI9VXZF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C,V)3MB86-K9W)O=6YD+6-O M;&]R.B`C1D9&1D9&.W!A9&1I;F6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)W=I9'1H.C`R+C8V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$Q+C(P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N-S`E.W!A9&1I;F3I4:6UE M6QE M/3-$)W=I9'1H.C`S+C8P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`Y+C$T)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,V."9N8G-P.PT* M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C`R+C6QE M/3-$)V1I3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+#@R-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXS-B4[8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)W=I9'1H.C`S+C8P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE M("-$.40Y1#D@.V)A8VMG6QE/3-$)V1I3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU+#8R,B9N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXV-B4[ M8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV M/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S M("A486)L97,I/&)R/CPO&5S(%M!8G-T2!/9B!0 M"!2 M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV M('-T>6QE/3-$;6%R9VEN+6QE9G0Z-S)P=#X-"@D)/&1I=B!S='EL93TS1'=I M9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M3I4:6UE6QE/3-$)W=I9'1H.C`Y+CDR)3MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE M.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)W=I9'1H.C$Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE M6QE M/3-$)W=I9'1H.C`Y+C$T)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X M+CDV)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`S,"P\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)VUA3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,RXR,B4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H M.C$S+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$S+C8T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE MF4Z.7!T.R<^,C`Q,3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C8V)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF M;VYT('-T>6QE/3-$)V1I6QE M/3-$=VED=&@Z,SDN-3(E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,C(E.W!A M9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C8X)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)W=I9'1H.C$P+C`T)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)V1I M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Y+CDR)3MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UEF4Z M(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C$Q+C,P)3MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`W.29N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XX,"4[ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^)#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$P+C`T)3MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#F4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+CDV)3MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY M+#$V,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4')O=FES:6]N(&9O6QE/3-$)V1I MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)V1IF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C8R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)W=I9'1H.C`Y+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF M;VYT+69A;6EL>3I4:6UE'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H M.C`S+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$P M+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXT.2XS)29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXV-B4[8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^)FYB MF4],T0Q/B`\+V9O M;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!A;&EG;CTS1&-E;G1EF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M9F%M:6QY.D-A;&EB6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T M;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I M9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`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`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z M,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C(R M+C`X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,"XY,B4[ M8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS M1"=W:61T:#HP,BXR-B4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H.C$Q+C$X M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE M/3-$)W=I9'1H.C`Y+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE M/3-$)V1I6QE/3-$)W=I M9'1H.C4Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^0F%S:6,Z/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X+CDR)3MB;W)D M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I M;F'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I M;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4:6UE M6QE M/3-$=VED=&@Z,#'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`X+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH,C0Y*0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,BXR-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`W+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#0V-"9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,BXR-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)V1I6QE/3-$=VED=&@Z-3$N,S`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`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUAF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$)W=I9'1H.C`W+C8X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PR-S8F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;F3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH-"PV,CDI#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMG6QE/3-$)W=I9'1H.C`R+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ.2PY-S`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.2PW M,3$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I M;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H M.C`R+C(V)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N M92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB6QE/3-$ M)VUA3I4:6UE M6QE M/3-$)W=I9'1H.C`W+C8R)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O M;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^<&5R('-H87)E)B-X,C`Q-#MB87-I8SH\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`R+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,"XP,2D-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M86QI9VXZ3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`X+CDR)3L[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXP+C(Q)FYB6QE/3-$=VED=&@Z,#(N,C8E.W!A M9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F6QE/3-$)V1I6QE/3-$=VED=&@Z-3$N,S`E.W!A9&1I;FF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE6QE/3-$ M=VED=&@Z,#'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3I4:6UE M6QE M/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A M9&1I;F6QE/3-$)VUA6QE/3-$)W=I9'1H.C`X+CDR M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE M/3-$=VED=&@Z-3$N,S`E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4:6UE M6QE M/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z M,#(N,C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE6QE/3-$ M=VED=&@Z,#(N,C8E.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^3F5T(&EN8V]M92`\+V9O;G0^ M/&9O;G0@3H@:6YL:6YE.R<^*&QO6QE/3-$)V1I3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUA6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I M;F'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$=VED=&@Z,#(N,C8E M.W!A9&1I;F'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#6QE/3-$=VED=&@Z-3$N,S`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`W+C8X)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)V1I3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`X+CDR)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW-R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXR-B4[8F%C M:V=R;W5N9"UC;VQOF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C(V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D) M)FYB'0M86QI M9VXZ6QE/3-$)VUA6QE/3-$)V1I M'0M M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N,C8E.W!A9&1I;F3I4 M:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE M("-$.40Y1#D@.W!A9&1I;F6QE/3-$)VUA M3I4:6UE6QE/3-$ M)W=I9'1H.C`X+CDR)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PW-3`F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)V1I M6QE/3-$)W=I9'1H.C`R+C(V M)3MB;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`R+C(V)3MB;W)D97(M=&]P M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`W+C8R)3MB M;W)D97(M=&]P.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M'0M86QI9VXZ MF4Z M(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`W+C8X)3MB;W)D97(M=&]P.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$ M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M6QE/3-$)W=I9'1H.C4Q+C,P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R<^<&5R M('-H87)E)B-X,C`Q-#MD:6QU=&5D.CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C(V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)V1I6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$)V1I'0M86QI9VXZ M3I4:6UE'0^/&1I=CX@/&1I=B!S='EL93TS1&UA6QE M/3-$)V)O6QE/3-$)W=I9'1H.C0Q+C0T)3MB86-K9W)O=6YD+6-O;&]R M.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G M:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)W=I9'1H.C$R+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D M:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C`S M+C`V)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T* M"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`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`Q,'!T M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,#8E.W!A9&1I M;F3I4:6UE6QE/3-$)W=I9'1H.C(W+C(V)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX- M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z M-#$N-#0E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUA6QE/3-$)VUA3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`S+C`V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W M:61T:#HP,RXP-B4[8F]R9&5R+71O<#HQ<'0@3I4:6UE6QE/3-$)W=I9'1H.C$R+C`T)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)VUA6QE/3-$)V1I6QE M/3-$)W=I9'1H.C$R+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)VUA6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N M,#8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$R+C`T)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$ M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D) M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$)W=I9'1H.C0Q+C0T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]M;6]N('-T;V-K(&]P=&EO;G,\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ,BXY."4[8F%C:V=R;W5N9"UC;VQO3I4:6UE M6QE M/3-$)W=I9'1H.C$R+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.SMF M;VYT+69A;6EL>3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C`V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$=VED=&@Z-#$N-#0E M.W!A9&1I;F3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXU,S@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)VUA3I4 M:6UE6QE M/3-$=VED=&@Z,#,N,#8E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C$R+C$V M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ M6QE/3-$=VED=&@Z,#,N,#8E.W!A9&1I;F3I4:6UE M6QE M/3-$)W=I9'1H.C$R+C`T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)OF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^("9N8G-P.RT\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$R+CDX)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`S+C`V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#0X-"9N8G-P.PT* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,RXP-B4[8F%C:V=R;W5N9"UC;VQO3I4:6UE6QE/3-$)W=I9'1H M.C$R+C`T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A M8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)VUA6QE/3-$)V1I3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y M9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/&1I=CX@/&1I=B!S='EL93TS1&UA6QE/3-$)V)O6QE/3-$)W=I9'1H.C0R+C$V)3MB86-K9W)O M=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C!P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)W=I9'1H.C`T+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C M875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q M,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)VUA6QE/3-$)V1I3I#86QI8G)I.V9O;G0M6QE/3-$=VED=&@Z-#(N M,38E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N.#(E.W!A9&1I M;F3I4:6UE6QE/3-$=VED M=&@Z,C8N-3`E.W!A9&1I;F3I4:6UE3I4:6UE3I4:6UE6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z-#(N,38E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#0N M.#(E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C`T+C@R)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D) M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@ M6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`T M+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C8X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-&1D9&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS."PP-30F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)/"]T6QE/3-$=VED=&@Z-#(N,38E.W!A9&1I;F3I4:6UE6QE M/3-$)W=I9'1H.C`T+C@R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O'0M86QI9VXZF4Z(#$P<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR.#8F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)/"]T6QE/3-$)W=I9'1H.C0R+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XX,B4[8F]R9&5R M+71O<#HQ<'0@6QE/3-$)VUA M3I4:6UE6QE/3-$)W=I9'1H.C`T+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9& M.W!A9&1I;F6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$)VUA6QE/3-$)V1I'0^/&1I=CX@ M/&1I=B!S='EL93TS1&UA6QE/3-$)V)O6QE/3-$)W=I M9'1H.C,S+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT M.C!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$S+CDX)3MB M86-K9W)O=6YD+6-O;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\ M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O=6YD+6-O M;&]R.B`C875T;SMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US M:7IE.B`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`Q,'!T)SX-"@D)"0D)"3QF;VYT M('-T>6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N-30E.W!A9&1I;F3I4:6UE6QE/3-$)W=I9'1H.C,Q+C0R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T M>6QE/3-$)V1I6QE/3-$=VED=&@Z,S,N-C(E.W!A9&1I M;FF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX- M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3(\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`S+C4T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CEP=#LG/C(P,3$\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,RXU-"4[8F]R9&5R+71O<#HQ<'0@3I4:6UE M6QE M/3-$)W=I9'1H.C$S+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M3I4:6UE6QE/3-$)VUA6QE/3-$)V1I M6QE/3-$)W=I9'1H.C$S+CDR M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$=VED=&@Z,#,N-30E.W!A9&1I;F3I4:6UE M6QE M/3-$)W=I9'1H.C$S+C@X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I M9'1H.C,S+C8R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^2'5M86YA/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ3I4:6UE6QE/3-$)W=I9'1H.C$S+C@X)3MB86-K9W)O=6YD M+6-O;&]R.B`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`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^56YI=&5D2&5A;'1H8V%R93PO9F]N=#X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/&9O;G0@3H@:6YL:6YE.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C4T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-&1D9&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C4T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-&1D9&.W!A9&1I;F6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)V1I6QE/3-$=VED=&@Z,3,N.3(E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,#,N-30E.W!A9&1I;F3I4:6UE6QE/3-$=VED=&@Z,3,N.#@E.W!A9&1I;F6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@6QE/3-$)V9O;G0M6QE/3-$ M)V1I3I4:6UE6QE M/3-$)V1I3I4:6UE2`\+V9O;G0^/&9O;G0@3H@:6YL:6YE M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG M/E=E;&QP;VEN="X\+V9O;G0^/&9O;G0@3H@:6YL M:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P M=#LG/B9N8G-P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^ M#0H)"3QD:78@F4Z,3%P=#LG/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z,3!P=#LG/E5N:71E9$AE86QT:&-A6QE M/3-$)V1I3I4:6UE2`\+V9O;G0^/&9O;G0@3H@:6YL:6YE M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#LG M/E5N:71E9$AE86QT:&-A6QE/3-$)V1I3I4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!/9B!"=7-I;F5S2!I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&]F(&-O;G-I9&5R M871I;VX@=')A;G-F97)R960L('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^-2!Y96%RF%T:6]N(&5X<&5N2!L971T97(@;V8@8W)E M9&ET(&9I;F%N8VEA;"!G=6%R86YT964@86UO=6YT+"!P97)C96YT86=E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,R!Y96%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-C4@ M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!/9B!"=7-I M;F5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!,971T97)S(&]F($-R961I="!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!M87)K970@9G5N9',\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-3)F M8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!S=&]C:R!S:&%R97,@<'5R8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!E;7!L;WEE97,@=&\@2!T M87@@=VET:&AO;&1I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V M-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA2!);F-E;G1I=F4@4&QA;B!;365M8F5R73QB M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.34L M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R/@T*("`@("`@("`\=&0@8V]L2!S=&]C:R!O9B`U+CD@;6EL;&EO;B!S M:&%R97,@86YD(#8N-2!M:6QL:6]N('-H87)EF5D M(&9O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES960\+W1D/@T*("`@("`@("`\=&0@ M8VQA'!E8W1E9"!T;R!V97-T(&%T M(%-E<'1E;6)E&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,3(\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5R8VES M960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!0'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,R!Y96%R'0^,R!Y96%R65A7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2P@=&AA="!C;W5L9"!B92!G M2!O<'1I;VYS(&%S(&]F M('1H;W-E(&1A=&5S+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V-3)F M8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,B!Y96%R'0^,2!Y96%R(#$Q(&UO;G1H3QS<&%N/CPO'0^,B!Y96%R'0^,2!Y96%R(#$Q M(&UO;G1H3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!S=&]C:R!O M9B`U+CD@;6EL;&EO;B!S:&%R97,@86YD(#8N-2!M:6QL:6]N('-H87)E2!T:&4@;G5M8F5R(&]F(')E2X\+W1D/@T*("`@ M("`@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!;06)S=')A8W1=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^-"!Y96%R7,\7,\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)FYB'0^)FYB7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!/<&5R M871I;F<@1G5N8W1I;VXI("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S M86YD'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S,Y/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(%!E'!E;G-E(%M-96UB M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#QS<&%N/CPOF5D(%!E'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#8X-CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&5S(%M!8G-T&5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-S0L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S"!B96YE9FET'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\V-3)F8C@X8U]B,&,P7S0X.31?8F,S.%\S-F$Y9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);G-U M2!);G-U2!);G-U2!);G-U'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share (Schedule Of Computation Of Basic And Diluted Net Income Per Share) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Net Income (Loss) Per Share [Abstract]        
Net income (loss) allocated to common stock $ 205 $ (249) $ 4,635 $ 4,464
Weighted average number of common stock shares 19,970 25,683 20,276 25,642
Weighted average number of common stock shares held in treasury   (4,629) (565) (4,378)
Net weighted average number of common stock shares outstanding 19,970 21,054 19,711 21,264
Net income (loss) per share-basic: $ 0.01 $ (0.01) $ 0.24 $ 0.21
Weighted average number of options 703   750 680
Weighted average number of restricted stock units 77   102 30
Total common stock shares used in per share calculation 20,750 21,054 20,563 21,974
Net income (loss) per share-diluted: $ 0.01 $ (0.01) $ 0.23 $ 0.20
XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Details) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Income Taxes [Abstract]        
Income before provision for income taxes $ 1,079,000 $ 22,000 $ 9,160,000 $ 8,799,000
Provision for income taxes 874,000 271,000 4,525,000 4,335,000
Effective income tax rate 81.00% 1231.80% 49.40% 49.30%
Increase in Additional paid-in capital related to excess federal and state tax benefits     $ 2,400,000 $ 2,700,000
XML 19 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share (Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share) (Details)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 1,484 4,103 1,327 2,065
Common Stock Options [Member]
       
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total 1,484 3,565 1,327 1,909
Restricted Stock Units [Member]
       
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total   538   156
XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographic Information And Significant Customers (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
customer
Dec. 31, 2011
customer
Sep. 30, 2012
Major Medical Individual And Family Insurance Plans [Member]
Sep. 30, 2011
Major Medical Individual And Family Insurance Plans [Member]
Sep. 30, 2012
Major Medical Individual And Family Insurance Plans [Member]
Sep. 30, 2011
Major Medical Individual And Family Insurance Plans [Member]
Sep. 30, 2012
Customer One [Member]
Sep. 30, 2012
Customer Two [Member]
Commission Revenue Components [Line Items]                
Commission revenue as percentage of accounts receivable     79.00% 86.00% 78.00% 88.00%    
Number of significant customers 2 1            
Significant customer percentage of accounts receivable 51.00% 73.00%         37.00% 14.00%
Accounts receivable $ 3,256 $ 8,055            
Concentration risk, percentage 10.00%              
XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
9 Months Ended
Sep. 30, 2012
Income Taxes [Abstract]  
Income Taxes

 

 

Note 4 – Income Taxes

 

The following table summarizes our provision for income taxes and our effective tax rates for the three and nine months ended September 30, 2011 and 2012 (provision for income taxes is in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes

$

22 

 

$

1,079 

 

$

8,799 

 

$

9,160 

Provision for income taxes

$

271 

 

$

874 

 

$

4,335 

 

$

4,525 

Effective tax rate

 

1,231.8% 

 

 

81.0% 

 

 

49.3% 

 

 

49.4% 

 

Our effective tax rates in the three and nine months ended September 30, 2011 and 2012 were higher than statutory federal and state tax rates due primarily to non-deductable lobbying expenses and tax shortfalls related to share-based payments.   

 

During the nine months ended September 30, 2011 and 2012, we utilized excess federal and state tax benefits related to share-based payments, which resulted in increases of $2.7 million and $2.4  million, respectively, in “Additional paid-in capital in the condensed consolidated balance sheets. These amounts are also classified in the condensed consolidated statements of cash flows as both a reduction to operating cash flows and as a financing cash inflow. 

XML 22 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Geographic Information And Significant Customers [Abstract]    
United States $ 38,054 $ 34,469
China 286 425
Total $ 38,340 $ 34,894
XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Current Assets:    
Cash and cash equivalents $ 130,800 $ 123,607
Accounts receivable 3,256 8,055
Deferred income taxes 4,306 4,622
Prepaid expenses and other current assets 5,078 3,377
Total current assets 143,440 139,661
Property and equipment, net 6,131 4,631
Deferred income taxes 3,735 3,390
Other assets 8,848 5,641
Intangible assets, net 9,265 10,526
Goodwill 14,096 14,096
Total assets 185,515 177,945
Current Liabilities:    
Accounts payable 4,571 2,391
Accrued compensation and benefits 8,819 7,904
Accrued marketing expenses 3,864 6,195
Deferred revenue 704 314
Other current liabilities 1,864 1,547
Total current liabilities 19,822 18,351
Non-current liabilities 4,117 3,920
Stockholders' equity:    
Common stock 27 26
Additional paid-in capital 225,070 215,364
Treasury stock, at cost (89,998) [1] (81,557) [1]
Retained earnings 26,296 21,661
Accumulated other comprehensive income 181 180
Total stockholders' equity 161,576 155,674
Total liabilities and stockholders' equity $ 185,515 $ 177,945
[1] Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.
XML 24 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Cash, Cash Equivalents And Accounts Receivable
9 Months Ended
Sep. 30, 2012
Cash, Cash Equivalents And Accounts Receivable [Abstract]  
Cash, Cash Equivalents And Accounts Receivable

 

Note 2 – Cash, Cash Equivalents and Accounts Receivable

 

Cash and Cash EquivalentsAs of December 31, 2011 and September 30, 2012, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At December 31, 2011 and September 30, 2012, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the three and nine months ended September 30, 2011 and 2012.   

 

As of December 31, 2011 and September 30, 2012, our cash and cash equivalent balances were invested as follows (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Cash

$

17,256 

 

$

17,441 

Money market funds

 

106,351 

 

 

113,359 

Total cash and cash equivalents

$

123,607 

 

$

130,800 

 

We used observable prices in active markets in determining the classification of our money market funds as Level 1. 

 

Accounts ReceivableAs of December 31, 2011 and September 30, 2012, our accounts receivable consisted of the following (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Accounts receivable - from other revenues

$

7,702 

 

$

1,862 

Commissions receivable

 

353 

 

 

1,394 

Total accounts receivable

$

8,055 

 

$

3,256 

 

XML 25 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
9 Months Ended 12 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Stockholders' Equity [Abstract]    
Number of Stock Options, Balance outstanding at December 31, 2011 3,412  
Number of Stock Options, Granted 731 [1]  
Number of Stock Options, Exercised (709)  
Number of Stock Options, Cancelled (280) [1]  
Number of Stock Options, Balance outstanding at September 30, 2012 3,154 3,412
Number of Stock Options, Vested and expected to vest at September 30, 2012 3,055  
Number of Stock Options, Exercisable at September 30, 2012 2,056  
Weighted Average Exercise Price, Balance outstanding at December 31, 2011 $ 11.36  
Weighted Average Exercise Price, Granted $ 16.86  
Weighted Average Exercise Price, Exercised $ 5.67  
Weighted Average Exercise Price, Cancelled $ 18.58  
Weighted Average Exercise Price, Balance outstanding at September 30, 2012 $ 13.27 $ 11.36
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2012 $ 13.17  
Weighted Average Exercise Price, Exercisable at September 30, 2012 $ 11.79  
Weighted-Average Remaining Contractual Life (years), Balance outstanding at December 31, 2011 3 years 11 months 23 days 3 years 9 months 18 days
Weighted-Average Remaining Contractual Life (years), Balance outstanding at September 30, 2012 3 years 11 months 23 days 3 years 9 months 18 days
Weighted-Average Remaining Contractual Life (years), Vested and expected to vest at September 30, 2012 3 years 10 months 24 days  
Weighted-Average Remaining Contractual Life (years), Exercisable at September 30, 2012 2 years 10 months 21 days  
Aggregate Intrinsic Value, Balance outstanding at December 31, 2011 $ 17,078 [2]  
Aggregate Intrinsic Value, Balance outstanding at September 30, 2012 18,787 [2] 17,078 [2]
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2012 18,536 [2]  
Aggregate Intrinsic Value, Exercisable at September 30, 2012 $ 15,767 [2]  
[1] Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so.
[2] The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 and the exercise price of in-the-money options as of those dates.
XML 26 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Stock Repurchase Activity Under Stock Repurchase Programs) (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Stockholders' Equity [Abstract]  
Total Number of Shares Purchased, Cumulative balance at December 31, 2011 5,797,806 [1]
Total Number of Shares Purchased, Repurchases of common stock 554,284
Total Number of Shares Purchased, Cumulative balance at September 30, 2012 6,352,090 [1]
Average Price Paid per Share, Cumulative balance at December 31, 2011 $ 14.07 [1],[2]
Average Price Paid per Share, Repurchases of common stock $ 15.23 [2]
Average Price Paid per Share, Cumulative balance at September 30, 2012 $ 14.17 [1],[2]
Amount of Repurchase, Cumulative balance at December 31, 2011 $ 81,557 [1]
Amount of Repurchase, Repurchases of common stock 8,441
Amount of Repurchase, Cumulative balance at September 30, 2012 $ 89,998 [1]
[1] Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.
[2] Average price paid per share includes commissions.
XML 27 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 28 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity
9 Months Ended
Sep. 30, 2012
Stockholders' Equity [Abstract]  
Stockholders' Equity

 

 

Note 3 – Stockholders’ Equity

 

Stock PlansThe following table summarizes option activity under our 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands, except per share amounts and weighted average remaining contractual life data): 

 

 

 

 

 

Shares Available for Grant (1)

Shares available for grant December 31, 2011

3,870 

Additional shares authorized (2)

795 

Options granted

(731)

Restricted stock units granted

(203)

Options cancelled

280 

Restricted stock units cancelled

75 

Shares available for grant September 30, 2012

4,086 

 

(1)

Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so. 

 

(2)

On January 1, 2012, the number of shares authorized for issuance under the 2006 Equity Incentive Plan was automatically increased pursuant to the terms of the 2006 Equity Incentive Plan by 0.8 million shares.   

 

The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Stock Options

 

Weighted Average Exercise Price

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding at December 31, 2011

3,412 

 

$

11.36 

 

3.80 

 

$

17,078 

Granted

731 

 

$

16.86 

 

 

 

 

 

Exercised

(709)

 

$

5.67 

 

 

 

 

 

Cancelled

(280)

 

$

18.58 

 

 

 

 

 

Balance outstanding at September 30, 2012

3,154 

 

$

13.27 

 

3.98 

 

$

18,787 

Vested and expected to vest at September 30, 2012

3,055 

 

$

13.17 

 

3.90 

 

$

18,536 

Exercisable at September 30, 2012

2,056 

 

$

11.79 

 

2.89 

 

$

15,767 

 

(1)

The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 and the exercise price of in-the-money options as of those dates. 

The total grant date fair value of stock options vested during the three months ended September 30, 2011 and 2012 was $0.9 million and $0.5 million, respectively. The total grant date fair value of stock options vested during the nine months ended September 30, 2011 and 2012 was $3.8  million and $1.9 million, respectively.

 

 

 

The following table summarizes restricted stock unit activity under the Stock Plans (in thousands, except weighted average remaining contractual life data): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number Outstanding

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding as of December 31, 2011

474 

 

1.92 

 

$

6,958 

Granted

203 

 

 

 

 

 

Vested

(235)

 

 

 

 

 

Cancelled

(75)

 

 

 

 

 

Balance outstanding as of September 30, 2012

367 

 

2.36 

 

$

6,890 
(1)

The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 multiplied by the number of restricted stock units outstanding as of December 31, 2011 and September 30, 2012, respectively.  

 

The fair value of the restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense is recognized on a straight-line basis over the vesting period. The total grant date fair value of restricted stock units vested during the nine months ended September 30, 2011 and 2012 was $1.7 million and $3.7 million, respectively. 

Stock Repurchase Programs—On September 10, 2012, we announced that our board of directors approved a stock repurchase program authorizing us to purchase up to an additional $30.0 million of our common stock. Purchases under this program may be made in the open market or unsolicited negotiated transactions and are expected to comply with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing of the purchases and the exact number of shares to be purchased will depend upon market conditions. The program does not require us to acquire a specific number of shares, and the program may be suspended from time to time or discontinued at any time. The cost of the repurchased shares will be funded from available working capital. 

For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. 

Stock repurchase activity under our stock repurchase programs during the nine months ended September 30, 2012 is summarized as follows (dollars in thousands, except share and per share amounts): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Number of Shares Purchased

 

Average Price Paid per Share (2)

 

Amount of Repurchase

Cumulative balance at December 31, 2011 (1)

5,797,806 

 

$

14.07 

 

$

81,557 

Repurchases of common stock

554,284 

 

$

15.23 

 

 

8,441 

Cumulative balance at September 30, 2012 (1)

6,352,090 

 

$

14.17 

 

$

89,998 
(1)

Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.  

(2)  Average price paid per share includes commissions. 

In addition to the 6.4 million shares repurchased under our repurchase programs as of September 30, 2012, we have in treasury 0.2 million shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2011 and September 30, 2012, we had a total of 5.9 million shares and 6.5 million shares, respectively, held in treasury. 

Stock-Based Compensation—The fair value of stock options granted to employees for the three and nine months ended September 30, 2011 and 2012 was estimated using the following weighted average assumptions: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

(1)

 

 

 

 

 

 

 

 

 

Expected term

 

N/A

 

 

4.6 years

 

 

4.6 years

 

 

4.7 years

Expected volatility

 

N/A

 

 

43.3% 

 

 

49.0% 

 

 

44.3% 

Expected dividend yield

 

N/A

 

 

0% 

 

 

0% 

 

 

0% 

Risk-free interest rate

 

N/A

 

 

0.61% 

 

 

2.02% 

 

 

0.90% 

Weighted-average fair value

$

N/A

 

$

6.46 

 

$

5.34 

 

$

6.41 

 

(1)

There were no stock options granted to employees during the three months ended September 30, 2011.   

The following table summarizes stock-based compensation expense recorded during the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Common stock options

$

845 

 

$

717 

 

$

2,893 

 

$

2,076 

Restricted stock units

 

979 

 

 

622 

 

 

2,729 

 

 

2,250 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

The following table summarizes stock-based compensation expense by operating function for the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and advertising

$

252 

 

$

330 

 

$

774 

 

$

932 

Customer care and enrollment

 

83 

 

 

90 

 

 

264 

 

 

243 

Technology and content

 

411 

 

 

233 

 

 

1,336 

 

 

783 

General and administrative

 

1,078 

 

 

686 

 

 

3,248 

 

 

2,368 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

 

XML 29 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $)
Share data in Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenue        
Commission $ 31,291,000 $ 28,206,000 $ 93,358,000 $ 89,045,000
Other 6,295,000 6,581,000 16,810,000 19,483,000
Total revenue 37,586,000 34,787,000 110,168,000 108,528,000
Operating costs and expenses:        
Cost of revenue 1,099,000 1,781,000 3,538,000 6,987,000
Marketing and advertising 13,988,000 13,826,000 39,142,000 38,403,000
Customer care and enrollment 8,823,000 6,245,000 21,152,000 16,265,000
Technology and content 5,503,000 5,548,000 16,018,000 16,433,000
General and administrative 6,744,000 6,917,000 19,938,000 20,299,000
Amortization of intangible assets 354,000 427,000 1,261,000 1,281,000
Total operating costs and expenses 36,511,000 34,744,000 101,049,000 99,668,000
Income from operations 1,075,000 43,000 9,119,000 8,860,000
Other income (expense), net 4,000 (21,000) 41,000 (61,000)
Income before provision for income taxes 1,079,000 22,000 9,160,000 8,799,000
Provision for income taxes 874,000 271,000 4,525,000 4,335,000
Net income (loss) 205,000 (249,000) 4,635,000 4,464,000
Net income (loss) per share:        
Basic $ 0.01 $ (0.01) $ 0.24 $ 0.21
Diluted $ 0.01 $ (0.01) $ 0.23 $ 0.20
Weighted-average number of shares used in per share amounts:        
Basic 19,970 21,054 19,711 21,264
Diluted 20,750 21,054 20,563 21,974
Comprehensive income (loss):        
Foreign currency translation adjustment 3,000 (9,000) 1,000 (24,000)
Comprehensive income (loss) $ 208,000 $ (258,000) $ 4,636,000 $ 4,440,000
XML 30 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary Of Business And Significant Accounting Policies (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
state
Sep. 30, 2011
Sep. 30, 2012
state
Sep. 30, 2011
Summary Of Business And Significant Accounting Policies [Line Items]        
Number of states in which the Company is licensed to market and sell health insurance 50   50  
Book-of-Business transfers total consideration $ 13.9   $ 13.9  
Book-of-Business transfers consideration during period     6.2  
Amortization of consideration transferred, period     5 years  
Amortization expense of consideration 0.6 0.1 2.0 0.4
Reduction of stanby letter of credit financial guarantee amount, percentage     25.00%  
Service obligations 0.7   0.7  
Service agreement term     3 years  
Gold River, California Lease Agreement [Member]
       
Summary Of Business And Significant Accounting Policies [Line Items]        
Base rent of operating lease     0.9  
South Jordan, Utah Lease Agreement [Member]
       
Summary Of Business And Significant Accounting Policies [Line Items]        
Operating lease term     65 months  
Base rent of operating lease     0.5  
Mountain View, California Lease Agreement [Member]
       
Summary Of Business And Significant Accounting Policies [Line Items]        
Operating lease term     10 years  
Base rent of operating lease     0.6  
Operating lease, percentage of annual base rent increase     3.00%  
Future minimum payments related to operating lease 6.8   6.8  
Standby Letters of Credit [Member]
       
Summary Of Business And Significant Accounting Policies [Line Items]        
Standby letter of credit $ 0.6   $ 0.6  
XML 31 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information
9 Months Ended
Sep. 30, 2012
Oct. 31, 2012
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2012  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q3  
Trading Symbol ehth  
Entity Registrant Name eHealth, Inc.  
Entity Central Index Key 0001333493  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   20,251,748
XML 32 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Cash, Cash Equivalents And Accounts Receivable (Schedule of Cash and Cash Equivalents) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Dec. 31, 2010
Cash, Cash Equivalents And Accounts Receivable [Abstract]        
Cash $ 17,441 $ 17,256    
Money market funds 113,359 106,351    
Total cash and cash equivalents $ 130,800 $ 123,607 $ 126,501 $ 128,074
ZIP 33 0001333493-12-000075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001333493-12-000075-xbrl.zip M4$L#!!0````(`(0P9D'Z=&8QY*H``#0(#0`1`!P`96AT:"TR,#$R,#DS,"YX M;6Q55`D``ZCNF%"H[IA0=7@+``$$)0X```0Y`0``[#UK<^.VM9_;F?X'5KG- M)#.63%(/2_)Z.[;7FVZZ7F]M;]-^\D`D)*%+$0I!6E9^_3T`28EZB]0+E)#, M)BL2.#AOG`,<@._^_M9SM%?L,4+=JX)1T@L:=BUJ$[=S50A8$3&+D,+?W__E MS^_^6BS^Y^;QLV93*^AAU]R2OV->>:-L? M('@2P=>JI7+)J)HE7>OZ?K]Y?CX8#$H>;\NBIB6+]HK%:+0;Q``Z]!/#FB5C M].8V&IFZ3NA0MARZ9#W.]+FO/7+<`K;OXVTWY0%JV-1J-Q+MZ.F@(@FXS:)N'6 MSL.7<5,;3[5CV"IUZ.LYO!"T%G6C6#:2D$D*&G'7[TXTQUV,'+\+[0*/-^1B M$./HC;(>]R*,5DSC8MDX88NX`ZA/!Z'^J$,;L99H'+V81PDC\Y@)T(WS_]Q_ M?K*ZN(>*(WI`RIKVCC.YR<2K1]S6!-.;_K"/KPJ,]/H.IUL\ZWJX?57@U!=C MXDIOS"YHYR$@KEG4]?$;Z"ZV?%!9H4CPQHH>$_NJ\`%XQ-^]&.9+67\!2,;+ M,WTQ7DS^=_,EHN[EJX/<+ZB'K]\(>^&#OCP/Z'.7!@RY]A-YN_L](/[P$]#A M^F`#O/D][K6P%Y(%H_(7_C#Z!;^)S9^T"?8T02Z>X%6L([>?_EEXKP/'RN5R MI5%^=S[N-@;%<(?;\.@!/`I5L(G?^@ZQB!_BHMD$VH7>(2*LF22L\)Y3UER3 MLG?G[\PD6O.MCCU`[086///\#N(+W7`I%T*:R#C!&3T<-L6O' MS83&Z28';2<:O3M/`']W'@E\F?2YQ&/9@R:$OW8NNY0LX;0:JU@260CF`:NQE.6L0]#5P?$???!`]ND4/:U',) M^HS!PUYW/(RY+LAM%$+]5Q$;6QF&GTM>;_WXD()5+ODDQ*Q^@/70OD.>2]P.^XJ] MIRZXK9OA?`!3.T/4^O[0%[ME^;#L'7(EN;$TS9;36>14:G=":B?/0HY2NU-1 M.ZG6'_:A=H^8^1ZQ(*D0G%::-]*\N9PY)N5;GFDIGW="/D^>!%_YO)/S>?M4 MON59+:\@MP,'`_MZ?8<.,3#*>R46#EG(3QQP)H-H!+1KQZ%6Q.]';-&.2_[` M]E>!T2UE/KL9/N(^]?S/Q,43&GB/O._8!_E=DC7+7 MS!IKY3K<.J8<6!(E_06[V$..8'J/N`1<`^+.0VGI7"U=BUU*3;>FIN&A&6QU M7>K0#DQOMCB>X_I*/R?T,SR"LXI/2C&WJYCQ_LXMP`26W[D>=9R>TLZYVKD> MLXY)19>FF*J.#1W<:@\ M^]XJ#I5*1Z6)0Z7:)5=QJ)Q:>O@X]+345,6AN8E#3U`Q51R:KSA4JEHD%8=* MI:,RQ:'R5"ZI.%1.+94B#CTA-55Q:)[BT%-33!6'YBX./7Q]:'1G::]'&)?# M(W[%;H`YAZD+M"3.(8NSO??8)A9R/KDV>25V(.:>CZA'G.&G^`YE?NNMY"7O MT=VE2XF.KRY-3_7Q%W,HIG=>YA M?Z*!W_V5>C9RO_FH>ZP7L*]!YC%-0!NKQ2_4L?FW7+SCOYM_35*5>JBO-^S] MZPT2!+&32G+PVY`D.'LR&:')Q9']Q*P+/P5"Q9=_0G8]$O;]9O@\["=7Z*8; MQ*M0SP,JM[\8?19D,8GQPMI*&N7]1,CV!?O@YF39=0/!CFB45[#+LTSI?-C> M;S`\_,2V;2.6Z,MD$Y<2?VG41MSH00P>>#CTSX",C]^=Q\]"Z+SG/!C5$0RQ9I0@@+?[ M$H!;1SX=N^[$8-''+IO?GCY,CA82-[^_`/L!N[1'W$6`Q=<\FXQO\[%%D&=! MO#M/4+"8X,I\IEG1'+8NW\HS8$*L^_#7=6&8,S`6LG0QD`5XS.->$@@HV'/0 M=_"TAL'S.T=D$676@MJ88IQGYU&<3QF!^B+_F&3<+-XH_PC*4:]%_E<+R%T!8- MR'%*/QS_[[P!1]!FAPMQR<+0I/M:"'%V0!XRIAH'YHQ_38[`08P!WPFO?"OB M3K[`C=_^B8>I1DBZ_8409P:DO1YUQ451HNR`/00^G]7XYZ$G1I^9D35N:^)5 M:*::C2W2`RNX*GSZ\I$SUJP:%Y7Z!#)+1IO&["-Q^%*=CSO42\>(:\O"#G?+ MV-8$E"0*$V"GQWS$'5%:YOI\92C5H/@?XC[W,^V3:Y62`T["'(_X["%.]M.P MUZ).NJ'`GXZD0 MIA*IE5C6:@DDU\5@ZUA/J]R_YH$7B\J"]:=3A01L0*;;% M%F?SF?3`=K[@@?9(>\B]U,1+1O[`3/XR'L$FK.^@85,CK@/DAU`' MF'2Z?A,\AQT^$(V;Q$?`BTL!C/.L2-O%F&O:B&U\A'/>BS?;UG`_HE[_\HV?:H`N]6D/-[^+X(H<$T:EF!%Q*H?:&OX4(7\$S78"(5,'L4>L(P/,B%1K\&+N8-3`!, M@=UKM2HC`4<<-[1KE.C$WM]O*KA_N(V*#.T?3,]8@"`$^SP@P# ME)AAGXT[?;@4C6#BH-/0'D3'.1U(J/#(LFBOC]QA%&':?$PQ%S#0?ULPHX4< M7LNAL2X&**$]3"@M-UR6MV%HH+:>&R M$A\PZ`MNI[:_-K`P@\T/(0-EI0P=N0*'/C649-):!WBD.YP8:U)=0CW\/8`9 M"6@7,J:\RAMZ@B>/6)<$/89HZ@I%-HWGV.EPY6)% MFD$J8WV,H,$?F+&28:?22D7U:Y!AL M-$]E0KB6OM-XQ/1]1R$`>#+NLL%.G6&HC>F!;::_<[1QC4RZ1A&6$)'BNN%B;1B]BX!Z>@I+1*]\XAA-A<+7`917 M'`;KB(\H[DW/.+>5%BAXG-B=]R?2O$G&@!.^*AB%4;8XP;M13_$CF53&/Z(< M.$TRF\B!.8OYG[O?`_(*NLE+;%W[VA(A$WL441%J.?CPB7`R[[WV"$QUWUQB M41MK]T^7X[S7`%B7*?/>!=ET`F@,,Y6<$]0.B`W,-G3];X58LCYG*^2/CM-' M-E^SNRKH!?&;]9$5_X[ZM[B3\HH6=1S49[@9_^4R!%RIU$H5SJ0D5_491OC> MZ&?XV]9`YJ3C7A5\VB],(CN"&:''X6FU4C6YJK">M-9?IA#$MHM7&&LW]I8P9>87H35N6]/3_J'/F*'*V'"?7B*C6M9Q(NAUV+6>L#J'P8GA@\/,FPE),E8LT6 M@$S&4AFB$3T#KAF6?B`/#;PP'L`)5R-"%\8#!^`[!(EXJ/7$MH18\A`.R.\B M/XI$PF68;Z6GDM;A::W+`XTBZ_,`A&?`8A6S[Q$1C[IVZ,GBU0W-!0\(^?!4 M=PB!Q&[X4&M!B!5V$2W%WSS<#SRKBP!B8C54S"T^7R,5:Q>MX0Q0.JZ8AD#< M5RJU1Y5"GD,AA)N0]K>) MA6#\Z6X03#,89QS<)D=.K$!FR+M$TBZT;YPP99#YQOD^2#V++/:JU/M2L9*V M25Z>+N4YW$R>/V35/+U[IYJ--1EZ3?G1>".#KX5[>#SSIX>,LOC/-LSM?"W^ M)['.00,&1+&?FS)8_W9RFK4B[0/G]%%2:(F`;MT4'^C42S!6]A2_17V?]J;R MT&JY9)A_NVPAZWO'@T#2Y@A0KZG]@`*?)K/3Q$"R)*818'XPK^61%+)=E:FN MQ3J]7"IOD779635)XZ9D&?52I79\9!VIM(Z4K/PI85T(- M2*/8>44_Y]S/.?KR*L\I>+]MN#:8Q2`3``Z8A>7,,(W211TFP#`I\&F?Q[2: M2UVL_?"AP?_5XI..U,JM) MDYBOU&O;Q-SWVS()R<*4''$NX4P$2&E8*?\4L]B#*`/*Q+;\64^^\HLY:TJW MMQ_AGSW2O<[<=CMOEVJ'ZX49F;!%U[D.5V9+DG>XUABQ9-TBT;GL*(!Q#3S4 MORJ$_Q_M%25VDMH.17Z3&_/H;5P*9UR;E"\/GQV#Y9>5!;U6MGY>I*8SVR9.9( M;$H6SIVX"1EE,*'&'N>[K45"6ORGL?-9,;J'(CY.,5U^G(/U/1/>VS3@%6#K MJJ4*67>X[K%5>1S4@9CELYI^H9)`9<[*G(_`G,OZ65W74\8#X4])3TOF[XS% M;U@+Q"5!+8:]\`!PWR-6>`.`N`\`1RFZ>&)C'WN]\#H@<3^`@Q@3QZCB^W/X MP8+>3&;/+[WYC%^QHQGI+HE9L#/,&\^>",T!TT^5GCDGS7>G!]L]&1Q=7#)[ MN5AXBF9TA-4;GZ&?./#*[20\;\*M9OK$B3H_HLZ/R%C*/+\:1QTHV<5>1*[) M.E)I'2E9^5/"`^Y_2>N%U0F3/!\2.`7NYQQ]>97G%-RA.F&R5`Z2E?RK$R9* MW=0)DW4=LCIAHDZ8J!,F\I6WR3_%J!,F6V9;_JPG7_F%#,45:^WZS-G!*6IM MC_:B;[U$%^'OL/A*%4SDHV3_XNQ"-U4!DE+IXU%IXZQ>6ZG2!UQUVJVT;Q.? MPO(6ER:<8-&\M)'Z:5?1EZME=0@EC_8D"^=.VWR,LW*CHHZ@K'$$94Y=6PZ6 M_E2UNEP+BD=3K5X_TZM5E?DI8U;&G']C+J]SF_P%ZN"']BS+4_&OG$36++S72Q?E$:*9AM\)`0N9/8M_ MU9`9_Y>`%3L(]5]F8-\,GX=]?/U&V`L??+9!//B#B^]%5<1J7I0OCIP7SP.Z M+B^,RO9X$76X11X&KW?G>M1Q^&?B[J)/+"_[8*R1_&#L:G]FU,Q:->$]5@R] M,987F;"LF95](CG_V[NKD#0-HVKNGY4IL:S7S7(F)#^Y%O_R(?Z`P_]_H^]0%_6?7ON^15B`B\V?ZT!>?X]R`OS.Z M7)_&>4T<=H'Z;U:IR_M!_1$S^&GYV'[R(2/AR&Q3>\II M)3`/GYW3E$XVAC[M(^4B*IO"3;O1#6GZ$O`(]*']-/[.;#QMLU3)6"6)Z:7_0SE MM7Q1_D0#O_LK]6SD?O-1-Q/)U:V0_(R]WN'%^_ZKH?]W+BD_7PIJ7K3Z&5:M;77=H5.J)N"PY3*K1,ZXG5.O&%@;/EKD8-3'XMDA/.7K- M;%17#CZ>8696LS9;/37B@9>,,!>/A_9X83N].L;F,P4!'O2I*S87QJ:/_D>] M>VQ#[`$3KDU>B0WF=NW:'\56RR>7P4B`\5<'N6S=Z;U>GR%[#D&;$3[7$@Y. M>&WWA"]UF(,\$9*PA^Q'5B<'HCZ?>3:K>%G[/L\";CU`#?_NLV*1,@_K[:`]ZM$.:V(].7CAU82:V M=Z?:J?NP9!2W8>E5/K(5%K=AZ7NP\I5I'[:%_JH M^[!R:D^R<.ZTS4?=AZ7NPU)7Z*@K=-1]6/N:DV51'F7,44)T4_I_6:+;V1W??NM0:^5JAG45++*W&NFT;8T$\`VF;/# M25_YC!_XC1[NADBGP/LZPG(`;4PJX\:F6`QU".05WNJ2`/EI4 M497@J=@6KQPJMAUO7GH,QG+0.72I^=1FCX(J1NYNH56&FHMU)CI^#QBVM2X\>R[S<+F.F)CK*G_51XG*8]F?6T M]:92Y#G[/G6RKQE1EB+HDPQ*M[MF>#Q%Z96S^NJS:2K+4]8LE35O=PGS>*RY M?E:NZ.J,R1CLML^8I#TN,O?,2?2ENU=$'-[X(_5^\9#K/U+'@;\/D&>K,R<; MGSFI7FSUTG%9RI_W4?T,`7VUXVKC-2#&0W?D:"Q2U<#O4@]`VK/924H' M\9.9SC^DT>E#JL]%8^6FD(RN;H]J]=`7'[L-/1VV]YD/2.!>?KHH&S^?L%-Y MQ,SWB,5+MYC/%POXAQUWKPP'%;FIEW^XS%)H'*O3*SLC(7R`U?Z!..CHF*G';$W]_D'7OLGO)W M_UHD1R&$_A>N8TCZ1%8PI:1LG(X0/Z+0P9').*98=J:(\R%E(#R@)!R6[BD(\GS9ASJ?V`H7(7\/GA11Z ML&_"SEO^+7+Y1W+/1X[,X4][LUUZ?]MY]..9/!:[6S.[6U:>D[_=[4-YR76E M?YAN9/K;/:_5BA:GDOT(5TAR(V+J8-\\S5#CW=8.@@@'D1!0@M]+'M$495(! MRM=_17:XE=ZZ^-P.;%:%5WQT3%=Z-@F0P+,0U^`X6_B)A;T`@'@3^1C<$%L@ M#"JV2+AK#`]P/VPK/*G(LROV[O*/4B%HQ&Y+*0M7FPD_A(9U<5C9NJYT<1@( M+#X8`M'Z"!&J%?]OLR5@>1&<.JMMCR,/GAZNXQ^_L$.@BY5X8SLZ$2GY[AN@ M;)S*2:ZX?3DP=H"@_60O(CR"`KQ$BIZT0J83KN!+B"B(T3,W&X#$I#G6('I8 MVR%VJL(5A/B/*\F+?`E9WGJ-?/@QK!F"R5Q+*[!0C\A%_I%ULEWRQ-+V@U#Z M"PP_F"?@\WH#4D2<)O(M_`_`D'R-H8N?"U>VOSC[7`"`N+NO9>G>[\$)$+D@B]PGDQ[0AS0)P;S$)!3 M_`ZP3Z%WA/CQ3[<#XL*@^>>D0.\P7H!.ES-=I=.1.E.5X0? M;##)?3>0)2RD/I'X@.R^]/L@UH'=#\F;7`^B8-B1?&"Q9#G(!*J4JYQM3_LK ME/FV#"SFS),)DKLV_P/N$3@$("+OT`($PBD^(KR"[>_7N%L\@:J8CX@HQ>[/'P%$Z96T@>W,\FURJ`2* M$3V"&H+:X)_'X@C_=1SO&<.^)2)W!TOC2#1R0F)HJ(T)CW737.-6_2=$NP7I M-3'`\?33\Z3#?XU7W%55Q+;-!]V#E?Z+UTRS!ZNE#^`\`U$K$P!#B8U1/,#O M!-`#[D$$VQMXJ!!4@^6DSNE M3IT"]BUE]<$.1*(*7%=&Q`B[84044R)_L/63'0RM88?"G+.B`.(7O,EAT:-U MC`"!N<0[+I9!V/G(/K/3NEP;(4M_P$ZSWCC>MOABH)&V0]Z/`(E8R7*7PC`F MF;TC_<Y@)V2PZ6>P2^8+BRC9%'F)_M,J24E@F4+Y%E1@$Z,168E#FF,B`^0&)P M%REV'L(S*BP1*0ZEC&,ANA`J^VAQR,*SV@(.Z>)HBW#1HTD";!N(9X6)8[7Q MO25$!`\VC@%.R7]V!:H1WW"&%/\TV+M1H8_%'?N5%I8,`'@9A9%/]Y>`;0JR M7Y;P:F!KA.TE-;3NL=-,N!T0ZQQ+`_4+J!*!%#P@:GU`0P\V]2S%3CDBY/O# MEQZ**GTUT1V2HC^R<><7(78B>@"-!(4F>S]X7,?&,OJJ]$HX.4.$XAZL,1@I\MH[W\=N,?[] MR^W^)Q_-+?[3'<[9Q#55_P*!0(NW[D>RZ9'$SBNP@F],V_^7"3'<1:C5--3J M#2G'(3_$3=<`#1QRVVO8GGZYN1W?_*K/2'E!@EC-D+=.I&DE(LT'1:-L\<^C MD3HL(DTK$6G<.1J!A?>_0#P?KWGW"#8/G"7TU@W!'0ILB]+(7OQR\Q;\O%N% MD"%-LKO@ZX?E5Z"4KA;0-OWFU\E\/&-!I6*@MT4E/8M*!24)$VDV9R)*[1&I MR5U.G;)1O)(H<$>VDN9*YX-LP6<!W!RU!PYRY>+Y>TJ`;^ M\`D((EHS7-V:09_3R2&B-4.5<=>3'DYB5.;RO(]HZ;+61[2TKLW-+(26JLIZ M'V?2JO*LFV@5G@2D&'024/=0S+.*:K?Z\!0V'PP[,PFTZD5K)L^[A5:J)/!: M%[6KKFB3OBB'$E#&Y^PL^-2W["SX&J]3ALOXBET%/_8).0:_K._',2I%?+S. M@D^='@%^F[X9A^`/P0=CX6#MS-PXQ\SIBCP5K1G+W1XY:,WX9>4C)+V#+U:! M]-I=5&JY5G2@+O,WX\O'-7CPW7$#)GG#H*B;V/`8 M^_6J7D,[U4%I=#UM;I,SK>X,$.8Q:@7IGC,?PSPTZ:ZA:5B'/"(]7\0FPH!R M:$#CGBGK8#&H)_>Q[[I'1+Z'TYLLVS`GM!MGQI MZ\CQ8`;L&N,!?\-@>5*_)LC6/Z__\K8BN%["GDI`>T]'`[DN3R%&T12K\+\?VI6M+/J2BJ MZ3EJPQNV?1A^#6ENG:;EC4@H=5[";)H0O&^\;SW-4L3JN24D-+4933T,_X:D MJ>I(F<[9*.O9NU)]5]:#*%(H*P-E+7Z4<1!^#DEQ9Z/IG)'BGKU\U7?%/0AD MA>+6[@\?1,!#4M;Y2)TT,EV1<7N(>D7L8PNQ+R/"]$`9+[>-:#5ZG*HUAX]M M\YSKGA+=E^V<;A2MNFU3H^9HB]>KY:5BJ2&)U*]UAK9$IUQXZR=OW]L-: M#B[']UR>ZW#,T[.N>=\P/>]S,_U8_S"JM?`5F$, M"L`V'ANSVD&KT*F>D$U1ZX>MPM`/0C:E/$?Q]+[(WWX.00KOZ"#,>R\(/R+: M:?[.^BNRRGY'UXWSF0Z533"_E)KL@&SA`+- M)LR@_&AN\>^84$_3YVHF7(>+5`2D.'V,\;0Z''O:L1*JF3(>9X*3M=150!4G MD:Z-)]5ABM81&?5(A`W/T/#1"HPB[,QTP_[="[#@?5C"1GT=[^"P(4WM'!R94AQG-W]&0J6-EE MCX#=#5[^:-KPP+VYL4/3N=*TJ&-]8AQ"E[U.56"*LU;3QLI4J0++?Z(@)#,( MO3,/[/Q=ZNJ^\;UU]K`:D!.6,Y>TZ3'KV<+:'B%*3E'2C$8)X4#@@DU"]N]K M"%G&$^W(=2@$0LU@?XW?_/6SM4*+R$$?EJ_)D&J$XO&=9^9944#@7Q^6GY+Q M[@LZJ@K[D\'+[2>T\?SP=PAT[[[9P5?L?GZ]CR<;WV-7$\+*W>CJ&/)WI'E< MOATX-D@#).6%"*D@%55=GPR9C,E"OY$!W0Z0\6ZQA@TW"'TR$;@<-74M#OL' M3LUWIO\G"FWWD=!S-XB\'#>W85O%KF1YUI'(+=31,_TP=/R>LMO*&J0Z8B M6P.O*M-V#3PGU&1BX+4Q%\YPR1RUH6M<>$R'8'?3P&M&NQ:>!U)>;^&G+>^3 M+5.1K877]`D7+GS;U&1BX>=ZNQ:^VBDDQ,1S_L#NIH6?*X.GY/4&7M.Y"(3: M-DEL#/QDUJ[[Q@DQF=AW(I?7TG(-X-G_C9$X.N$*F!8,:<>G@A>7OA[,:ADD M@QP'-0=EQ3(B;=(*,4N"J8^-ZE"ZH;VPG0C;F,_(BGP[M%'P^IOE1`NTP`=- M6+BC,'[9:]-W08."71G-Z:%P.0$^V0:4R5$E`PL`V\5Y9X^N7/CE-OL%!S;O M$X(MP[:P?<*E3]E&[D30CTLU!-%+$9V0^L,&OR$H2/&Y,N\PR0M9_=,LK:+W M#6?^=7NLSP31&]5M?=R'/>RR$W*:3SCVZ+J/,^=BUG&2%_)U3W`V9D;?<.9= MS)H@^6E,5+Z.=SJ=&T=V-RO@.;=4F<+;\5@MNA*3^FY5GT^.0]'TV\LM7`)3 M0S<,I>BZ+\W`#CXLXSIOX/E'S[&M+?W?W26J,IO.K_&=N=V-KM3].7J+C3;" MFVJIZV@7[R+:[@+@?J'.:KOL1AX\G8"%?_P"UW+:%KT/1Z@E>4OIHX\"@(G0 M@5R2^^X;(&^<3H'*O6+W984D$ZB_WICN%NB/2;W`V2A\I]"FNY#`$")I[9')Q(A,)DX3$9-$5+@[M`?S-K&P47B&K_%SLH_O!NMH@AYX!TP7R M\N&\$[Z1&&!%M` M>1S>>/X:=JG;_V^GR%MD^EB[RK\,57CFPN3"W@G,2'I>V=:*R,W2=H#SSW:X M(D3?.\-$[\$C7IGN(Y+`'5[;`6G5"O__.].W5M=03!TWM]N6?X8:F@,O)*4N MP+ZAPGM(W+I37*]$%'/W@1P&*HD4;`* M>HE54JX`0[E6">VYNFR`K1&VH@YQIFBMS"<\:`BY$GAX&].G$H5?YR_(=DG$ M]9_R9UEZI*?VSA9_C7V3!?D=C8+@<=@E[(V#@I$$]KF\/)`URC_VV]W=QU'< M'3J$+6Z=PM-VX>]K$G/(TAW!"4#%;@/HWU9:>%B;DMU-`M2P.X!5,_,51`V7 MGA=2%?11?+?_8=LLM@19S&X'A2B3JU7>_*7\(ZN4ZW6MT`%Y,>$#$\^](D$C M;#UEO91JEK!95^#$[)9_Q*&(J]AFZ\P*;FLU,IF"HK MV2'>%H+(@?]6,$5+R=L@FBH,#O,J%8/RKN8M*JA.];Q%A262G<4H*=-D$YQ(\1PX-24J1T/'P;5>W!"QW:G5XTG6/ M+=65IY7'[9'P.PNM4N+X;FH8:H%%<,T^_.SCEY=>ND1#LFFYE8\;SV4VO+M2/XWC MTI0+ZUX)8+5++K?:>-80@!6O^4_T$XFJEX(E`=24R@0,0GQ;[`FY$=--83*? M':M":J720%3LOS,]NN1U'1#5A$<_+BQG0HFR-[24^;P,$*3'-[VAQ_3:W7P^ MF9Q2([U:%5BJ28=N3`V#.2P5;]"!/VV<5A>H27R?=R1 M-.F^2'_V$KEH:;/KCDE`FQ]:XIRUV0%:UB+K1SYQ)4!C_612&ZNK1B9`AVM4 MA*.$IZU4!P.H1LMJ6?6#-HY[<%Y8Z1J0RG044K(%O!)$[SW78B([^E'OALN+ M70E8"4LUU<=7P`4^DF734R^65\NG1WMM>J&*()3=3J;&,;_.@7!R.\(,;.L* M:,4% M.S%2SH,4KW<%4'6(TO50514GO0%2L12I0D!Q>#.FF;%0^P?59)Q8J6+"%,K) M/#KE^]TP+3(+2[*0X\1#RWZY46[(YV!C6LGG^/D'SU\@'\\`<\Q-@%XD__B9 MOM@P)K*!"9$F[>$,-++D^8&UH;V=JIIHTD<>'<\_8%DU6N;Y$GG[O MA24/X[/?4ZYT.?L=TKX:1_]9PMWY:>S!`KX??BW+2%_BB^LG+T1^QE!K3\ M:??J>&U<_)BBG_EL^HL`P^JCI4/+?FR7/@7_1+%W*>W1`AZ:FXUC6[M"6%)5 M%4_(BP%8HW"%>7%-07"1*IZNWU9I$E@L#4OP1+UGHC'$H27="T!)XYM2UK[5 M`F;L`]E@L(0M.-&I'VQ\?<&+`@`*M`$L-(*-=_^]2=I!!#^^X$+RAA/XQ!ZD MA?#5H*)Q$.`)`:_R??4X*',8\UB5]>SIZ684>J6'3C?FQ:9??`\(/OAV"=[F M^;E%)W9KV7.L*Y&N.JF8C^<^,XB\VVCUE%L]16LFS[4>HM53;O44K:D\$4(H MT&I="&>=0JMD(O626]I5][-)_Y-#"2CC9W86_(Y3O^/@4_^PL^!WG/H=!Y_Z M=9T%O^/4[SCXU!_C$/R2?M?I`3;O3A<+CPJ](J2/J.W,M4=C_P">5.GR_+!Y)1 M)RB]H*GE!BM5]B^;)]!^(:T#WGFD=<#KTXZK0W2(BTN?)BLS(7W5I>\];C+# M2/AZ;UBSRZA865HM1]95A>9Z#V4]6UJ%L&<).RXLOLJFG$AVJ5$^[2IS9`\A3P14^;R3(B8L)X]M)X@VG-#B':3UI/A MV4W&B=7]_1OX_QJ4S2()!5(8_J*V/:9%&\".`RFQ)HOQDXV+BY4$D>O/V/*@ MT/4@)J2G_J,Z062AHD)%.96>N-!-$%FHJ%!1/J4G+@,41&[D<)QA46)RVUF: MU![*OH_6>%(#\(:;E"F_"E6M_)!??+A/:0]-O*H4*/*+CQ`OKMA1K8217WR$ M>''%CFI%CAUW[)AYN#N73]7J]_GV309,Q_$L,HDP]`Z:8]1WN,%C3%"$:O]7 M`TG.WIN.27(1I3U&:B8Y;B`:>_;-S2\W]+\W"=RIA@1+QS/#%SCZVWV;]&/Z M03/F/_+$;VXLG1#DXG>O.1!D31GO)8`GO@N!YE>@S][CYD"@C9$Q,81("Y&N ME`[F5*0G>JZ5;B\AVZT+2\.*.\6=<`'^E7YK9\'O./7[9HK$)7$!_I7N&8?@ MM^=V-7@._@JYWMIVQ4FX<+H$^,+IZC'U^V:*A-,EP+]&>'KO=-5P1JWCF2PU M>V1_Y`ZQH*,0Z-"*VGPV+E/(3;7OYB`SK(U'DYDN3CN&B1C/Y\KJ?#2?*D(R MA1'E_L08&U%#$Z(Z3,1X/OC5E)$VG?![\KOS>36-^+SI&432[9PS+UA:(8?, M%TO&A=7G%G>RS2!G6T9F)XHF2=EJ?:DQFF@L*DP[:Y<[ITG<4"ZS/P3'E),4 M63V98MM<-9FTI_\M-X=;W`A3Y]20WPTMLRG$@#8T?3H3&UJ'-(D;RF6V:AB, MXHPGXS-JP_4QB#9M(2#$E_?RYWL?!(6I>=1-Q8-7=!G1X/N%%^&IN$6%=PCI M1=9="YF2N=4,DCI2QN(ZS("4E!NJLFY3V!N=%$=C0]-)?C=.UHT*>Z.DL'%J MXA[ID)24&ZJR[DS8&YV$C7.JJOP>A_;O(FQ*""]($1\3-_C=9$^B4T'+*^6R ML[9=J%6-`::@I5`K(0K,0T)!2Z%60A281W6"EAFT;"]X:ZG'Z$GHEOOP#XX7 M!#]6>'"#?'KH2=CQW3=-40V(]&N=UC;`3F(TVFNU9$"1%564V@Q2]G!(U*;L M8=%CF347,M@U&:3Q0[LRJ`D9'+H,SEJ7P=S30W%2T0LAYZ)[%+_X"!O*%3O$ M'"4A7K5GC_N#CQ`OKM@AYBBU5.-4Q,U[93M1B!;U91.'4)&9UVZJ/YCVO2QR M`"S,ZT#5'TR%L':>A7D]J/J#J1#6SK,PKRU5%S!M+[\I9L3S*=4BMRGP$LY_]K_`4`^L+,T@,K!B'3/YA:(@?6B^E5DB'O)G[[A(S+$'&[T_6&'R!`+?$2&.`N?]MR_ M!HL#7B'76]NN*`\0SI_`AS]\A/,GG#_A_`V6/WW#9Y#.7PWE`;.$*KO)-089 M;UI_R0"/LVMX3+HW?.>JU?-.,<%%B&HWCN;%8!,AJATY=!?C/82H=N0PG?>I M%X=^<[T^\A_G_6-O$]J>&X@L:SU95DF7-3&DFVM#W2<);;N-Z53163H'0K(X MP:?]YJ23&=,(24@6)_BTWW)T.LZ5+/[SKJWYCSX*0M^V\)0A.-[]S9WT0`"YUO*,$>-\$+E51V`J$IM".=LF$18W2\Q^U5+U:Y<5:L4P#AV0 M6BFC`KEGH59"K1A$D`-2*W4TGXK=2JA5$['?@-1*&8TGN=4=[85Y_>M.(X;> MUQ*["5HVO!WRCH^0C5J".4%+X78*46`>S`E:BNU+Z%G]T9V@908M&89W8CY! MX0=W9X:$4=]]TQ35@*A]B%-CBY!K<#,*%%E1Q9`"(?^AKPW._W*CQ M19UL]AU`M3$?T>V#C\P_;\UEB/P7IO-L;H.L@Z#--6AEXW7->=09KTUF'^-2T$""\J MK/\9;4)$[D#J2OFG1Y)6X2E5K8`@)A'$B^6?U*J@]8RDE;F0`F1%OAW:A[WV M@-5F*%E>Y"RDC1>"H-FFXVPE&LF"0/C`R\=@7R([DAZBD`A(7$2[]+TU^6P& M0;0&QEF>^X3\P/9<"8O4-^1;=H!BL8)_I`!Y1CZL\D#(!::&]BT!UGY" MYY]*%\0#,A(=$"`Z9L6,KI^P`*0OL`$,2VZNEYSC> M,\;Y!R)(7A0`#8(?3Y,Q+=AM-G40><"GO(S$+RN%2LK9H$Z/JBC?[[8[XBQ( M%G*(T*[A,CKD)T(OD'S_3=0!/"#.5 M[W^F-*3)W$/?LDI6TU!EP\CTVS`IM-H`;=4P:VNH(6YU4.T^LLMA>$FTI$#P7CK[.H6V>0>R:$$ ME-'7KH(?[WE=!;\'U.\P^-VGOE+!.O.W]X3>IF,;#XM=!1P(")D!??WF,I^U MF:RUVWCDBH,>F@*HV06@^:T7#YZS2.W_\P3:+R0E_8YDHJ77)*^E[ST^!F$D?,*PLDII,;LL.#AYUI2,XZXR?#F5RB1IP)0I MM9;XR'E2396R'.C5E)X:ERZ:DV=>_I M:IFM;`#.VLT.&R_V+E[_Y4"X94(4>FP2V/LS_9.#DCY(R>JQQF]W%'%([M,- M;FN;('B^+HR#:Q#Z:#P9L[G9<[:6I>,W>\Y7BG'`/W5DS!@U">PS_[B]]*R. MYLI<\*]:-1D7_-.UW'DK#+=6OC;03PU-3X]CJK8'I3T1GA$2J7YHY7>"(\V4D0^M>'SF-X(3Y5D$OU8 MMBE1,\T5+E5][&"_LL$1/)E&6DI_^-M/47#[:)J;%Z_CIBP?D?\9]\+X`IQ[ MZ7C6G[_^[_](TM]V/R-]2NPG]):TZ?AB?OMDAN@>%K7=")[_L$$^:>L1X&8: MF/V?T/*7FU<1_>M7%?X/U[)]_>)]G7_5%?+AAF3%R`__"?]0]1MI@2Q[;3H! MOE#PJR(;*T)XHWW8I]5@GZD**]@_ M+%]_LU:F^XCP4Q_<>S-8W;D+_)_7?T4V6'/DAM>(O):&_A;`O]6QF3Z&OQ@< M-6%PF?XG&&BLX%]O'&^+T"?DP#.+WVWSP79(JZ?[R/?A]P=`WP5?/RR_`JRZ M6HS0T[EB'$*:M][UX!4GXFRFSEE`]QGY3[:%B&E_:09H<>^M-\@-"(,Q^=\X MWC/E$?[T3_C%%^\S"D,'W3V;_H*M;(^-62925T/9!O(EU>)V/E<;01XL6[C] MPUZ@5W9@.5X0^:!POR'O$=RNE6W=^<@,?O?VK9L!UVG8[IA3([$F"ET#6->G-GZ3!D;G"/^QO/!S77INW$#O:M8 M;6AC!O@>P]00GB4VM]FD030_H2?D1NB=^1_/OX\"".F0#XXZ+GW#[?>*F^:O M\;N_'KPJN/MF!U_1*EQ]_7L$`8WYCEPGO>AA:=C#4B99%+@,;44<[<4O-V]# MM+Y5%!VXP1!EC!M:K)#IA"L+;&]1Y%6C#>2U&5/D_\"=]SS;#0MCK36&=?$@ MC+58SUL1:^4,9ZNA7%FL]5;$>L(4^?)BK;8KUIF^)&.Q5MNQUOIE@U42Y8Z) M]9PI\N7%NCFLBV=N6(MU.]9:O6RPFA+KYK;CM%A/F2+?AEA_LU`0?#&_O40N M6MKA&]];9T?>;VS7='$GXCN\[2[.`LF]U4 MKP`3),@WG3MW<;=8`R^"$(/RA%Y_PS)4)LU1X&Q"FQ\F)',69P!IH>/#$T@G MPNO5H(U M11>+3-]TPVWJ4*GZNF!AIT<&-N/]AP#0LUEL,/`VDG4X^Q(M/7]_AHN"U]^` M69Z_`#?!WV+W-'CON1AHWW,<>/0MOAV,@I"E]9A-CXQ'C7"W3*!J1DO3!D*> M:J9RKDZ4@1"HFH56E6FK"@8OV!_C["JARHC`KW%-VZ[B*E7?EIY',]52Y6+G M:M$:FMB6JMW+Z71_IC2M".C#&5H4/Y\SI<@P)K*!"5%Y2E%&KZODG:D"6&DB MCP^K5AN_$'O2&(SVL_5")!GEQG9EO^G_[8:FZS]+5)$E8@KJO(G#FOJ=:#C& MI,*VR3F47PYFN5']#:(U0`-OQ+,+?6GC>T\V&3`(&TD\A0Y^">)#1BOBGZ"D MAA#_70+[CR<5PH_QI+C,.97QU,F#!LUX2*.:3&O4I!\NK&L'TH6I<_59+I[& MK>ES>9P]]%F,6\N_'W%F7C:O0X:*H34_-]B^VVCI="Q#W]#2SHVX[C1:JBKK M2O_04E1YUDVT=@,HM)P!%(HAC[N)8IY55+LU4:ZP^>CA_+^^HC63Y]U"JV2T M=\E%[:HKVJ0ORJ$$E/$Y.PL^]2T["S[U(;L*?NPK=A7\V"?D&/RROA_'J!3Q M\3H+/G5Z!/AM^F8<@C\$'XR%@[4S<^,<,Z'SA&/7KK$[ M%&#^YIIFD';'#9CDSR"=BPFX5T@8GD'*7FP'HV]BPV/LUZNZ/!8#V:Z1X:OG M"UX\T^K.8!D>HU:0;C%CF,>AK-WQB/*FLH.(380!Y="`QN=$PH!>94!56@@C MI+LQ`UK2Q3VMHAR"?WMQH"![B>V+WE\@VSPKL!=DRY>VCAP/9L`>UY<)EIA5VPO"39XF)`0;9Z4O\\ MS+TH$B3%-_$>R`7="]>L:DD_IZ*H>F2,'1<:'E7V?S70^R#\:IK>K0ZUT5A- MM#ES!ZCB!+?ZIN'5M\I$Z4DG/Z&,?" M#=\X+")B'UN(?1D1I@?*>+EM1*O1XU2M.7QLF^=<]Y3HOFSG=*-HU6V;,IH4 MW=G.%(5BJ2&)R[/=3CFZ5G7O&^8GO>Y.9#>F2HKC$27 M\2D'-_P[[WEW4%(9N-0<2*TQEW5&4LLXQ<^O&1H0IF?]93Y$U\@5W2./F7[D MN6WVF?LM.^#+M_^O$=@/V1VZ3SST:V[UY#Y+^G6CT8^DE9@(!#N\FZZ\&LSA.C\AXW#WAJG[0QMVM0V4"NL$)*>[ID M/3H%[*O()W,,P-+D3!MHUOH=C#8H__@(]$V*0ML!NBQ`TO%DR3-Z]D"G3>9* M,+QR95LK^%D0.?AW8*"K6'7+1R;6.F_9+$5/\X[Y3)"G5;8/VW%LSVT6.\S3 MAFAB7&7*UA5DAM!SA"5O0WT29SNJ)'L5'OI_NU$X]S_?E7\<(@8\VPJT;F/: M"[!JDF5N[-!TKH'D504!D6)_RO*P80WH`%ARA80H_8/IF*Z%0/,1"LN_/9"E M+RL4@-NUAG@"C`G8CX85P`F\"NRU'#,([*5-[=D%`APA6"Y@8K"2((AY M!DP#"8*L586U39!H[);@,A8PNEXRU??@[:#7L()9X?7+9-XS?9_MXC=6\$/* M[>>'KX7MYY<;-;8!QROOGDP';%+ZP_'8NNQIRY!5PE1\6J>"QV6K-8)4?THC)-=8:(EA_W[IW MED5,WD=S2T="L9$S.@)Z,CZ!\?+R+*$M.]!7E64);DKSZ/$^" M2\+Z>KUQO"U"GVAL=6X<])5$-L8G!K8P'#5A4'J.KUX;!A_`J_/O(^":&];$ M@%O5F.:QX`P8=4!?5NJ-$[^!(>P?$K?V+@A0R%;NYWF[8Q8$S*$NNT_JDSK` M_N@C'&+&S@M;Z9Y-)SD0'Z[.$-:R&Z0Z5?(V]=[BV7:<`U#O@J\?EE\!0ETMQF!5&6O' M#,Y?DPF4)7BL38[5I"R,OZ,P1'[P87D/;IL=?HC"`%Z!?W]'&=;WOWS0YV7WW&;WO8'BWSCIP;7,9O?//K1#ET./.`/4)MOQ6#$'T. M/>O/E>=@V*]1#8SBI#!4<`-*0O'.]/]$Q-UR M%W>+)^2'=@"?:O"G])FA'(8[E]>^'LYJ+H"JSXYVB+KAK!JUJX;6!CU+PJGJ M\]FL,IRPT]V;P8K.N^2;+\=_ADK(;(=CQ5#C-.Q0&I!8&R M`8&N'/E@C.%_ZSZA(*R/`>.9/BL"?P8+]2:2"J;7:WFG%BYJX`HAJS MC,G1R2(32I3-3RG%8=CY4AEILO*^HS$[2N@=O[_TZB620 M5AGK502HFO8:>DW@5#W.4.?UTJ?L+J`#E]KVY1B210G[U#F\63UI>>[MDG6OGOT$:F\*9I3F2EGA/,R*D?XXQ1\G&-B%!N/)T<'+9EK M5`.CN"C,9L:L$A3WWGKCHQ5$)O83VHO-&\]']J-+$PS6]HMONH%)BIH@J"&? M',+RN\5_HB#$Q(8-YX/:I4=&KFO29*18^XUS2I>%+1 M#DV2:HI[+PCOUIX?VO\E#[-.NL&N8!QO"@769P5Q!>4=4SEM"^(*FC6FL7+; M1"X)\O$!3$6(F1\FC(WI*5QY^?SBH)0Y9YED[*R%(`%OPCMT,^LH3IADV/.S M*U\/9=7L0K-05DP_M$+*LD!6AC'Q]6$+^X0VD6^M(!SXL,1'\9Y+C@M9"J8Z M4_3#;35_?:;PEJ3KS#AB?U5POWAWUE^1[2/"FX^^1^XX/"'V]5_Z_*A$I1@( MS,$N2>F)9F0+QE5@P\]!!\+M1\=T0_#%\)GW9GUL_J\5ZOE1-6]Q,&H!OWQ! MSHP-^`FA`U!@118@%J?E6)G.KH70LQ!:!&]\;TWLR8<- MR0V]_H9\RXYO8+$SQ\81M#F+LX2U]!:G7@MLMA!#*':=6!H373V&[.Q25P%5 MPIRJE6&"?2TV`!^6OWONXQ?DK^_I_4R2*TPE+)D>>!WN6B6@J`?\TE:4%?A! MZ-M6B&BM5@W!@3;5YD>P9BU9':QJTO2R36]^HE5VEO2*D"%SQ+0 MXK7INQ`3!'>6%:TC< MF-H]59F-CQRP9)DRBU=3.MV8SJ97KUTQY:PJZH09XF7-]70\.Y:%K+4_6RNT MB!P(\>[(2<"_T>+B^D:@F MSQE.,^"F79\N*PS[??."%G!+%=SJ"EJ86SU$J[_N#'6V=7 MM\@F]T@.):",OG85_'C/ZRKX/:!^A\'O/O65"M:9O[TG]#8=VWA8["J[QOAZ M3F-\;49'=-#H&8AU?A1GX4&>I`^?]!VM+\J=Y'E%HW::`JC9!7BF+'_PG$5J M_Y\GT'XA#:S?>:03[>L"G6@'8%F*2]]4UB9"^JI+WWOXW(,/+U,!C_!U8(>O=10GVO"Y;Q3?32>C%G-1C]3R]+Q M`=/G*\4XX)\Z,F:&X%^UVC$N^#=7YH)_U:K)N."?KDU+SHMNLKJLW@UT?QLF MWD3Q98`:M]#VCE7;E+&Q/F-I(3IL!S)">X[/UB5=UL;P'X7^OU.YJ%"(MR+C,@+`ISB\)C;B$AHC2OW4WZXF6-7.;OS$.#[Q=> MA.\L%A5@/KUR8Z0JNHBJ&CTHZ8WPB)1*\T;:2(?&K#YS&]$9XJR23Z M$?<9.'Y;\FU]A1^%G)\S51\[V#<'L"9(T-?"FK_=9_2B,MI3_L>TZP M[RYQKGO%O>E8D1,__3Y:X\:0GG_G+EXAUUO;+O[TUCUY+6:@Z%QQ37PP5F5= M$9TK*FTU&KVUTIW[VL70FLF3/J+54V[U%*V9/-=ZB%9/N=53M*;R1`BA0*MU M(>Q6QR46:>O8+>VJ^]FD_\FA!)3Q,SL+?L>IWW'PJ7_86?`[3OV.@T_]NLZ" MWW'J=QQ\ZH]Q"'Y)O^OTQ@KO3A<+CVK7DV:QV-0+2LEFP\7_]L MPXSGBK8J6B=QV3JI.YY"GH@ITQ+=H`=AQ@>&.FGF(E0>3Z,[8\*'0]B`GIJ?^H3A!9J*A044ZE M)RYT$T06*BI4E$_IB07'R%>7+&C6I%CQQT[]DV25*U^GP^%\-GR MUD@R'<>S3-Q6,O0D*]6EN;[##1YC@B)4^[\:2'+VWC0'/3)^T(SYCSSQFQM+ M)P2Y^-UK#@194QCU"1("/1R!/GN/FP.!-D;&A%'?-"'2@Q)I;JZ:KAC%J7Q[5[9'^0;!M:2.83\LU' M)+D1:<7A+0\.JJ4`MW6O810BSRGDIMIW*&)"7(=/]V5I9=RWL MS2QO31TI8W$=9D!*R@U56;DDOQLGZT:%O5%2V#@U<8]T2$K* M#559=R;LC4["QCE557Z/0_MW$38EA!>DB(^)&_QNLB?1J:#EE7+96=LNU*K& M`%/04JB5$`7F(:&@I5`K(0K,HSI!RPQ:MA>\M=1C]"1TRWWX!\<+@A\K/+A! M/CWT).SX[INFJ`9$^K5.:QM@)S$:[;5:,J#(BBI*;08I>S@D:E/VL.BQS)H+ M&>R:#-+XH5T9U(0,#ET&9ZW+8.[IH3BIZ(60<]$]BE]\A`WEBAUBCI(0K]JS MQ_W!1X@75^P05/W!5`AKYUF8UY:J"YBVE]\4,^+YE&J1VQ3XB&1GT_SI./C\ MLD,D.P4^(ON9A0^/V<_^5WB*@?6%&20&UHN<@A#D#@X6$`/KA4#W:OR`&%@O M1+IG^Y?@\4!KY#K MK6U7E`<(YT_@PQ\^POD3SI]P_@;+G[[A,TCGKX;R@%E"E=WD&H.,-ZV_9(#' MV34\)MT;OG/5ZGFGF.`B1+4;1_-BL(D0U8X=*%O]YU];\1Q\%H6];^$N:8XU<.ZS/G6QQFOT0`KK, M@>"=)/(0'._^YDYZ((!<:WG&B'$^B-RJ(S`5B4VAG&T3.7.T.!]$;E,Y=7%` M)I2S=2)GSACG@\BMGK4H6@<.6O3K]+6(V__%"TTGL^8H"B!"MEUI-TU.LDS' MBAP3'[\T%2YGRUHA4;TP=K'+@Q.O"(N;)6:_:JGZM`M&/)H12QR]+OJWO/.>:PYP=[)L#6`_]=ECSEQLUOO1S M5A322$OI#W_[*0IN'TUS\^*SM4*+R$$?EO?[RL`/R]V@W#MWD>J+^]9];?HN MZ$7P$?F?<7#P!1/X"W#[I>-9?_[ZO_\C27_+>G>P@C?A_[S^*[)!#I$;!H?/ M2A:@`!\^H>4O-Z\BGT#R587_@\A#^_K%^SK_JBODP\VOL>3L$$M)$64F#9>G M6HHK1[^C4J\JRO<[:2/2(EG(<6+U_^5&N2&?@XUI)9]C);(`!>3OE"B.LT%G M'',3H!?)/WZFZX"`@)\!$6@:O$/C4BFLU64U>QLRH]#C]S0S_6(0//O!M],F M)`&WUO-.7=89DHZ7G4V=R4;VSM9IM'K*K9ZBU3TA9))CI,:XJT:W2:O+H024 M$>RN@M]QZG<_:+!\]9I#:A>0+M*V0ATNU%5T<2Q'SJ$+@@Z)%,=T'_@?:E7AW( M[U7HC"%#5Z?L7XN6KSU^N-XVT1^HS\)]M"I$[]I1F@Q;VWWB`W()7E=PZ\(JYV M_X0L[]$%+!8?D6][\+L`UFJT,/VL%8G'FE\Q;Z>8_[9"\`:@R3/8.8D6P@?1 M&J"!-P82Z2I\^X")B!L-[Z@HH6_XWTCR@82@S`MI$?GD#?"^<.6C*E>6L0/I MPJ<*CZ[A!ZM`0BX&I?SCNS(`25?*/TT+58C_BX5!^L%V@09>%,!?@A]/[TPS MULD<"=(T>=R824G9X)RJTFQD^G9/PU!EPQ#W-"IYAH:L97=NX+66O!A:\WZB MILZ"W['J=]Q\*D_QB'X@_&[ M4=/1EZ3DY'T.<>H!I>YFNUA2;?J M=VUSY7$J:X:0Q^KR^!X?[3$21V&,V1KCO(OFJBX;I\;XRMMM@Y+^FGH9Q%DY M<>OP*NG6:)-X(=U72'>Y1@?]]R>*"!WS"\-#$SIA4ODUJ0K3`99#E.Y:>\=T MTB=NK.I(:'_5PB9!N:&E;,6&>=TQFZ"<4!G!^%*'BX)R0F4$XTL=J0K*U10L M\7`IMTC8=.^MUYY+KW1)W@9?XZKC?O[9:QN#O5-[_LH'!]=:9\:8S0WUL_7! M[?.]J4KH]C%M3\+/W"?A0,*G*J,>#*SY+@2::X'FMA&?-IK--&"(0^U7N2,A1]TD93 M36Q90L5:.'D9CHIIX[+M$KDXAVF\?7)>E[VF`C]>VGP.,Q?#+S_:M"+J:*89 M(MG)8`OG19H&J=ULZ_QZI-VZSM0-[^_I')_",TQE%AW2LY1Y/&*)2[(1V M]UR[V19+]D:[C9&NE3V1I1_+3#\P<+/R)`#O5"?\AZWD;1">$@"/+R/7(M\N M/9_TQ#^1U%QX:!?]74]\VN&^_&M:[(E?_JF,^[SY",9]]\L_>7J],G\QT=M? M]/9/I1T9]B_FI;EJTZUEE+$\[68;Z.(H]K;G_Z2;G!LD6C-YS'`4"3=H:?*T MC[JERY,^HC67U7X*82]-1D_1FLGS;J%U%%9?XZYVU2UMRR_E4!JJ^I\3?X2(<6!`)\*`7BW=JCPY M=7Z%=//3J1]X,D#_]CSVR9&_T/N">I]!PKD\%R2L(GDZGQG)0K"+W?(ZK8&M M4HRXZ&DT<$%Q]!KR)WWC>N86HS*/F@9`MLZ M)&!Z9_I_(G)]#%]I,A=/R`_M`#[7EIT;V,W/,@5SL=:;:P?,E MZS-US.UCRH&T)V$-E]*NZ[D]Q-JQ>-P(]]F;(GT6[HJW3#@0Z.F463LK;HV: M,-]U2_C9*RP<2/A1NWD/,"W]!5DK%P!\W!*OU8+?-^RRMA_FU>ZR M\AG)&:HJ4LV]R574[LWR*<2:SBPD$QED[F6VNXEAW`L]M\'J\(R0P)3_C.\T M/^LUP(SO;\A%ONG$U1QKV[6#$/<'?JICH$]F37R35YC[$:*6]MN'.=M+'2G3 MF4AT5]JKA(HV')4,4T4G,V;.9!_R^T+K&HBKAJEI^D@SF&V&0\GVB\VPN9AQ MF&JIC?1)KEKR>)XSA/FSK*]PB[%7-4>VO/"FW:B7X2S:@1V(\2E-P]9TYO?9 M>Z3I#.?2]OO4D$_AZ:5B5XC!>>%'F\K,="[M4(X;Q;;-EW:S[A'0&^UN9BZM MPJQ]6B$).M+F1)1VL!]."4V0H*^%-7^Y4^[IY,(RVE/_SMIRBX?33- MS8O/U@HM(@=]6+Y>;QQOB]!GY#_9%OJ\,GWT$J<+[E/9@CO'\2SRKP_+3\CR M'EV`9/$1^;8'OPO"X`MP_B7\YL]?__=_).EOI\M\0D_(C=#+[3OS/YZ?7)@* M7FX_H8WGX\X(G]$COB\5?,&\V[V/UJ1^"S^AY2\WKR*?`/%5A?_#K?F^?O&^ MSK_J"OEP\VLL63N\4U*6G@\ZU5),._I=+\:7ZCKM^RC&EY8VQJHNSQF2CIL] M7^_EA$C,K5G_T!+76K%O<8G'@$V^=7=TBF]PC.92`,OK:5?!C*]I5 M\`7U!?6OW9,X!'\(>P^+C:7P\!==E8UVZ\XZ/KJ@A;%QW!N74M(GQL9=(7V\ MC8T;@FTME-@2LV"JBG1-DX[B[$%W.D2S9$L]"28AXU?(>!T#X[AW#(18"=,Y M=-,Y$S+>J.DLZ=:>#I<0/FT=/FW7IVN('5DP7C!>,+YWC&?OGW2=\0P38SQ< M8BCB3OP]@O>8];D27-;!SK]G4^)^ME"EX_=5SA<6<<`\57"OP]R;".95K!+C M@'EJ/O=:/%NJ=Z/\`SG.1\^&7YULEKF9#K+N+$'C!_7'VO;;5J5#9:K;'=9@ M;'Y;Y80N.,$))S3!B?VNQKE.###\^Z=KAVCQ=V0ZX0H/VRJUM^7EH\ONBUI] M^R*G_A1;.\V#T`THE&%LVP7WFN6>(;C7X4BTT=U\\"?"9;ORZ;(VWC?GX[AU M1^?=Z@J79P1W!'<$=ZI=?>*!.T<;&_U8MD$+`=QV%\@-7ZBSRGRY9H/:`7_0 MH:5([Y#X^YN\)B*[I_S=OQ9)8Q'B5EPH!I/TB:Q@2DG9.!TA?D2A@P8DF+[D M(2DS]4M9FP==\IL=,_..W]-."+EAGN;PI:O.A1A;PO?;I<\W%=/G)9:Q7&^C7SX^.RBA?2PK7?U'9)RKNDZ MWX=E0-ZV]25K5[V+EN9-E=SCZA(/1M"UCR&7=-Q]P) M[IY-?W%GA?:3'6Y;:$V6YPMIFCQF%L$73X+G]1FI[BMUJ<^:,94UABUR>&DB M4]A@7!/.C&4CNW@_14B>RWL,65SWE5D_14E59R>[0S"M:1YF/ M:_:8KNXE36XF'$I`&7WM*OCQYM!5\#M._8Z#'QMU#L$?C/'.N=?<1!0@VBQ5 M9,[[B'14^A"%06BZ&!/V3*IH83CN=1!',T+J*DK='^1KM+B]>T*^^8BD3VAM MVBY@)-W#KWW3"B/3D7ZWETCZ88M,/ZBA4K*+8EE\?)=!A\@)$:THHG>/CSYZ M-$,DO06!M-W`MJ1_F4Y4Y3SANNLP#/T('HKV<@A&?OS2=$S70I*WWY8D,Y"\ MI?0*67$/0'4DU=,5*-NG:/*F.)\EB,:4T7S+L]FEKA>09KH%0G!4>&YUDSGU08-;\!:DCCFD1MM*O9D-!\W,T6]4AJDP5GIO_DFN*R+VIR1-KFL M*3I+Z]WQW;UO6\S0\>$%_(IY;`[JL;D(2!NT]?]"09VFGL^M_@=-'__(D^O. MC=Z>K6QIWUUNJBI$8-H583U;`=,A%@XBH+C'^4_'J7.?:>]HH-6-;,IB'^NL M`1!!3!_QX05\$<1T\U3M9)/)?==N&%?Y1_'X+JF>.3',C^XT^'[A1?A>2='- MC<_X39],^3R"X<9TY<5QK:9@97W")_MXWTFYQ+2(E:SQ&(M+$9^,9G.EY%D2 M_3C<"]X,FRND.7_GVZ8C_=.U+6^!I'>?TZS7:KV[_:64-U'V[2LDF;NJ+GM7 MU?5$JKKL0+),QXH<^')1[ZUM\+EJ?3^B%\*),GWW#3RM^<^`G.,%V.$+\,UD M:>/;5LTWXP_KM?::'1=NU;IVO6^7P'>NEW;I4;>U+E0_*S1I'3FAO7%LV@\A M!"UT:=$YB(>_NS$?"V:$[\P?1"A"2(60UBZD(RR)&X3;-"!GVUH;C8:6X;U; M!Y/N&N5:=Y!7?MC@?P9\=>O8'3KHDZ.;737UVA'].?8)/EW6LIMIB_X<>?'W MO)\='S1Y)M#J#%IS>=RMC@]#YI9JR&H/VX[TE%M]1:MS)N,H*7J-H]-5AZ9) MCX9#"2BCKP+\-LU*9\'O-O5CSZ*KX'><^ET'GUO5'GGHK5=M-UQ,4Q:#DE)RZ'7WY!OV0&2/N*S<"&. MA=,S0@2O%,%VNUYU4"R%E6R]Z]6)(!8[1MPUO?(,:CZ`ROQ#LYO>"1&VTJLJHRNT'!6I&Y MO4&1[>\+6=+E6>Y%!2%*8I,0FT3'%%N=CI1I,_WL*B7=^]#/+HXTVF3S5%=9 MFN^..^Z#-7^M6IJ)/&/JCO;&4ZAX4L\M/GWC3^_PJ7:XW]F.)8PSH@VZ),EY M77U."9]>Z0]397Y5QZJ^9QY%9%>@>)D#01[+K'K0<,SXIFY$]`W3X?!T0)CF M6:,N8#J(=$^-W4;;KY]LU7G39@H#YZWC+MI@';%6X*'),0^)/ M[_`1.:;N5=V=[`FY+^*S)2[STK[^M,0=J6-&$RU%BFUHGAV?(JV"Z14Y-L8Y MMG9KS>9,??@!\)-G3(7-RHI31]-9KM%J+PU7,[OI-#G2K1-]PQTHX4/H24_P MYWZ[H1?\R'J*#MOU-97Q6%2=\1#;#S@CJ,LJ4^^P-SY#[`.V[.DQO570&]ZT MC\^`+<9L-,Z_-S7`I&%+8T:..#G?5\11%&QW@=SPA:;)X\K^ M7B&&'LEWPMD=&J5'8,3?USMQ;FZPFC@WG=0Q<:Z!22;%](&\E)O)PJY&Y5NGWX29L9)&[((C6]&\MS*?JVX`G?2I/Q("G:CZI M+BL]G/^A*DQ'?O&"5D^YU5.T0`AU(80"K=:%<-8_M'K*K9ZB!4*H#F\<5^R6 M=M7];-+_Y%`"ROB9706_X]3O./BQ?]A5\#M._8Z#'_MU706_X]3O./BQ/\8A M^$/PNU@X5;MA*N.<82K:7)ZNTNT-$AUA!] M8B%]CLI5?LT>K+X9"M=UICW;!^4/M0T.2E.N[772[\+QKZ` M=.M"NJ^4[CKN`W3'GR@@8H8F1$P8T+X:4(WYK*:A27H32554Z?;A*-]3S#Z$^#-5G)L@F M-AK!\GQ-4=N=S-F)C8;A<41W&HXDO>&0OZXO"\,!-9JZSE%QX)DN:^/CF\C- MW2U__].=8+Y`[/S]D&ZT2##DR8D8YSXD;9'IGUYX%5(R.,3.WTP1XB^DI/>( MG;\3TQ7QGS8B_@S#!$Z#@2?/,4/;L<-M;7:APTI29>9>?]W[KC*RX^#'KGJ9 M[BBL&W09NJQ_OT=KN+SH./BQV]NJ*,UE18A2]\&/7^&2*1\Q+)RWXRLN/@?@^2E)BN:$*7N@\]!\E*1YXVZ<3RXZ$5\@#_(O42TN#6?D&\^(FEIVCZ= M<]&!'%;W!P6)U.>`HUZA#]U*FDYD@]$\2R'1@Y)H;A.N8UDWA$0+B>Y/LA9L MM%K2SZ'&DXGK$::6@D).OS2,,5\I'TC/_']20Z(#"9(_?H MFRZY3>A):+UQO"V"URTB'X\2Q./H0M*Z=.V1[I'HM'LD&[F]=\P@$./@KLFV&!IIH\5M2Z:B]B178:[9KB?R MM,/)PX[G/CL.OJK+8S&X0H!?37C&O`ZN.(H`^KOWU-L-N\B^(QK"5V7.%R\T M'>E]1'QX;RD1US20/D:^M<(.:FV9]D[TE$D0*MYR=2*/Q8""*^3Q+CXB_$@F MGG\T`?,-2"81RPH#YLG+9\G+?]`RPOJ>M^,J+KJSK%[80G2+B^[:B^`-8$0_ MH4UL/TN)&T.'@8<<>9&4XWVTCO!M]2"%-=FCC,T\^'DWGT]%,$0>:G'>[%R=/)]D(+KG1IC*KAJQ,A2(+ M1>Z,(H_;[C#,IR+/U-%XG*O)+6:OZI6TO7,>8%_=\M9KSZ4GH7W,3[7J_XV- MD39C6OS3\:UA@%:8NE.M>BYC6=.%$)[S3SJ2XKE6_FLY=AJH89^-C-(5<,-- M9Y7*69'W[,JJRC^:%&)I`TF5:?#]PHMP45%1S>'3+9^,]+$V4N:*B+%%K72E MC!678JT:LBK21LVFC9C:Q`'J$^O$46_VJ-E\-)_/F%]]X.8N@3YA=9=`G?7_ M+L%]>0^SQ-M/7.D@?30L77$B7`((T\VXXZ#A,OK`#O!9?ZVK2P&MQO)W*;"\*,MX.'$F]&8#2%*566LSJO5AR MH4BQH66NO+1RNA,G]_/!JAU=)9-NL7FJ\RI95J75I8?2Q-)R0$MCM/1G2CTB.]6?4(;SP_!.WAE!Y;CP<.HV?M0>1<[B2ZR MJ=@NGN7)NQ64S5\65[N*W>4RC(EL9&EWX;MYF;E6U);]VEYZ^)!26.Y6<0%7MI6R:\\SX"#W*-ZAW5=$$J^59L MAII;R5$\W8UJW'U.#1C^\0L[!"Y:EX2JHNM"%,?X^8X4>QQ%C^5?J:KEGR': M4/ZQP["S_/.`=H6'RC\R(O&GX[F/MPY$ZPL('0,4!DF,#'\`AQ:$#60)LP#B M4O!JPRVA"OHKLC?821M)CYZW>+9QY`E_]\(5X(TE8Y\ MA1:R]/O):Q^VJ7>8#OZY2=LM0$2]!!_'>PZD'^"5X0H":P`_^/%%!9'*C6K. M^.?"%>6XR\"9AC?'_A.'-T#/9R";N`2J&/(L^_RK$NEX.1;25'F:7?O0:;1Z MRJV>H@5".,GN+,00_.MS M)IR;/A9VK?"=>&U2J3,1;Q?3@ZR#ZK9TN!N-/##G*VP/G>>\L!\UV(]N7KC@ M08!/RGV$&:MBQH0`5A7`T^(O84Y9F],+[97BI$I[5[@Y=/'SR99D#@79^AN7 M]D%96MU#+ZK/I-W&$9T@),-$*P]W>HIL=/_$)\T+Z7-HAJA<+C92QKDM6QC:?KXL_/W*=LWZ M+'LGXW"^.F]D!S=#Z;QA:&.6^TW7=Q6A3\QVHV'JDS;+;4[+8YRSN]LWKWU' M)!,"FMH1>;ED/TBGE&W.L#=-#R#*F\T9-3'L>Y3'I_0,4IO9IC#[H\VSD6[D M]M@ZVO/IQXY?JV)_4Z1=?(I=,"QV>!G?$OL^M)2NA2W)G22)7 MCY!TD,F6*RQV;_J^C5_LHXV/`I`)/"965;Z7`.^UYR-\V0O?#`O)A*F$*K!\ M^;4PP%6>*D;X\F]N^.Y@M9M\Y*9:S)H]W^G%J`?D>,_EWUGAIIJXGM:/ZVFZ M+D\87F_AY:9$$Q]_!FD*++X^QVC)U&"W.K6Q>>!+=ZAU9_N37K%K=8 MY'[CK;.K6V23>R2'$E!&7[L*?FQ%NPJ^H+Z@_K5[$H?@#V'O87H;2\^Y#*.K MLM'9\3<\7(;Y0C)J[V@B[?5I!I.]7\"_<2DE?9TM6>%!^M[C+"XCX1.VE6%B MB^D]B4&)=$TW6N/L@;B_PB[!)&3\"ADO=V>V)XZ!$"MA.H=N.F="QALUG27= MVM.KK\*GK<.G'<;5>;$C"\9W$'S!^.$RGKU_TG7&,TR,\7#+H8@[\?<(WE/# MG=_S=5\5LH4K'+[2<+RSB@'FJX%Z'N3<1S*M8)<8!\]1\[K5X MME3O1OD'T.:S`VOZUR0A>< MX(03FN#$?E?C7"<&&/[1FY!_1Z83KBS31Z7VMKQ\=-E],6-L=K_C4,9VF@>A M&U`HP]BV"^XURSU#<*_#D6BCN_G@3X3+-NC296V\[]/%;_NW[KO5%2[/".X( M[@CN5+OZQ`-WCC8V^I'3]DR7-J@=\*5[A\3?W^0U$=D]Y>_^M4@:BQ"WXD(Q MF*1/9`532LK&Z0CQ(PH=-"#!]"4/29FI7\K:/.B2W^R8F7?\GG9"R`WS-(7;3`\^EK77V'I%SK M,KD.WY%8_;27_\N&HM^ZEY5>ND[WLN^Q\:5XQQF^/NO?,:X=5<.V]^M[;[VV M@\#V7,DOGQ".>]V98>C;#Q$U&J$GK^_\D_'W0++/SB`_H)5T/)1L$%6:#^!!%=J.LF[6E;@ MP&S6H%I66JL&M4QUY!1:R9=6_H&D!5IB_I1_%Q:3\D]EJQS6,!"])?+!G08U M"ZY0U)'TO+*ME;3PP%$-I=A%D]Z15_GHUD<.:8Z;^70*B`H4\6,_$%YG.X[I M`V*^MXBL,)"""$`RJ[PU6.-.PP]1`'\)`+M@Y?GA;8C\-?P[!'+MXVN9,FG>H6-K`*X\=;W?S-9E8`?#M[\JIC%D&@E[I!=_FG3LKS( M#7&G;0O93R1L*H_)@^E@72S_I"Q1H;EBNZT`;C)MNXIDAL_>%9)9P1I76"T1 M_PK8H0I&N6*)$GE6GS;GH*I&A;6JR$B5\&'O)8U(=W\3N\0/-D[KT";WE;1D M7,'-^UZZAJ&)4:L@"A7,1R.K[(QSVM2V;CC?>TD2<#>&X;IM3ZT0@)P9R)!! M'(B,3UV#BHK,PO:36.0!.39$FR3.W'@A(J,VB/KAQO=8(8'K$)9&X"8]V^"\ MF^YV%['NR&Y#]&"[$*0[V.%N;3<[5(8S'N'A:\'3^^5&I:\Y67GW)/D0YU"E M](>__10%MX^FN7GQ&3VN@7J?T`9B!5"/5W9@.1ZXZ.@+.,85./CXCU]5^#\L+5^_>%_G M7W6%?+B1(M>F/\1I:56[@8#$PDP(?KFYU6]^'4\T35&4%(R92UX-EI8&2\L% MR]"U"2.P[GR(@!X1)OS+[?XG'\TM_M/=L^DO7O\5V>'VK1N$?H3_&'S`)N/+ MRG0_;/`K@C>>OT0XJ__6_0@1E+>0[,4O-V]!&&\!RLG-%:@?8SX=%\"[%IR: M(N9O\(HPR*2DP9*2FJ(W1,I#C)JBXWO/?4(!,/!]1+:+-.7N@J\?EE^!8+J: M:0=.]&UJ-$2K(ZCY(59AN=(GTW[3ZL/>@?N#'""CQ=T3\LU']`FM3=C#W<=[ M()]O6F%D.E^0OP[RMZ24+/[Z4?VWJKY37S5!PPK(=)7.1^;QUX_:OXUWJC)T M,O^+J-!NOV&XP>A-[=6'*#`BW!O3]O]E.A&Z`]=]31=Z_0T'V&CQ"N?UD;OX M9(;H"G=33Y,,)!*/Q6)`KZ*0-TVH;X']PK6=7VZ`C^@F[=EH^AG/9EJ0C#_Q MQ/3+:C(PIE]B:]<(]9"_W$.9Y;"=5\O8CU\_&O^>OIL<;UFUP-48_FD[H):R M`[]^5/[=*U*4J5J_9*&$M6A9%UB;GG]Y#KS&`4>'I5.A8[-IS.NV MFX?`-T^M"YZ%U@'/H@3O2VR9E/>&WG/>,W(P*+7TWE#KDQW\^<9'Z"UN$@WQ M$4NK8A!G3%.TFHB5!7O3I+I@4LZE87DP*:797D)%*-N5VG83'MC.R)K$I)JH MW2,53:9^6-XM%C9^Q'3([X*[*%QYOOU?="Y'I"4B3_*97S5*LAB>KQ\=TWUO MKM'=-SOXBE;AZNN79^_+RHL"TUU\MK\E21[PQ MCSZ;,I:E,T"W0)II%FD*BXVAS(H<.-="F2H1W8?$ZT*^90=X`;"4ONT&MD5, MZ4'60IXFG7F50OT%P((WGCN*JN9NZRE0:,X"ODSI'7"%?OH)0:Q>279%1.9:XL:P;=1$J%X]V MB7@AUW+.-A;*M8S9Y5IJ$(]R!FDB&RR2"5T4C^HYF0PB3GI"Q%1%T6&(<&#, M9^4"XM/09JI,9TPM^%FXVR#/_,K`;S:=,2IV;(TZ#*IC=4,M4B1_!7C-8U^\ MW%4=,ZH-;ASYDE'O>8'("'MUAG:V(,B\T*EXC*'+VI0',ET1:I20#=-JAJW"Y7A=G$=(FPM8FE8 M&*6>=9)Z-A@:2G:8E!3;H-C9`6HZD3J6)V6$EBD:C$EX,=ZO+1$]D6=E?&EV M2&10;^4Y"^0'M%8#A/QDI6!W4[N4(N+[X.F[X:D>M^D^L5,MU4ZH2",E39/' MS$8]Y%VD)P\^TU4>@%!Q/U+\XQ=V:#JVE>Y0FM.@M'K?[9R6OT?=<7&+`G,3 MH!?)/WZ.N_O"FV5X^4&?7N6D">Z%61VG'8.35V9,*R$M>%-MWJ4)9ER15O6U ML;LZQXOP]Y"W5P]&:8C8S5&2//W>"Y&DTTXRWWT#4Z'_+'T.P;C$=FC_Q?QG MB1JE=HC]DPL8:=I+!8N9A*L0R_7.*OK^O>@:%?HC?5DA(('C M>,^XBU#<\SU:`SF!)('DD:U>,G$O*-`)\#!`6RHVR]0491+KEK2KSB2$&4GJ M?#Z3]I2*FX(JX_3??DB:X-"N5*09ZP[W^P,Z[_[\ZNR:2.C^0G;CCQ6V(_G'2EE!9F:/[X@EE' ML_IV]MA,81[ALMFF-OK,R2WCJ6Q,"NT^?`WK2K\X8PS`E;MZ(=(9VKEA=95( M5YU458?=7",P716,)B5#2$`_Y_@EBG]I;DG\)1V;1_N<.QQ]E"H9A2" MAZFEA=H/4NJ;!]1_)!<13GHV-J4\V>)?6'LROS^G/'P.8=5'LZG2Q!C6:N8[ M&=(GS6N7S_U-)1H0@*CN+UQ=:R!JF8L>RW2;XC.=CQL4'F:FKD&QBO/JU-)E M=+ZN,1[@P+S\,-75'P=L5#ZA(/1M?-`'/\.I#'R:4[\PM,IR3='K9WF738&% MVW$[SN",@383GL8%H]"`6+07.K;JI'321VDO'$M/&:-MWSL0CVGP_<*+,"9% M99)/*VF,E-FDI,#2C]>D3CF9*]7"&\;B.\>$U\NMSJ8B7/'+>H*!O=%Q= MZ",SB/QMO.U5FS8C5YC,FDQ7J?!DG`LH_V2UL2,3>5P=O2N`W2?A]II*LW'E M7U9Y8F3YQPZWJO+/MS.C$I]S`\4M+W(6T@-*PD')KJ(0SU5F`BT0GK483W[" M4R6#"A/'V,U!W&\!1^;PFGG;.X]^/"/5,V)W:V!WR\IS\K>[?2@ON:[T#].- M3'^[YW6EJ9.9[G0!^X$K8UQZRP+VS=,,-=YM\10I,J^45O3@1TA]3OGU3BIZ MRK^"E/>0^=(1^.=FB&?>.EL\NA9[`0#Q)O(QN"&V0!C4D(QH`.0X@/NARGQZ M1:XPG?J*J9Q4"!JQV^EQ?6V8<*["D[;G\^:4]U40).*.EW\NNY`0JV^J;D_J M=.%=KE"FZTM(`5::\9]6W6`Q MM#1Y)M#J#%IS>T.FIW'7QN57^OD[&":;"A"#*N+8=);2(J; M"TE)=R&)M!<2XE@X/2-$\$H1O$U$<-=M34JU6Y-^QZ=-/VR1Z0<9U0U#%$MA M)9L2T5U_3VG7X%,B'3Y/!+'8,6*[5Y;/']]Q62/_TG1(.8VW;\\HF8U<5\YV M8P`>1><*8TS%IUY]_[]:%)F<7O#(C385F M,Z(-NB3)>5U]3@F?7ND/4V5^IL&5R#SR&CZW'-EQ*=-F"@/GK>,NVF`=L59S3#-YG)O,[@@7 M18YI2/SI'3XBQ]2]JKN3/2'W1;OF@.4?K;'S+?/2OMYTOM5'ZMC@,R'!C>7B M.%85*;8,GP],K\BQ,M(_/@"W&;#3.OS!:S8T6.21+!`9EHL["72^0C7)CP@,)GA%P)_1V93K@BTOC=-P@` MYC_#DXX7X(H%.E-G@UO9X5?4BDW909IEWW_2\(ADQPN,"68)Q!FE9[T,Q@SS M&R7=""D+@<2@??#%[=IST5;RXEGN9CRQS`O(0**2X[C*`E=N+&24M3=N/%1X/U*,3:6.N/M$SH$7DDPE;^/&5CY`$O`]7@80` M[*NFE5;/,5#5P\I&9NN=NC:Y;U*N&:"+5R__=$75/>.\%<"PP@S=:V",B7,X MY%66&(A=>5A<^%<5_O(FV8U(BEYI8N->5-;EG^Z0'JE5+`5[/2K@XV\.EX!] MXI<;-6;6^:ULMRUMS$=T^^`C\\];'/H*O@=IW['P8^-.H?@#\9XMS@]+HD"Q$":BLR)I\=]V%_. M9L^DBA:&XTE=D[9[[G1]$)$KY_45:$VXW!45RN3 MNLXF&KDL_\_L&4)*,QH8UI7M4XCQ#<:443>/L]FECG?SR'8+A."H\IS1D#?6 MDL-OC7:,*8^B-+SR\"1QS",WVE3LR6B>WP*QO31('^;YQ,Y(JU=L%)VE]>[X M[MZW+6;H^/`"?L4\=F>;6#(.2!NT];2C4'UQ)Y=;_0^:/KZJT7;?@SX>W>6F MJD($IET1UK,5,!UBX2`"BAHG1K1_9MKJ1C9EL8]UU@"((*:/^/`"O@ABNGFJ M=K+)Y+Z+S_Y:S(_N^M.,G]5LP-ZZQGEQ7*LI6#F_2Z"(X3J#:1$K6>,Q%I%;R'0?9=DM*,WY.]\V'>F?KFUY"R2] M^YQFO79RYS&W^JF+78)JA:/N_D&%&QG5C66J7FNOV7'A5JUKU_MVTMFBUA72 MO9AJ7:A^5FC2.G)">^/8H%8/6W*-WJ5%YR`>F3?O@X,(10BI$-+:A?12CQ+6 MBUVX#]/0,O6V_^I8]Y$FNI4==HG")O",X0,OY,$,X(_>F7Z$Z>W;^,&Q,/QD>4]NH`)6<"$M_DF=MYO,;AX9?B- M]Q0W.\'MJ[`!WB#?]A9RA211@8Y99^@@6F>"?_S"!K6TK5AFB>9]0IO(MU9@?J2/ MO@<:NP[VMLGX@F9N-#S9R03 M:(,_FJ`SBX6-[3-8QRJ*H,CEG*Y#A06,,'JP3X"YHWBPTX="SWZ,"1+LVFO! MWI/0K_SKUN96>JAD[LT%3@:0/<:#C1+^X/^)JHP<\7Q`!9\U6#;>NUSTZ(4V MR2;`+@N;L46[0E:1RRH;D>FC@XEWY=^`O0BG_&/;"EQXML.5]"ER$&C]PZTZ M2_=<0Q9X`:$-DO+Z&XB,^XBD.RO$(JS.=6.$C[#,-=FN*_LH]AIK:NR:;7:2 MN6\>#,Q+1:W!"HA+U/IA__,%(.$XT@*!$"U`S;V=*%F>2U4]H$U$$RE?>/`2 MUPO!@OP5@7V)385IT4]@7X![]M*V3I8>[4!+WD7E7PJB8$,]EZ7OK3%BV`.C M_P7Y!`K@+G2V&V'[%<);MN2[JH2SO"#<>[1[2L0$>B[_5DS"2GJ\C/9HFT^F M[9#<[K/G_TEZ[YD;O.%5".P*;)]==?(C?^,%6++2>\(! M4ZE*5K"+L-$SV-7\:B[:):2)"(?M!$'7Z,"<0A=_L&K@^ZR MJ6DLV$A[JHD\[6?;4T6@U16T5%T>9X]^[31: M/>563]%2Q[+.L--Y`VC1SU<6B-.MLZM;9)-[)(<24$9?!?AM[FU=!;_CU.\X M^/&>Q"'X@]E[VFP=',=FHD-F1>9\(94][W='4Y]I_C@YV*WAYG)%>].1CJT3 M.H-:R&-%>4QZ"7\DQ7$?39MF,HE87M^T5187W9EL:$)T MKQ!=DF?'1O33^2/2AAP&'JYV%CE@N(_6^+*._80+5^G%9C,\7\JO-MZW^0HO M1+26'(^F\^EHIC"[]GHFJ=;Q6\L)8CR*SP`OV,:9=AZYT:8RJX:L,&L_(!19 M*'+MBAR?5O#(C385>::.QN-<36XQ>U6OI.V=6[6WG+'B4JQ5 M0U9%VJC9M!%3FSA`?6*=..K-'C6;C^;SLL/"Z$?1X#$MHA4;/*;KNDC)==': MWQU?BA82%VE.=5_>PRSQ]A-7.D@?#4M7G`B7:2WG+J3TO<38M;8\-[#)K?E: M5T]N\Z8O^-HN7MU%I!$%;;EP^=KIOB$*_/X?D;.5M"E!0R'W!/\1@=E1#4I, MTH?A&12*]&/`%X6?;"\*,M[NX.8GNS<#4)I2;_^XF>CG5K*?VV[0B3XYNHDI MW=9]MSJKTNK20VEB:3F@I3$Y-KOX,[7EDQCF%,6ON`Q=_HF[\H_$I6^T+]PF M*7VCEWAMUW*B!=`!GU?800#*7WZ!8"A7^]_N.S.1SBDK)$UD8]@!:1\W M%O!I`UJTWCC>%M'^/;A%8K#<2J'YC6R(*\_!WB'NN("R]LMT7T1\`HC\T(2? M977Z]0%0CPD0>7[WT82/`T4F[DP'8 M.O)@T=:`Y?V:`F^^?4FLYWVJ5>EU[09/&ZU27?0VM/':(YW1C-5^;P.6GE^Q MK4JX\A'MEX$;K,1M0RN(9J=ZGI1KPWR->[R+H*)/Y0G#A@F\W.9NXE)=7[L7@`IW'/S8/^PJ^!VG?L?!C_VZKH+?<>IW'/S8'^,0_"'X72R5TGU: MN#(QM"LB&W)Z[0^W)D2\J3 MND.VIO7\4*VO;4_1Q6;.0NG8*YT^7*4;ZOF'4!^&ZM-NB\U.DDUHRN!8GE2[ M=8=LK6PT#(\C>.@35"0.>_T-7V+$5]J0OZXO"\,!-9JZSE$-,4F7M?'Q'<[F M^AB]_^FT8X!@_N`0.W\_I!OMN`QY\<.]S69A=!S\V.UM593FLB)$J?O@QRYDJZ)D%+!*0\[T M`IWL!7(7TM9&3GTCUGF@B\CYBIROB/JOS/FV:$1`N)[D^R%FRT6M+/IQ]+ MCF'-&@E5C9.%V'BFK<<._-)#G^+OZQV\/9ZQ&KQM)"3K\>#M+RL\@9.,X70] MJ<"`O$7D)Z/3Z,0[.N@N'EMW,N!:K7?6LI22T0;G(3B`GY1^_?KQA M/&>5S`_\`4_W7'E1`'\)?A33_08\W<]098/A3!Q>QJOD\):-GVK0AG+=F;M3 M#*UY/]'2Y)E`JS-HS>5Q']'J*;=ZBA8(8;<&JPV:6SU%"[;C;HV8/,KU7..6 M=M7];-+_Y%`"ROB9G06?FAL!?IO^86?![SCU.PX^]>LZ"W['J=]Q\*D_QB'X M@_&[&IHWE3M^;49S%&+\6D5&M3#\KYKM:;55>'%YG,K::4-A(8^='0M.N^XV3'NN=&NR+J3[2NFN8_A?E_V)(D(G)DX*D]I; MDZHPG[@R-.FN=1Q@)WWBQJJ.A/97+6P2E!M:RE9LF-<=LPG*"941C"]UN"@H M)U1&,+[4D:J@7$W!$@]7A(N$3??>>NVYA]?PZ@N@Q/7B`E<^.+A>/#/&;.[+ MGZT/;I_O355"MX]I>Q)^YCX)!Q(^5:=\2K@0:*X%FMN.$-IH-M?Y%&EAM#LE MXV>NOG`AX\HTMS55BR<>]7+[$PI"WR8S6*B['KEV6*.SWLF:-LX,3.;Q1Y.D M;%-=Y],YRPVI/U*1F;42"L;LL&0H"C;1M#85C!LA$/I4[TG*4/1)&TTUL64) M%6OAY&4X*J:-E09#.'8MQY/_-Z\]T/OBA:8CY779:RKPN^),4(/O%UZ$^[,5 ME4V1BZFQ>(XI/]JT(NIHIC'JZ,QQ"I#S6@FAW7S5^?5(NW6=J1O>W],Y/H5G MF,K,M`*Q-\H\'C'.4G$I=D*[>Z[=;(LE>Z/=QDC7RI[(TH]E^M\;\LFPKXYT MPG_82MX&^?!'>'P9N1;Y=NGYI"?^B:3FPD.[Z.]ZXM,.]^5?TV)/_/)/9=SG MS4_J*W?RKMR+!_,2_-59MN+:.,Y6DWVT`71[&W/?\G MW>3<(-&:R6.&HTBX04N3IWW4+5V>]!&MN:SV4PA[:3)ZBM9,GG<+K:.P^AIW MM:MN:5M^*8?24-7_Y!B5(F9(@-^FW]A9\*E_V%GPJ1_86?"IO]=9\#NNNAT' MG_II'((_!'^,J;,US6_V/].Z6G3,0[?(5IK]<[ZQEFGMKPCINT+Z>&SM/QC; MJN>WXIV([N;7B'=MC:;9-P#O>E^N\M*MRS/11OU*Z:ZG=W]7W(,"O+=VJ/#EU?H5T\].I'W@R0/_V//;)D;_0^X)ZGT'"N3P7)*PB M>3J?&-ZYA:C,H^:!D"VSIS9B2V& M%=GB>C1!MGJ.`7BX$UXD8'IG^G\B6G1O8S<\R!7-S M;ON9:V-FEZQUIMK!\R7K,W7,[6/*@;0G80V7TJ[KN3W$VK%XW`CWV9LB?1;N MBK=,.!#HZ919.RMNC9HPWW5+^-DK+!Q(^%S/=5#J]>[?O.'0N[^/`L`!^9)E M^K2O`W)]SW'6".2B00>_(G':M`YE_?8VA7_&;#++&>>\@_RK:-T[B&E9G[M5 M,\W4L>Z?^]Q!\2OB%;>:NIC4[?OVCFG#P92ZM*V*IY&[>0\P+?T%62L7`'S< M$J_5@M\W[+*V'^;5[K+R&KPC)#`E/^,[S0_ZS7`C.]OR$6^Z<35'&O;M8,0]P=^JF.@3V9-?)-7 MF/L1HI;VVX;RLQT+NU0CAO% MMLV7=K/N$=`;[6YF+JW"K'U:(0DZTN9$E':P'TX)39"@KX4U?[E1R6M.Q[[N MGDPC+:4__.VG*+A]-,W-B\\KTT]>>O__L_DO2WW=/`87MI6Z8;WED62`WN;/`1!-:RT?X96D[Z+?R$ MEK_TPO9TV.]/9N&7G16@ M8Q&JA08I;3Q=KZBZG79Y[,:(-$/NT(BG_\P@Y!7BU&E.<7OVOEC,4DZ/CYV&4Y-_K9,"8RW@ZJCW[.:+Z: MO#/EA4H3/(B[]I(S4W+--;SOO1>B`&^.;VS7="W;=#Z'9HC(=KQWD`KM%B?L M)L_C!215NI4^1VL`?HNWI9=1``\$`:EG2^WNTGY[EY+]O90#7/(,AC5'FIUP M>$+J,YI3DFC5/%I^34Q-)K1=?%ZAP/+M#3E:2RG4"=^9T>Z[;^`X&Z>"E>L^ MHK\CTPE7(^FM:\G2#^$*2?L7WO]\[ZTWIKL=[?_VZN>#'R3/G_W!,SKXRO,/ MOHV"]+<_2G8@81`<9&+U/HUJ1*83C"0B)6#*B+D+UJ;C2`\QP^"/MDL@^J=KAWC:#;:^@2Q]64%X_+B2 M8!GI&3T$\*4$)LFGS_Q0GM&G?'U^?I9CZLJ6MRY/BI%TP>):5AZ3=HA$C4SGTS;,1]`'T/BBARO=OPBO%H%-GO+)?)W+R>OBLED!V"R0\]S M*")H$5DD4P%46`,`/GA@`:%5'F0C^(/E1!7-V`ZTN\43>%[F(]I3'EPUX!CQ M`0F,N[]_-/U0>B5M_-3NL_"C1PI0>2#DJFI*GOX`IA$!44%T@29AZFZQ$W@2 M7#LD`4JSH+K:4:X\,@T2GPR`E/`R*_!`G]2M`DQB30LA:9K"2 MEH[W'.P@+;\BP:C\8P']@#^9E8V"J^011A3_LF]?=?5!CGT#)@NP$M]`CJ0^(`XU91HAU1: M)@G%M!Y1EY4XLU5B;_#X[EP71PR?T,8#9Q2V@/(XO/'\->Q2M__?3I&WR/2Q M=E5(;U1XYAJGMVL"`T[PRK961&Z6M@.?-_;J7G\#/]9] M1.#.K==V$)#4EBN],\&_O89BZKBYW;9*"'3BA:34)5AYD0,&!X&M,HG2@(K] M)W(M$GKM*%E<_S"ADWC2)4$^/C4W`1R&*DD4K()>8I6L$KQTQ=7M'K!%/>1, M65N9X.(](.3BA`%.$!$1PZ_S%V3_)/+[3_FS+#W2_@80^<+7V%E9D-_%1T$; M'[8-&T+E8$32NZ4%A*Q1_K'?[NX^CN)T+L[,K%-XVB[\?4V"$)D<6_DX$8/] M"%#(K;3PL'HEVQV)D\$_P+J:^0J:`/.\D.JDC_Z*;$ROAVVSV!)D:5HB1)E< MK?+F+^4?6:5\L6N%SJ,)]L"$4..!1)%F4-IMJ68:F_4-3NQP^5?L7*-F(1=^ M6/U^Q:7MD+OX3!2&5;Q?AQ"%.IR><6)JV3Q*]2:JE6GP3'YJDLZT5\L1[ M5<10[#5TXP4V-9^=RLE46BR"(X.6`0(H7WL([MF M&/F(1I.)G3A,J':10Y6T`6B$?>]D3X.PB!PU6Z1?6N*&)S0*/1Q=X]OI%O'^ MR"'U5@JBAP"<<+SC_!69/GC_./+8;8YV8`'U$V\%TW_G#QSM[DU)RC6^3*=" MTJX`2QXL<*[U&9D!/O6UP^WUIUEN1#049#RSN"+GH!N$?FV'6`W"5/71_H@= MU@QQR`I!5I`*V<&I]!'I^`!A$GYB:?O!7F_BZA!RIDR^A?\!&)*OJ5M*O@E7 MMK\X^UR`34'>LP(!$B M%^OL63+M"7%`GQC,0T!.\3O`/H7>$>+'SQU@+TN?;<(?*4B5Q^*X+G;%\1/K MZTOU.F:F<^GDR0W+7Y M'\\_JHY*:J%\7/CH$(DF^^"A1,,#R+16=%]<1,0OP3_;O<6D"8K]M"H)*ZFW MP(<$(*&[BB?DV(\V+MU/E5&2Q>'GB87RI/BX`%:P4Z56NWJF@J5+E@=J@W^^ MV]P!-N\9P[XE(G=/H%]Z\9Q0FH'(AF5@P*+N)YM M)_('6S_9P=`:=BC,.>M@0AV]3.$N\X\:969I52K0NUT:0BDY8P/&VQ1?# M!P@.>3^XZ8F2Y2Z%84S\^2/]QRN?7X^>D`1QH'9(JA5X@LA/M(J2FF;]TX8@ M.'`+]OI'J_#2?D=EZ#NC%% M1C@]0.QH(#>;*>^4)>P4L"^IY76/O6C"_H"8ZU@\J*-`M8IF/(@Y"L+#73Y+ MTU.>"?G^\*6'LDM?392)%MX?&KWSBQ##$3V`BH*&$V<`7+!C:YGI*_57'HLF M$/J&STO/^_/66][N+HE^@>@T6.*:_3*\+D6^RDF7/^+$`]EBR-X`.A"@)SJM M`3;A^`"9E#J8TH/O_0D2#%MGZ.)M"\(>'\6!>?Q'DEP)8Y3Q*RW8BDR;!/TX MR8^^V0&)^0\OEZR)MT+RF='N@#M>#I[$$82_.PJ/@-F^0PHZ$H>=AN940ZF" MX2T[H3S=2.+-[SU$3"2'`#13=@7Y:]A5\3+8C8(?_2."?93N4K0S*#YDMQ?H MT.T[6(-&4-2G..U[DY_-U^5YE8,+VW$`HA'&^KG\\Z2XK0*T$[E*;GNOZQ7J MJRBBV*M*W!WLO.W(GW(\"M1=:R0!E\-1^ZC@,W4O\R..`>Q%*G>$'?00[Q9$ MTG!$'00H/+B^2?--L'\F#&`_$&4KK*/]@5`.]13)*$0WP&L0;%QB`Y]A+M@MVT\F]+-H4JSH_4*]/DEM!DF1`$Z6!@K^NRT ML'27E3JTO\]H)SLDE78H+E0.$W^+\-B+<\_8O:2D2[_ZA,P';#B_ZQPL!*%V M6F)BRQ!O77'*[PC.O='!PA7<>A6XLI?'>LY+*W#N]&Y+B/=0@*/"3J/(5!)LQ'JS@5(7PBATEC^9=?);X8TEKL$=96@&-<)2@4MJ0"F M)E>Y/GJ&Q_=X\S@TC<0MH97V+CHJM#_9PE+>*]XX=ELAL77PEB=$G75R%9W> M=:BVMUV7_39P!YMD&,"%>1470\$[?#<=]ZFPO`62WGW^>1\*JMI)(Z3"->[YKFZ.X'`@W7K$3Y^?9HQX9MN\VB9B\_6F!%!?]&++TB9PGQ(TM MP8(X#K7-)2US6225DD%P:2(F]AZH]@#Q&L963[8?HYR;6H,9&)25/+$]TCMS MFU+?=$X*2W&2CL*>"-6%8SWX[$7`TG^0"SHCZ9^AN:)Q,+QH':>%ZI6NN$H9 MA\0$0+MDM7/9!2?E+@>6UQ;JMV'](.4SKD4]`&S'8U-+*4S1S3Y=#4BJ_8!7 MQ(B=G$62AC+[T\R4TT'O_0$N%OF0,EY'!#^QCB;.V-/$C./1XJ!SDG)H\AX0 MZ!1)!<;'^3M+0>V@N8&H\IN-F]X`KG5;Q;KY'%M%H"8]*DDJZ'8[`V`_33MQ MNW\Q%G!A,TO;3-]:E;*:IO00V0XI^Z6I/>S!AWYDT2Y-TCN<&,$I^W_9Z/G0 MH3`7_S&M^&58?U?(7*2.VK#>G5C'WU:@MUH&I=8]>;`(=5-'9+>&8' M23LH&I1'-8.2G)#4MVZ+7JY)%%EB[ZO^<=' M8\2VQVI)E)%J:XK&NSV;5AXBT+JE[KV[^7I3>T>`2/G5]'Z_T.?Y!+ MQ\V9CNP4=DEP_F.]^U4#`=!$GC4C&+MC'#"7MW3/3]EL2H&-$P5)G4220`_Q M$5-\D6=WMKNC7'(>-DK59>\+ED+S&Z*909(XMTP'`G33/ZFX):N/P.3A&#T#)"LG;GARF]0Y7)`$ZA1B*=HD!WR8 M:?%IF(-V%_;C762;\-Q%S[A2/>4,)'L.X[B8I0,G*JPN`/M/+`$D**.*52'Q M?-89K/"NV*PF'NFH0L+]Q,--7:=^!/V!R!/%Y]XTP0V**FCKBV>7P*SQ*3^ZQ+20G\8O(HJXZV:ZOZ&>G56@N]/W.K_=M$&H< M"M.C5!QD(UP9FRJ7&R56CGJ1M![7Q68'7VU$N_J\`[.&[=4(%]3]A]2&TE"# M&"][WWB%V$1ZXX=,28!%;'KU!YT>(&]!FA9OA2L$V"-&:)IW^ MBNP-?J,L?8X7\?:G+R>.8CJF+N\1QA9D>L5AYMT-ZI^(QLFE7L:,*K^,>-ED5;32(3[V!M-_"-;0X M^PT!@>NYM]XSKLZEEPY)#I_,NH^'VAVT$T=DPAWV-/8%`;CSF80OE-"M%@0A M\B`V/&ALDUELY]$J^&=<5DQN32$2UF$/#5D103W=G>L`D86'Z!6:_55)R8:? MQIBM\1$$\8>PS8_O;],2S#.0D&N:IDM>0N[PG/_U_N668P:!O;0I3UP4IJ@. MF\$.6O@W6BYI;<9!US7:\)_/'A`O'*S27>ED[;+ZAC6AI#28)O%J87 MHGE;XOZ0"T>A[Z7+0O#-JH6WH5?A4P3=+WON=B0IPDDR?N0=L=R%![@N;-)_ MD1:/F[O._TLH@UE7U*&'&\"F>8J M+A;"J`"W0("NV3[TNHDETJ?B2-#WF@\7HO1PJ MJ&OS3RQN(*].8C?Q"X,@,4&@X$2E;9(M7GMD)L"?.%<,%L,E(DN-HIL/)2G_ M)C#2VF`S[KZ'85\@[`K1XN?#-?>MR`!J0(4TG,#$`Z`Q-OL;=!1W0C59NMLA M&]\:W/50Q&5WIF-%3G(00%J;/9E.1'OI%,&$#%HH"(L4N0XI#2.W3@E(";;) MEI)'72(KQR2DA@P_=$L?NL4/W=*'P"2LR,5\?+8!N%"*@W4A)I*N8J\\6L!, M%B8KCI7O#V7GQ`;'=I>VL:#F^`C?(*$,W4!2O7%.S?2^*/;83FO2#[1YQKZS M#L[A_?BSM/*>$2G,@;_A!J&)3;6#?3N`$4ZP/MFDRC(A8$Q[?)T&TVB+PC2@ M89*@/V$?UBSJ8.`?9??`_`,E'3YW]R\SK'V6NN/I(<3FNW7:^D/?J\`87_RO MJO-M3Z>K5K"_Q4.'"M7,9XE79H0M0S3+#+5-?SPW7;G0?.2CFRUZ02_W-SJ-[^JX_%D:BB* MD@+K9(D*(.QG-N=",%''TTEY"-X297]%#D\^$O>2#*8.R)+N*;&4+&%D3ZR28$W5:36H/J%D<-M'WWOTS?4=#;__BQ9W M-'W-BGCCFU^QF"FG<.;"<`CW%WP2'_E;\NR=1?W!.]KN!U^0`P4CVB79BU]N MWL+F?JLH&AX07!F1<1H1#5M%6=/W2!0%Z`(:[TG[K@]+:A;^CIQ%*;M]3.CQ M_(C..8M="UDQZPB`3<;,`*,_2C-9-6XJ4^WM^S=`MNE\.E,F9Z"C"Y:#:)H% M42%J$8`F^EB#_>0Z@!*)9+3)44J-#6UF7(0K6?8"?/\BT5J:7I-R'#S=-,!A MF9X7,+)@*8#FI1AX"L]\/I]="4]"2&Q*WD%,[5W#R8QMUE!S`#P%X!#D/T@J M>6?R$BU^93L1_)5*PX1293AZ8Z5V1.A3-#S`HQ`MELHQGAA:$0Q.@&`)>C5U&$]F MA:2H5M`K*H!V%"&T2/5RH*OS^;20R%\#>DI#F`N\JDT*&=%L2)@C4>].T!`2 ME90`MF55Y0B))M3A"B0.7"Z&"F'HTUEQ!`Z@8`M])4TP)MJ<"^@KJV;>'(8'JF(`;F]I5\YMOOGBV2LV._P0?I&_A1N-^B7F^1Z]TW\5]_# M&>]5&&Y>_/33\_.S_.W!=V3/?_P)G`/])_SU3_B'-^3ER>L=SSIX*[DDZ/G) M2U<^1OR[)$K2DK\[Y@-R]M&3]M5Y<&ZDGPY>G4!^YQ\N8?I6\AKX9P[8\2]^ M6II6>)N\,7DROOE)J'KK6+<2+B)AX_/48Z@+$<`_0P!=!X(H#=` M@/$9`HQY(,#X/`'&YPG`$923'93:=6R:G6'3C`ZCS8 M4_V"/9TS,B?:&3G5>)!3[8($S!@10%?.2(#"`0$2(&J5@,D9"9AP0(`$B%HE MX(Q+H?/@4N@77`IF$C`_(P%S#@B0`%&K!*AG)$#E@``)$+5*P/2,!$PY($`" M1)T2H)PQ@@H/1E"Y8`155@0PSA#`X($`1OT$T,[L`AH/NX!V81>8LB+`&2.H M\6`$M0M&D!D!SL0"&@^Q@'8A%F!&@#,V0./!!F@7;``K`BAG)$#A00*4"Q)P MP0AR!*7&*&A7SE@JA0=+I5RP5,PVZS/NFL*#NZ9<<-=8$4`](P$J#Q*@7I`` MG94$G,D"*SQD@94+^55F*G#&75-X<->4"^X:,W_UC`1H/$B`=D$"F&W69S*7 M"@^92^5"YI*9#3B3ME%X2-LH%](VK`B@GDG=JCRD;M4+J5M6!-#.$$#C@0#: M!0),6$G`F8A%Y2%B42]$+!=.V=@%U`N[0(&#Y@,0?11XD6_M%BI2;7,,7$RB@ZJ,;VL'_NX^_G*# MW-M_?K[YE8Q]>GST\;!9W(TC]&T7U[O1&^]VL+\-3^Z(H[\CW";Q_\7-2^!K MQR.#;TE[$VGCDXY1I,_8KLG&=]_NE)_C40=T]LSI?#AI'3FA3?MKQ!,.75+* M1.??!`"610>>X&5PB13NE+DOT*ZPY-%PE[_]=,"-EE@TSF#1?;2.Z(S49.I< M@/NL'T^1.$O:N#T?)E!`KQ+YNYMQF;-K\`5S2NC]#_&5>7R'CER$)PV"R$`[ MVL-B.MI/=R0M>%1C%+?A(4/6'(=V=-CXZ,FFC6R.WXZ'J.W?#$`!T6:<,&62 MP92XWBZ6>#(%"'=SI[U:XS&&07K`'R>XS#-PP86&:$$UVSJ`/^[88_J^35J. M/[M4/X^?X`2Y609R?X#T;3R;-EN^C-7NIYR@HV:@$U\&-)],VR&=&'';C4?< MB%-"WPA^>*`SJ?J,M0S4?BS/=\WL8A.`574BCT_^'%YC1$>TGX;E1.MT4H M.!S%?C(2\'0*&R>X:QFX?]B-X:!"H(Y2?8KV^W(B,[MKU;314!!$I'D)G6J& M'P%P)E+J*#08U\_*IP-WX3Q&?7 MPO3".T&5%7EV)-JC0V272Q!-VF4L?$;(K>*:Y;H.26LR%#>1B-^" MATN[M_#%+<@XVN[TPHRYXP6T"W8VT8_^]CM\@+__[2=,3OC'_Q]02P,$%``` M``@`A#!F05"7UW[2#0``6+L``!4`'`!E:'1H+3(P,3(P.3,P7V-A;"YX;6Q5 M5`D``ZCNF%"H[IA0=7@+``$$)0X```0Y`0``[5UM;^,V$OY^P/T'7OKA6N`< MOVUV-\'N%<[++@QDUT&27ONM4"3:YJU,^D@IB>_7WY"6;,D2)4JV(\D^%&T= MB4/.S#,<#LDA]>G7UYF+GC$7A-'/)]W3S@G"U&8.H9//)[YH6<(FY.37?_[U M+Y_^UFK]<7E_BQQF^S-,/61S;'G802_$FZ(KSH08$X[1TP+=DV?LH0!+4C\Y.^Z?=L]YI!TT];W[1;K^\O)QR658$14]M-FNU@M8N+0&U`YUJMG?: M7;VY"EIF]`)UN^VS=J_3[:'W%]V/%_T>NONV*O@-)!F3W)(NH3^>H#4$VJ#B M\TF$O=(\7`A;>8X\\G@LSFKF1M"7UV#GO=R3]3P\> MP"%MXHI1!U.`#7X(YA)'PG1IN5+ZARD&H$^0;.:W^V%,&CS%ENM-05$^EV6E M';1EP7:AJMO[%63U5HS&5VPVY\`V%6"_0^@R,WP+/6"WXADU^)9"6V+ZQ64O M^Q1SW<36@ET38;L,F,&R5OGOS7]\\FRYLJD!=0:VS7SX>8]M#(^?7"P[K..[ M>,D'%-D@NL:>1=S"XN^1D4J5E'Q7@8(RF-BA!L4SRYBW6'*AW M:K22G13,6[GKFU?Y8&(V!+V(# M>-?$]:&7KTA#LJTULQ=F=JBLKYA-N#6?$GM(QXS/%"O`PP.94`A+;`O\H2\\ MX(*+-=NWC$YNP<<[`R%@5+M,QXTBD$U%8&-+/*DP#*+IB67-503:QJXGPB?*?%J=;A"-_10\_G.IYK!F MUWK"KHK)8R_;E3%VY7,.&LSD+RCSY_O^NX\?/O3?][O=_MGYNW[O0X3SB)4, M>%P(B]MA_?`S83CQ$#NK-G!/&P55_/NE5@U%ZV##PKBS.%S"[^Y?E^EB#G1%M M73'-0BZ)=GE1&V$%R=@(!KZ!>UE!`_S?U1Q_-L?< M6]Q!>.J!;'+8FLM0%HQ;"[R>I*Z(I^-:4([&.N[OC-J%??>:J$F@EI"D$7XZ MXG-RT4PMVR00S05HA(_]RICS0EQ7`U?XNDD(9?(<@')6:U"&U+/HA$"XOO(3 M-Z^VZ\N]RAS`3$B;!&9I>0*@W]<:Z%MB/1&7>`3+I?_D\K<&Y'RRBH7)CLZ3 M!6,(?CCK]KKG%5ND*3)16S64JU'+*7?60BX;F"VDQ`O7&M0L'O7K*`8"-@+= MF]G<90N,[[$K=P",>VXNW0%A7D[6/<_#DGMP\HFT3^YCYYO%?V`/1L9@/6!S M1R6S[`%`5UR^1LROPGGC/7[&U,_QQ>F%#P#<$@(V8@:F)I3&'EA3^H#P+2)A M(V9S$5ERET=2R]8:W#+1<8YHC5C+-)ZL)0L>!IZ&$!X&@J7ZVI;=8#T7B;;4>S<6)Q" M1"\@Q/=GOIJ6031(;*(;3O,)#PCRDL(VPD%'9%'QH>:(P'?LC<:/UJM^G:I( M+0=D&[N0O!&SJ8'CD"5?=Q9QAO3*FA//TNV6:$H?$O`%)"PYF_K4WDA^?I., M:*,#0U%LM'G2/=,\Z763:#1&L4;1LE7TLVSWERI2J%-TD.,-,RFJZ+NQ0PX: MIF-EZM=/#5"(]LY\:1H1I#"#*:8ZXT)B[QF/%`(:`++&Y> M/6Z!<(1:?#$$?:I%`:`$50-_DR'U,,="%]CML<7Z&56^E:3MF[^M@HK9:;^B MI=:E\%*4'#>34K)^=O'6&*>LU1JJJ1%>+-A0T)E$^+I^=F"*0MJ4,4.F1G3I M81@WR@4L(N3E"W()\PO6XIA!43]H,P%*\_K%9-MSO]3L5JL9:"!9V@YU]'UC M(3&3I-A61[>JU7&ACJ9KL@ITQ>H'77E':21;,Q93I2BC<7KW2RU3/QR-T$@' M,5NJ1@QYJ\P6>5N$\XRY1\0ZST6#:#;1P4!<0LQB+K@PYIHQ,+QTX,KB\MC6 M#94!N%Q;2H?1B*;Q*):7<[6]SJ!J/]S9R%MMGJ&B4'[4V3R& MHMM/RB0Z&-!+B%GL.$Y5ZX-RNO:=41:?)V3W]&RB^F%>@U7#XAIK1$K@2F.! M))?@&\?:W!1-Z?H93/GM!S/AFC%MSDJ;^`+=A4SH,E/97CQRBPK+5B!11_T5 M0.;\&X+;X!A_UM;L?AJKGVD5W"Y]0[64=#@UR(58WRIJE/WPKF3V`S2#ENW4 MYLJO.PR`.&`2,O<17^/E_W5+7`6JD!;2[_5[9_UN!_XY_]@YJ^C&%9P%%:SI3KVO.A8AWRL6B"_)4RI MN.?(6\P=O*OV2&FQ*4L.U1'`7T8#Q?IZ908!0;5-E$*UZ*^+'`74.>(VX^#$ MGI@2V45H-@8%\;)J!J'7^M;ZR0E4SXJ,T M$F-%!&9RWC0SV;B5K[`3">B.TCA,=!"N9'5JO4J9E$U_BK.$IK*:B. MT'#>^%Q)JI4;WXMH3GW`)K`+383HUWMS(RGDQL6"QKYB@^Z`K6,['81V4>\% M4TT<%=Q"6&8LT=`?I9T4T45H+_5>4DW*&/\FC[&9Q,F.TCH,5!`:A7[%=^LA4JD M?60#&]3&L?9S;QJ;,:^@?C:S)<7<)F)]9B3YK=5LNOI9R)9PICB44CIHQ(F!<,W_`?-G8N/TY)7PM-'R M$(7\2VKTD3U@SW/QX,7BCC:#:%?U'X&9[5=7C3A<:YY093[8;57G,9C=SO73 MJ.G9%\;O\=SG]A3$5;=,AY_(R(FS]81'8#0EE9`;*M4BO@:)`O%&XUM&)X^8 MSX(KU6]E6#EZ8N"QD8*U'`$QK*M-G+SKS56LZ]SVM=$V"Z#QUCJ:6,F M(B_)223N/=A3[/@N7I[<3DY?KN57/5RST]SO.KU.#[70F@MYG!OJ^\?RO':D M6@0MH9`;M&8'_1PRA%APRMN"DIODOZ"?`\:JN>P^554#,$[.%V"'F1]Q,J.M MY&I&X"F#Z_KY@T(XQ*YBU(G3B*E1:;O3$QT8M@4%K=EM&]MX\>2[HAZ\OTL/ MGE*@8M^=5)",*HR^+YY.4N7GT0&#X([GD#-A+$TF;?W\@0EN:=],+RYF-;>2 M1ZY,-S!-$Y+F8EA:NMHZ\N0'M-8N6[U++&D$62G%O'>_\V'3>T=;_CM:MAWQ MT:/QLD1+,8"B'*"`A:H=MJLJQT[ZTD]VGILI<363>>%Q8JL+M`"!;$'2"]>P MBQ="*SX7-Y:P$?>D1_9C9"9`-KSIA0\)W@(2EKR=:/]>/';[SAWF2@F1%130 MA.^%Z6:6(#8$']?$]4%?*]*0K)AC/^MT-QT[U!C_[!^"JI&J.^[?(VS)/Q5C M*GH/6(O6M*JB8J?_NT(:.X-GS*T)_N[/GC`?C0..%8=BY'O"LZ@#4SM-KRI< M2Q5^0L-D@CN%6S%!T^NHGU(C&D;XP=F(PNNY&^FD_\&+&],>GZC9)$%N]VE1VI.1BKHEA& MRAO.=;YB-N'6?$KL(1TSOE0KS!H>R(22,;$MZH6?2A+K*9#<1+\ESZ!=E)S>4US6B"&=J0A/A#:V8BT^&)(-(<8B6+*++!8HRB127 M%4]_Y/M4*73#,(8TO#!?+@CSC!RY MG51>/R^D0SB6_[8_V1L1O9:3?TDEEO(OP+&S&;&)]GZ>W39R3(962`<[W)GY MU)8"/%D"PQ__`U!+`P04````"`"$,&9!9NECM]0,``#LI0``%0`<`&5H=&@M M,C`Q,C`Y,S!?9&5F+GAM;%54"0`#J.Z84*CNF%!U>`L``00E#@``!#D!``#M M74MSVS@2OF_5_@>LYK#)099EQ4[BBG=*?HZG[,@E.YNYI2`2DC`A"0T`VM;\ M^@4H4B(M/D"*(&'7WFP1C7Y\#:#1:!)??GUV'?"(*,/$.^GT]_8[`'D6L;$W M.^GXK`N9A7'GU__\\Q]?_M7M_G$ZO@$VL7P7>1Q8%$&.;/"$^1R<4<+8%%,$ M)DLPQH^(@WLRY4]0_!+V#P[W!GO]PX.]?3#G?''U1V9:%3?[#77S\Y"SD3[QCT^[W#WL%^_P`<'?<_'0\.P-WMNN&MT&2* M"ULZV/LY$=R`L(;'3CHQ\9XGU-DC="8(]P>]J&%GU?+XF>%$ZZ=!U+;?^^/V MYMZ:(Q=VL<PFC:[_^?/G7O!TW52PM_FZ;5R:P][JH6C*\#$+6-T0 M"_(`RD(50&8+^5\W:M:5/W7[!]U!?^^9V1UA+@"^4.*@,9J"0-9COER@DP[# M[L*1.@:_S2F:GG30G,^[TN3[GP?[DOZ7<\PLAS"?HGO?=2%=CJ:G/L,>8FSH MV?=XY@G`+.CQH641W^/"$>^(@RV,V#GB$#NL`R3W;^/KA))HCJ##Y\+4/I6V MEI[4DPU[=7#LU:@V)];/.7%L,2@N_O(Q7THOL7T'C:;!L]%"(LC&Q'$N"16C MPMY=\1UX-JEZ,.+/B+M`'@O\^.)9_HE.EZ,%HE!"<^E[EGRBWR95A*G16%\1 MOQ8SL8MNQ,1ZA^C]7,R/&Q&'PE'/L>-S,7T&C]C%L^7X-K(O*7&EV#X/I!Y- MUSU%O>QLNR9DJ]&45XC,*%S,L77M30EU`][)L7_F,RZDH+M/,I68M:3L!K(Q M>D2>+WS[%OY):#O64)DEJK%,A:[:`V5J]QA8,BYZ():_@1U;2RB'!FW M=$#(*&Z`=2_8XSW1M!>VZ:5VH%'@-9>N35R(2TJ[3=V,J&@*?8=7EC4BUREL M8(^NB]P)HB4%39)J%!(Z3CG1`H)0(&%%[&$Y(&\$ZU``V:K!P"IN"?3,D2<6 MB?6OF$M9/NSW]_N@"S;LQ#\A1S":@H@G$$Q!C"O8L`417_`NY/Q^%<@**SC$ M2DCAR!":T*()5_[RH[3>#W"RP=J!$^2L^J[<4Z^4&G'OF$(V"5Q$[/)F$"Z" MG5$/.9Q%OP0*=_?[8>C_2_CS#['[LC&_A!9V1-0T?,;LA49Y#=<";[QO2).B M"U^-.@S=MN*L2Z@([L2N-NIM*J*/'>T=RDGRE?29$)D$,35T3`#I/)S<%6`Z M3ZP#M0.UO>"DHU3L;-D@1"J\?AA^'`T^?/KX<7`TZ/<_[!\=BKUX$\A$RZLN M:%+5,@"M>PX]>[*\09R+<',T7$NIA>(,@ M0\,914@>K*2N-^5(VUQW2OKG&B]EY;0C=$]\/O]=:`>];QS.5=%1(FL4F;1U MJ0(R2HII1^56KI="O/]B]%1^Z)2A;A2C03T8E=%/_P`J&_OV#+`9O!5C"-?X+K*'!Y;PK/0,[]P`H6E!`#=B#7?OA:3ES?#PG.'C"$^=*41,G!6)V]](J\7;'7%34,\ M6V(6*94!MA)EHSA_T(ZSDL[:%W'A2Y3CO\.#>A&2,&P'=0_$>Z#08U-$A2!W M2,CQ$KP*](U">*AWR2ZGN6EC=<3GB)ZCE9!GA/&X.F$-3,9@52-M%.HC[:-5 M36GMPW5=E!3$_`^(NFF#,JU5HWA\U#OTTO1KV/1">D]LW,8BK$X?+8HTC<+R MJ4E8TK1M&"19W"?YKR2Y]F0M,Y-%:);X$\ M]+E/T:U`Q?7=.[B4>V!V[F>N:ZK4S>9=]_6O;:J*FX;WBU/,D<]E";Y\K2%W M:UE,UBS"^G)+ZAIKGYG'R/:M5:R<.(..9%H)DC\WE^^C62#U98(JJF_:@+WR MH=@:\>4-AA-9J(`STWRI+9M%4W^J)U5)_7E[1!^QM3DPR-I%I+=K%@-]:9@< M%8L1^-)+EM767FJ[PZL\<20RBVT'^P=;Q;8QGO\&*Z[@7<07D.FJ!0A9`\D; MA,S?5RVYK:FB:V,<^7;)UCL]0RHL/0L09J?+39LPN!E*%=**=C7TW\:L>^=` M+Z/:*KU)^^6[VI"-3[])I0U8'B.!+2S7GHQ1\2.2,F77S-3'Z1ID/;QBL%0IU]/A<:_IU9"Z&58YNU M,H:[9)[9WHQ7AIOW8+"Q:V]5G7`EO^I3MS?F<6JSDL=0+\PSUYOQOBCH92*X M""*8H*KB80Z]5/7K=LG2[-LL5S+43TO;\,TX;ZB?"%6F",L34IEWOGA>X%7- MES:O5>?;9LF5H>ZJ;KPWXZ>%(S0TABP[;6F>39&@S?(T0WVWBAE-\^('63/D MTV5P=)3<_/V&G"S/*Z1JLVI.K[<4JOX*#B>K?%-/\=3R4\E3RU%X:AE^9C0N M%`BE`J=+L)8+1((9MJTE!%BNG M?I)(,Z]6%LV:53E=CM&"4"Z';,[IJ7ZV)I[(:O#,]$RX+J,:L#[6H]I&L=RC M3%W,##F!;FKPQYU4ETG_[YIU,#/ZM/[MN*NI'_JZA?0GDE&=V/,/[4=$.6;B MOS#NR_W@EQJI"54'>H=IW'G4;*+E.TCAMX'/A&XR?^,),SGNYL6B[`(254H3 MCFKU(UG*)-KKD!^0-?>(0V9+(8;\&(H*H`I$)IQQ-H2E@C5,RPA=(4_LM9U@ M#G$%/(S+G?A?LA.5S__PPBJQ&\GV,AU+55SM)_1;N*F$Z4$]^'V:SFB1[#J$KR3XKT' MHFL0])W,U&E(`\*\=/$* M7[0I)C,DS]S`T"MV%\->I=*$N=$)7,/\P-0L;/Q]Y8)+%K8;FI!A5?7MY#4+ MV[H8@,48,4ZQ)6-R*6`N'!EM3=B\5$$D0QT#0-EQ'BG*A]37?7N)D+I-E)X! MJ2?@>[6IC]VTS_^8;SU]FSOWU..*-9FI_81*I>M1E3(D1]NW!&Z8@1BWK8L" MUPQKOAY00.)B)@/'\$)3B1'Q9,%NYD6`Q32M7&-&@M?15Z7Q8\Q^GBX?!,^\ MN__R*-K?TY?")W&=69Y>!H0,6_))Z?+OG!_N2#%57IK("5V=P<' M_4^?#\W9"=<'7*J:FJ[62LH0+0\C+Z^<1('*A"VK@NO%;]`JU*F)F\[2A7AX M(A7@B%&9$#/6`D=,IP;@R%PSLZ]L+"`QY,;&,N&`FF)MHI%W"V`AD1D7,RIY MF@H:#5[+J`,/(U=X/1BEJJK_:CGX)Z&WR!;;0>?:L_$CMOV@;NH2NMB1+UJN M-K3R6USIF>KJW1AP5:.BSV[NFJNB9YMC+RL16H*NI8ODRBBE,LI:RT1F@+;Y M)+6\*.>%V&EH%1"T?KU;)<`*E-(^=-9O$Z_81ADFC%XPQ=[L?A4SJGY6HGK/[;PV&IM>2T-^0T+-L-$U=#9^OQEE`Q M,CE6$U*-G7G]YKO0@]F9K>1S$\ZQ"OUG'/'Y'CK,@0K=L:VXU,>$D M2MV@6^)KM^DW>1^VO0H,+4ASCF&S6IKPYK>ZA;.T,&W'NA4^))3+RKJ6IF[Q M-=MR"F:\/EL]R'JM%:/Y=LN\RK$\N0DSYPY.HJYHI4WWEY[D.($,B7_^!U!+ M`P04````"`"$,&9!_(XG_R-```#FX@,`%0`<`&5H=&@M,C`Q,C`Y,S!?;&%B M+GAM;%54"0`#J.Z84*CNF%!U>`L``00E#@``!#D!``#M?6USY#:2YO>+N/^` M\WY83X34[;9C-\Z.F=THJ26/[M0MA5J>V0O'Q@;%0JDX9I$U)$NMFE]_>.-; M$0`!OB!!>;_8+0D)Y)/,3"2`1.*/__ZZB]$+SO(H3?[TS8=WWWV#+A%ZS0\['!2H###08'7Z&M4;-%E MEN;Y)LHP>CJBA^@%%^A+NBF^!N0WHG_T+^]^>/?A7[Y_]QW:%L7^I_?OOW[] M^BZC;7/1]%V8[L[/Q6@704YZ)W1LV._??:C^ M_>M/'_[W3S]\C^X_50T_$22;J+=E'"6_/9'1$)%&DO_IFP9[KT]9_"[-G@GA M=S^\+QM^PUO^])I'K=9??RC;?GC_'Y]NOX1;O`O.HR0O@B2LJ6@W,KH//_[X MXWOV5](TCW[*&?UM&@8%^SZ]?"%E"_K3>=GLG/[J_,/WYS]\>/>:K[\A,D#H MCUD:XP>\08R!GXKC'O_IFSS:[6/*./O=-L,;.1=QEKVG].\3_$P_#1WA1SK" MAW^E(_R3^/5M\(3C;Q!M^\B(+PJ+LB+'/>S*D>U^Q2$E769O/(`O+KLD_>V"+%N_# ME&CCOCB/N60Y^29+=U:,"392"Z+_BI_B4T0M.!G.TT,68IOO6#HD-M)0.7/. MB'T22NK[<'+^RY=O_JTD14&R1IP8-:C1KR7]?_[Q/1MR6FBM#S0UI)4M)!,3 M$7@8EDV0/S%`9")Y#H(]<[[O<5SDY6^8,9U_]T$XHG\2O_ZO+^1C8LKD8_!4 MNQ\A`%4CMX:B9Y5:A;S%+"8@TQ/=\!VEJ!JA7UDS'[X]I&I!?5=[MD71[ M@J3[9[>?7,4>_="G?W/V>>4#JST_;>/J6Z[(B&LZZG4DI$['[1J@V@CU]9YC[,H)>''^B/Q%1J-/&D'9Z]2AD\-M]4(Q((E M'*A-F3:N=>`ZRL,@_G\XR*[);TYG:FU+.#U0,'VJ"2?-0'1!RH-: M&WAS1-LC1@"C#UPIS32BU19:)R2,R[6BT1!0+SI<]&J&,Q"^A^XI?C M[BF583KYNWL=D#)8?O?6'YU^:\G(G>\KVB#>R-47Y;L&#_@YHCL%2?$YV,D" M`'DS]]]7QV[YF65MG'YM-0.=CRXV;>JVB#9V^_$OB5/)@O@F6>/7_XN/2D"= M=E"?7\%P^_N?-`)0`"D'*@T0C1%KC4AS5SIP>ME13BF,$C'2,\2)48/:@W.!N\UUE`1)&)$%4)I'FE-6.U+@LP,#6-+3 M!`T=W/E"+U/=^2LE04Q",S[(O_(TCM8LQ>,BB&GJ!-%$C(O-`126RD7RL!<:/',&2.&>CR$]9_@]/HRR+>K9$W_=_7W0_02Q(2M M?%5\^GNEEIAOJ"A*4530P1C&`=VX+03\"=U;P$6\P87G]&+SR:*O7"+04,#9@ M`*)I`IKFSBV@EY?NT;J@0(2D#.X)$1)4<$'+)%#.*):S$LP9/4J@<[G8CH&, M6&:!=U%%*W,B[(U51F"+DC#=850$KQ@H.IGEPS!7#>>6[S.\#Z+UU>N>[DV2 MV.NNV.*LM8962,.($L9-6X!JNFL#,N=NVYBGCNX)2B1(SV;UV[V&/QX'YJ0Y MB^Y32HU"L7T32'C<`C1<=!2'M:WV"ZO6,,M.>\8AUY)#Q>R53=XD!>$S>HIQY6RN M7L/X0*.AG]-T_36*5?C-2&$LU@96TX!-Z)S;LSE3';V[CI*HP.>WT0N9&^I^ MFE,$7"@_+RZ?8OJYD7IR7C`"9@-9()#-MQS?RU@E]_CUJ%=M\X]@[G@ MGL]>_AG.EQHRZ)-3-&;9DZT+8WZ].!#0;A[#'@&H]_Z!-OVMTN==;O+K$X:` M=_5OH^`IBJ,BPODJ6;,K6MLT7I,@@>[.%<>>A']S&3>JU8UFT]B=5Y&JW MC],CQ@\X9I6L.S:K@&]`!Z/[QH":9M!+Y-PB##F2:5IVP&L4ICN:E,0+)M-Y M^0DG>!-!Q:Y#X91TYQDG;,X-4QB1HEZZD.*G(/L-%V25*3*\3E=0/6T!ZJ+W M,5[50E5.(WRE"+_12$8D^64$P?H% M9T64TY]SG+U$(2YO;9#F]`.A%YRLTRQ_AW[)>0]$`6,<%HSC,BUKGV;,8@60 M)LO?K@^8O601D3\G&!UI_1S"G_@5;9[0$NDQHKD1`6,M/(8$142PI\DSSOXP MST5%F1\;\EE+WU6U+S,K9[I@J=R\'L-\K1=EOBM\#LH#)LIWZ`EA58UA7[`:Y_2DZ9`XTE>IB]:U%]1:@*90V=?K=>L MOFP0WP?1^B:Y#/8184AUL*AJ#726K&>^=9@L;^K^-%G'1W?CMFJ-Z&W^\RA! M(2>`9+\.1T@8/_TF.$@/V3'WCA-UA#&*ZE9;CJD M;BOGODC%@N2=)-Z0S[5GM$!EF.83+[BESY8O@&\;WVG,^6I'L#WA-6 MM@&OX;([Q$$1O=3'R`32%Z*/>/>$,_3#=V>(VA&D*YT%XD<<"H0?&,(/<`[I M`1=!E.#U59!1-Y^OPI"SC-\^PUN@U=5U&K;"U@*\Q"P)[G--EU`)#W;\R?+.ZI45135:_8C MJI<`+F4G1\D/Y5O](-X1^I9V]0=VIY8&/:0_GUPQN"@\\=3@? M$S2SDS,/3LRT>1`FM]7<^4ICYCUP9E[PVNMJ9E`'?V[3]B<=*,C`LV6T<&QN MS7IW6];PEFS[G)Z3OILIR]TB2<4&$K>8^`287Q;$8X#JS<>>Q!5E:ZB"55KF MVS6JI$T!RE)I^#!]4+,BS]'=IAG4A2=!G1=O;8IT^+[7-KO-H/8AY>RV=QW; M;0#V&&4,2#9NI)59>>1MS79>M_X0Y. M.);\'>!>KHS!ZBYN\X\P]V^['*B<+;W4FCXGT3_(1+T^9'0OB=X\Y8M&?M$U MQL$:/>.$74)-DS-4X'";I''Z?"3A8DAGSK]9_DVVG>A@R%=$`06_.CM$.A"0P]S?$TX MPK]/=".TO`!_F>8%G9?*N]L]0;H!'=`M45-`K?NB?43N;XZ:<=3U8G5!`TK( M'Q\1I*"W&_+B;B,/.Q1MH.XU2!AM7VIH-`"XT=`971(^YNS\1OB6\WP;T.`# M*GG>FF&HY'ES1JM[_<"G8U7!#>(?5G4D*%R%`F@?$8S=F4%I&J*>PKEEFK#3 M4:A/JLHX,#8P`88&6?W8W]0UIRX/>9'N<'899/05PJN$P(OIJDVN^88T`&M= M4R#5^K>/`&9-;,95-P0FJV&FDV6$TEPQBSI-8K7L[(U!C$K!I6'N4%V^HB_0?[/5EZ!W1/ M_>LV)7W',2(B.QF-K,T+^H**?-"3?AJK_T.RQMG7+&(&0Z"0QJZ7ZP._5DF& M*!W;!ZPI2U,'6-F/12/1G0D]U6.UGT-XNTR)SFB=E+8Y@'\R8+]R39JV,%ZI MEZ$Q#HF6NVMLUE$%"OD0Q.%(?U\_ZDM^01T.,?]H1T+S^$AC2F452K&0HP.2 ML?,T23"K7IZ&$7.)M*@=6I.(-$[WY2R,DRUQ9_0GZKF^XJ<\*G"+7^+<<$S[ M0;L@2FA6[TEKQTYIP,>JT5!G)&@`/=$H"`U%`7S;A.U$QRSZVQ&-H#L-].Z+ M?D'12P7T$HH9F-8#*7H2]^^FF/#3?4J#4XDE19,.Z.6/T2C:=!.L*R:Z9;"C M)4C_P5SVW>;TW2.%-/J(@.X0&$%I71G04KB_(6#`CNS.7T5$Y^`@_/LAXN^8 MGKRG!;-Y-@DH1UAZ,]FGP")Y$PS8!YQNSVMV%]O-X+:W9>R>[G`WVX!LD[EVJV!#[IZS(M/=NKF\&=YIWR M(,FZ8EF;+#M$Z`I9+0(5@)V8:\=UCC^G2=I&H%_']!$!5CWNA=(I?JRD@*F! MW,..(E](/"?_K7"0?P!\U700BF;[*A_[J@(#_GAU:=771./HAD64'`BG=Y4! M7^!-FHEKAH_!*\ZO7LD:+,W641)DQYL"[UBM3D))MTZ94$A,BW/]K8&91H2\ M>3"K$+NW%V89#N@&Q(Q85-/4$^NV]"X%[1@JG1E6`NPHC>49T]WE^>71_W3T M4N3AVDL3K&+>N.#'`EH)2EI#>DPQ)J:@4[?-!2%'&ZQ]F7+4V?T*=\JYL#/5_9PW[KU4I% M6_>/56H9D>I1^R(O(42,4G.EUTWT.@!*VR1(5(=HQ]-G:4@,^XA!5!GZN9 MU0:#QIVZM^\&QCT-A=OT6[9].'=HPQCL*&[9S7G`^T$)ZXAFTC#MS=$A MYYG-E4*C@-5!A[PK:@I>%ZI;]N&W*BM#>ZL.O%5B3P/J*=BG,\=7T0_J&F%S M&ZBTR+3NV3L3%--D1P1V$E3WXI49]H$U,$15%[Z8HIX_OT+/:2"()WTE=M>= M"<,@#MGC']W:44Z?A3PM^%P6>^X)Z(PHP1Z/-`5U\IYD'QG$$Y-F/,FJ?)F5 MX%X5118]'8J`ICT7*;H/V(N]T-N_4R%OK:P`PTY=??7K-"/N)^'/A8?'QRQ( M!EN6099/P=4\0178N\VC8&JS8ER^U2**D=]M+H-\>QVG7_NJ".I) MH-YOZ8?1?LE%W1[@39<^9@:6EB>=(=:;%Y7DB7E0CECVY1JO+XZ_$/YODNK" MTJHJA=NC@$,Z`LLR'`CY)!71LA>(?,5!+&I*8=:5D2%?MB]#G/PQ?<#TBTS$$TU3]'A+G6FS$3_=P M0E"507_S4H.@A-FB&`D'_D[)]-_#GTLF'S%91]%":MT:SU='"),M1-H*S0BDE>/*M1?0;*]*RXGK[2;KMJST6:_D;^>\BC!.-VN28LA"JL.@M!XH-@YD-Y7EN<'XO">RRLM7TXB>Q'/ MTZH-J+J83+`1\S_?Y.42_D'??%Z0T*`4-\*4A7F M&U'!A/@6K$F+W+-MV2WY+6Z^39'A/0T>Z<,4O,B]*'G/KX20EIC\&!0HRD7S M_!"S$W7Z$^&8).$;O0>V'-WHA^ZO,X:1?&;A?;I MZAO1S6>:\'L>TV+11'A:?NI0(J5&\&IE6H7D_BOE"]"3_=$N^$ MJBQK08R^04J=2DD,-:\/PT0I*)@UHZ$%?S=H$[W2ZS^`A<2GP[(7)+QP\=\/ MT1XNY7%.K0,_F>AZZ?I)T&`?$=YZL@!L.@"K#F<)\:1@G"$U1`TY*]:Z.5DL M-J-OE34/RYD#88871\%3%$,?G'=AKL*0W1Y^P"&.7FANI;&$9*2^J*4:EEXA MNW0>J****;,@MJ1&-3G4!#T"6H4BFPF%1078&3%`NH)[LIH,HK5\O\"C-_\VC0>F+V-(;?;?EH1_H/.0H)UGW3K&Z(U`E=Q7;_#1631EMUCX;9X" M-#YWC0HTC*7\U5NANK>R3(E]<1(Z:#VAJX32`X>A9DMQ)6P.(QKC'+P`8%&\ M>3C["K?-4=6I\)X\FZ6.>^Z#XZ!U0T7GBS-0`#);,0@B#UR`E"/+M8*@]<L3X@3]9?UMOU1B+2->% M+^ZM'Z;>TZGI/7!Z?&K6F]B(/HP^<)AE#1>I+1H:>/VE:1E1I MX+K2P)[\C$"8XZX0UCHHA MH;Z2WA?CZ0%HL*W9)?;`F+2<@=NA]A]-OR,Z M33CONJZ-0F8V'?A>QT;F8LRI/:Y;HRD6;E0K`^R-/B!\X/9WD[S@?(JZ4MJ. MO+)'`\@&=JGIQ1?[[&51,J\("B]4]CXXBH(_J_#OARC#90;K/6&Z6"7KJS)) M5R$7FPY@5-0>8E,US:F=JZ0M:]T$$,+--J"9'XY2L\T/W9:'S70B'(],=$`+ M9(DN&GGGK)GV@/A!KTWA,B3WQ+EIH6L\BI83W*AJV ME%9'C2[U(*5G%)A6P0S$4N7(`I#H1()Y'>JO4;'MELA@9;TW9+6]A$!T=+3C M?^`Y+N#T.-"T62A]*QZHH7L8_?$GZ))P`-+R]1T3;.!6>!TE01).L!S4=N25 M51I`-K!.32^^6&DOB]U7(4H*+U26X`DQ7N>L"@4M%G&WIS-=?O6*LS#*E8\0 M&]`!A6>F@%J161^1^Z#,C"-)BC^GX^4_L&C=>3PPY;W!G#L,Q4:]_WX4/H>E MCD06T!>7>)4T5/O-KV.7^[,&>4;*>$;IJP'H!>-_=7`#X62I/$ M'RK!CNO3]T)I&D$,*Y0FZ=#C0FE*;E6UPFA];=$KHMTBUB]B':-FSZ@.6%Z>XNB9>2A5!`XP_&`"RZ1@LR)U["&O>9%I9G@02K:1]G!,3V"'1"V+= MH$8_4`YD/-3[+"+3]YZ`JB!+3F)"`3RFG0+%)"!8E[#%/7H?U?\M[7%;V1YO M89L>OVP,]K)!CY9FQN9P1X#M=-QMR'*%U7I[(#[XCNV#K)(U_1_-_7@)8NH^ M5*LGJRZ`UOL#8+:6]Q;T[E?SULQU5ZNL"SK]8]$)RD@OHC@SJ[[)E)AF`[%_ MX+I+&,.<%'39":*]4+"7)5CVCT97X!E0CLN@!Z+7P`S-;S MX1;T[M\3MV9..JU4UW0C[ZQS:H2-B\@V8!T^J\L+@I!I_3Z-H]#@<5P-`=`3 MM[T06@_5*EN[?VZVAY7NVT*'W2[(CJT'MXBVHB_1O7AR MO,%C%_L`Z"GL$:! M&V:!$Q8XH5/3R?1$&.A6O56X\8%]`!0[&0JT*GEBVP%,X9-A7$J/\<\Z43_3 M34G):_#;&OFG"5C_K.=%3>UP:8'TA M(AC4@*^T1WD8I_DAXX>]5>J&J,AVF>9%SO)&6'9'>4K`BT0@,8ZN-G M&@`]E$6>>^((=7.@T+V'_5:(KFCK/A37,M)].A:GSUFPWT8A49]-FNWXA9K3 M`Y3+0UX0W;DV/8(_]OGW69$L,8F!VTIHV943HW,QNV.BK)B&G"8DU^Q@_'C^A7 M\7_P#98)$-[1!]!Q7AXQ37C:^`4'>9H$<50<38S$D`;@+-$42'5TV$<`5#TIWOC\4QHMQ=I^MO=ILP5>BPKXQG;L!T]@#T/`5C9 MM@TQC)W;<]B=&D@7K82QJA=O7,";0JGW#A-!/;_;G'>A`JY2PRU>'V)ZJ"M- M87_4I2(-[01H[3H(:FL9:]6#^Q7M`/:ZTYGHA$;=REM!Z%?6%WSL/2WD.P%Y M)8$\94Q>,2U)'>I-_;.AAHC3K<'5$;LQ*5#L;LF?UK;DZ6U.K$H=T;\1@#UQ M_F0H[Z0H9_$4[)`D7[T$44S'N$ZSGTGP4#RD<4S^3O4R5B3R%-8U@8OS5S.9N=GB'6/1/]G92G'([BC M<"<>XC,X?0W^EV1-$SF8:.@[.EYL:,CQ/^"\R**PP&O&[B])5.2LT.VD?L1Z M%#^=RD!AV7@8RR&\#^!_H>^JQA*VQT1`;;GF>:&+)$;O"0ZL=A90N M+!C`1@E8J2$V_GZ?T02DG1=FV;D@PSQ3,WCZ2Q`?F!];Y?EAQW\W.'88,PBT MD4\IJK[(8?@(7@0.8]DWCAO$0#PTZ"Q:JN%08SP//9`+P1%'=1U$&9-)PVWI M9>6#AS)ZX&,5,U[(O^XV#SA,GY/H'T2:K"X9N[)K[JPF'P_:;\TD0+D+FW@P M0&\V"Q*M8RM'1&)(S0JI'I<2UB,C/C1B8WOHZ1P+M71SYY)G2JY>Z;\G/<7B MQ:_N-JRJ<$Z?%4FSZL8&G2Z(7^@M8D-3C,&M\IQ)G65**HC[;&]@AT MPC4-V[I":U7/[$2C=?^8)GA4W;.[I*P0+OB)U^]8*#TG8!Y*QH<@\#*(PT,L MYH3/Q.0R.B;A]R-.TEV4T)]NDLX]3=NDOBD&@0[WIA25*BEP_`B@28-3L=^3 M5%@-0W^L!F*)AHVA:.%CR:UG:'<$(S>:F4B"M`.?4%F^=)!'(?-,'Z/X0+>\ M&[>K?;A676=9)46TICP2Y_D%AX>,/0%Q]1K&AS5>T[?G&M!(*&Q9D6".@:!] MU=0BD_NKJ48!]%G30M#G,S:&0O58J!R,OW;8M%*Z=%V"`W,EQ#LNQ/-:BCSU MJ)+@]:D$"<547JTWPY(^.G5+N%JO\AP7^<6QO@\=$!>``_WN_NC>0#,LAX*7 M9%C:=@6=83F,7ZV6TRX1ZQ/Q3M'%$36[1:Q?^/7F[T@(IAF6<)+P(59[P"\X M.>"+XZ?@;VE6E7JX.%;U)$1]"=NCSN$=0\=B8T4BC[V&]@H8:XUC61M;B:YI M-@3KO%'*A_RJKK-2#@#N-#R1SAR;].7M5%HE5/OD!86AW:NS[`ER.WX0Z.X> MO%4WP!OO`WB=[F$AUBG4[KJ'R!V^IY?A=51RAD!OXRE9 M;KV`UVGE_IT[!0O=!P!80U2V1+_2MMXHQ<=T%T2GSD/?U`?%:+.M5@W>#E@Y MFDSTJP=O#13CS,"XPZ5-$23KI^,M+BC.NPWG\!/>/>%,@5=/`K0<,8#16FAH MVKM?0O0R(ZDVSTB0H&'G'URW?N5T4/'^>"AI+Y0QCTNE":M[>@CBNZF9A M(%F$?`YV6#+7&])`/!UE"*1^*:J'`.AA*".NNGZT)D,-.KIO1"D5\<*\X;-3 M*#.9@#2R,:;RS`RZ\8XAB7^FH`\J^C1HSNAHD#GX"Z?G?3/7F$:8^<]IO'Z( M7G!V&<31)LV2*+BE#V:OGC.,J2)*8SP[4@"#MX156;TA'8SI6S'7K4M-J!$C MIV_FE1T@U@.JNI@W,%2Z@:F@@2'3>P30+S=F-SL]%-O_DV;K(/FE"+:FGL&( M#&*?VAQ.O2G=3P.T`VW*6'7.4*S$EA/((M?QUU*SM`M` M?]^25C<%WDGWU,;TMH1S\`[XX6?A55<+.0\_X7>ZDV':,6(]^WXP#B$"=T=& MGP_4M]QMOA"EP?E-\M=M%&ZO"*O%\6Y/+W=@U9&Y$27,`9(%J.8YD@&9\^,D M8YZZ[P\R2E8K@]'2*T9?*37BY*BDASE`J_/LARO#Z.DJB`K/,V1OB MPI/GZ"G&+(5VM:/.0R%'(,KZ1._,L7(. MEVF21VNJ^O0V2/E^!UH>,QM9[5AUFPG4R,?^LB/XA[@*V++MAV+PHC6RQ84`K!:_=H0PZQW[3GLZ&"S"WXS7>G>[Z7J-^]R]LT@U&^W30V3+![:'J1H MPASN1Z:9J._(0B;[B#D[M-A5DW=1LDKA;,U(8:9J&UC-N=J$SOED;LT8FB0_@.Q,5=C-+34 M*,HHZV3V2]N6/)L1TT$I:YS)FR2DA18P"8I#JGC/!B;=WP.X@9N"5)A['[D/ MQF_&8^\$QW20F8\PI;(GMHX3?4'ZAL7CM'$=H\'&'-*^HJ"N)>"(GRIW$XF. M`1>O;8]Y?2@.&?X4)='NL!.5[?./!^7ZU90::`EK!ZZUBC4C=;^0M>&K=]H^ M0[P#)'HH'V?($>D#:#T["J"`LQ-P]B6<#,=!P<^6>^9W-V=9#C\C^$'6R8W4 MNT.1TWNGA'WM47D_&8Q3,873]"9]-,[=B!E#'<7K7A1N4+)=L4/W;58W?F,@ MHO(*=,S(V>X7HY\P['_`ZT/(M\);=[1+5CE_^L#?O@^`T'\HT"KXM^T`)OP? MQF5'\ZIN^),7S9OXC9H"O#.X-^)1(G@S91$B1A1-8$SX>` MOFN-,0J$$/9*(;B;NG_F7!UOH^")EDV)E/FETI8P$[2&Z>:<+&GF?!I6\M"] MKRA:HD93F(G6G.?R3:2TOG8]Y:T(WGMU\T)UGB1O!W&30<-P?4=!T@CH]H&2 M$^6'KF_!N#]9\I/=GDN,]CP'%<]#3Y@F*LL6Y%N%@^!_`BJ[UF"K56:-_-Y] M6;5JT&Y5"O*G612.)\-<)6N="^]A[`Q=L843N@AB6;;]A(R2""LK1K%Z@9^C M)-%PZ]8FKOY^B%Z"F&Z^K(K+(,N.A#7V@*<&H(X(SH[ZH9Q:F)H"Q/;ZV)%J M%&I0G:&@0"4A?X85J,[A$#2?T@0?RZLTFT.RGBE@[-OKG.M3@&]LBGN"]$XB MR\)ZP"$F_#[%./^,B\M#1L]X%$(QI(6Z!60!K'T%R(`0X/Z/,5?='#E!R^ZB M\53`!OD9?0/F#(DNH&[^3(`NJXC0.7\M*&58,U[??\,F)*45*NH&L;`GD.:TQ*42[]%H>@K9B\,3(M+-EL)T9';'@DQD>< M`723E*^_,QX090)1+F9<;*AWT/Y;J'/M\\%(EBV/T#,3PIH*84.%\$(I^*%4 M&OZ&4B&\%S:&%W,&C3P?MT$",GE8#[ZH662@:">83BQ'7MJ\,@C>'+Z0+=LH M)SZXQ1GFFO\6M,OY9QII]TQ$!'"112&5'9^3#DE4C)F1IGJ?A?#R@/?D6VQI M\G=&7\7;.$U+(*6G9`C(YWP6[:JQ]6=V-Y(S&64/89 MS=W8$RPY"RBJU5=MEFLRZZUI`X6YSH*?L/>4.I'`/9/`?1"MF1@8R5G#Y^:\ M\,!N1V(P)@)/?!%C5)7T*&WI@8=I,ZUT)KP9K-]H\M#C(LZXULQSBFV4-V/! M.8MX&T4]66-T7QH[/3/<'6(2A[]@],035^@)]Q?RF5G]:/3#=V>(*BAD\LW\ M>#_B4,#]P.!^\,#-FZDD]],YQUDY\:GWS_(O[."'3`QX?9UFC\'K7Z-BNTUC MFI]%?B%?V2G7@$.[@]KC&@>_O6LUK"_`?:@Q#,LW/'+4Z!*1+A#I%#5Z9;]3 M[8T`[!#]+D1@L'C@CO]G%ZQ)@6?$64/M\<44%D\[4>:5`:R`Q! M656-FB'Y,XY5E5![J3P(UM1@E(%;EP0VB%/QTQO0=0(&2NM!"&`/*.>`DKK: M.0>TE0!RN(49;O'Z$&.!1+<%G*OV@!]I+HEJ8VJZ_H$V0J<64&NO=*K.W6^G M3LMY=PH2_5>6?_ZD/8K)Z0S5;-@^B_F5C07X+L<]0:=XQUK>!$;;96PV%;;Y M=^0NP#Z]]QK?QZ4$>(9Z8V1'[ M`H]?T\=M>L@#^A+2*[TB41QO$GI5/'K!=&3U,X+&I`#K?4M8U=K>D`YF'6_% M7#>X_)JBDAP1>L0[0%4/B"D:S+N!RX>F7W>/PT=&^5=+3`Y7!4/306X5[PI. MV3'0.F`RD;06`*-[=1_Y3\2R?->I)\SOB?)O?7B";["`VGL*JY<@BNFJY3K- M6![5U-^C=[B%&9JA^"8QOYZQEF.41D"F-U7)QEXU-MJD&4^,A#O'A9!GCH*6 M"'@VI%_GO?[(I?=<>$$.?[5>1Y0DB(5XJK2[N3Z#;L2%NOU^(4[J^=7#+<_Y M]V&9U__7HU=3034^4#:M`FR_,T]3%ML8O2>8QR[&7,[D-`C;'C%>=3E2-.:W<^7-Q$.(W`'^1W M5)K M_<[PRXE5AF(#7/-7'"TX@IE,[+(5W5+#F,F$HEC[SQO?@*[^9U&7!4R_`GX# M#T<@"+L[K1*<,=$W'7ES\:P=L5G\NRI>+377&#*T%17_M+F:>_0AG MI,"5_K,A/=R0'BUB;A9.+\?/BJF"/4TUIT.5C+-,SZD4V)0NLC/(XGRA`@&< MTVLPM&RG9RK9ONB0W=)[8]ZLX?G_BJ/G;5&5MRY#8E:[>OZ-"?WHR_1\EL*= M:6]4-_3BO*05+G?[J"4O5?G^DAM>^OU-;+`.D'>/6'Y_VZ\.9>C3YFR?`)5E M%*7)QW-,5%-RX.ED-;V0K2:LZ8;W;]*:&MN@B4M?)E1[R1-B^AH?]L\N]5[7 MZ__=ACX95<<8D,[5DHF%^M=!HI[4Q5IQL#PO.P#>O(Y6NF,7'\+I!;5E.>OYT?IPT6:9SAS@V_3Z]IF3RL$OA[T) M?5;<+%O.]-M__@TP_XYE:ID3\#2?PFV:S9N:@J>`ZTE*SIN9 MR0/@]8U'7Z9[MQ3N3+E`;\IA6^'R)&_H37KF<1_"=)O+VW2CIW[)/5D?A3]@ M^E04^?UEFA19$!:'('[$V>Y[W3=TS0F@*X81>L].>'(88OS_A+B<2L5Y= MJ^3^828-F)+!9<8MTW^B*<.9Z;A;7)0S-71?=Q$=1T:S3RJS?[=!<\W2=AQ' M?`#UQH'KV640)\N<1D8(?]YW-:2[Y MW!#X49)'X5^"^.#@ZN3I>,L\,.H5X$S7(]N#+>Y0J`>)NWW%:G3$AG\35QZ- M)+IZ?LY8D:93$2QI']!K>?FV[31K4D M[+/XZ$==2EWC*-_B%DGO\P*?T^2%*<\\%?7LQU]8;#M4P&Z>KSD9?#FQZS!D M@$_75/PLN++_1$*7O43RMK=CW`ON+>S+]$J-1S5@KZN=#O_69B:Y>-U,3.VQ MW]"\)`,&."V)A0'\0PFP`I=Y5DZXL.TCU^)X"].(?9)5[ORS#>+QK4U((SZ4 MFUEK`(-O:&H;C!YP_AN:99J_Q>7;=!_PC5_-^1U)?Y*%)-X66S:O?_?C#]^Q M69W^9L0AV8GHS`[F'8WI=M9U*D@ZBSH9<)99<9V&S/(8KQ"ZH9OMT(5^MKL0 MLYUHUYKMQ,SVV)C9')_CR`*._Q;I?+$`I&R7FE2W+)EYM('[F.$@/V1']O0. MDTZ^"DDTDRE?:M52P*Q*#4`TUXB:YLY7;+V\=-2MI."O)9UQ-T=6.R49U"Z? M/9('O"=\;(DUTL>?PG2W(TX\YZARU@',!MUBD)`5P%,Z-196:A(U'N5B1.A> M`"3+[QIM?@IWP@5$BW.QV+E,\^(>9XPEA9NRI`4(Z&V!58&Y*2%,@&W'78]; MJW9I:`_T^$)$<_,XN;Y`=_G0^@/.D1A+4*R6%@FWHS7:E]#.T.5A=XB)YKQ@ M]"1"(K]"1P#TO@:!+'0M\5(9?,+%5GD";T;J05C8`TL9'RKH8`-%+5.]$:-8 MG)3T9]P3\2Z\B![MX*F#+P_"1Z^AV,:/=F!6N_20%!1(#6ORX!'X[L%U$&5< M*GE^V)5IR>)6QQQU)`P&7-C=`V,13G+WH'>TY=P],(0RQP$L'9I/(Z@Q^%E] M_V"!I1J&BK.^83"T3Q$.4_W:=87H2CLEG M*USY/_FX;\#_Z00ZF_^3#;IL_Z=&Y-+_42X090.5?+P5!V@A7]KT?$.%$)5" MR"1"6(`#-'G`GOWQ(\%726WJSS&4BX4YQW'"GK(&6QL))KO2(BL9` MCDO+>LN_2%NZ=P,:-KK6RE)-T@S]DD2%,#Q$R9"@`S(E&PR7C;-!E');@E/U M!Q+89!%=Z3$0>E57-891=3WK3567MW2NZCHV)(?F96/4UGI031\*@6O[@?`/ MJ.NKF'5.>)=.?7K=-R6&L04[:$W;,*-T;BLV;'5S-$IBI`SO0*UH%#B>R,O.'N)0JR(I+DLR+_N-@\X M3)^3Z!\DD&;1,LTRRA]I63Y51#'/6$`QZ9R":X6T#T4WH!9CT:2U MYX31O=47FJYTJH!M>'>J6?HEM'RD3MFZV9)Y($8 MQSA`$T&Z\W^?@NPW7-`7%Y+U:OV"LR+*R4]B^?4):\IBFY'"^"8;6$U/8T+G MW&^8,]51WXH4$5K4("YW-="OG![(EB>!%EA"&W$G^_*0%^D.9Y?T2F2RODH( MS)@>=^D,QHH2X#ZV':CJ-K89&NLA,G($!$41=!E,H=4&&/@J@2@QF;'6WE2LZ MID""$MCDEPA&;^>.$;D+IG_&"4%MPU5%"02OBZ2:U)R'U%.`">W!+V[*CZ^^;`BNKG4\^RI(WZ3K"FGYW MKAIBH=MR)_S/OI&$?F4[2&Q(2&/<;'!('<1-$I+P^S%XI8GR=&J.D@-9C-_M M<<:@*.W,H@,@$[*&V+(.8VKWBF_)6E>GRPX0[P&1+MC]CS-4]X+J;H#VBZ># M&7&8!8$IN^'A)G/&^6<[0RS?!C`;;_TWLKJG2[['=+5>1Y2K(*95QFZ2RV`? M$>8J67!PU\2"Y8[\,RY4&4E3CP*4WS>/L%J)@-,.X3YC<`[^NZF%U2CT-=IZ M'%X>+TJ0&.JL:89\.$0_J29"((,"I2,ZD1SI@E;=HOZV*;<]&>:<_"KD`Z$, MQX%XZQ>_ACC/T0:OJ_5+7M"K,]15/Y%5S4:23NPHT?$-*!OX#'!R9X@7Y[W; M\-*\-WE^P&LBK"A4?`-S]J@MQG8K,O`]:9)[T M`N,/I\)87FE+*HS-NH"*$MJ>F%^K0N(0.9UTX*$)2B$:&V&+VB\SE+!F;XAD M=F@56(4JH3H=4B-S1%LTYE(?^O`LDKK^*V;[9"PE'R[OT M;@]CWPQ"_0GM!#`U7F7$3>8QCN/D0BJ](3O75T%&7TK-RV<]S"Z63C,(]$VT*44EOW5`?#^R,12[B"8&:[P7!'YG=*2\+H[R#C3716<=$>BX M:GXAMHZNYAO._3'6W%BZIPP*TX6^Q2D'\CG8Z>]C]I/Y9!-=./V*7=-XHIVG M#!FK&"4$OG@X+:(S/220$G:Y-D59UA"\=%VN3C[NMH(L69=K,V_Y4JI\C!LV M@]B8Z7*A:,0[6*$ZK4XKVGI1IDZMV=*&T$7JM*K2V36`5?%1K+--!`_T?&3\ M=]N3`3]=]SY%4TCA<7??YSG0Y1]+]*T MVH*9T*YXQTLSJB;7*C^+1RFD9`@S,3524>2%`;Y3EAY`&_X.2`*6MI M@A-Y&49#&HBR#H9`ZH(./01`I1R,N)*N33@9$G2H)E3M'<][9N<2B;M)\I*J M85+PNR+T*92+XR,94[.+K:6`F=`,0#2G*4USYY-/+R\2A6I0\"=\*`7X+FX' M">5*NX&KI?!$D[H@M)I4-X?7I%->S#4)=)]V?ARCPHL3YLK"-7>)KGJ4`15( MB&$*IA%D])%`A1EF?)GH3E6+Z"X!*Q2U2#@]]:$&8S(!,(=-/WY-!]AT@\HG MF^Z`Z;?IBL0SFS[AR\H("*UO-NTUG($VW8O)!,`\VP"2I8T9B5^;`*>+&Y/V MWFT!:) M"32\&P#K'P&W\@<#^H#Q$(,9E=35)CTAT16J^V(5#WEOJ.J.O:@Y<[Z2TI.\ M802?!Q.VO"R)CXX[8G(Z1GEKM5YWF`A2'S M01IA(OK(^H0E7I3FBYR3:D!DW M*=`^GX\.QPR8=;JB*4] M@99=H@?E'`-TC/1&@`\\B20,F^9$'0:0N] M'%`PI`NENW8#M1+PEWG318`I@C;;&6EXUC!6P$<4DB(JCG^-UOACE(=QFA\R M?)?\C-/G+-AOHW!%2^W=ILGS;?2"UZL\QT5^DW"J_))ZE^QXM_F8[J(P4I9S MF7H0H,<89A%5Z\&&24=P_ZC##.QW#*GN&A%#JCM'K/H8C>=86,2P/?I^.B.=0 M5)V>T=]5_:*R8_B+FFWLFON9LH8P:JUFN:FEW5;.E4[%@B+AIFH)?N>2UB"[ MV[38U]ZXU+0'B@/Z`+0"`E5C]Y&!GI/N&1BM%7>W.7$VP!-XZXEEO M5_,(&^*00JRO6['E;4_!2F-JZ&,&(W#R!!@0%?DL*JC.:LLQZX]:'X MHQY;G7PP2#1-=9(:H,^@QJ$D<.I M"56^ M)P``BMH"`!4`'`!E:'1H+3(P,3(P.3,P7W!R92YX;6Q55`D``ZCNF%"H[IA0 M=7@+``$$)0X```0Y`0``[5WK<^,VDO]^5?<_\&8_7%*UGK'\'*>2VY)?L][S MV"[;D^Q]VJ))2$)"D5J0U%CYZP\`2;U(D``)$""E2F5L2WAU]P^-1J/1^/EO M[U//F@,4PL#_YMM83W#.8BLEV`4?;?Q)VG[UNG' MXX^#TZ./A]8DBF8_??KT_?OWCXB4#=.B'YU@>G"0]G9IA[AU7(]V>_1QL/SF M*NTY\'^R!H-/IY^.#@='UME/@\\_'1]93U^7!;]B2D:PLJ0'_3_><&\6YH8? M_O)A;7CO;\C[&*`QKGAX_"DK^"$I^=-["#=*?S_.R@X^_?/K_8LS`5/[`/IA M9/O.JA9IIJC>X.+BXA/]%A<-X4\AK7\?.'9$Y5,Y+HM9@OQUD!4[(!\=#(X. MC@'AQ?$CJ_^4ZA43V<^B[-WX$H\6=/PK0E([^@T7:__9\MT$&F`#;BR:80S$B M+"(`^$0*?N)K\U/3H;]$&$FD_:O`=X&/$8=_"0,/N@1AE[9'1O4R`1BCHA0( M-:V8D.6WX>/H*IC.$!ZV'^*I=X=G^Q3X2GN/^TT?`8.P!^_D1;KTL??@TSY18'SQR3P M7+P(DHZC10,!%;0E<:C)U'RUWYN`:*,1B8-[`-%*=3P!]#+!]D+]83*:DSC@ M+R`8(WLV@<[:BK4YHZ[B,,)#0`W8+=:+3KU$?S8!?]T.->BH5_)/`ZF*]J-4 M7S4EAMVB&MW5=+P%3:G68TV'7-JH)IW6E*8Z?>G4;]<@LJ'7IOFU[%&#AB-; M6S?V0&+VXB);E1IS0_I`M#(I_YT&!I4,0ND"TGQFL)M4.O`5Z^AWCS.B@L+G MP/-N`_3=1JX"ROC[;(GT9`1#)X)S_/DWO`E&M/B39_L2E%[CGEMBPS,((P0= MNN?'I;[Y,-+!DQK#:'.*/(-9C)R)'8+\J%;?/2&RM$_5%IBV:T-T:^V M%V]-=O)18NV$83Q-/E/*JCKC:!-5]"2`>!&!'](!W;R37YNOH4A=CTMT/H8#/N&GHQ MUO'+JEFUQK0J&4Q[S!KB#1`=#IP#^E5X\^YXL0O<6Q1,-T;?.N^DC$W39KTQ M;VIUIHG8EX#T0(I_-"F[9GAZXBTS;?,>'% MH75@90VM_XH;M9)6K?5F*0V8"B]P-GKP2*A`@*HD3C[Y5]FXAV]XEV$[4=:0 M9[\!+VF)L]XGH2&F#*>/2Z0Q,;WW1=%-3FI+(XTR"(C"-L5,,`TN==V5#8[-LIU7S;\9*4R M.M8HHUN\TMG>_P$;W>)/PA(I;97LCYQX"$LE=:)=4@FH^&2U5K9OTJHB+977 MJ09YO2*;1*Z^+*9O@5<@HXWONR^7:G)269QID$5"Q3,80S)X/WJPIT4+45&Q M[DN&FZI40.?:!'2%*4.V=X?W)>__"Q9,"6V5ZXN(>,A*9?19@XRN8H0VEDFV M1<Z+B)>H;)=ZJ$_?!=-IX-,3 MC,1'^QA'Y'8&64C9RJ^D4E^$)TQC)DN6R^'G3]L^-EF>-Z&+%5P.N,$A<<`M MV\6_+YNVUMNVTL:MM/7:H!W9X1L5;AP>C&U[EB`7>%&8?;(-X?3C?RT'^3BZ MA3X>#,0F>1#"$K>=6-7Z,[$^48F7NV+XFX6,F7=U!$.FG@!93.<>)G,$\.KH MWB>L8I)!:8@`"@$MJ5/*Z7+.)>RMLL;)G$-V+('SD*9`[C.\>4=8W5.'B@X0 M%$=I#J,K&Z$%7FMH'`H#%%QU#04)C[SS6*E/L5+LG&E2(+D`U@<0I8QEZ9&2 M*KU"BC"AS%,*[2KB.@7HJ_V><*12RB4U>B5D43J9IQP=5@)/",QLZ*;A9E@Y M/D83@#:XRD`)1\U>H:4NOZ5$0P M`RA:D#AXZ@K!IM.,;,VPNF3J!G:5#;X=GW_&_W40"L(4EBP>F7R/S3$0'@+? M$;815I7Z(>,:-)8H>\U27ENM*H5;6+8?,N4GC7GR+F/=UJ3*[["$_#'$VYDE MH).H:KSY_1($[G?H;9_TBU3M!T1J4\J,#^BP@ZD"%?V2/(]T\\$%VE5[0FNI M&=X/^930P@PKZ+#A?0_M-^C!"`*:O"!WAZS"Z<];W3ALU#W[:42P@C!C*9+G M.^!A5S!.NHVD5"IT'LI+'/G9;#_2ZXY_LA?$W\SGB-\L;+*L>83#]L-ST,DA M64UZ_&8Z\X(%`,_`(V$/>:8PA%Q9KW_RKD%`8EBX'ZUT1^` MW,I.W<';UE=IV?Z(39Q,I6$TT[3[I=XB M;GW-*-T_V8H06N)&TRQ<;KEV2Z1JC&K1=;?YIEL_*BK]Y(5E=P@;?!YT-6N] M)G@(>V$ZY'>1#)1Z#I@R*T#3SGPMF+\TGG*KF''R;2Q1+@K[&&8[=%V8D/%D M0_?.O[)G,+)9AR*,TNO<.CV_./P\T!YCWQ`/(H1R[-$U3>]7D@`H1HO*"9XO MV#^1A`UF+ M?'7%_B&E)LV2PB$]0R"S1C7=%3->YWD`T>/HU7YGN_-%6ND?F&0P@,/3H&F% M*7IIAG.S8)RHE6\21&7;V^/]FL?Z?4=,+?IEA6:5XT?7)6VNY^'6)W5[U:7U.+(V.K627JT?2+\_ZKC5G0Q@.<0*#PVSM!X3E!Z75-W>WBYFW*2O M$,&F(BB6Y`[!^:H89SHN.21%Z,HB6;YB1C' M_=0831E2=,2__GW7!F0=VA1:2KKNOF1O M*%P%(7W7*0M1J5AE*^L9APB!9;<><4:%R9*1+W.4,T]EULH8)Z]Z0B@ZF:FB MLH\9+)8A9^2I-G<.4`3#50`:`Q#EE7J+D!IDJSBR8=A9VO/]-&G[5NZK).U MTDJ]E7P-LOMX>WF;BR5[A/5BO84%%Z$E%YV[[P'(GXBP]ORKDL;!H8]K3J1#XX248 M!1L/E=Z\8Q9BRJ%OH\4=YBL-;<:*L@TO:R`L/T%4TF.7T=C# M+V9']@8PMN)'S-!#1NGNXX:/)`5O\M27W,:3M@QY;93ILI2J"5%@2&JYOI\& MN&:O"U<<&K&*=UG60C3)2L6C.;_^-LWT_6Y.F=.RQ@E<2(K5(&`3:59HAQHX MI,^XSFW&V`\*3PDVPNSN(5 MV7Z(^4'DZ+OT+R^1JOM['$9I(ONR*XMJ.C,.?G4QQ?#%M\,PI?LO3;?E2@0A MKNUZ##-1JMMYL<2(FW%V.+GU@N^\=^%.:MZ%P]U823]Z'S1=TLO_D&E!%4U^ M=#*2)Q3,(9;,Y>(;YOF=OSS+'F+5.$]N@):3)MZ0<9J!1Z!;;GD9)!MUWZ[[ MYRJ2I-+@%*9L#SS0E54ILV;"U^`9.('O0/K0XHJBUT".(E#1U>Z`K#7NF;OI MSM+9BAW.5]0R#D&M"3J/L3JL4KK/T?8:&QZ\`ZG4F:A:%=E#2(`O9MU=9F68 MWPC=O@R"/_"_<0A]$(9DVX%YAHK0(59YCQLI'#/K8M7^GH7!:&O`J3[>Y,I" M2(B_9DI6^K(5K[CP'E6U.,1QPTO3AO#FW<%:%]M^J=%'PH:+"2M@&"L2ITF; M>X2I9&33&V<5261E&628M20I+K@&R<\[?_6V2>D-9:Z*>X@UYI:L../"Y5&3 M*OQB0Y^P^M&_AN$L??SP<90].\Y0=A6U]EAKQJJFD@-*XQ0R"UNTKSA&6O.&(&`S@G#SER(RE?U3@,-10D#S(XN=#4 M'UJAG\Y-P=,3`C,;NN6W>JNJ[2*..#C0U$=:@:$+4S!$P[%66KS,M\57>1?Q MQ,V'?KX7PE;4Z7O%PLM<6F\7L<3#`J6.4$U)#/.<8#^"S(TG=A.[""U!;LC* M(Z`T,W7A!.)^FIJ_=G_Q(H,12I-F:3J9*7/$E67:K:S77R@U8X%2_Z4QIE%R M_R%Y+K;.DL:HOXN@$F&%@FP,VL'%'^C8."[<.'BIC"1NPA.E[P9H,LT9++GS MYR"4<0^AI"'C<"?I'H(HR4:]-X"WINE1P=#Y=PP1R$Z+GCS;CTA>3?SIC!1A MX("_`>/D+TF>>:`TY(EBG[>F%2['%+KD8\ZX,>%S>2P>7^4=1A@_/Q1[P\VR MGPHXW7@]VQV4->2)4OO)+)S=0M_V'0GV4TE#QN%.DOTD2C(35EI6-10X`+@T M'2Q]N/61#B>\>0?(@2$SFUIE/>.D+4EZ!6M9+5;T,B%?ZM1_`6@.'5`R*NP.UFKQH&NU0 ML?G4Y%3%'$C9\3BZ#_SQ*T#3]&#DGAQO/+YY<)P\#\"`ED`+NX.QIDQI&O1@ M9FP[/[L;[SQW!VH->2(K9L(D3T=BS#Z.L%$QL?TQ>,:3X)&:NN2M1OR#.+'G MMD?F)\ML$VC".*R)>C<:$\M<&[7D)BP<]Q/`J'2W3^\9TA=IHO/2;TQL3U[Z M*>;#$&M7A!98D?YJ>^QWS7GJ]A0I/%1*6F5F%)1XV"C:,:`,=@,I`VGQ=PE4 M;GQW`RCJ,I]>P]#Q`OPQ>(FG4QLM5HEK,"->X-B'(^B0,_0DLAXSX2GPH+-F M[)9F0!TFQS954D"2RIH M29%2)L)7++5+C^U_X:MLW`)1+;2-K"?UB51P)-+>A"=:;EO3^2[[FFW%/#_* MSW/2^E^37,9KG="IGG5CK?4CXT8#+U&,65RS#2F7,7B[94W:>HT8,WD;B6]Y M%4,._9V>U]07/`D\3$)(V+!*]%$Q@X\+5NJUMO[;2EO3D=!R.2CJ\5Z>JJ27 ML>B3Y/3;0B7F&G+$Z=EE%K5PB[8C#%:0BX@):L/JK4E?I]=885_Y*ALW]<4\WPV(5#;_&SI17X`=DH'@[3N/N+GJ=%3*]6E3$"0O M1;B;#VO0)TWQ<$)N08O4[[+0&].I(`C=O'.M5_(/G]5^?'AT>-SL=,OZ(>E/ M<"WO\#&7)-/=F0`W]D`2P9$/SG@M.Q*KUX@Q4[_QD9A$^HU=\)>D,69X^=+/ M7;L_H)!!N#(+0<\!J=!2<)Q?"HJ.26LJ_/UY*>]\IUV%P[D-/<+HVP!]P2*/ MG@//P[^3*Z`B\U^T-6/T@?P34168L=##K*9^^^1!SFTQ?J4`5[&6/6BD<4[9AUP7A5W)O)T8+ MRI++Q95GA]5!37RU=PIRXIQ0D![?%&V8LHY.KO6U@ESK2`0>AO$T^:RV,JS? MR4X!4QG#%"3>UXM?KH0X0X^.!9+GY\@39&,?_HE92V\343GQ0UER?SN%ZC9X MI^"Y`"TQID).EY.\TV4]TE2KLT5JR"D1^?G%Z='@_.+SX:)(D+C0LG>67_9$0\6UKH6:8L8K3PY):KM[#&,W M2=I_N5AQU?:&Q&,F+)6M3 M5HMZ%^LVW$FH*2:_TTN-\,V%:Q#9T.-;<$XDYNJQ?DA[WK6["U7.%U[!O18\ M_=R@)>,T@4@,NSR*2Y:<+/GGD:;L;%CQP.C6=L@[C(OA.V2E^,P7-$:VLJ65 M7Q,XB><0\\`$,5\'4QOZ7().BAHC:D&!5$FRA+J^6(F1[;MOBWL0D9$\CA+Z MOX+I&T`L^Z^DBN%`*)%G@:$G2J=V2+!N900^7<%BVUO+E'ZY>+"GH$"C<]4Q M1M#JE'M]/I38\K7U?`W9%JIQSEIFR;>6%`0DV:Z>EX^"+X'G/L,Y0%>V!T[@@4O'-R:]$[!X">)H\@\\5-O_%MD37DAP5.LC M'.J2K?3M+EE0^$H60,R(7R'X+JXD^&OW$1@-J5?Z=)8T52%J0=WC4G<1F!9: MC_5;,PL_ZNQ*R1PJP9AF!])#3";&XXCFO`_O_-\FT)G<8-*BQ>.,A!.PGR>J MKMEQM)3+-+\CKPM]&`%ZZ'>'9>V/(;E?3([_AE/";J9G MG:_ZCB&L$5O,,H3DP(S-B##C%0-A'#5W#%QU.:+4@#J69$#A>8$B^&<:9H0- MSQ"Z1"7C/[-,-RB+IB\RF43J[PANY/!%P<4Q[5KI,9H`=)T.G]S-6.?2S3NY MTL%Z,HFGZH[@JS%+%-SIDK^S2RQ#S!ZZ825/IQ:IGWRI'0&!"/4*KCBIEC?F MDQ_;WC/F;;%>X*JSNUC@Y(6D9];4FBB;E)'[?X2LA,#L:4J\D#I$EF,.G%2U ML+NHJ<69%$.?S=`ND@R5S-&3$]& M:T)@^;S(H]=A24W!$(B7(@`XHA M;F9FPG>::6-Y/LS:=Q>5VQ'!B]&?B5WQ,;I)F<"KTB.+7:(YRK__(9HJ/!N0 M%8R26EC9YZK_6/>.S<[G%"6.L2RSJ5T96-T`(K M/)()C+5U+:_43U$*TMN3_*;%NID?)95U^PF6>F3+.@H.(MLS]@60LB3XHFM^ MX^=!UM?\@@+[U;[A96`R-'H`N1I7^`"BJQB1:2?AQ&S!8X+DF@4O@^C M,T-&CQ^(*_:T-4=$.HY4^ MC5$I\G,HZ^.?J:9*?6804^UU8OM:D"S8^1[2*AG9$\N,KIO/8!8C9T+B>A!) M,C<=QM$D0"1G>FG<`5_E'N-0`B-Z\J[,QBLHV16(X1P@>PP(0[,DI0PD\5;? M`2PU8D5/GI;9X$'R.AX/<)*2NX:1$JJUO]129H"%+W1_BT<(W-L`O=KOO\%H M0O9PT!_C#XK7=Z9)5:^Y'H-%"6N4/8VB4<$L[R)37OT=>*Q[D!6U>HRE)AQ0 M<*%`IZMJ[8&MM:>TGE=OM8KZLG*Q+,6^K/73*UK"2KNV2-]6VGGM0ZS>.KWH MDS*GG\^/+TY.+HZ/,#HU15!6O5*YMG,-65O7HIRUTMOOF1XK!$#!'DXI^SCR MI0K?C9(#RR?/]AGI$XN*&`<.M7++XZ22&>:FQLV&7IH4=[.0<>*N9#];8B:G MP&5LE%Z_!Z^3(`YM$JC\GI@"=SZY?`#G@-#%3G3&6=58`?,G-6M":1_S"=5V MC-\S$J'):]@XM+6]>BAB(4>:7DU)TVH3O+F[',[QGH;P&>]SZ`F-;(A6=&<> M<-4`22)BZW!4DCJ>T9.\E\A&4?,4!(;,@Z'KPH0;*4.7ITNJI@*[Q_UL:(NI M2A/1=6TJI`XOJC["U7E]$$HW6-@][:&OFIE-3\0O$LC[8$R<0SG0GW4,]-E^ M)HQ03,W0[?"53;[*G@F"W>^GAQ8.-SWWKY@SIQV;,RGCL*DY`I#DE*&/PK_/ M8))M4=EDX>UW/TO:9:W2[(8G'9LP#YMJ>E?0C!W? M6J['9`(JVN'E^C%.ZRFXY-(*SY2=`'41SGM/M]F0%G1I-SW%F0/T%NB_+G@7 MAC%PKV-$,B4F\RRY9;`6#WWS#I`#0_;AI'!#NP!'.4Q1W#YMRL/4_*-IPE3"/M?/'M^2>*;L3FRW@+PVZW\#<#R)EIDNLAW. M$X(.\\)C.[WO0:^4DY).0#KB\&->(BGT**F8%/)&L)\8RKFIX)&S3DZ+C%-: M9X;0(/:3HPV&JGBUS<@)TM1;IL&\:C2F_?31P%\5#]=U<39U=5NR=[3*9*6L MU_EVP_^J8:(T&]1^A='!8!5O'W9Q0JVY"37,',[>]U-$*2>SN=#U;+TKCI?S M\$UXE7X&)`<0_OPJ\*D(8]LCSZH>ER*W/$`*YF\T7.@;@1KN+]K.GY MYL4$MF;SINFQN3$;F09,%39I6;P>*)I,\@:X7YET,SN;>+TXYF_`9K:1W/;L MJC&2_31JC:O9?)%Y&[*+SH$U_7.'V0;]$#IE;V\KZV]7L-\:[S*$-SW0-V@+ MTU.<]W,[TA[SLBMO34_FC=ET*/6C#\=C1.^+G/K;)/J+Q3DX(_L5DAE`AYAU/+]&`_L??JRV7F/D4- M!R?%PTFD9WE4,<8-1%RXQ7=$W4J?/5YY]/'/D#P\NPWCWFAOC0R4E#.G6!OK/E&FWSV#68R< M">9:_C1Y]=T3"L;(G@H?+9^*'RTGI\:KKHM/E=>^S\:V/V,VXXQYX^D:.CB6 M_5M0LL?+L2C5O3IA+2!ZZ.#9CYA9_4MJ["9(2JGOS=&C;.W1&RM(F.RFIV\J M=Y(;1*0;9<*+)VQY$)(8ND&H;H^U1',^-#V!,G=QR<@NX`B/(BFIWF-`26&% MI`.<)FN06>JF-VN/!$9(/5S0>[JWP8BRNS7Y@KNF0BI=A'+\W$8M0)3F;#(0 M!GX%T809V,-3=2=1P\D&2:YFPS8^C;5*;Y8>4:I[[;&]M2&BM*?.VRP4$W^4 M2#<,XVGRF:BG]DS<4TM&8]'AK/RVZ8C^:BW'9*T-:N^B-<-%6_M2WA*`:T)= M7DY5D6NELL,=6!M;9IXDO[,1UX3K'!B6<>W7``L1>E@5/F-AR@[KX>]Y5U"O M@8N2/.F]A/\UG$,76Q!M@W^]WSWT%?%0TGE!KX#_#,,_;A$@L2(`(RMJ"_A% M_>Z!KXB'DLY".@M\GN?%Z)?7F(-+3LN>!O5&L9\4K7!4TM&.>5E5Z'?SD^//9Q=' MYQ=GGX\T63M+M-U,9UZP`.`%H#ET`&,ODDQ3_!M)4^@$8Q_^B:FC^PU*\BM) MW\@REE3TU3/=6`B,`O.K-5:66&\P0%A!4,W;!^A>+I[!+$`15NE@^`Z95[D5 M=VLWEP0RR.]16[W9$/^ MU49_`&)G#GUWZ,X!BF"(_THMT:^@))D43U7C@-HB0O+PK,TQ!6!KH(89MP:N MXC`*I@!=D>!VW[WQ<9\>L"]W5.#@?;QS1)6Q9M3._)RI*JU?@JCDU*:^C0 M`\F`[H,PO,5SA=B3T(_QSC8]Q0K\\!*,@@T!WKSC\6)H0M]&"SH3'@+\K1^1 MK4SRT"$-0RQE@9(>C=,X'`!95Q5MLZ8GGK`E.[*S86RICF#E%-PLW0_L\)'% M-$NT6-*C$2")[U:H)O'+1>!G&QQ&Q&?V&@Q=%R94 M/-G0O?.O[!F,;&\U&2C'B#8MMKX>`$M-2.ZEZ]!K@QW*KB>T8>%BHE;+=Y8I M9K6_)?3'4;JOP!R!SM!WKZ$7D['ZTGDE"4 MM+T9T+0V+/(G'9B%1V:E0UMO:=F$YGBF&QN1+.-+)E>8W.SB.I37!DP8(]XH M8YSBJ&+_NM:HID22":H_J\G6=9/D_9?'49*W\"X,8^#2V<60.6_U3L.A$9$] MB9:F\L2&$Z*W7FT/6^G3P$^38T<1@F_89G_SP&N0WGPM"JH0 MJ=])8CA/XBC" MFW?'BUW@)B>7:\[.QM[-H]K>33+*`S<=9E(@M+*!6F2DVP[0_KH[LYMUYQ># MP\'YR='I^9GN>VM$/)ET7H`3(QC!$B!M4\9WUU)&)YU16H5"SNNQ%KC#<8E, M5^1;,Y(O%\4-E%R95-BC<DKWTFD6^8$>05"''@B65C]*>`&#+;U**@<*R?84!/[$]..+QUT4XJYZ;!=UV:D3V_9!#IW_BA`TP0.OOL"QSX<0`5F[-\_."J,VNM-QH8N-:? MM>Q0KX?L!8S)04]RKY7D:"CWD+&*4^?)V?'AX.)T<(J9\OGB5%9^A6`ZA6$( M21:L.?!C0.`<^"3Q59$3BZN.<3I#B*U;AW6UB#4W-==5@">Q'R6Q^"0[^^7B M%?=9XB(JJ6&,H.M+*J_Q1>DUU^.2HX304>IL*:EAC*SKRHE#TA74:M\A,W7X M%AW9XO?HE^7'J:QEOL@K!)93Y;4H[D:>)!9MK]^#&AA8UMH9#)13W(D$1R4+ M8,'ZSE/%&.G+6.!K$\SA/FA!A(4+-U^ESHB18_%N0'$G%/E7^_<`?04NWL9Z M=[Y+'@R+:6JC6WL*O<5=MA$G;SL4GW#4;:8S*.'7]K*XT`GDE'",Y(E&65NB,#'E]M#5)5CJ93R2) M?GD]J,"'6B3YLO+]%+PPQ4IM>&%WGN@^;AWG0\`LJ=G]0* MKXBJ1(O'$=ZQ0P)_FK-MR9Q1.H3CS.D@52\R-VMLDJB18+U_0/.$KDEX>)YS,,#>`C]SQ M>1QMD%$:OL.-F)B6#+!U=) M62>.VG\#GC<+H!^Q1;A5I%]2Y"&N$R%S)*T6<)-=@8-YQI9G</->&0N5'-D550)``.H[IA0J.Z84'5X"P`!!"4.```$ M.0$``.U=6U/C.!9^WZK]#]J\;$_5A!!HV(&"F0K0]+`%#172,_,VI=A*HL66 M,K(.[<7"JU@]-)_:YZGR6SI%DY>*7-]M"*R([_\_/>_7?RCW__C:GR/3&ZX-F$2&8)@24ST2N4"70ON M.#,J")JNT9BNB$3/?"9?,5SQY:.3@^.#X7U\/A*)U?-(# M@]O]OJ_M"CL@'?BTVJ.#87CGVM?,V3D:#@GS`Q1R8#H>#/Q[NGS5=SR,\?YL*B\;(U96` MX7A`F2,Q,TA`;U'VDD.N;D_!Y5!\@MZW9GAV=C;0=WM(8C$G\ANVB;/$!HF1 MDP7!EER`&:Y0=JC&U?X?GAVK.%M$A?&6"_N&S+!KR7RZV=(/U$)92T*DK M28S`91$2ST[FVNE>F5(,Y'I)!D!!!#5"!LY*\'#6W^(#.*I;FPC-L#/57,$= M[5W_<-@_'D:#9,J0)=KD)P/O9D!*%G)1H0$!.`A=8,:XQ!+@K;^K*\LE93/N M?X4+*E+G@EMD`C8B]>'[^*Y8D2(@"ML*?+G M!8%'J(>H>=FKPA":&!AIDAEE5#L#B#\\1'T4RH//H4@4E8E\HC'8%K6M MQ04)C^QG_7DIB`/"=0/>PP6?VR?)XS2P9;A6#<:-9=E\_M4@:!\1R_"N\SB[ MYC8TS`)HH'.\@_[8)O?0O9:))B#@$&E!@!=J8@3X%AB#N(PD#Y3;[#^B3;U#7D^P$8\E[C>$K6W01 MMHZ;Q%8*08>J2JAZEMQX67#+A%I.-;]<;X*L[^EJ324!,&1H%[^\J8]94'JW MO'S\'!_^:QL_48W_1)[."$I@+-,4?MD9U8Q\U1UD*D'F&Y&;I/.)B.<%5/B1 MH0=:V/7:Y'$&C4X->)1OJ`4EIQFR!FP9*-J%BGQ@G1P.MX$%DN+Y+@*12,N, MXRMBCOJJ#=+]EV]25%(HH@-=)=!])7PN\')!C3LHPH6MO8`V?J9S1F?4P)`R MNXZ$)A;.!BCWG,WOH6XQ1XX#->S5>B,&6R-!<%;&M6MU^6`\369@&TDH8I%& M6<0F%!H51Z@R#&G+D&<:NEJCJ'%(6]=AL@PF_7G2X'\(P14]:%!!=V$JD/*YM8[&&D<-U*"..$W^N_9R2LOD3U,8& M)J*:Y3"N)VG/*0IE0>772*H^.EPA/\ENQ:H[?RX_$Y&0\_Q=;<71QJ%G*E M2K&"V%0KIKI0-5O^O*>6*0CL:3*P50N3+MH[R%#U_\DQKJ:8/`Q`^I(L3FMF MJ^B3I[`K-AM,6R?J3^T9?I\[#P''34SB>WJZP-?*9=-#G$F7'\SC9##39]2[ MD-5)<--CE23(#]+G9)"BR6X7G/=FO>EARB/-#]A),F"YRPE=_':2"J>'M8:$ M_&B?)J-=?;Z^@\#N\N.LQ>JZI%!V]T&I.<`N:HWN M0'E<*ON<,;>L6RY>L3#K[CW)EE04]V3)F[_KA/N[3I"O$BF=R%?:+;,V!A"O M>4>&I"NX_IT!C29_LC#+[/7?*Z\(+"4+JN@"O:<7!8J1UNQ#2.ON,-,89L;$ MD8(:>C\U4'T'4YL#4'7A16CZ7!U-&R-\""DS.G!]V(@U)DM7&`OLD&3L-_>> MA"H1[#HH>X>6(KB=U-Q?B38JTY$6N1_8U.&N,=S=8BI^PY:[E>JH2UYYZSBN M[5VK@;<:THMP=EH=9\H*I,W8H,ZWY$<4VH(BQG0`^YC-X%?KQR416-6NMRXS MU)VF]X?GJ"B"VD_-;QE7^R=#>U!@4`>WNM/D&6A)H<@/=L&ND"X^#6[T'S%) M]0YWNB+ZEO/ES;!#=W_5[>C_J@S6<9DAO2)*^?JG)'+GD/MI=KY[5U; M"#*[[*GC0_K!Z2!_@KL';[85D"CY.6>_:)ANMY"O.!"!A9&0DC@1!H1P2#J>&UI0#HOZU@_X^NI2?WC4/QX>O#EF8&,5$S9M4,V$@._=)IQYD65D MKDX(*6>&)42,2QEQIHP8GI8S0DMRB'$PYRL`%8T=_I1A02J/^M#?,-=H@N1) M5V5:8)NK<@N4.#FKFAV]G+N4\M2NW@N>Q(H M>LCK;?5Y_]?\>*8EB)8[=1W;BW%5:33/.B^B@71/@)?>#6 MUK66#"_"8U!T7&-!-,Y@O+`4B=_F@32#PVD8T1`M,=)!\L2[Z>K9=^7V.X^:_#M5U=:^D41\B:O+&Z\5/4\RICJ MNG>,Z+D,Z!J)?I:[SP!-SK`%`YWW+I+W-^%=";KVG;GB_&6SEW4B,'/@B7-R M':O(T[Z3>6>035*168FC?0>+1KT'8D^)*#M&AM1YCIGE0[]7%D0SU)_^LO_JES3:E)/*:@3X/,XTG+#.NX:CQMAW$,G9CA MV?H,9:`Y7=\3*8D`TW6^#>Y`WY8,9`V^5D/Y3,2*&F0T%T3?B3Y?&??:#LWD ME4\6W'6P6@UZ\_:3P#,"-'1%U`[+K2ZN-'G+'9U>D$YLR!D)>#KFFO1JO2%Y MPFL]<:!VN`?[PX@CB7G'O&?H*[#)&RQ)N)LL#.ON]>QGF5'?<57H3Q:8?5A+ M5U>XGTVNQRYU"5O0!&"(MU%CY/\L@LX'N>]DK)8MSY-7T6G&G3ZTI8Q-V:9> MS=L,`>VZ7N4DQJ):H8:$]FN'7UT;,QP?;;:NM3RD**`0T]O280`@XK9FWFW9 MZM^)92TY93)N;O)RRW:JYY4ZZD=Y_$E@U,E70]-3V9;?Z.8MX6)(V'*P]`Z]<0T+[O?.FQM)'6,?Q M&?A81-1N;=94^CB:0PFG]@?<,=6=.-3839J:K:>=I=JB98PR.PW; MI,;0-?'.FRTQG.J MN/K48ZW$)6R[Z0$W7Y.3$[4G)(KUGH^;;0"+^8P)CHR>(%M9/SE4D'" MY:L*]'DU@Z;=;=ZCES:\1AE3YR58LHY6.FG'[X>C3$WV'59*A4Y_ M(^SIGP1?49420B$4>7U:[0V9S8@ZF$-=&$-)G#''TH"@]J=:,GN-1[:]@:8, M9>O3NADV3EYY26^BE"U[\Q4*=?5+\J)<`EN>_`/]NAAX+R/`Q_\!4$L!`AX# M%`````@`A#!F0?IT9C'DJ@``-`@-`!$`&````````0```*2!`````&5H=&@M M,C`Q,C`Y,S`N>&UL550%``.H[IA0=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`A#!F05"7UW[2#0``6+L``!4`&````````0```*2!+ZL``&5H=&@M,C`Q M,C`Y,S!?8V%L+GAM;%54!0`#J.Z84'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`(0P9D%FZ6.WU`P``.RE```5`!@```````$```"D@5"Y``!E:'1H+3(P M,3(P.3,P7V1E9BYX;6Q55`4``ZCNF%!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"$,&9!_(XG_R-```#FX@,`%0`8```````!````I(%SQ@``96AT:"TR M,#$R,#DS,%]L86(N>&UL550%``.H[IA0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`A#!F02$>"56^)P``BMH"`!4`&````````0```*2!Y08!`&5H=&@M M,C`Q,C`Y,S!?<')E+GAM;%54!0`#J.Z84'5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`(0P9D&\ XML 34 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Operating activities    
Net income $ 4,635 $ 4,464
Adjustments to reconcile net income to net cash provided by operating activities:    
Deferred income taxes 2,373 3,696
Depreciation and amortization 1,740 1,799
Amortization of book-of-business consideration 1,990 366
Amortization of intangible assets 1,261 1,281
Stock-based compensation expense 4,326 5,622
Excess tax benefits from stock-based compensation (2,358) (2,734)
Deferred rent 50 7
Loss on disposal of fixed assets 1 38
Changes in operating assets and liabilities:    
Accounts receivable 4,799 7,698
Prepaid expenses and other current assets 1,708 1,876
Other assets (2,364) (494)
Accounts payable 2,180 (1,654)
Accrued compensation and benefits 913 455
Accrued marketing expenses (2,332) 691
Deferred revenue 390 (1,632)
Other current liabilities 341 (1,475)
Net cash provided by operating activities 19,653 20,004
Investing activities    
Purchases of property and equipment (3,128) (1,932)
Consideration paid in connection with book-of-business transfers (6,243) (3,906)
Net cash used in investing activities (9,371) (5,838)
Financing activities    
Net proceeds from exercise of common stock options 4,014 184
Cash used to net-share settle equity awards (991) (548)
Excess tax benefits from stock-based compensation 2,358 2,734
Repurchase of common stock (8,441) (18,033)
Principal payments in connection with capital leases (31) (46)
Net cash used in financing activities (3,091) (15,709)
Effect of exchange rate changes on cash and cash equivalents 2 (30)
Net increase (decrease) in cash and cash equivalents 7,193 (1,573)
Cash and cash equivalents at beginning of period 123,607 128,074
Cash and cash equivalents at end of period $ 130,800 $ 126,501
XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Cash, Cash Equivalents And Accounts Receivable (Tables)
9 Months Ended
Sep. 30, 2012
Cash, Cash Equivalents And Accounts Receivable [Abstract]  
Schedule Of Cash And Cash Equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Cash

$

17,256 

 

$

17,441 

Money market funds

 

106,351 

 

 

113,359 

Total cash and cash equivalents

$

123,607 

 

$

130,800 

 

Schedule Of Accounts Receivable

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

Accounts receivable - from other revenues

$

7,702 

 

$

1,862 

Commissions receivable

 

353 

 

 

1,394 

Total accounts receivable

$

8,055 

 

$

3,256 

 

XML 36 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary Of Business And Significant Accounting Policies (Policy)
9 Months Ended
Sep. 30, 2012
Summary Of Business And Significant Accounting Policies [Abstract]  
Basis Of Presentation

Basis of Presentation—The accompanying condensed consolidated balance sheet as of September 30, 2012, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2011 and 2012 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2011 and 2012, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2011 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011, which was filed with the Securities and Exchange Commission on March 15, 2012. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  

 

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2011, and include all adjustments necessary for the fair presentation of eHealth’s statement of financial position as of September 30, 2012, its results of operations for the three and nine months ended September 30, 2011 and 2012 and its cash flows for the nine months ended September 30, 2011 and 2012. All adjustments are of a normal recurring nature. The results for the three months ended September 30, 2012 are not necessarily indicative of the results to be expected for any subsequent quarter or for the fiscal year ending December 31, 2012.

Seasonality

Seasonality—The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear.  

 

The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year. 

 

In the third quarters of 2011 and 2012, we significantly increased our temporary customer care center staff in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur in future years.  

 

Based on these seasonal trends, we expect our revenue to be highest in the first and fourth quarters of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year.

Book-Of-Business Transfers

Book-of-Business TransfersWe have entered into several agreements with a broker partner, whereby the partner has transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these transfers occurred in November 2010 and the most recent in June 2012. Total consideration for these transfers amounted to $13.9 million, of which $6.2  million is related to transfers during the nine months ended September 30, 2012. Consideration for these transfers is included in “Prepaid expenses and other current assets” and also in “Other assets” in the accompanying condensed consolidated balance sheets. The consideration, which was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member, is being amortized to “Cost of revenue” in the condensed consolidated statements of comprehensive income (loss) and is presented as “Amortization of book-of-business consideration” in the condensed consolidated statements of cash flows as we recognize commission revenue related to the transferred Medicare plan members, over a period of up to five years. The amount of consideration we amortize to cost of revenue each quarter is proportional to the amount of commission revenue we recognize on the underlying policies each quarter. Amortization expense recorded to cost of revenue for these books-of-business for the three months ended September 30, 2011 and 2012 totaled $0.1 million and  $0.6 million, respectively. Amortization expense recorded to cost of revenue for these books-of-business for the nine months ended September 30, 2011 and 2012 totaled $0.4 million and $2.0 million, respectively. Cash consideration paid in connection with the book-of-business transfers are presented under investing activities in the condensed consolidated statements of cash flows. 

XML 37 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) (USD $)
In Thousands, unless otherwise specified
9 Months Ended 12 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Stockholders' Equity [Abstract]    
Number Outstanding, Balance outstanding at December 31, 2011 474  
Number Outstanding, Granted 203 [1]  
Number Outstanding, Vested (235)  
Number Outstanding, Cancelled (75) [1]  
Number Outstanding, Balance outstanding at September 30, 2012 367 474
Weighted-Average Remaining Contractual Life (years), Balance outstanding at December 31, 2011 2 years 4 months 10 days 1 year 11 months 1 day
Weighted-Average Remaining Contractual Life (years), Balance outstanding at September 30, 2012 2 years 4 months 10 days 1 year 11 months 1 day
Aggregate Intrinsic Value, Balance outstanding at December 31, 2011 $ 6,958 [2]  
Aggregate Intrinsic Value, Balance outstanding at September 30, 2012 $ 6,890 [2] $ 6,958 [2]
[1] Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so.
[2] The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 multiplied by the number of restricted stock units outstanding as of December 31, 2011 and September 30, 2012, respectively.
XML 38 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Cash, Cash Equivalents And Accounts Receivable (Schedule of Accounts Receivable) (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2012
Dec. 31, 2011
Cash, Cash Equivalents And Accounts Receivable [Abstract]    
Accounts receivable - from other revenues $ 1,862 $ 7,702
Commissions receivable 1,394 353
Total accounts receivable $ 3,256 $ 8,055
XML 39 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2012
Net Income (Loss) Per Share [Abstract]  
Schedule Of Computation Of Basic And Diluted Net Income Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

Basic:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common stock shares

 

25,683 

 

 

19,970 

 

 

25,642 

 

 

20,276 

Weighted average number of common stock shares held in treasury

 

(4,629)

 

 

 -

 

 

(4,378)

 

 

(565)

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—basic:

$

(0.01)

 

$

0.01 

 

$

0.21 

 

$

0.24 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted:

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) allocated to common stock

$

(249)

 

$

205 

 

$

4,464 

 

$

4,635 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Net weighted average number of common stock shares outstanding

 

21,054 

 

 

19,970 

 

 

21,264 

 

 

19,711 

Weighted average number of options

 

 -

 

 

703 

 

 

680 

 

 

750 

Weighted average number of restricted stock units

 

 -

 

 

77 

 

 

30 

 

 

102 

Total common stock shares used in per share calculation

 

21,054 

 

 

20,750 

 

 

21,974 

 

 

20,563 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share—diluted:

$

(0.01)

 

$

0.01 

 

$

0.20 

 

$

0.23 

 

Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Common stock options

3,565 

 

1,484 

 

1,909 

 

1,327 

Restricted stock units

538 

 

 -

 

156 

 

 -

Total

4,103 

 

1,484 

 

2,065 

 

1,327 

 

XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2012
Stockholders' Equity [Abstract]  
Schedule Of Shares Available For Grant

 

 

 

 

 

Shares Available for Grant (1)

Shares available for grant December 31, 2011

3,870 

Additional shares authorized (2)

795 

Options granted

(731)

Restricted stock units granted

(203)

Options cancelled

280 

Restricted stock units cancelled

75 

Shares available for grant September 30, 2012

4,086 

 

(1)

Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so. 

 

(2)

On January 1, 2012, the number of shares authorized for issuance under the 2006 Equity Incentive Plan was automatically increased pursuant to the terms of the 2006 Equity Incentive Plan by 0.8 million shares.   

Schedule Of Option Activity Under Stock Plans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of Stock Options

 

Weighted Average Exercise Price

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding at December 31, 2011

3,412 

 

$

11.36 

 

3.80 

 

$

17,078 

Granted

731 

 

$

16.86 

 

 

 

 

 

Exercised

(709)

 

$

5.67 

 

 

 

 

 

Cancelled

(280)

 

$

18.58 

 

 

 

 

 

Balance outstanding at September 30, 2012

3,154 

 

$

13.27 

 

3.98 

 

$

18,787 

Vested and expected to vest at September 30, 2012

3,055 

 

$

13.17 

 

3.90 

 

$

18,536 

Exercisable at September 30, 2012

2,056 

 

$

11.79 

 

2.89 

 

$

15,767 

 

(1)

The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 and the exercise price of in-the-money options as of those dates. 

Schedule Of Restricted Stock Unit Activity Under Stock Plans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number Outstanding

 

Weighted-Average Remaining Contractual Life (years)

 

Aggregate Intrinsic Value (1)

Balance outstanding as of December 31, 2011

474 

 

1.92 

 

$

6,958 

Granted

203 

 

 

 

 

 

Vested

(235)

 

 

 

 

 

Cancelled

(75)

 

 

 

 

 

Balance outstanding as of September 30, 2012

367 

 

2.36 

 

$

6,890 
(1)

The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2011 and September 30, 2012 multiplied by the number of restricted stock units outstanding as of December 31, 2011 and September 30, 2012, respectively.  

Schedule Of Stock Repurchase Activity Under Stock Repurchase Programs

 

 

 

 

 

 

 

 

 

Total Number of Shares Purchased

 

Average Price Paid per Share (2)

 

Amount of Repurchase

Cumulative balance at December 31, 2011 (1)

5,797,806 

 

$

14.07 

 

$

81,557 

Repurchases of common stock

554,284 

 

$

15.23 

 

 

8,441 

Cumulative balance at September 30, 2012 (1)

6,352,090 

 

$

14.17 

 

$

89,998 
(1)

Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.  

(2)  Average price paid per share includes commissions. 

Schedule Of Fair Value Of Stock Options, Valuation Assumptions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

(1)

 

 

 

 

 

 

 

 

 

Expected term

 

N/A

 

 

4.6 years

 

 

4.6 years

 

 

4.7 years

Expected volatility

 

N/A

 

 

43.3% 

 

 

49.0% 

 

 

44.3% 

Expected dividend yield

 

N/A

 

 

0% 

 

 

0% 

 

 

0% 

Risk-free interest rate

 

N/A

 

 

0.61% 

 

 

2.02% 

 

 

0.90% 

Weighted-average fair value

$

N/A

 

$

6.46 

 

$

5.34 

 

$

6.41 

 

(1)

There were no stock options granted to employees during the three months ended September 30, 2011.   

Schedule Of Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense recorded during the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Common stock options

$

845 

 

$

717 

 

$

2,893 

 

$

2,076 

Restricted stock units

 

979 

 

 

622 

 

 

2,729 

 

 

2,250 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

The following table summarizes stock-based compensation expense by operating function for the three and nine months ended September 30, 2011 and 2012 (in thousands): 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and advertising

$

252 

 

$

330 

 

$

774 

 

$

932 

Customer care and enrollment

 

83 

 

 

90 

 

 

264 

 

 

243 

Technology and content

 

411 

 

 

233 

 

 

1,336 

 

 

783 

General and administrative

 

1,078 

 

 

686 

 

 

3,248 

 

 

2,368 

Total stock-based compensation expense

$

1,824 

 

$

1,339 

 

$

5,622 

 

$

4,326 

 

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Tables)
9 Months Ended
Sep. 30, 2012
Income Taxes [Abstract]  
Summary Of Provision For Income Taxes And Effective Tax Rate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes

$

22 

 

$

1,079 

 

$

8,799 

 

$

9,160 

Provision for income taxes

$

271 

 

$

874 

 

$

4,335 

 

$

4,525 

Effective tax rate

 

1,231.8% 

 

 

81.0% 

 

 

49.3% 

 

 

49.4% 

 

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographic Information And Significant Customers (Tables)
9 Months Ended
Sep. 30, 2012
Geographic Information And Significant Customers [Abstract]  
Schedule Of Long Lived Assets By Geographical Areas

 

 

 

 

 

 

 

 

 

 

 

 

 

As of

 

As of

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

United States

$

34,469 

 

$

38,054 

China

 

425 

 

 

286 

Total

$

34,894 

 

$

38,340 

 

Schedule of Revenue by Major Customers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Humana

9% 

 

19% 

 

6% 

 

16% 

WellPoint (1)

11% 

 

13% 

 

12% 

 

13% 

UnitedHealthcare (2)

13% 

 

12% 

 

14% 

 

13% 

 

 

 

 

 

 

 

 

 

(1)

Wellpoint includes other carriers owned by Wellpoint. 

(2)

UnitedHealthcare includes other carriers owned by UnitedHealthcare. 

XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule of Stock Options Roll Forward) (Details)
9 Months Ended 0 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Jan. 02, 2012
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares available for grant December 31, 2011 3,870,000 [1]    
Additional shares authorized 795,000 [1],[2]   800,000
Options granted (731,000) [1]    
Restricted stock units granted (203,000) [1]    
Options cancelled 280,000 [1]    
Restricted stock units cancelled 75,000 [1]    
Shares available for grant September 30, 2012 4,086,000 [1]    
Treasury stock, number of shares held 6,500,000 5,900,000  
[1] Shares available for grant exclude treasury stock of 5.9 million shares and 6.5 million shares at December 31, 2011 and September 30, 2012, respectively, that could be granted if we determined to do so.
[2] On January 1, 2012, the number of shares authorized for issuance under the 2006 Equity Incentive Plan was automatically increased pursuant to the terms of the 2006 Equity Incentive Plan by 0.8 million shares.
XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Stockholders' Equity [Abstract]        
Common stock options $ 717 $ 845 $ 2,076 $ 2,893
Restricted stock units 622 979 2,250 2,729
Total stock-based compensation expense $ 1,339 $ 1,824 $ 4,326 $ 5,622
XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary Of Business And Significant Accounting Policies
9 Months Ended
Sep. 30, 2012
Summary Of Business And Significant Accounting Policies [Abstract]  
Summary Of Business And Significant Accounting Policies

 

 

 

 

 

Note 1 - Summary of Business and Significant Accounting Policies

 

 

Description of BusinesseHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is the leading online source of health insurance for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com,  www.eHealthInsurance.com,  www.eHealthMedicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans.  Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process. We are licensed to market and sell health insurance in all 50 states and the District of Columbia. 

  

Basis of Presentation—The accompanying condensed consolidated balance sheet as of September 30, 2012, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2011 and 2012 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2011 and 2012, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2011 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2011, which was filed with the Securities and Exchange Commission on March 15, 2012. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  

 

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2011, and include all adjustments necessary for the fair presentation of eHealth’s statement of financial position as of September 30, 2012, its results of operations for the three and nine months ended September 30, 2011 and 2012 and its cash flows for the nine months ended September 30, 2011 and 2012. All adjustments are of a normal recurring nature. The results for the three months ended September 30, 2012 are not necessarily indicative of the results to be expected for any subsequent quarter or for the fiscal year ending December 31, 2012.   

 

Seasonality—The number of individual and family health insurance applications submitted through our ecommerce platform has generally increased in our first quarter compared to our fourth quarter and in our third quarter compared to our second quarter. Conversely, we have generally experienced a decline or flattening of individual and family submitted applications in our second quarter compared to our first quarter and in our fourth quarter compared to our third quarter. Since a significant portion of our marketing and advertising expenses are driven by the number of health insurance applications submitted on our ecommerce platform, those expenses are influenced by these patterns. The reasons for these seasonal patterns are not entirely clear.  

 

The vast majority of Medicare plans are sold in the fourth quarter of each year during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we generate a significant amount of Medicare plan-related revenue in the fourth quarter of the year. Additionally, we recognize a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year. 

 

In the third quarters of 2011 and 2012, we significantly increased our temporary customer care center staff in preparation for the Medicare annual enrollment period. We employ our temporary customer care center staff until the end of the Medicare annual enrollment period in December. As a result, our customer care center staffing costs are significantly higher in the third and fourth quarters compared to the first and second quarters. We also incur significantly greater Medicare plan-related online advertising expenses during the third and fourth quarters compared to the first and second quarters. Because the majority of our Medicare plan-related revenue is not generated until the fourth quarter, our temporary customer care center staffing costs and Medicare-related online advertising expenses incurred in the third quarters of 2011 and 2012 had a significant negative impact on our profitability during the third quarters of 2011 and 2012. We expect this seasonal trend to occur in future years.  

 

Based on these seasonal trends, we expect our revenue to be highest in the first and fourth quarters of the year and we expect our profitability to be relatively higher in the first and fourth quarters and substantially lower in the third quarter of the year.  

 

Book-of-Business TransfersWe have entered into several agreements with a broker partner, whereby the partner has transferred certain of its existing Medicare plan members to us as the broker of record on the underlying policies. The first of these transfers occurred in November 2010 and the most recent in June 2012. Total consideration for these transfers amounted to $13.9 million, of which $6.2  million is related to transfers during the nine months ended September 30, 2012. Consideration for these transfers is included in “Prepaid expenses and other current assets” and also in “Other assets” in the accompanying condensed consolidated balance sheets. The consideration, which was based on the discounted commissions expected to be received over the remaining life of each transferred Medicare plan member, is being amortized to “Cost of revenue” in the condensed consolidated statements of comprehensive income (loss) and is presented as “Amortization of book-of-business consideration” in the condensed consolidated statements of cash flows as we recognize commission revenue related to the transferred Medicare plan members, over a period of up to five years. The amount of consideration we amortize to cost of revenue each quarter is proportional to the amount of commission revenue we recognize on the underlying policies each quarter. Amortization expense recorded to cost of revenue for these books-of-business for the three months ended September 30, 2011 and 2012 totaled $0.1 million and  $0.6 million, respectively. Amortization expense recorded to cost of revenue for these books-of-business for the nine months ended September 30, 2011 and 2012 totaled $0.4 million and $2.0 million, respectively. Cash consideration paid in connection with the book-of-business transfers are presented under investing activities in the condensed consolidated statements of cash flows. 

Recent Contractual Obligations—In August 2012, we extended our existing lease for office space in Gold River, California, for an additional two years expiring on December 31, 2014. Rent payments will total $0.9 million in both 2013 and 2014. 

In May 2012, we entered into an agreement to lease office space in South Jordan, Utah. The term of the operating lease is 65 months and commences in August 2012. The lease significantly increases our office space for our customer care and enrollment activities and replaces an expiring operating lease for office space at another location in South Jordan, Utah. Rent payments begin in January 2013 and total approximately $0.5 million per year through December 2017.    

In March 2012, we entered into an agreement to lease a building to be constructed in Mountain View, California, adjacent to our headquarters office. The term of the operating lease is ten years from the date the building is delivered to us and the base rent is approximately $0.6 million for the first year of the lease. The base rent increases annually by 3%. Future minimum payments related to this operating lease are estimated to total $6.8 million over the ten-year term of the lease plus our proportionate share of certain operating expenses, insurance costs and taxes for each calendar year during the lease, but may differ depending on actual rentable square footage. Lease payments are expected to begin in the second or third quarter of 2013, although the actual commencement of lease payments will depend upon the date of completion and delivery of the newly constructed building. 

 

Upon signing the Mountain View, California lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.  

 

In March 2012, we entered into a service agreement with a vendor to support our customer care center telephonic system and equipment. Service obligations related to this agreement total $0.7 million over the three-year term of the agreement.   

 

Recent Accounting PronouncementsIn June 2011, the FASB issued authoritative guidance related to the presentation of comprehensive income. The guidance requires that all non-owner changes in stockholders’ equity be presented in a single continuous statement of comprehensive income or in two separate but consecutive statements. The guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. This guidance is effective for interim and annual periods beginning after December 15, 2011. The new guidance is to be applied retrospectively. We adopted the guidance beginning in the first quarter of 2012 and the adoption of this guidance did not have a material impact on our consolidated financial results. 

 

In July 2012, the FASB updated the accounting guidance related to testing indefinite-lived intangible assets for impairment. This update permits an entity to first make a qualitative assessment of whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. An entity is not required to calculate the fair value of an indefinite-lived intangible asset and perform the quantitative impairment test unless the entity determines that it is more likely than not that the asset is impaired. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This update is effective for annual and interim impairment tests performed in fiscal years beginning after September 15, 2012 (our fiscal year 2013); however, early adoption is permitted, provided that the entity has not yet performed its annual impairment test or issued its financial statements. We do not expect the adoption of this accounting guidance to have an impact on our consolidated financial results. 

1 

 

XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Geographic Information And Significant Customers
9 Months Ended
Sep. 30, 2012
Geographic Information And Significant Customers [Abstract]  
Geographic Information And Significant Customers

 

 

Note 6  – Geographic Information and Significant Customers

 

Geographic Information—As of December 31, 2011 and September 30, 2012, our long-lived assets consisted primarily of property and equipment, goodwill and other indefinite-lived intangible assets and finite-lived intangible assets. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area were as follows (in thousands):   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of

 

As of

 

December 31, 2011

 

September 30, 2012

 

 

 

 

 

 

United States

$

34,469 

 

$

38,054 

China

 

425 

 

 

286 

Total

$

34,894 

 

$

38,340 

 

Significant Customers—Substantially all revenue for the three and nine months ended September 30, 2011 and 2012 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three and nine months ended September 30, 2011 and 2012 are presented in the table below: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2011

 

2012

 

2011

 

2012

 

 

 

 

 

 

 

 

Humana

9% 

 

19% 

 

6% 

 

16% 

WellPoint (1)

11% 

 

13% 

 

12% 

 

13% 

UnitedHealthcare (2)

13% 

 

12% 

 

14% 

 

13% 

 

 

 

 

 

 

 

 

 

(1)

Wellpoint includes other carriers owned by Wellpoint. 

(2)

UnitedHealthcare includes other carriers owned by UnitedHealthcare. 

Commission revenue attributable to major medical individual and family health insurance plans was approximately 86% and 79% of our commission revenue in the three months ended September 30, 2011 and 2012, respectively. Commission revenue attributable to major medical individual and family health insurance plans was approximately 88% and 78% of our commission revenue in the nine months ended September 30, 2011 and 2012, respectively. We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related health insurance plan offerings or other ancillary products such as small business, short-term, stand-alone dental, life and student insurance plan offerings. 

 

As of December 31, 2011, one customer represented 73% of our $8.1 million outstanding accounts receivable balance. As of September 30, 2012, two customers represented 37% and 14%, respectively, for a combined total of 51%  of our $3.3 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2011 and September 30, 2012. We believe the potential for collection issues with any of our customers is minimal as of September 30, 2012.

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense $ 1,339 $ 1,824 $ 4,326 $ 5,622
Marketing and Advertising Expense [Member]
       
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense 330 252 932 774
Customer Care And Enrollment Expense [Member]
       
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense 90 83 243 264
Technology And Content Expense [Member]
       
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense 233 411 783 1,336
General and Administrative Expense [Member]
       
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense $ 686 $ 1,078 $ 2,368 $ 3,248
XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 56 182 1 true 17 0 false 6 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.ehealthinsurance.com/role/DocumentDocumentAndEntityInformation Document And Entity Information true false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.ehealthinsurance.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 00200 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss) Sheet http://www.ehealthinsurance.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements Of Comprehensive Income (Loss) false false R4.htm 00400 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.ehealthinsurance.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows false false R5.htm 10101 - Disclosure - Summary Of Business And Significant Accounting Policies Sheet http://www.ehealthinsurance.com/role/DisclosureSummaryOfBusinessAndSignificantAccountingPolicies Summary Of Business And Significant Accounting Policies false false R6.htm 10201 - Disclosure - Cash, Cash Equivalents And Accounts Receivable Sheet http://www.ehealthinsurance.com/role/DisclosureCashCashEquivalentsAndAccountsReceivable Cash, Cash Equivalents And Accounts Receivable false false R7.htm 10301 - Disclosure - Stockholders' Equity Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquity Stockholders' Equity false false R8.htm 10401 - Disclosure - Income Taxes Sheet http://www.ehealthinsurance.com/role/DisclosureIncomeTaxes Income Taxes false false R9.htm 10501 - Disclosure - Net Income (Loss) Per Share Sheet http://www.ehealthinsurance.com/role/DisclosureNetIncomeLossPerShare Net Income (Loss) Per Share false false R10.htm 10601 - Disclosure - Geographic Information And Significant Customers Sheet http://www.ehealthinsurance.com/role/DisclosureGeographicInformationAndSignificantCustomers Geographic Information And Significant Customers false false R11.htm 20102 - Disclosure - Summary Of Business And Significant Accounting Policies (Policy) Sheet http://www.ehealthinsurance.com/role/DisclosureSummaryOfBusinessAndSignificantAccountingPoliciesPolicy Summary Of Business And Significant Accounting Policies (Policy) false false R12.htm 30203 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Tables) Sheet http://www.ehealthinsurance.com/role/DisclosureCashCashEquivalentsAndAccountsReceivableTables Cash, Cash Equivalents And Accounts Receivable (Tables) false false R13.htm 30303 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) false false R14.htm 30403 - Disclosure - Income Taxes (Tables) Sheet http://www.ehealthinsurance.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) false false R15.htm 30503 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.ehealthinsurance.com/role/DisclosureNetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) false false R16.htm 30603 - Disclosure - Geographic Information And Significant Customers (Tables) Sheet http://www.ehealthinsurance.com/role/DisclosureGeographicInformationAndSignificantCustomersTables Geographic Information And Significant Customers (Tables) false false R17.htm 40101 - Disclosure - Summary Of Business And Significant Accounting Policies (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureSummaryOfBusinessAndSignificantAccountingPoliciesDetails Summary Of Business And Significant Accounting Policies (Details) false false R18.htm 40202 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Schedule of Cash and Cash Equivalents) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureCashCashEquivalentsAndAccountsReceivableScheduleOfCashAndCashEquivalentsDetails Cash, Cash Equivalents And Accounts Receivable (Schedule of Cash and Cash Equivalents) (Details) false false R19.htm 40203 - Disclosure - Cash, Cash Equivalents And Accounts Receivable (Schedule of Accounts Receivable) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureCashCashEquivalentsAndAccountsReceivableScheduleOfAccountsReceivableDetails Cash, Cash Equivalents And Accounts Receivable (Schedule of Accounts Receivable) (Details) false false R20.htm 40301 - Disclosure - Stockholders' Equity (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) false false R21.htm 40302 - Disclosure - Stockholders' Equity (Schedule of Stock Options Roll Forward) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfStockOptionsRollForwardDetails Stockholders' Equity (Schedule of Stock Options Roll Forward) (Details) false false R22.htm 40303 - Disclosure - Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfOptionActivityUnderStockPlansDetails Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) false false R23.htm 40304 - Disclosure - Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfRestrictedStockUnitActivityUnderStockPlansDetails Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) false false R24.htm 40305 - Disclosure - Stockholders' Equity (Schedule Of Stock Repurchase Activity Under Stock Repurchase Programs) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfStockRepurchaseActivityUnderStockRepurchaseProgramsDetails Stockholders' Equity (Schedule Of Stock Repurchase Activity Under Stock Repurchase Programs) (Details) false false R25.htm 40306 - Disclosure - Stockholders' Equity (Schedule Of Fair Value Of Stock Options, Valuation Assumptions) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfFairValueOfStockOptionsValuationAssumptionsDetails Stockholders' Equity (Schedule Of Fair Value Of Stock Options, Valuation Assumptions) (Details) false false R26.htm 40307 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseDetails Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) false false R27.htm 40308 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseByOperatingFunctionDetails Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) false false R28.htm 40401 - Disclosure - Income Taxes (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) false false R29.htm 40501 - Disclosure - Net Income (Loss) Per Share (Schedule Of Computation Of Basic And Diluted Net Income Per Share) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureNetIncomeLossPerShareScheduleOfComputationOfBasicAndDilutedNetIncomePerShareDetails Net Income (Loss) Per Share (Schedule Of Computation Of Basic And Diluted Net Income Per Share) (Details) false false R30.htm 40502 - Disclosure - Net Income (Loss) Per Share (Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureNetIncomeLossPerShareScheduleOfAntiDilutiveSharesExcludedFromComputationOfNetIncomePerShareDetails Net Income (Loss) Per Share (Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) false false R31.htm 40601 - Disclosure - Geographic Information And Significant Customers (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureGeographicInformationAndSignificantCustomersDetails Geographic Information And Significant Customers (Details) false false R32.htm 40602 - Disclosure - Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureGeographicInformationAndSignificantCustomersScheduleOfLongLivedAssetsByGeographicalAreasDetails Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) false false R33.htm 40603 - Disclosure - Geographic Information And Significant Customers (Schedule of Revenue by Major Customers) (Details) Sheet http://www.ehealthinsurance.com/role/DisclosureGeographicInformationAndSignificantCustomersScheduleOfRevenueByMajorCustomersDetails Geographic Information And Significant Customers (Schedule of Revenue by Major Customers) (Details) false false All Reports Book All Reports Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '00200 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss)' had a mix of different decimal attribute values. 'Shares' elements on report '40302 - Disclosure - Stockholders' Equity (Schedule of Stock Options Roll Forward) (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40401 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. Process Flow-Through: 00100 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 00200 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss) Process Flow-Through: 00400 - Statement - Condensed Consolidated Statements Of Cash Flows ehth-20120930.xml ehth-20120930.xsd ehth-20120930_cal.xml ehth-20120930_def.xml ehth-20120930_lab.xml ehth-20120930_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stockholders' Equity (Details) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Stockholders' Equity [Abstract]          
Total grant date fair value of stock options vested $ 0.5 $ 0.9 $ 1.9 $ 3.8  
Total grant date fair value of restricted stock units vested     3.7 1.7  
Stock repurchase program, authorized amount     $ 30.0    
Average price per share of stock repurchased under stock repurchase program     $ 15.23 [1]    
Treasury stock shares purchased 6,352,090 [2]   6,352,090 [2]   5,797,806 [2]
Shares surrendered by employees to satisfy tax withholdings 200,000   200,000    
Treasury stock, number of shares held 6,500,000   6,500,000   5,900,000
[1] Average price paid per share includes commissions.
[2] Cumulative balances at December 31, 2011 and September 30, 2012 consist of shares repurchased in connection with our stock repurchase programs announced on July 27, 2010 and June 14, 2011, as well as a previous stock repurchase plan announced in 2008.